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SUMMARY 
 
Modification of naturally occurring nucleosides is an important area in the search for new agents with 
therapeutic potential. The work presented herein focuses on modified pyrimidine nucleosides as well 
as nucleoside phosphonates. The first part presents the synthesis and biological evaluation of several 
thymidine kinase 2 inhibitors. In the second part, the synthesis and biological evaluation of a series of 
new TMPKmt inhibitors will be discussed. The third part is dedicated to the search for new P2Y2 
receptor ligands and in the last part, the synthesis and antiviral activity of a series of nucleoside 
phosphonates will be presented. 
 
Thymidine kinase 2 (TK-2) is a mitochondrial deoxynucleoside kinase that plays an important role in 
the first phosphorylation of pyrimidine nucleosides needed for mtDNA synthesis. Furthermore, it is 
assumed that TK-2 could be involved in the mitochondrial toxicity associated with antiviral nucleoside 
analogues. However, there are still many open questions related to the real contribution of TK-2 to 
these issues. Potent and selective TK-2 inhibitors could be valuable tools to unravel the role of TK-2 in 
mitochondrial deoxytriphosphate pools and homeostasis, and may help to clarify the contribution of 
TK-2 catalyzed phosphorylation of antiviral drugs to the mitochondrial toxicity of these agents. Two 
series of thymidine analogues that were originally designed as TMPKmt inhibitors, were evaluated for 
their inhibitory activity against a panel of other nucleoside kinases (TK-1, TK-2, herpes simples virus 1 
and varicella zoster virus TK). Several substituted 3’-thiourea derivatives of β-dThd proved highly 
inhibitory to and selective for human mitochondrial TK-2 compared to related kinases. As it was 
demonstrated that the 3’-substituent of these analogues was responsible for extra interactions with 
TK-2, we decided to investigate if the thiourea moiety, earlier described as the perpetrator of toxicity, 
could be replaced by alternative linkages to connect the C-3’ atom of the deoxyribose moiety to 
several substituents. In Chapter 2 we explored thymidine analogues containing a triazole ring instead 
of the thiourea moiety. Therefore, a series of 1,4- and 1,5-disubstituted 3’-(1,2,3-triazol-1-yl)-3’-deoxy-
β-D-thymidine analogues was synthesized via Huisgen [3+2] cycloaddition. Combination of a favorable 
3’-(4-substituted-1,2,3-triazole) moiety with a (E)-5-(2-bromovinyl)-substituent, known as a privileged 
scaffold for TK-2 binding, resulted in several potent and selective TK-2 inhibitors, e.g., compound 1.66 
(IC50 = 0.036 μM). Chapter 3 described the synthesis and biological evaluation of several thymidine 
and BVDU analogues containing a substituted amine, guanidine or 1,5-disubstituted tetrazole instead 
of a thiourea. The latter modification resulted in analogue 1.100 (IC50 = 0.014 μM) which is the most 
potent and selective TK-2 inhibitor reported so far. 
 
Mycobacterial thymidine monophosphate kinase (TMPKmt) catalyses the reversible phosphorylation of 
thymidine monophosphate to thymidine diphosphate in Mycobacterium tuberculosis. Because its 
crucial role in thymidine metabolism and in view of its low sequence identity with the human isoenzym, 
TMPKmt represents an attractive target for blocking the mycobacterial DNA synthesis. To gain further 
insight into the S.A.R. of several thiourea analogues known for their inhibitory activity against 
TMPKmt, different analogues of these lead compounds were synthesized including 3’- and 5’-modified 
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α- and β-derivatives. In addition, several analogues were synthesized in which the 4-oxygen was 
replaced by a more lipophilic sulfur atom. In both the 3’- and 5’- modified thymidine analogues, the 
anomer that places the thymine base trans to the aromatic substituent showed the best TMPKmt 
inhibition. Several compounds showed an inhibitory potency in the low micromolar range, with the 5’-
arylthiourea 4-thio-α-D-thymidine analogue 2.24 being the most active one (Ki = 0.17 μM).  
 
The P2Y2 receptor is a G-protein coupled receptor belonging to the purinergic receptor family which is 
activated by ATP and UTP. P2Y2 agonists are promising potential therapeutics for cystic fibrosis, while 
P2Y2 antagonists exhibit anti-inflammatory and neuroprotective properties. UTP as well as most 
reported analogues are sensitive to enzymatic degradation. Replacement of the α-phosphate group of 
UTP by an isosteric phosphonate group didn’t result in an increased metabolic stability. The resulting 
uridine 5’-phosphonodiphosphate (3.6) suffered from complete chemical hydrolysis to the 
corresponding 5’-phosphonate (3.7) in the buffer storage solution. Surprisingly, when tested in its pure 
form, compound 3.7 showed partial P2Y2 receptor agonist activity while being inactive at the P2Y4 
receptor. In PART III, we introduced several (hetero)aromatic substituents at C-5 of the 5’-methylene 
phosphonate analogue 3.7. All 5-modified analogues caused P2Y2-dependent IP3 accumulation but 
none of the phosphonate analogues had the same maximal activity as UTP. Within this series, a 5-(2-
furanyl) modification (3.49) gave the highest efficacy, while 5-(4-fluorophenyl) substitution (3.46) 
afforded the highest potency. Remarkably, these analogues failed to inhibit activity of UTP down to the 
level of activity seen with the 5-modified analogues alone as would be expected for classical partial 
agonists. A possible explanation for this phenomenon is that these phosphonates are producing their 
effects by interacting with a receptor site distinct from the orthosteric site. In addition, we also 
envisaged replacement of the 2’-OH group of compound 3.7 with a 2’-chloro and a 2’-amino group. 
Both 2’-modified analogues gave marginal activation of the receptor. Another phosphonate bio-
isostere of uridine 5’-monophosphate, obtained by the inversion of the 4’-CH2-O group of uridine 
monophosphate, was significantly less active than the lead phosphonate.  
 
A number of C-5 modified 2’-deoxypyrimidine analogues are known to possess potent and selective 
antiviral activity. However, relatively few examples of 5-(hetero)aryl-modified nucleosides with 
promising antiviral activity have been reported. This may be due to the fact that these nucleosides are 
not efficiently converted into their triphosphate form. This led us to investigate a small series of 2’-
deoxyuridine analogues that combine different aromatic substituents at position 5 of the base with a 
5’-methylene phosphonate group to bypass a possibly difficult first intracellular phosphorylation step. 
An unexpected anomerisation during the last step of the synthesis allowed us to investigate the β- as 
well as the α-anomers of the corresponding phosphonates. None of these analogues exhibited 
significant antiviral activity.  
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SAMENVATTING 
 
Het modificeren van nucleosiden is een veelgebruikte methode in de zoektocht naar nieuwe 
verbindingen met therapeutisch potentieel. In dit werk wordt gefocust op gemodificeerde pyrimidine 
nucleosiden en nucleoside fosfonaat analogen. In het eerste deel wordt de synthese en biologische 
evaluatie van een aantal thymidine kinase 2 inhibitoren voorgesteld. Het tweede deel behandelt de 
synthese en evaluatie van nieuwe TMPKmt inhibitoren. Het derde deel is gewijd aan de zoektocht 
naar P2Y2 liganden gevolgd door een laatste deel waarin de synthese en antivirale activiteit van 
nucleoside fosfonaten beschreven wordt. 
 
Thymidine kinase 2 (TK-2) is een mitochondriaal deoxynucleoside kinase dat een belangrijke rol 
speelt in de eerste fosforylering van pyrimidine nucleosiden nodig voor mtDNA synthese. Daarnaast 
zou TK-2 ook betrokken zijn bij de mitochondriale toxiciteit geassocieerd met nucleoside-analoog 
therapie. Er zijn echter nog vele vragen omtrent de bijdrage van TK-2 in beide processen. De 
synthese van potente en selectieve TK-2 inhibitoren zou een belangrijk hulpmiddel kunnen zijn in het 
onderzoek naar de rol van TK-2 in mitochondriale deoxynucleoside trifosfaat pools en homeostase, 
alsook naar de bijdrage van TK-2 gekatalyseerde fosforylering in de mitochondriale toxiciteit van 
antivirale middelen. Twee reeksen thymidine analogen die oorspronkelijk gesynthetiseerd werden als 
TMPKmt inhibitoren, werden getest voor hun inhiberende werking op verschillende TK’s (TK-1, TK-2, 
Herpes Simplex TK 1 en varicella zoster virus TK). Een aantal gesubstitueerde 3’-thioureum derivaten 
van β-dThd vertoonden een hoge en selectieve inhiberende activiteit voor humaan TK-2 in vergelijking 
met de andere kinasen. Aangezien de substituent op het C-3’ atoom van het deoxyribose gedeelte 
verantwoordelijk bleek voor extra interacties maar de thioureum functie in het verleden reeds toxische 
nevenwerkingen veroorzaakte, werd op zoek gegaan naar alternatieve linkers tussen C-3’ en de 
verschillende substituenten. In hoofdstuk 2 werd de thioureum functie vervangen door een triazool 
ring. Hiervoor werd via Huisgen [3+2] cycloadditie een reeks 1,4- en 1,5-digesubstitueerde 3’-(1,2,3-
triazol-1-yl)-3’-deoxy-β-D-thymidine analogen gesynthetiseerd. Combinatie van de meest actieve 3’-
(1,2,3-triazol-1-yl) modificatie met een (E)-5-(2-bromovinyl) substituent, die een positieve invloed op 
TK-2 affiniteit heeft, leverde een aantal zeer potente en selectieve TK-2 inhibitoren op (bv. verbinding 
1.66, IC50 = 0.036 μM). In hoofdstuk 3 werd de synthese en biologische evaluatie van een aantal 
thymidine en BVDU analogen beschreven waarin de thioureum functie vervangen werd door een 
gesubstitueerde amine, guanidine of 1,5-digesubstitueerde tetrazool linker. Deze laatste modificatie 
resulteerde in analoog 1.100 (IC50 = 0.014 μM), de meest potente en selectieve TK-2 inhibitor 
beschreven tot dusver. 
 
Mycobacterieel thymidine monofosfaat kinase (TMPKmt) katalyseert de reversibele fosforylering van 
thymidine monofosfaat naar thymidine difosfaat in Mycobacterium tuberculosis. Zijn essentiële rol in 
het thymidine metabolisme gecombineerd met een lage aminozuur sequentie overeenkomst met het 
humane iso-enzym (TMPKh), maken van TMPKmt een aantrekkelijk target voor het blokkeren van de 
mycobacteriële DNA synthese. Om een beter inzicht te krijgen in de S.A.R van een aantal gekende 
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thioureum analogen die TMPKmt inhiberen, werden in deel II verschillende structurele varianten van 
deze lead verbindingen gesynthetiseerd waaronder 3’- en 5’- gemodificeerde α- en β-derivaten. In 
sommige analogen werd tevens het zuurstofatoom op positie 4 van de base vervangen door het meer 
lipofiele zwavel. Zowel voor de 3’- als 5’-gemodificeerde analogen, gaf het anomeer waarbij de 
thymine base trans stond ten opzichte van de aromatische substituent de beste TMPKmt inhiberende 
activiteit. Verschillende analogen vertoonden een Ki in de lage micromolaire concentratie, met het 5’-
arylthioureum 4-thio-α-thymidine analoog 2.24 als meest actieve verbinding (Ki = 0.17 μM).  
 
De P2Y2 receptor is een G-proteïne gekoppelde receptor die behoort tot de familie van de purinerge 
receptoren en die geactiveerd wordt door ATP en UTP. P2Y2 agonisten zijn potentiële 
geneesmiddelen voor de behandeling van mucoviscidose, terwijl P2Y2 antagonisten anti-inflammatoire 
en neuroprotectieve eigenschappen bezitten. UTP, alsook de diverse reeds gerapporteerde UTP 
analogen zijn onderhevig aan enzymatische degradatie. Vervanging van de α-fosfaat groep van UTP 
door een isostere fosfonomethylgroep leidde in het verleden niet tot de verhoopte toename in 
metabole stabiliteit. Uridine 5’-fosfonodifosfaat (3.6) onderging chemische hydrolyse tot het 
overeenkomstige 5’-methylfosfonaat (3.7) in de bufferoplossing voor bewaring. Opmerkelijk hierbij was 
dat 3.7 zich als aan partiële P2Y2 receptor agonist gedroeg terwijl het inactief was ten opzichte van de 
P2Y4 receptor. In deel III werden analogen gesynthetiseerd waarbij de 5’-methylfosfonaat groep van 
3.7 gecombineerd werd met verschillende (hetero)aromatische substituenten op C-5. Alle analogen 
veroorzaakten een P2Y2 receptor afhankelijke IP3 accumulatie maar geen enkel fosfonaat had 
hetzelfde maximaal effect als UTP. Een 5-(2-furanyl) modificatie (3.49) bezat de hoogste efficacy 
terwijl een 5-(4-fluorofenyl) (3.46) substitutie de hoogste potency vertoonde. Opmerkelijk hierbij was 
dat de analogen er niet in slaagden de activiteit van UTP te inhiberen tot het activiteitsniveau van de 
5-gemodificeerde analogen alleen zoals te verwachten voor klassieke partiële agonisten. Mogelijks 
veroorzaken de fosfonaten hun effect via een allosterisch werkingsmechanisme. In een tweede reeks 
analogen werd de 2’-OH groep van verbinding 3.7 vervangen door een 2’-chloor en een 2’-amino. 
Beide analogen vertoonden een matige activatie van de P2Y2 receptor. Analoog 3.68, een fosfonaat 
bioisosteer van uridine 5’-monofosfaat verkregen door omkering van de 4’-CH2-O groep van uridine 
monofosfaat, veroorzaakte slechts een beperkte receptor activatie. 
 
Een aantal C-5 gemodificeerde 2’-deoxypyrimidine analogen zijn gekend omwille van hun potente en 
selectieve antivirale activiteit. Binnen deze groep is slechts een beperkt aantal 5-(hetero)aryl derivaten 
gerapporteerd. Mogelijks is dit te wijten aan een inefficiënte omzetting tot hun actieve trifosfaat vorm. 
Om dit na te gaan werden in deel IV de synthese en antivirale activiteit van een kleine reeks 2’-
deoxyuridine analogen beschreven die verschillende aromatische substituenten op C-5 combineerden 
met een 5’-methylfosfonaat functie. Introductie van dit fosfonaat zou de eerste en vaak moeilijkste 
fosforylering stap moeten overbruggen. Een onverwachte anomerisatie in de laatste synthese stap liet 
toe om de antivirale activiteit van zowel de β- als de α- fosfonaten te onderzoeken. Geen enkel 
analoog vertoonde een significante antivirale activiteit. 
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LIST OF ABBREVIATIONS 
 
ACV    Acyclovir 
ADP    Adenosine 5’-diphosphate 
AIDS    Acquired immune deficiency syndrome 
Ala    Alanine 
AMP    Adenosine 5’-monophosphate 
Ara-C    Arabinofuranosyl cytosine 
Ara-T    Arabinofuranosyl thymine 
Ara-U    Arabinofuranosyl uracil 
Arg    Arginine 
ASL    Airway surface liquid 
Asn    Asparagine 
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NUCLEOSIDE NOMENCLATURE 
 
Since IUPAC nomenclature does not allow rapid visualization of modified nucleosides, the typical 
nucleoside notation starts from the name of the natural nucleoside, to which the chemical 
modifications at the different positions are added. This nomenclature is generally accepted in the 
nucleoside chemistry and is therefore used throughout this work. As these conventions can lead to 
misinterpretations if changes on the nucleoside structure alter the parent nucleoside too much, 
sometimes the IUPAC nomenclature will be used (e.g., compounds 1.67 and 1.68 (PART I) and the 
(2’-deoxy)uridine phosphonate derivatives described in PARTS III and IV). In addition, the generally 
used numbering system for nucleosides is depicted in Figure I. 
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Figure I. Generally used numbering system for nucleosides. 
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PREFACE 
 
Modification of naturally occurring nucleosides has been proven a successful strategy in the search for 
new drugs. Structural modifications of nucleosides have given rise to widely used drugs such as 
zidovudine (Retrovir®) and acyclovir (Zovirax®), which demonstrates that this strategy offers interesting 
opportunities to synthesize new therapeutically useful compounds. 
 
This work comprises four different parts that, from a target point of view, don’t have much in common 
except that these targets all use a nucleoside or a nucleotide as endogenous ligand. Hence, from a 
chemical point of view, interesting similarities may be uncovered in the substrate-based design of 
compounds capable of modulating these targets. 
 
In PART I, efforts will be made to synthesize highly active and selective inhibitors for human 
mitochondrial thymidine kinase 2. Thymidine kinase 2 inhibitor 1.43, a 3’-modified analogue of the 
natural ligand thymidine, will be used as a template to synthesize new compounds in which the toxic 
thiourea group is replaced with an alternative linker (Figure II). Based on the structural relationship of 
TK-2 and thymidine monophosphate kinase and some of their inhibitors, PART II aims at evaluating 
selected TK-2 inhibitors for their inhibitory activity against mycobacterial thymidylate kinase to gain 
further insight into the S.A.R. of known TMPKmt inhibitors.  
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In the third part, attempts will be made to increase the potency of a known P2Y2 ligand, compound 3.7, 
by introducing aromatic substituents at position 5 of the uracil base (Figure III). The same chemical 
modifications will be carried out in search for new nucleoside analogues possessing antiviral activity 
(PART IV). The only difference is that for putative P2Y2 receptor ligands we will start from uridine (in 
analogy with the natural ligand UTP), while as possible agents acting against DNA viruses, 2’-
deoxyuridine will be used as a nucleoside scaffold.  
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1 INTRODUCTION 
1.1 DEOXYRIBONUCLEOTIDES 
DNA replication and repair strongly depends on a balanced pool of the four deoxyribonucleoside 
triphosphates (dNTPs). In most living organisms the synthesis of these essential building blocks is 
performed by two pathways: the de novo and the salvage pathway. Most organisms can synthesize 
purine and pyrimidine nucleotides from low-molecular-weight precursors in amounts sufficient for their 
needs. These so-called de novo pathways are essentially identical throughout the biological world. 
Most organisms can also synthesize nucleotides from nucleosides or bases that become available 
either via the diet or through enzymatic breakdown of nucleic acids. These processes are called 
salvage pathways, because they involve the utilization of preformed purine and pyrimidine compounds 
that would otherwise be lost in biodegradation (Figure I.1).1  
 
 
 
Figure I.1. The de novo and salvage pathways of (deoxy)ribonucleotides. 
 
 
            dNK                            NMPK                          NDPK
dN                          dNMP                         dNDP                             dNTP                        DNA
                                                         
                                                          RNR
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                                                                            NMPK                                                              
                                                 NK
                                    N                             NMP
                                                                                                          de novo
                                                           amino acids, PRPP
                                                              ATP, NH3, CO2
dN = deoxynucleoside, dNK = deoxynucleoside kinase, dNMP = deoxynucleoside monophosphate, NMPK =
nucleoside monophosphate kinase, dNDP = deoxynucleoside diphosphate, NDPK = nucleoside diphosphate
kinase, dNTP = deoxynucleoside triphosphate, DNA = deoxynucleic acid, RNR = ribonucleoside diphosphate
reductase, NDP = nucleoside diphosphate, NTP = nucleoside triphosphate, RNA = ribonucleic acid, NMP =
nucleoside monophosphate, NK = nucleoside kinase, N = nucleoside, PRPP = phosphoribosyl pyrophosphate, 
ATP = adenosine triphosphate.
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1.1.1 The de novo Pathway 
In mammalian cells the majority of the deoxyribonucleotides are synthesized by the de novo pathway 
(Figure I.1). In proliferating cells this pathway is the main provider of dNTPs needed for DNA 
replication.2,3 Initially, ribonucleoside monophosphates are synthesized from low molecular weight 
precursors like ribose, amino acids, CO2 and NH3.2 The monophosphates are then further 
phosphorylated to their diphosphate counterparts by nucleoside monophosphate kinases (NMPK). 
The regulatory step in the de novo synthesis of deoxyribonucleotides is the reduction of the 2’-hydroxyl 
group of the ribonucleoside diphosphate to the corresponding deoxyribonucleoside diphosphate. This 
reaction is catalyzed by ribonucleotide reductase (RNR).2 The final step in the de novo pathway is the 
addition of the third phosphate group in a reaction catalyzed by a family of nucleoside diphosphate 
kinases (NDPK). 
1.1.2 Salvage Pathway 
A complementing and less energy demanding salvage pathway is found in quiescent or terminally 
differentiated cells. During the salvage pathway, extracellular (deoxy)nucleosides ((d)Ns) originating 
from degraded cells or nutrients are transported into the cell via non-specific nucleoside carrier 
proteins and undergo three successive phosphorylation steps. In the first step, deoxyribonucleoside 
kinases (dNKs) and ribonucleoside kinases (NKs) phosphorylate deoxyribonucleosides or 
ribonucleosides, respectively. Addition of negative charges in form of phosphates will trap the 
phosphorylated nucleosides inside the cell. The continued phosphorylation of the monophosphates to 
their corresponding diphosphates and triphosphates occurs in two subsequent reversible steps that 
are catalyzed by nucleoside monophosphate kinases and nucleoside diphosphate kinases (Figure 
I.1).4  
 
An alternative salvage pathway synthesizes nucleoside 5’-phosphates directly from free bases. This 
route involves the reversible transfer of a free base to the ribose of 5-phospho-α-D-ribo-1-
pyrophosphate (PRPP) catalyzed by a phosphoribosyl transferase.1  
1.2 DEOXYNUCLEOSIDE KINASES 
Before being built in DNA, deoxynucleosides require activation into their triphosphate form by different 
enzymes. As described above, deoxynucleoside kinases catalyze the first of three phosphorylation 
steps. Besides their role in the salvage pathway, dNKs are instruments in the activation of nucleosides 
that are used against cancer cells and/or viruses.5 They catalyze the initial, and often limiting, first 
phosphorylation step in the conversion of the nucleoside analogues into their active form.  
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In mammalian cells, four cellular deoxynucleoside kinases can be found including two cytosolic 
enzymes, thymidine kinase 1 (TK-1) and deoxycytidine kinase (dCK), as well as two mitochondrial 
enzymes, thymidine kinase 2 (TK-2) and deoxyguanosine kinase (dGK). Three of the kinases (dCK, 
TK-2 and dGK) are evolutionary closely related and their amino acid sequences share 40% identity. 
Several nucleoside triphosphates can act as phosphate donors, with ATP being accepted by all dNKs. 
Besides their different localization, these enzymes have variable and overlapping substrate 
specificities as well as different patterns of expression according to the cell cycle and the nature of 
origin of the cell (Figure I.2).6,7 
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Figure I.2. Phosphorylation reaction catalyzed by deoxynucleoside kinases.8 
 
In addition, the fruit fly Drosophila melanogaster contains only one single deoxyribonucleoside kinase 
(Dm-dNK) that was cloned by two independent groups in the late 1990s.7,9 Johansson et al. showed 
that Dm-dNK is closely related to the human deoxyribonucleoside kinase family, in particular with TK-
2. However, in contrast to human enzymes, Dm-dNK is a multisubstrate nucleoside kinase. It 
phosphorylates all the natural nucleosides as well as several anticancer and antiviral nucleoside 
analogs, although pyrimidine nucleosides are the preferred substrate.9 The catalytic rate of 
deoxyribonucleoside phosphorylation of Dm-dNK depends on the substrate, but is generally 10 to 100-
fold higher than that of mammalian enzymes.10 
1.3 THYMIDINE KINASES (TK-2 vs. TK-1)  
1.3.1 Localization and Expression 
In mammals there are two enzymes able to phosphorylate thymidine: a cytosolic (TK-1) and a 
mitochondrial (TK-2) enzyme. TK-1, which was cloned in 1983, is expressed only in S-phase cells,11 
while TK-2 is expressed in most tissues throughout the whole cell cycle with the highest expression in 
liver, pancreas, muscles and brain.1213,14 In many resting cells, such as nerve and muscle cells, TK-2 
is the only pyrimidine deoxynucleoside phosphorylating enzyme expressed. In these tissues, where de 
novo synthesis of DNA precursors is undetectable,12 TK-2 is likely to be responsible for the supply of 
deoxyribonucleotides required for mitochondrial DNA synthesis. The physiological role of TK-2 is not 
well defined but in cells with no TK-1 activity, TK-2-mediated phosphorylation of thymidine leads to a 
product that finally gets into mitochondrial DNA.15 
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1.3.2 Substrate Specificities 
1.3.2.1 Thymidine Kinase 2 
Human TK-2 utilizes thymidine (dThd, 1.1), 2’-deoxycytidine (dCyd, 1.2) and 2’-deoxyuridine (dUrd, 
1.3) as substrates but with different efficiency and kinetic mechanisms. dThd is the preferred substrate 
while ATP (1.4) and CTP (1.5) can be used as phosphate donors (Figure I.3).16  
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Figure I.3 
 
Concerning nucleoside analogues used as antivirals, the anti-HIV drug 3’-azido-3’-deoxythymidine 
(AZT, zidovudine, 1.6) is a poor substrate for TK-2, although its level of phosphorylation is significant 
in non-dividing tissues.8 Other drugs that are well phosphorylated by TK-2 include the antiherpetic 
drugs 1-(β-D-arabinofuranosyl)thymine (Ara-T, 1.8), (E)-5-(2-bromovinyl)-2’-deoxyuridine (BVDU, 1.10) 
and its arabinosyl counterpart 1-β-D-arabinofuranosyl-(E)-5-(2-bromovinyl)uracil (BVaraU, 1.11). 
Another compound that is effectively recognized by TK-2 is 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-
5-iodouracil (FIAU, 1.12), a potent anti-hepatitis B nucleoside analogue (Figure I.4).6,16,17,18  
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Figure I.4 
 
In addition, 3’-deoxy-3’-fluoro-β-D-thymidine (1.7) and ribothymidine (1.13) are phosphorylated as well, 
but with relatively low efficiency. Other substrates are 1-β-D-arabinofuranosyluracil (Ara-U, 1.9), 2’-
deoxy-2’,2’-difluorouridine (dFdU, 1.14) and a few 5-substituted dUrd analogues (e.g., halogen, amino 
or ethyl).6,16,17 2’-Deoxycytidine analogs with a 5-modification, such as 5-(2-chloroethyl) (1.15) and 5-
(2-bromovinyl) (1.16), showed activity with TK-2, and modifications of the sugar moiety, such as 
gemcitabine (dFdC, 1.17) and 1-β-D-arabinofuranosylcytosine (Ara-C, 1.18), are also accepted but 
with low efficiency (Figure I.5).6  
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Figure I.5 
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1.3.2.2 Thymidine Kinase 1 
The substrate specificity of TK-1 is mainly restricted to thymidine (1.1) and deoxyuridine (1.3), but 
some modifications are allowed at the 5 position of the pyrimidine ring and the 3’ position of the 
deoxyribose.19 ATP (1.4) and dATP (1.19) are the preferred phosphate donors (Figure I.6).  
 
Several 5-substituted dUrd analogs are accepted by TK-1, e.g., 5-fluoro, 5-chloro, 5- iodo, 5-bromo 
and 5-ethyl dUrd, while bulkier substitutions, such as 5-propenyl, 5-(2-chloroethyl) and 5-(2-
bromovinyl), are not recognized as substrates.20 A number of large substitutions at the N3 position, 
e.g., o-carboranylalkyl dThd, have been shown to be good substrates for TK-1.21 
 
Examples of clinically important 3’-modified nucleoside analogues phosphorylated by TK-1 are the 
anti-HIV agents AZT (1.6), 3’-deoxythymidine (ddT, 1.20), 3’-deoxy-3’-fluoro-β-D-thymidine (1.7) and 
2’,3’-didehydro-3’-deoxythymidine (d4T, 1.21) (Figure I.6).22,23  
 
O N
HO NH
O
1.20
O N
HO NH
O
1.21
O N
O
HO
1.19
P
O
O
OH
POP
O
OH
O
HO
OH
N
N N
NH2
O O
 
Figure I.6 
1.3.3 Structure 
1.3.3.1 Thymidine Kinase 2 
Human thymidine kinase 2 was cloned in the 1990s by two independent research groups.8 It is a dimer 
of 58 kDa compromising a mitochondrial targeting signal. On the basis of its amino acid sequence, TK-
2 belongs to a large group of dNKs that includes other human enzymes such as deoxycytidine kinase 
and deoxyguanosine kinase, together with other dNKs of different origins, such as the multisubstrate 
dNK of the fruitfly, Drosophila melanogaster, and to a lesser extent, the thymidine kinase of herpes 
simplex virus type 1 (HSV-1 TK).6 The amino acid sequence identity between human TK-2 and Dm-
dNK is about 40% and there are no long insertions or deletions in their genes.  
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There are no crystal structures reported for TK-2. Therefore, efforts have been made to build a reliable 
model of the enzyme. Because of its high sequence identity with TK-2, Dm-dNK has been used as a 
template to construct a homology model of TK-2 (Figure I.7).6,24,25,26  
 
 
 
 
Figure I.7. Homology model of TK-2 monomeric subunit. Active-site residues are 
shown as sticks and colored green.26 
 
Two amino acid sequence motifs that are common to several nucleotide kinases of the same family 
are present in TK-2: 
 
- a conserved -GXXGXGKS/TT- sequence that corresponds to a glycine-rich loop found among 
ATP/GTP binding proteins. This motif forms a turn without hydrogen bonds, also known as the 
P-loop, which accommodates the γ-phosphate of ATP, 
 
- an arginine rich region that function as a LID for the active site cleft. The consensus sequence 
-RXXXRXRXXE- forms a turn with several hydrogen bonds. 
 
 
  
 
LID region 
P-loop 
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1.3.3.2 Thymidine Kinase 1 
Thymidine kinase 1 is a tetramer of ~100 kDa.27,28 It only shares significant sequence similarity with 
other deoxyribonucleoside kinases at the N-terminus within the P-loop, which binds the phosphate 
donor. The recently determined structure reveals that tetrameric TK-1 has a completely different 
overall monomer structure than other dNKs (Figure. I.8). 
 
 
 
Figure I.8. Overall monomer structure of human TK-1 with dTTP.29 
1.3.4 Mechanism of Action 
The generally accepted mechanism for the phosphorylation reaction catalyzed by dNK is depicted in 
figure I.9. Activation of the 5’-OH of the deoxyribose is required in order to make a nucleophilic attack 
on the γ-phosphate of the phosphate donor. The Glu carboxylate close to the 5’-OH in the active site 
was suggested to act as a base in this deprotonation reaction. The transition state may be stabilized 
by a Mg2+-ion and arginines and lysines that commonly occur at the catalytic sites of dNKs.30,31,32  
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Figure I.9. General reaction mechanism for phosphate transfer as catalyzed by dNKs. Because of its high 
abundance ATP is considered as the preferred biological phosphate donor.6 
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1.4 THE ROLE OF TK-2 
1.4.1 mtDNA Synthesis 
The synthesis of DNA requires a supply of deoxyribonucleotides. In eukaryotic cells the bulk of DNA is 
located in the nucleus and is replicated once during the S phase. Terminally differentiated cells or 
resting cells in culture only rarely or never replicate DNA and their de novo synthesis of dNTPs is shut 
down. In addition to nuclear DNA, eukaryotic cells also contain mitochondrial DNA (mtDNA) that 
represents ~ 5% of the total cellular DNA.33 mtDNA replication occurs during all phases of the cell 
cycle, even in postmitotic cells in which nuclear DNA synthesis has ceased. The measured half-life of 
mtDNA in mammalian cells is 10-30 days.34 Without the ongoing process of mitochondrial DNA 
replication, mtDNA depletion occurs rapidly, eventually disrupting the production of ATP and causing 
failure of cell function. 
 
A mitochondrion is surrounded by a double membrane defining two separate compartments within the 
organelle: the intermembrane space between the outer and inner membranes and the matrix space 
within the inner membrane. The mtDNA molecules are located within the matrix space. The outer 
membrane is highly porous to all nucleosides and nucleotides. Therefore, it is considered that the 
intermembrane space is in equilibrium with the cell cytoplasm. The mitochondrial inner membrane is 
highly impermeable to solutes, but it contains specific transporters to provide the precursors needed 
for mtDNA synthesis (Figure I.10). The inner membrane contains at least two proteins that transport 
DNA precursors into the mitochondrial matrix: the deoxynucleotide carrier (DNC) and an equilibrative 
nucleoside transporter (ENT). ENT carries nucleosides where DNC transports deoxynucleoside 
diphosphates into the mitochondrial matrix in exchange for ADP or ATP.35 The DNC also transports 
deoxynucleoside triphosphates, but less efficiently than dNDPs.36  
 
 
 
Figure I.10. General deoxynucleotide metabolism in a mitochondrion.36 
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So, the mitochondrial deoxynucleotide metabolism is connected to cytoplasmic deoxynucleotide 
metabolism at both ends of the phosphorylation process: at the deoxynucleoside level (via ENT) and 
at the diphosphate and triphosphate levels (via DNC).  
 
Once transported into the mitochondrial matrix space, deoxynucleosides must be phosphorylated to 
the triphosphate form to be incorporated into mtDNA. Two irreversible enzymes, deoxyguanosine 
kinase for purines and TK-2 for pyrimidines, catalyze the first phosphorylation step.6 In addition, 
mitochondrial nucleotidase enzymes remove the phosphate group form dNMP molecules. Separate 
reversible nucleoside monophosphate kinases for dAMP, dCMP, dGMP and dTMP are believed to 
exist to catalyze the second phosphorylation step. The final phosphorylation uses the reversible 
nucleoside diphosphate kinase enzymes for all dNDP. 
 
After phosphorylation, dNTPs will be incorporated into a growing mtDNA strand. Synthesis of mtDNA 
is catalyzed by DNA polymerase γ. The action of Pol-γ occurs in two stages. The polymerase inserts a 
nucleotide into the growing mtDNA strand followed by proofreading in which incorrect nucleotides can 
be excised by the exonuclease domain of Pol-γ. This exonuclease activity is important to ensure the 
fidelity of mtDNA replication.36,37 
1.4.2 TK-2 Deficiency 
1.4.2.1 General 
In healthy tissues, mitochondria contain two separate potential pathways to provide thymidine 
triphosphate for mtDNA replication: (1) deoxynucleotide transporters in the membrane introduce dTDP 
and dTTP from the cytosol and (2) equilibrative nucleoside transporters bring thymidine into the matrix. 
Phosphorylation of thymidine using TK-2 will provide dTMP which is further phosphorylated to dTTP 
using NMPK and NDPK (Figure I.11).38,39  
 
 
 
Figure I.11. Two pathways for dTTP: 1) 
import of nucleotides synthesized in the 
cytosol; 2) import of thymidine followed by 
intra-mitochondrial phosphorylation. cdN = 
cytosolic 5’-deoxyribonucleotidase, mdN = 
mitochondrial 5’-deoxyribonucleotidase. 
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Depending on the cell type and the cell cycle phase, one or both pathways will occur. In replicating 
cells both processes exist and as a result, a dysfunction of TK-2 will not necessarily cause a lot of 
damage because mitochondria can use cytosolic dTDP/dTTP for the synthesis of mtDNA.  
 
In non-replicating cells, cytosolic dNTP synthesis is down regulated, and substrates for mtDNA 
synthesis should normally derive from the mitochondrial salvage pathway in which TK-2 plays an 
important role (pathway 2). In this case, TK-2 defiency will lead to a decreased level of mtDNA causing 
fatal myopathy due to impaired respiratory chain function.  
1.4.2.2 Mitochondrial Depletion Syndrome (MDS) 
Mitochondrial DNA depletion syndrome is a devastating disorder that was first described in 1991.40 
Unlike other mitochondrial diseases, MDS is characterized by a quantitative, rather than qualitative, 
defect of mtDNA. Affected tissues have a markedly reduced number of mtDNA copies which impairs 
the synthesis of respiratory chain components. MDS can be tissue-specific or multisystemic,41 and is 
inherent as an autosomal recessive trait. In late 2001, mutations in 2 nuclear genes were identified in 
patients with MDS: changes in the deoxyguanosine kinase gene were identified in patients with the 
hepatocerebral form,42 and changes in the thymidine kinase 2 gene were associated with the 
myopathic form.43  
 
Patients with the myopathic form of MDS usually suffer from progressive weakness, hypotonia and 
areflexia soon after birth and die before 10 years of age as a result of decreased mtDNA levels. In 
tissues of patients with TK-2 mutations, the combined activities of the cytoplasmic TK-1 and dCK could 
normally compensate for the loss of TK-2. However, TK-1 is down regulated in non-replicative tissues 
and dCK has been reported to be low in liver and brain, rendering these tissues to the deleterious 
effect of TK-2 deficiency.44  
 
Intact mitochondrial DNA is required for the production of the key catalytic subunits for the 
mitochondrial respiratory chain complexes and therefore is essential for oxidative ATP-production. The 
energy metabolism during fetal life relies heavily on glycolysis, and even the severest functional 
defects of mitochondria typically manifest only after birth. The decrease in mtDNA inhibits the 
synthesis of adequate proteins that are essential for oxidative phosphorylation (OXPHOS). A 
disruption of OXPHOS leads to energy (ATP) loss and an increase in electron leakage from the 
electron-transport chain, which increases the production of reactive oxygen species. This increase 
damages proteins, lipids and mtDNA, setting off a cascade of further oxidative damage.45,46 
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1.4.2.3 AZT Toxicity 
mtDNA depletion may also occur as a secondary, iatrogenic phenomenon. For example, antiretroviral 
therapy with nucleoside analogues can affect the mtDNA synthesis, since these analogues may serve 
as a substrate for the host polymerases. This kind of mtDNA depletion, however, is transient and 
mtDNA levels recover to normal level upon termination of the treatment.45  
 
AZT (1.6) was the first nucleoside analogue approved to combat HIV, and continues to be a major 
component of HAART (highly active antiretroviral therapy), the currently accepted treatment for HIV 
infection.47 AZT is an analogue of the natural nucleoside thymidine, whereby the 3’-OH has been 
replaced by an azido group. AZT typically interacts with the same enzymes as dThd and follows the 
same metabolic pathways in the cell although with radically altered kinetic parameters. AZT itself is a 
prodrug. The pharmaceutically active form is the triphosphate, AZTTP. This can interact with DNA 
polymerases and can be incorporated into a replicating DNA strand in the place of thymidine 
triphosphate. The azido group prevents further replication of the DNA molecule, causing chain 
termination. The use of AZT and other nucleoside analogues does not completely destroy HIV, so life-
long HAART is mandated.37 
 
Specific tissue toxicities are associated with the prolonged use of AZT and other nucleoside 
analogues. Symptoms of AZT toxicity often include mitochondrial myopathy and cardiomyopathy with 
mtDNA depletion in patients, but other symptoms may occur. AZT also causes increased oxidative 
stress that may lead to mtDNA mutations. The exact mechanism by which AZT causes toxicity is not 
known.47  
 
It has been proposed that the AZT-related toxicities are the consequence of mitochondrial damage 
due to mitochondrial DNA depletion. Different mechanisms of AZT-related mitochondrial damage may 
be involved.48 The initial hypothesis postulated that the inhibition of DNA polymerase γ by AZT-
triphosphate leads to depletion of mtDNA and consequently to depletion of mitochondrial RNA and 
polypeptides involved in oxidative phosphorylation (‘DNA pol-γ hypothesis’).46,48 However, recently, 
some investigators disagree with this explanation, since they believe that the concentration of AZTTP 
required for efficiently inhibiting DNA polymerase γ is very difficult to achieve under physiological 
conditions.49,50 Therefore, it was proposed that the mechanism underlying mitochondrial toxicity may 
instead be related to the inhibition exerted by AZT on thymidine phosphorylation by TK-2. In non-
mitotic tissues like heart and liver, TK-2 is virtually the only enzyme able to phosphorylate thymidine. 
Studies performed in isolated heart and liver mitochondria have indeed shown that AZT exerts a 
competitive inhibition of thymidine phosphorylation by TK-2. Since TK-2 is the only TK enzyme in 
these organs and thymidine phosphorylation is competitively inhibited in the presence of AZT, dTTP 
pools are depleted resulting in a decrease of mtDNA. This mechanism of toxicity also provides a 
possible solution to overcoming AZT toxicity, namely by raising thymidine levels in the AZT-treated 
patient through exogenous dThd administration.50 
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1.5 TK-2 INHIBITORS 
1.5.1 Role of TK-2 Inhibitors 
From the above described features, it should be clear that TK-2 is implicated in the phosphorylation of 
pyrimidine nucleosides needed for mtDNA synthesis and could also be involved in the mitochondrial 
toxicity associated to antiviral nucleoside analogues. However, there are still many open questions 
related to the real contribution of TK-2 to these issues. Potent and selective TK-2 inhibitors could be 
valuable tools to unravel the role of TK-2 in mitochondrial dNTP pools and homeostasis, and may help 
to clarify the contribution of TK-2 catalyzed phosphorylation of antiviral drugs to the mitochondrial 
toxicity of these agents. Such inhibitors could also be helpful to investigate the activity of TK-1 and TK-
2 in different cell types.51  
 
On the other hand, potent and selective TK-2 inhibitors may become of potential practical use when 
added at subtoxic concentrations (that partially suppress TK-2 activity) in combination with antiviral 
and anticancer agents that display toxic side effects consequent to their activation by TK-2 in the 
mitochondrial environment.52 
1.5.2 Structure of TK-2 Inhibitors 
1.5.2.1 Ara-, Ribo- and 2’-Deoxyribonucleoside Analogues 
In 1999, several nucleoside analogues modified at the sugar moiety, including O-alkyl analogues were 
tested as substrates or inhibitors of TK-1 and TK-2.53 It was found that 3’-O-methyl- and 3’-O-ethyl-2’-
deoxyuridine (1.22 and 1.23) were between 20 and 100-fold more inhibitory to TK-2 than to TK-1, with 
Ki values of 15 and 10 μM, respectively. Even more pronounced was the inhibitory effect of 3’-
hexanoylamino-3’-deoxythymidine (1.24), with a more than 1000-fold higher affinity for TK-2 and a Ki 
value of 0.15 μM (Figure I.12).  
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Figure I.12 
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In 2000, several ribofuranosyl nucleosides were examined for TK-2 inhibition.52 In contrast to BVDU 
(1.10), which is an excellent substrate for TK-2, its ribo analogue (5-(E)-(2-bromovinyl)uridine, 1.25) 
was found to be an inhibitor of thymidine phosphorylation. Also, the 3’-spironucleoside 1.26 inhibited 
dThd phosphorylation by TK-2 with an IC50 of 4.6 μM (Figure I.13). Despite the presence of a free 5’-
OH, no phosphoryl transfer from [γ-32P]ATP to the 5’-position of these ribonucleosides was observed, 
confirming a direct inhibitory activity rather than an alternative substrate behavior of these compounds. 
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Figure I.13 
 
Arabinofuranosyl nucleosides have also been explored as TK-2 inhibitors. In 2001 Manfredini et al.54 
communicated the first compounds within this series, and a full report on these derivatives has 
recently been published.55 While Ara-T (1.8) is a good substrate for TK-2, introduction of a long chain 
acyl substituent (i.e., the decanoyl and dodecanoyl esters 1.27 and 1.28) at the 2’-OH shifted the 
nucleosides from substrates to inhibitors. By shortening the 2’-O-acyl chain to a pentanoyl moiety, or 
by replacing the acyl chain by an alkyl moiety, an important decrease in the inhibitory activity was 
observed.54,55 A similar approach has been applied to BVAraU (1.11) derivatives 1.29-1.30 (Figure 
I.14).  
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Figure I.14 
 
Interestingly, the above described 2’-O-acylderivatives are highly selective in inhibiting TK-2 catalyzed 
dThd-phosphorylation, while no inhibitory effect was detected against HSV-1 TK or Dm-dNK. 
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1.5.2.2 Acyclic Nucleoside Analogues 
This line of research started with the observation that 5’-O-(4,4’-dimethoxytrityl)thymidine (1.31) 
showed inhibitory activity against HSV-1 TK-catalyzed dThd phosphorylation (IC50 = 14 μM), while 
inhibition of TK-2 could only be achieved at a higher concentration (IC50 = 468 μM). Replacement of 
the acid labile dimethoxytrityl group by the more stable trityl analogue resulted in 5’-O-Tr-thymidine 
(1.32) (Figure I.15) that was a markedly more potent inhibitor against both enzymes, particularly 
against TK-2 (IC50 = 33 μM). In both compounds, the presence of the dimethoxytrityl group at the 5’-
position of thymidine converted the thymidine substrate into an inhibitor since both compounds lack a 
free available 5’-OH group susceptible of being phosphorylated by TK-2.56  
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Figure I.15 
 
On the basis of this observation, it was hypothesized that the role of the 2’-deoxyribose moiety in 
compounds 1.31 and 1.32 was to locate the thymine base and the trityl substituents in the right way to 
interact with the enzyme, which encouraged Pérez-Pérez et al. to replace the sugar moiety by acyclic 
spacers.56 These modifications were further accompanied by replacement of the thymine base by 
structurally related analogues and by exploration of the distal site with lipophilic groups different from 
the trityl present in the lead compounds 1.31 and 1.32.8  
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N
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1.34: X = H (Ki = 3.3 ± 1.2 µM)
1.35: X = OH (Ki = 3.6 ± 0.4 µM)
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Figure I.16 
 
Replacement of the 2’-deoxyribose moiety of 5’-O-trityl-β-D-thymidine (1.32) by a (Z)-butenyl spacer, 
as in compound 1.33, allowed a significant increase in the inhibitory activity against TK-2.56 However 
other spacers like (E)-butenyl or butynyl led to considerably less active molecules against TK-2. 
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Compounds with a four-member spacer but with increased conformational freedom as in 1.34 or 1.35, 
also showed potent TK-2 inhibition but were less selective vs. HSV-1 TK and Dm-dNK (Figure I.16). 
Therefore, the (Z)-butenyl spacer was kept present in most of the synthesized structures.51 
 
It was observed that, concerning the base part, the thymine base can be replaced by structurally 
related analogues like 5-iodouracil (1.36) without compromising the inhibitory activity. Interestingly, the 
5-(E)-(2-bromovinyl)uracil derivative (1.37) was equipotent with the thymine analogue against TK-2, 
but showed no inhibition of TK-1, HSV-1 TK or Dm-dNK, therefore becoming the most selective 
compound against TK-2 in this series (Figure I.17).57  
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Figure I.17 
 
When considering the distal substituent, alternatives to the trityl group have been explored including 
acyl groups, amines and carboxamides. The most potent molecules are presented in Figure I.18. 
Compound 1.41 emerged as the most potent TK-2 inhibitor in a series of thymine derived 
carboxamides with cyano and/or phenyl groups at the distal site.58 
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Figure I.18 
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In a last series of acyclic TK-2 inhibitors the thymine base is kept intact to allow interaction with the 
substrate binding site and connected to an O-trityl moiety via more flexible spacers of different lengths 
(e.g., -(CH2)3-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)3-O-(CH2)3-). These modifications have been 
combined with the incorporation of small substituents at position 4 of one of the phenyl rings of the 
trityl moiety as depicted in Figure I.19. It is interesting to note the strong relationship between the 
length of the spacer and the inhibitory activity against TK-2. Derivatives with short linkers afford TK-2 
inhibition at an IC50 around 45 μM, while those with intermediate length linkers afforded at least 10-fold 
better inhibitory values. The hexamethylene linker gave the highest inhibitory potency against TK-2 
with an IC50 of 0.50 μM. By replacement of one of the phenyl rings of the trityl by other aryl moieties, it 
is interesting to note that the 4-pyridyl derivatives keep similar activity as the parent trityl.24  
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2 SYNTHESIS AND BIOLOGICAL EVALUATION OF 3’-
TRIAZOLE-SUBSTITUTED THYMIDINE AND BVDU 
DERIVATIVES 
2.1 OBJECTIVES 
Two series of thymidine analogues that were originally designed as TMPKmt inhibitors, were 
evaluated for their inhibitory activity against a panel of other nucleoside kinases (TK-1, TK-2, herpes 
simples virus 1 and varicella zoster virus (VZV) TK). Several substituted 3’-thiourea derivatives of β-
dThd proved highly inhibitory to and selective for human mitochondrial TK-2 compared to related 
kinases. Compound 1.43 (Figure I.20), which emerged as the most potent analogue of this series, 
inhibited TK-2 at concentrations 2100-fold lower than those required to inhibit cytosolic TK-1 (IC50 for 
TK-1 = 316 μM; IC50 for TK-2 = 0.15 μM).59  
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Figure I.20 
 
Kinetic experiments indicated that this inhibitor specifically binds to the enzyme-ATP complex, and in 
consonance with this finding, molecular modeling studies suggested that the nitrogen atoms of the 
thiourea group of 1.43 could interact favorably with the oxygens of the γ-phosphate of the cosubstrate 
ATP. As it was demonstrated that the 3’-substituent of 1.43 and related analogues was responsible for 
extra interactions with TK-2 (after binding of the ATP phosphoryl donor), we decided to investigate if 
the thiourea moiety, earlier described as the perpetrator of toxicity,60 could be replaced by alternative 
linkages to connect the C-3’ atom of the deoxyribose moiety to several substituents.  
 
In this chapter, we explore thymidine analogues containing a triazole ring instead of the thiourea 
moiety. Because of its synthetic convenience and the accessibility of AZT as the azide precursor, we 
decided to apply “click chemistry“ reactions to synthesize a series of 3’-(1,2,3-triazol-1-yl) analogues of 
dThd. It should be noted that, in search for new antivirals resembling AZT, Wigerinck et al. already 
reported 3’-triazole thymidine analogues in 1989.61 However, at that time, these were obtained by 
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classical (thermal) Huisgen reaction conditions62 (i.e., in the absence of a Cu+ catalyst), which 
generally resulted in mixtures of the 1,4- and the 1,5-regioisomers that are not always easy to 
separate by classical chromatographic procedures. 
 
As a further extension of this study, we also wanted to explore the effect of analogues that combined a 
favorable 3’-(4-substituted-1,2,3-triazole) moiety with a (E)-5-(2-bromovinyl)-substituent, known as a 
privileged scaffold for TK-2 binding (cf. infra). 
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2.2 CHEMISTRY 
2.2.1 Synthesis of 3’-Triazole-Substituted Thymidine Analogues  
The synthesis of 3’-triazole-substituted thymidine analogues is based on the Huisgen [3+2] 
cycloaddition of an organic azide and a terminal alkyne.63,64 Although AZT (1.6), acting as azide 
precursor, is commercially available, it can be synthesized quite easily and in a minimum of steps 
starting form β-D-thymidine (1.1). We adapted Glinski’s synthetic procedure65 which started with the 
protection of 5’-OH followed by mesylation of the 3’ hydroxyl group as depicted in Scheme I.1. 
Treatment of the 5’-tritylated derivative of 3’-O-mesyl-thymidine (1.45) with DBU and opening of the 
anhydro derivative 1.46 with NaN3 in DMF afforded azidonucleoside 1.47, which was deprotected 
under acidic conditions.66  
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Scheme I.1. Reagents and conditions: (a) trityl chloride, pyridine, 65 °C, overnight, 100%; (b) MsCl, pyridine, 0 
°C, 3 h; (c) DBU, CH3CN, reflux, overnight, 88% over 2 steps; (d) NaN3, DMF, reflux, overnight, 87%; (e) 
CH3COOH 80%, 90 °C, 25 min, 62%. 
 
AZT (1.6) was converted into the 1,4-disubstituted 1,2,3-triazoles 1.48-1.55 using different alkynes in 
the presence of copper(II) sulfate and sodium ascorbate.67 The isomeric 1,5-disubstituted 1,2,3-
triazoles 1.56 and 1.57 were obtained in moderate yield upon reaction of AZT with the appropriate 
alkynes in the presence of [Cp*RuCl(PPh3)2].68 
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1.48: R = H 
1.49: R = butyl
1.50: R = phenyl
1.51: R = benzyl
1.52: R = cyclopentylmethyl
1.53: R = 4-chlorophenyl
1.54: R = 3,4-dichlorophenyl
1.55: R = 2-pyridinyl
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Scheme I.2. Reagents and conditions: (a) (i) trimethylsilylacetylene, CuSO4.5H2O, sodium ascorbate, 
H2O/tBuOH (1:1), 45 °C, 24 h; (ii) 1M TBAF in THF, rt, overnight, 40% over 2 steps; (b) appropriate alkyne, 
CuSO4.5H2O, sodium ascorbate, H2O/tBuOH (1:1), rt, 24 h, 14-69%; (c) appropriate alkyne, Cp*RuCl(PPh3)2, 
THF, 65 °C, 8 h, 20-29%. 
 
Unambiguous assignment of the substitution pattern of the triazole moiety of isomers 1.50 and 1.56 
could be inferred from comparison of their 13C NMR spectra with that of the monosubstituted triazole 
1.48 (Table I.1). In the case of 1.50, the largest resonance shift is found for the C-4” (13.0 ppm), while 
the shift for C-5” is relatively weak and has the sign changed (-3.5 ppm). An opposite phenomenon is 
observed for 1.56, where these shifts are 4.7 ppm for C-4” and 8.7 ppm for C-5”. The observed 
downfield shifts of the substituted carbon atoms is expected given the electron withdrawing nature of 
the phenyl ring.  
 
Table I.1. 13C-NMR data of the triazole moieties of 1.48, 1.50 and 1.56. 
 
Compound C-4” C-5” 
1.48 133.57 124.49 
1.50 146.57 121.01 
1.56 138.22 133.16 
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2.2.2 Synthesis of 5’-O-Protected Isothiocyanate Analogue 1.59 
5’-O-Protected isothiocyanate 1.59 was prepared from its 3’-azido counterpart 1.47 by catalytic 
hydrogenation of the azido group in the presence of Pd/C, followed by treatment with 4-chloro-3-
(trifluoromethyl)phenyl isothiocyanate in DMF (Scheme I.3).69 
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Scheme I.3. Reagents and conditions: (a) H2, Pd/C, MeOH, rt, 5 h, 73%; (b) 4-chloro-3-(trifluoromethyl)phenyl 
isothiocyanate, DMF, 0 °C, 3 h, 98%. 
2.2.3 Synthesis of 3’-Triazole-Substituted BVDU Analogues  
The synthesis of the 5-(E)-(2-bromovinyl) analogues is depicted in Scheme I.4. After tritylation of the 5’ 
hydroxyl group of BVDU (1.10), the corresponding 2,3’-O-anhydro intermediate 1.62 was prepared by 
consecutive mesylation and treatment of the mesylate with Et3N in EtOH. Treatment of 1.62 with 
sodium azide in the presence of p-nitrophenol70 and detritylation afforded azido derivative 1.64, which 
was converted to the 1,4-triazoles 1.65-1.66 under “click” conditions. 
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1.10 1.60
1.65: R = phenyl
1.66: R = 4-chlorophenyl
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Scheme I.4. Reagents and conditions: (a) TrCl, pyridine, 65 °C, overnight, 65%; (b) MsCl, pyridine, 0 °C, 2 h; 
(c) Et3N, EtOH, reflux, overnight, 75% over 2 steps; (d) NaN3, p-NO2-phenol, DMF, 110 °C, 7 h, 79%; (e) ZnBr2, 
CH2Cl2/iPrOH (85:15), rt, overnight, 90%; (f) appropriate alkyne, CuSO4∙5H2O, sodium ascorbate, H2O/tBuOH 
(1:1), rt, 24 h, 6%. 
 
Conversion of 1.62 into the corresponding azide using the same conditions as described for the 
synthesis of the 3’-triazole-substituted dThd analogs (NaN3, DMF, reflux, overnight) resulted in a new 
derivative, which was identified as 1.67 (Scheme I.5). The structural assignment of this compound. 
was based on a downfield shift of the 13C NMR resonance signal from C-8 (110 → 145 ppm) which 
was in agreement with the reported signal of a similar reported derivative.71 Mass spectroscopy 
confirmed the absence of the bromine atom by the disappearance of the typical 1:1 isotope peaks of 
Br as seen in compound 1.62. 
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Scheme I.5. Reagents and conditions: (a) NaN3, DMF, reflux, overnight, 54%; (b) ZnBr2, CH2Cl2/iPrOH (85:15), 
rt, overnight, 39%. 
 
Compound 1.67 appeared to be formed by the nucleophilic displacement of bromine by a negatively 
charged oxygen at the C-4 of the pyrimidine ring (intermediate III, Scheme I.5). This nucleophilic 
displacement has been previously observed by Jones and coworkers in the treatment of 5-(2-
bromovinyl)uracil with potassium tert-butoxide.71 To avoid the formation of 1.67, stabilization of the 
negative charge at N3 was necessary (intermediate II). Therefore a compound with a pKa lower than 
the pyrimidine base (pKa between 9-10) was added to the reaction mixture. Opening of anhydro 1.62 
in the presence of NaN3 and p-nitrophenol (pKa 7.15) successfully prevented formation of 1.67 and 
gave azide 1.63 in good yield.70 
2.3 BIOLOGICAL EVALUATION 
The 3’-triazole-substituted dThd and BVDU derivatives were evaluated for their inhibitory activity 
against dThd phosphorylation by recombinant purified human cytosolic TK-1, human mitochondrial 
TK-2, HSV-1 TK, VZV TK, and Dm-dNK under the guidance of Prof. Dr. Jan Balzarini at the 
Laboratory of Virology and Chemotherapy, Rega Institute, K.U.Leuven.  
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Table I.2. Inhibitory effects of thymidine and BVDU analogues on 1 μM [CH3-3H]dThd phosphorylation by 
deoxyribonucleoside kinases from different origins 
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Compd R1 R2 
IC50a (µM) 
TK-1 TK-2 HSV-1 TK VZV TK Dm-dNK 
1.48 H H ≥ 500 4.7 ± 2.1 212 ± 17 15 ± 5 40 ± 1 
1.49 n-Bu H 366 ± 4 0.23 ± 0.05 95 ± 1 4.3 ± 0.3 4.1 ± 0.8 
1.50 Ph H 54 ± 16 0.32 ± 0.01 28 ± 6 2.5 ± 0.3 2.2 ± 0.8 
1.51 -CH2-Ph H 318 ± 110 0.30 ± 0.12 158 ± 42 6.4 ± 4.0 3.9 ± 0.6 
1.52 -CH2-c-pentyl H 177 ± 182 0.15 ± 0.02 48 ± 2 3.1 ± 0.2 3.0 ± 0.4 
1.53 4-Cl-Ph H 71 ± 0 0.046 ± 0.002 27 ± 5 3.3 ± 0.2 1.8 ± 0.9 
1.54 3,4-diCl2Ph H 75 ± 49 0.042 ± 0.008 30 ± 2 2.7 ± 0.3 0.99 ± 0.53 
1.55 2-pyridinyl H 316 ± 17 1.3 ± 0.4 46 ± 1 3.1 ± 0.2 3.8 ± 0.1 
1.56 H Ph ≥ 500 1.1 ± 0.6 445 ± 78 19 ± 3 17 ± 0 
1.57 H 4-Cl-Ph 109 ± 79 4.0 ± 0.0 392 ± 18 30 ± 0 30 ± 4 
1.59 - - > 500 > 500 > 500 > 500 > 500 
1.65 Ph - > 500 0.25 ±0.09 36 ± 6 3.7 ± 0.5 2.9 ± 0.8 
1.66 4-Cl-Ph - > 500 0.036 ± 0.003 4.5 ± 0.6 1.7 ± 0.4 0.46 ± 0.06 
1.68 - - > 500 354 ± 11 > 500 162 ± 81 107 ± 65 
1.43   316 ± 1.2 0.15 ± 0.01 195 ± 54 24 ± 3.0 - 
1.6   52 4 - - 1.1 ± 0.37,23 
aIC50 is the 50% inhibitory concentration of the test compounds, which was measured as the concentration 
required to inhibit 1 μM [CH3-3H]dThd phosphorylation by 50%. The Km values of TK-1, TK-2, HSV-1 TK, VZV TK, 
and Dm-dNK for the natural substrate dThd were 2.3, 1.1, 1.44, 3.4, and 3.5 μM, respectively. 
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Compound 1.43 and AZT (1.6), were included as references. In the 1,4-triazole series, the anti-TK-2 
activity was clearly influenced by the nature of the substituent at C-4 of the triazole. Both a n-butyl 
(1.49) or phenyl (1.50) substituent gave submicromolar inhibition. Introduction of a -CH2- group 
between the triazole and the phenyl (1.51) did not drastically alter the IC50 value, while replacement of 
the benzyl by a cyclopentylmethyl substituent (1.52) caused a 2-fold drop in IC50. Introduction of an 
electron-withdrawing Cl in the para position of the phenyl (1.53) significantly improved the inhibitory 
activity. A similar effect had previously been observed in the thiourea series.59 Remarkably, this 
increased activity could not be obtained with an electron-deficient pyridin-2-yl substituent (1.55). With 
analogues 1.56 and 1.57, which are regioisomers of 1.50 and 1.53, we could infer that the 4-position is 
the preferred site for triazole derivatization. 
 
Introduction of an additional 5-(2-bromovinyl) group, known to be a privileged substituent for TK-2 
binding, only slightly improved the inhibitory activity but caused a significant increase in the selectivity 
for TK-2 versus TK-1 as seen from the complete lack of inhibitory effect against TK-1-catalyzed dThd 
phosphorylation. Compound 1.66 showed an outstanding selectivity against TK-2 when compared to 
TK-1 (SI ≥ 14000), and is one of the most potent inhibitor of TK-2 (IC50 of 0.036 μM) reported so far. 
Because the Km values of the natural substrate dThd for TK-1 (2.3 μM) and TK-2 (1.1 μM) were very 
similar and the IC50 values of the inhibitors were determined in the presence of 1 μM dThd, the IC50 
values of the different inhibitors fairly reflect the degree of affinity of these compounds for both 
enzymes. In addition, 1.66 showed relatively poor inhibitory activity against the closely related HSV-1 
and VZV TKs.  
 
The mode of TK-2 inhibition by 1.66 was investigated (Figure I.21). First, its Ki value was determined 
in the presence of a fixed saturating concentration of ATP and variable concentrations of the dThd 
substrate. This revealed that 1.66 inhibited the enzyme in a purely competitive fashion and had Ki 
values as low as 0.012 μM. Its Ki/Km ratios were markedly lower than 1 (0.011), pointing to an affinity 
for the enzyme that largely exceeds the affinity of the natural substrate. Second, the Ki values of this 
inhibitor were also determined in the presence of a fixed saturating concentration of dThd and variable 
concentrations of the cosubstrate ATP. Compound 1.66 showed a Ki value that was higher (0.41 μM) 
than that observed in the presence of dThd as the variable substrate. However, the Ki/Km ratio was 
again much lower than 1 (0.019). Interestingly, under these conditions, 1.66 behaved kinetically 
differently and displayed an uncompetitive mechanism of enzyme inhibition, as revealed by the 
(virtually) parallel kinetic lines in the Lineweaver-Burk plots. These features point toward a specific 
binding of the inhibitor to an enzyme-ATP complex. Compound 1.59 was synthesized to assess the 
compatibility of combining the thiourea moiety of 1.43 with a 5’-O-trityl group. Combination of the 3’-
modification and the 5’-O-trityl substituent led, as expected, to an analogue that was completely 
devoid of affinity for TK-2. Also for compound 1.68, a very weak inhibitory activity was observed (IC50 
= 354 ± 11 μM). 
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Figure I.21. Kinetics of 1.66 against purified recombinant mitochondrial TK-2. 
2.4 MOLECULAR MODELING AND STRUCTURE-ACTIVITY 
RELATIONSHIP 
To gain insight into the mode of binding of this new class of inhibitors, docking experiments were 
performed under the supervision of Prof. Dr. Federico Gago at the Centre for Computational Drug 
Discovery in Madrid, using a previously reported homology-based model of TK-2 as the target.59 This 
model is largely, but not exclusively, based on many similarities with the well-characterized structure of 
Dm-dNK although relatively major uncertainties remain. 
 
As previously proposed for 1.43 and related thiourea derived inhibitors,59 the thymine ring of β-
thymidine containing compounds can stack on the phenyl ring of Phe143, whereas O4 and N3 atoms 
are held in place by virtue of two highly directional hydrogen bonds with the carboxamide group of 
Gln110 (equivalent to Gln81 in Dm-dNK). On the other hand, a free 5’-hydroxyl of a nucleosidic ligand 
can be hydrogen bonded by the guanidinium nitrogen of Arg134 and the carboxylate of Glu81, whose 
equivalent residues in Dm-dNK have been shown to be crucial for the phosphoryl transfer reaction.72 
Thus, on the basis of the results from multiple sequence alignments (Figure I.22) and the homology-
built model presented herein, Glu81 in TK-2 most likely acts as the base that deprotonates the 5’-OH 
of thymidine, whereas Arg134 plays a crucial role in the stabilization of the transition state during the 
phosphoryl transfer reaction. 
 
Taking all TK-2’s conformational features into account, the best docking solution for 1.53, supported 
and refined by subsequent molecular dynamics (MD) simulation in water, suggests that the thymidine 
moiety of this inhibitor fills the same volume that is usually occupied by the substrate thus giving rise to 
the same interactions as reported for thymidine (Figure I.23).73 
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Figure I.22. Multiple sequence alignment (Clustal 2.0.10) and numbering of human TK-2 (KITM_HUMAN), related 
mitochondrial kinases and Dm-dNK (DNK_DROME). Residues discussed in the text are colored. Highlighted in 
grey is the LID loop region. 
 
The direct interaction between the triazole moiety and the γ-phosphate group of ATP that was 
envisioned at the outset of this project was not supported by the docking and simulation studies. 
Instead, the results strongly suggest that the triazole appears to displace the side chain of a tyrosine 
residue (Tyr99) that is involved in anchoring the 3’-OH of the substrate in the thymidine binding 
pocket. Relatively small readjustments allow the triazole N-2 atom to hydrogen bond the carboxylate of 
Glu200 from the LID loop through the intervention of a bridging water molecule that is also hydrogen-
bonded to the side chain of Arg198. This orientation allows the phenyl ring attached at position 4 of 
the triazole to occupy a hydrophobic cavity and increase the binding affinity. At this point it is worth 
noting that a 180 rotation of the triazole ring relative to the sugar would lead to a steric clash of the 
attached phenyl ring with the LID loop and also that this model does not favor substitution at position 5 
of the triazole ring, in good agreement with the much lower inhibitory activity measured for the 1,5-
substituted derivatives 1.56 and 1.57. On the contrary, this binding orientation is fully compatible with 
the modulation of the inhibitory activity upon introduction of substituents at position 4.  
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Interestingly, interaction with the carboxylate of Glu200 happens to be mediated by a bridging water 
molecule that is also bonded to Arg198. As these two residues are part of the LID loop, this 
arrangement can account for the fact that the loop is closed over the active site and therefore the ATP 
molecule can get trapped. 
 
It is important to highlight that the model provides an explanation to the 10-fold improvement in activity 
that is achieved upon incorporation of the phenyl ring to the unsubstituted triazole derivative 1.48. The 
phenyl ring in 1.53 is proposed to make van der Waals interactions with Val203 and Ile204 within the 
VIPLEY sequence that immediately follows the LID loop so that these hydrophobic contacts can 
contribute to stabilization of the closed form of the enzyme. We are also aware that these proposed 
interactions are more favorable in TK-2 than those possible with the Cys and Val of CVPLKY in Dm-
dNK. Taken together, sequence differences at these positions can account for the better inhibition of 
human TK-2 relative to Dm-dNK by the title compounds. It is also interesting to note that 1.65 and 
1.66, both containing a BVDU moiety in place of the thymine, are only marginally more potent than 
1.50 and 1.53, respectively, an observation that is in line with the facts that (i) the Km value of BVDU 
when used as a substrate for Dm-DNK is only ∼ 4-fold lower than that of AZT,68 (ii) the nucleobases 
binding site in Dm-DNK and human TK-2 are highly comparable, and (iii) AZT and BVDU binding to 
Dm-dNK show similar characteristics, as inferred from comparison of PDB structures 2JJ8 and 2VQS. 
Finally, our finding that a 5’-O-trityl substituent renders the inhibitors in the present series inactive is 
also consistent with the proposed binding mode insofar as the 5’-hydroxyl is used, as described above 
and reported previously for thiourea-derived inhibitors,59 to anchor the inhibitor in the substrate binding 
site through hydrogen bonding interactions with the catalytically important Arg134 and Glu81.  
 
 
Figure I.23. Proposed binding mode 
for inhibitor 1.53 (C atoms in cyan), in 
the active site of human TK-2 (green 
ribbon). ATP is shown as sticks, with 
C atoms colored in orange, and Mg2+ 
is displayed as a semitransparent 
sphere colored in magenta. Some of 
the protein side-chains relevant to the 
discussion are labeled and shown as 
sticks. Note the “close” conformation 
of the lid loop that normally covers the 
substrate-binding cleft during 
catalysis and the water molecule that 
bridges the interaction between the 
triazole of the inhibitor and the 
carboxylate of Glu200. 
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To reveal whether the TK-2 inhibitors are able to be taken up by the cells, Balzarini et al. chose the 
most active compound 1.66 for further studies. Because of the lack of TK-2 gene-transduced tumor 
cells, human osteosarcoma cells (OST TK-) were used that were transfected with the Drosophila 
melanogaster multifunctional deoxynucleoside kinase gene (OST TK-/Dm-dNK+). Alike TK-2, the Dm-
dNK enzyme is sensitive to the inhibitory activity of compound 1.66 at an IC50 of 0.46 μM (Table I.2). 
The cytostatic agents (E)-5-(2-bromovinyl)-2’-deoxyuridine (BVDU, 1.10) and 5-fluoro-2’-deoyxuridine 
(5FdUrd, 1.69, Figure I.24) were exposed to these cell cultures in the presence or absence of 1.66 
(used at subtoxic concentrations (10 μM and 4 μM)) (Table I.3). Whereas BVDU and 5FdUrd were 
cytostatic at an IC50 of 0.76 and 0.066 μM, respectively, their antiproliferative effect was significantly 
(4-fold) decreased in the presence of 1.66 at 10 μM (IC50: 2.95 and 0.263 μM, respectively) and at 4 
μM (IC50: 1.64 and 0.110 μM, respectively). The conversion of BVDU and 5FdUrd to their toxic 
metabolites by Dm-dNK could be dose-dependently blocked by 80% in the presence of the TK-2 (Dm-
dNK) inhibitor under the experimental conditions. These data revealed that the TK-2 inhibitors such as 
1.66 can enter the intact tumor cells and be inhibitory to the nucleoside kinase present in the cytosol. It 
would now be imperative to investigate whether these compounds are also taken up by mitochondria 
after their penetration into the intact cells, enabling targeting TK-2 in the mitochondrial environment. 
 
O N
HO
HO
H
NO O
F
1.69  
 
Figure I. 24 
 
Table I.3. Cytostatic Activity of BVDU and 5FdUrd against Dm-dNK expressing OST TK-/Dm-dNK+ cells in the 
absence or presence of compound 1.66. 
 
Compound 
IC50a (μM) 
 Compound 1.66 
As such 4 μM 10 μM 
BVDU (1.10) 0.76 ± 0.001 1.64 ± 0.07 2.95 ± 0.96 
5FdUrd (1.69) 0.066 ± 0.003 0.110 ± 0.035 0.263 ± 0.104 
a50% Inhibitory concentration or compound concentration required to inhibit OST TK-/dNK+ cell proliferation by 
50%. Data are the mean ± SD of two independent experiments. The IC50 of compound 1.66 as such is 23 ± 15 
μM. 
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2.5 PHOTOPHYSICAL EVALUATION 
In 2004, Berry and co-workers reported a series of pyrimidines fused to furano and pyrrolo moieties to 
produce fluorescent analogs of thymidine and 2’-deoxycytidine to study DNA structure.74 Additionally, 
Li et al. reported the synthesis of fluorescent nucleoside analogs with modified sugar moieties (e.g., 
sugars other than ribose and 2’-deoxyribose).75 All these compounds represent promising tools for 
studying nucleoside metabolism inside living cells, including cellular uptake and phosphorylation 
(Figure I.25).  
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Figure I.25. Nucleoside analogs with fluorescent properties 
 
Based on the structural similarity between compound 1.68 and the reported nucleoside analogs 1.70-
1.76, the fluorescence properties of azide 1.68 were determined at the Laboratory of General 
Biochemistry and Physical Pharmacy (UGent) and found to be similar to previously reported analogs 
having excitation wavelengths of 322 ± 2 nm and emission maxima ranging from 413 - 415 nm (Figure 
I.26). 
 
 
 
 
 
 
 
 
 
 
 
Figure I.26. Excitation and emission spectrum of compound 1.68. 
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2.6 CONCLUSIONS 
Cycloaddition of organic azides and alkynes is the most direct route to 1,2,3-triazoles. In this chapter, 
we used two different catalysts to achieve this reaction: the Cu(I) catalyst, which provided the 1,4-
disubstituted 1,2,3-triazole regioisomers, and the [Cp*RuClP(Ph3)2] catalyst, which has recently been 
described for regioselective synthesis of 1,5-disubstituted 1,2,3-triazole systems. By replacing the 
thiourea linker of an earlier identified TK-2 inhibitor 1.43 by a 1,4-substituted triazole ring, we 
successfully generated a new generation of very potent TK-2 inhibitors. Combining such a favorable 
sugar modification with a bromovinyl substituent at position 5 of the pyrimidine moiety further 
enhanced the selectivity vis-à-vis TK-1. The direct interaction between the triazole moiety and the γ-
phosphate group of ATP that was envisioned at the outset of this project was not supported by the 
docking and simulation studies. Instead, it is proposed that the best inhibitors in this series stabilize, 
through a well-defined set of interactions, a closed conformation of the enzyme that traps an ATP 
molecule in the cofactor binding site. This binding mode provides a rationale to the biochemical 
evidence and an explanation to the structure-activity relationship in atomic detail. 
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2.7 EXPERIMENTAL PART 
2.7.1 Synthesis 
General 
 
All reagents were from standard commercial sources and of analytical grade. Precoated Merck silica 
gel F254 plates were purchased for TLC, spots were examined under ultraviolet light at 254 nm and 
further visualized by sulfuric acid-anisaldehyde spray. Column chromatography was performed on 
silica gel (63-200 μm, 60 Å, Biosolve, Valkenswaard, The Netherlands). NMR spectra were 
determined using a Varian Mercury 300 MHz spectrometer. Chemical shifts are given in ppm (δ) 
relative to the residual solvent signals, which in the case of DMSO-d6 were 2.54 ppm for 1H and 40.5 
ppm for 13C. Structural assignment was confirmed with COSY and DEPT. All signals assigned to 
hydroxyl groups were exchangeable with D2O. Exact mass measurements were performed on a 
Waters LCT Premier XETM Time of flight (TOF) mass spectrometer equipped with a standard 
electrospray ionization (ESI) and modular LockSpray TM interface. Samples were infused in a 
CH3CN/water (1:1) mixture at 10 μL/min. 
 
5’-O-Triphenylmethyl-β-D-thymidine (1.44) 
 
O N
TrO
HO
NH
O
O
 
 
To a solution of β-D-thymidine (2.50 g, 10.32 mmol) in anhydrous pyridine (24 mL) was added trityl 
chloride (3.37 g, 12.11 mmol). The mixture was heated to 65 °C and stirred overnight. Then it was 
diluted with CH2Cl2 (25 mL), washed with saturated aqueous NaHCO3 (3 x 50 mL), and dried over 
anhydrous MgSO4. The solvent was removed under reduced pressure and the resulting residue was 
purified by column chromatography (CH2Cl2/MeOH 98:2), affording compound 1.44 (5.27 g, 100%) as 
a white foam. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.47 (3H, d, J= 0.9 Hz, 5-CH3), 2.11-2.18 (1H, m, H-2’a), 2.21-2.30 
(1H, m, H-2’b), 3.17 (1H, dd, J= 3.0 Hz, J= 10.5 Hz, H-5’a), 3.24 (1H, dd, J= 4.8 Hz, J= 10.8 Hz, H-
5’b), 3.87 (1H, app q, J= 4.2 Hz, H-4’), 4.32 (1H, s, H-3’), 5.33 (1H, app s, 3’-OH), 6.21 (1H, app t, J= 
7.2 Hz, H-1’), 7.25-7.41 (15H, m, Tr), 7.49 (1H, d, J= 0.9 Hz, H-6), 11.33 (1H, s, 3-NH). 
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13C NMR (75 MHz, DMSO-d6): δ 12.45 (5-CH3), (C-2’ under DMSO-signal), 4.67 (C-5’), 71.12 (C-3’), 
84.40 (C-1’), 86.05 (C-4’), 87.07 (Tr), 110.25 (C-5), 127.86, 128.67 and 128.94 (Tr), 136.37 (C-6), 
144.17 (Tr), 151.06 (C-2), 164.34 (C-4). 
Exact Mass (ESI-MS) for C29H29N2O5 [M+H]+ found: 485.2054, calcd: 485.2071. 
 
2,3’-O-Anhydro-5’-O-triphenylmethyl-β-D-thymidine (1.46) 
 
O N
TrO
N O
O
 
 
To an ice-cooled solution of compound 1.44 (2.80 g, 5.79 mmol) in pyridine (15.5 mL) was added 
methanesulfonyl chloride (0.90 mL, 11.57 mmol). The reaction mixture was stirred for 3 hours at room 
temperature, quenched with NaHCO3 and extracted with CH2Cl2 (3 x 20 mL). The combined organic 
layers were dried over MgSO4 and evaporated to dryness. The residue was dissolved in 26 mL 
CH3CN and DBU (1.00 mL, 11.95 mmol) was added. After refluxing overnight, the mixture was 
evaporated to dryness and extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were dried 
over MgSO4 and evaporated to dryness. Further purification by column chromatography 
(CH2Cl2/MeOH 97:3) gave 2.38 g of compound 1.46 as a yellow, brownish foam (88%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.77 (3H, d, J= 1.2 Hz, 5-CH3), 2.47-2.60 (2H, m, H-2’a and H-2’b), 
3.06-3.16 (2H, m, H-5’a and H-5’b), 4.40-4.46 (1H, m, H-4’), 5.32 (1H, app s, H-3’), 5.88 (1H, app d, 
J= 3.5 Hz, H-1’), 7.21-7.39 (15H, m, Tr), 7.61 (1H, d, J= 1.2 Hz, H-6).  
   
13C NMR (75 MHz, DMSO-d6): δ 13.70 (5-CH3), 33.39 (C-2’), 63.19 (C-5’), 77.73 (C-3’), 84.12 (C-1’), 
87.03 (C-4’), 87.50 (Tr), 116.81 (C-5), 127.74, 128.59 and 128.86 (Tr), 137.36 (C-6), 143.95 (Tr), 
153.95 (C-2), 171.40 (C-4).  
 
Exact Mass (ESI-MS) for C29H29N2O4 [M+H]+ found: 467.1926, calcd: 467.1965. 
 
3’-Azido-3’-deoxy-5’-O-triphenylmethyl-β-D-thymidine (1.47) 
 
O N
TrO
N3
NH
O
O
 
 
A mixture of compound 1.46 (2.38 g, 5.10 mmol) and NaN3 (1.66 g, 25.50 mmol) was dissolved in 
DMF (8.5 mL) and heated to 150 °C. The reaction was refluxed overnight and then quenched with 
water (5 ml). The reaction mixture was extracted with CH2Cl2 (3 x 10 mL) and the combined organic 
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layers were dried over MgSO4 and evaporated to dryness. The residue was purified by column 
chromatography (CH2Cl2/MeOH 93:7), affording compound 1.47 as a yellow oil (87%, 2.80 g). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.56 (3H, d, J= 0.9 Hz, 5-CH3), 2.31-2.40 (1H, m, H-2’a), 2.46-2.55 
(1H, m, H-2’b), 3.25 (2H, d, J= 3.6 Hz, H-5’a and H-5’b), 3.85-3.90 (1H, m, H-4’), 4.55-4.62 (1H, m, H-
3’), 6.13 (1H, dd, J= 5.7 Hz en J= 7.2 Hz, H-1’), 7.23-7.42 (15H, m, Tr), 7.52 (1H, d, J= 1.2 Hz, H-6), 
11.36 (1H, s, 3-NH). The spectrum is accordance with the literature report.76 
 
13C NMR (75 MHz, DMSO-d6): δ 12.57 (5-CH3), 36.66 (C-2’), 60.41 (C-3’), 63.82 (C-5’), 82.63 (C-1’), 
83.99 (C-4’), 87.19 (Tr), 110.42 (C-5), 127.91, 128.70 and 128.94 (Tr), 136.56 (C-6), 144.06 (Tr), 
151.05 (C-2), 164.35 (C-4). 
 
Exact Mass (ESI-MS) for C29H28N5O4 [M+H]+ found: 210.2138, calcd: 210.2136. 
 
3’-Azido-3’-deoxy-β-D-thymidine (1.6) 
 
O N
HO
N3
NH
O
O
 
 
A suspension of compound 1.47 (1.13 g, 2.21 mmol) in 23 mL of 80% aqueous acetic acid was heated 
at 90 °C with stirring for 25 minutes. The solution was evaporated in vacuo and the residue was 
purified on a silica column (CH2Cl2/MeOH 95:5) affording 364 mg of crude 1.6 as light brown crystals 
(62%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.87 (3H, s, 5-CH3), 2.19-2.38 (2H, m, H-2’a and H-2’b), 3.36-3.63 
(2H, m, H-5’a and H-5’b), 3.79 (1H, app q, J= 4.2 Hz, H-4’), 4.32-4.38 (1H, m, H-3’), 5.26 (1H, t, J= 6.0 
Hz, 5’-OH), 6.05 (1H, t, J= 6 Hz, H-1’), 7.91 (1H, s, H-6), 11.29 (1H, s, 3-NH). The spectrum is 
accordance with the literature report.76 
 
13C NMR (75 MHz, DMSO-d6): δ 12.85 (CH3), 36.51 (C-2’), 55.48 (C-3’), 60.84 (C-5’), 84.09 (C-4’), 
84.61 (C-1’), 110.26 (C-5), 136.79 (C-6), 163.17 (C-2), 172.80 (C-4). 
 
Exact Mass (ESI-MS) for C10H14N5O4 [M+H]+ found: 268.1028, calcd: 268.10403. 
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3’-Deoxy-3’-(1,2,3-triazol-1-yl)-β-D-thymidine (1.48)  
 
O N
HO
N
NH
N
N
O
O
 
 
To a solution of trimethylsilylacetylene (85 μL, 0.59 mmol) in 3 mL of a H2O/tBuOH (1:1; v:v) mixture, 
was added sodium ascorbate (18 mg, 0.089 mmol) and CuSO4∙5H2O (11 mg, 0.044 mmol). The 
mixture was stirred for 15 min. Compound 1.6 (80 mg, 0.30 mmol) was added, and the resulting 
mixture was stirred at 45 °C for 24 h. The reaction mixture was washed with EtOAc (3 x 5 mL), and the 
combined organic phases were washed with water, dried over anhydrous Na2SO4, and evaporated to 
dryness. Without further purification, 1M TBAF in THF was added (1.2 mL) and the mixture was stirred 
at room temperature. After 16 h, TLC analysis revealed almost complete disappearance of all starting 
material. The solvent was evaporated and the mixture purified by column chromatography 
(EtOAc/MeOH, 100:0 → 95:5) yielding compound 1.48 as a white powder (35 mg, 40%).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.79 (3H, d, J=0.9 Hz, 5-CH3), 2.63-2.72 (2H, m, H-2’a and H-2’b), 
3.58-3.71 (2H, m, H-5’a and H-5’b), 4.17-4.21 (1H, m, H-4’), 5.21-5.32 (1H, m, 5’-OH), 5.37-5.39 (1H, 
m, H-3’), 6.41 (1H, app t, J= 6.3 Hz, H-1’), 7.78 (1H, d, J= 0.9 Hz, H-4”), 7.81 (1H, d, J= 1.2 Hz, H-6), 
8.30 (1H, d, J= 0.9 Hz, H-5”), 11.33 (1H, s, 3-NH).  
 
13C NMR (75 MHz, DMSO-d6): δ 12.27 (5-CH3), 37.22 (C-2’), 58.97 (C-5’), 60.72 (C-3’), 83.89 (C-1’), 
84.52 (C-4’), 109.63 (C-5), 124.49 (C-5”), 133.57 (C-4”), 136.26 (C-6), 150.45 (C-2), 163.74 (C-4). 
 
Exact Mass (ESI-MS) for C12H16N5O4 [M+H]+ found: 350.1820, calcd: 350.1823. 
 
General procedure for the synthesis of 4”-substituted 3’-deoxy-3’-(1,2,3-triazol-1-yl)-β-D-
thymidine derivatives 1.49-1.55 
 
Compound 1.6 (1 mmol, 1 equiv), sodium ascorbate (0.05 equiv), and CuSO4∙5H2O (0.04 equiv) were 
suspended in 10 mL of H2O/tBuOH (1:1). The appropriate alkyne (2 equiv) was added after 15 min, 
and the mixture was stirred at room temperature for 24 h. The reaction mixture was washed with 
CH2Cl2, and the combined organic phases were washed with water, dried over anhydrous MgSO4, and 
evaporated to dryness. The crude product was purified by column chromatography, affording the 
triazole in moderate yield. 
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3’-(4-Butyl-1,2,3-triazol-1-yl)-3’-deoxy-β-D-thymidine (1.49)  
 
O N
HO
N
NH
N
N
O
O
 
 
Reaction of compound 1.6 (66 mg, 0.24 mmol) with 1-hexyne (60 μL, 0.49 mmol) following the general 
procedure for the synthesis of 4”-substituted 3’-deoxy-3’-(1,2,3-triazol-1-yl)-β-D-thymidine derivatives 
gave compound 1.49 (47 mg, 55%) as a white powder.  
 
1H NMR (300 MHz, DMSO-d6): δ 0.90 (3H, t, J= 7.2 Hz, butyl), 1.24-1.40 (2H, m, butyl), 1.54-1.64 (2H, 
m, butyl), 1.79 (3H, d, J= 0.9 Hz, 5-CH3), 2.58-2.77 (4H, m, H-2’a, H-2’b and butyl), 3.53-3.72 (2H, m, 
H-5’a and H-5’b), 4.14-4.18 (1H, m, H-4’), 5.26-5.31 (2H, m, H-3’ and 5’-OH), 6.40 (1H, app t, J= 6.6 
Hz, H-1’), 7.81 (1H, d, J= 1.2 Hz, H-6), 8.04 (1H, s, H-5”), 11.33 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.26 (5-CH3), 13.71, 22.71, 24.70, and 31.03 (butyl), 37.12 (C-2’), 
58.95 (C-5’), 60.76 (C-3’), 83.88 (C-1’), 84.51 (C-4’), 109.63 (C-5), 121.39 (C-5”), 136.27 (C-6), 147.22 
(C-4”), 150.46 (C-2), 163.76 (C-4). 
 
Exact Mass (ESI-MS) for C16H24N5O4 [M+H]+ found: 350.1820, calcd: 350.1823. 
 
3’-Deoxy-3’-(4-phenyl-1,2,3-triazol-1-yl)-β-D-thymidine (1.50)  
 
O N
HO
N
NH
N
N
O
O
 
 
Reaction of compound 1.6 (50 mg, 0.19 mmol) with phenylacetylene (41 μL, 0.37 mmol) following the 
general procedure for the synthesis of 4”-substituted 3’-deoxy-3’-(1,2,3-triazol-1-yl)-β-D-thymidine 
derivatives afforded compound 1.50 in 72% yield (49 mg).  
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1H NMR (300 MHz, DMSO-d6): δ 1.82 (3H, d, J= 0.9 Hz, 5-CH3), 2.65-2.86 (2H, m, H-2’a and H-2’b), 
3.61-3.77 (2H, m, H-5’a and H-5’b), 4.27-4.31 (1H, m, H-4’), 5.31 (1H, app br s, 5’-OH), 5.38-5.45 (1H, 
m, H-3’), 6.46 (1H, app t, J= 6.3 Hz, H-1’), 7.33-7.38 (1H, m, Ph), 7.44-7.49 (2H, m, Ph), 7.85-7.88 
(3H, m, Ph and H-6), 8.78 (1H, s, H-5”), 11.36 (1H, s, 3-NH).  
 
13C NMR (75 MHz, DMSO-d6): δ 12.27 (5-CH3), 37.15 (C-2’), 59.37 (C-5’), 60.76 (C-3’), 83.90 (C-1’), 
84.43 (C-4’), 109.65 (C-5), 121.01 (C-5”), 125.17, 128.00, 128.95 and 130.58 (Ph), 136.26 (C-6), 
146.57 (C-4”), 150.46 (C-2), 163.75 (C-4).  
 
Exact Mass (ESI-MS) for C18H20N5O4 [M+H]+ found: 370.1517, calcd: 370.1510. 
 
3’-(4-Benzyl-1,2,3-triazol-1-yl)-3’-deoxy-β-D-thymidine (1.51)  
 
O N
HO
N
NH
N
N
O
O
 
 
Reaction of compound 1.6 (50 mg, 0.19 mmol) with 3-phenyl-1-propyne (58 μL, 0.47 mmol) following 
the general procedure for the synthesis of 4”-substituted 3’-deoxy-3’-(1,2,3-triazol-1-yl)-β-D-thymidine 
derivatives gave compound 1.51 (42 mg, 59%) as a white powder.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.80 (3H, d, J= 1.2 Hz, 5-CH3), 2.56-2.75 (2H, m, H-2’a and H-2’b), 
3.53-3.64 (2H, m, H-5’a and H-5’b), 4.00 (2H, s, Bn), 4.16-4.20 (1H, m, H-4’), 5.24-5.34 (2H, m, 5’-OH 
and H-3’), 6.40 (1H, app t, J= 6.6 Hz, H-1’), 7.18-7.33 (5H, m, Bn), 7.80 (1H, d, J= 1.2 Hz, H-6), 8.03 
(1H, s, H-5”), 11.33 (1H, s, 3-NH).  
 
13C NMR (75 MHz, DMSO-d6): δ 12.24 (5-CH3), 31.28 (Bn), 37.08 (C-2’), 59.05 (C-5’), 60.75 (C-3’), 
83.83 (C-1’), 84.43 (C-4’), 109.60 (C-5), 122.15 (C-5”), 126.20, 128.44, and 128.56 (Bn), 136.23 (C-6), 
139.41 (Bn), 146.34 (C-4”), 150.43 (C-2), 163.72 (C-4).  
 
Exact Mass (ESI-MS) for C19H22N5O4 [M+H]+ found: 384.1672, calcd: 384.1666. 
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3’-(4-Cyclopentylmethyl-1,2,3-triazol-1-yl)-3’-deoxy-β-D-thymidine (1.52) 
 
O N
HO
N
NH
N
N
O
O
 
 
Reaction of compound 1.6 (89 mg, 0.33 mmol) with 3-cyclopentyl-1-propyne (88 μL, 0.66 mmol) 
following the general procedure for the synthesis of 4”-substituted 3’-deoxy-3’-(1,2,3-triazol-1-yl)-β-D-
thymidine derivatives yielded compound 1.52 (86 mg, 69%) as a white powder.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.16-1.23 (2H, m, cyclopentyl), 1.46-1.59 (4H, m, cyclopentyl), 1.76-
1.76 (2H, m, cyclopentyl), 1.81 (3H, d, J= 1.2 Hz, 5-CH3), 2.06-2.16 (1H, m, cyclopentyl), 2.44-2.63 
(4H, m, H-2’a, H-2’b and CH2), 3.60-3.63 (2H, m, H-5’a and H-5’b), 4.14-4.21 (1H, m, H-4’), 5.22-5.35 
(2H, m, H-3’ and 5’-OH), 6.40 (1H, app t, J= 6.6 Hz, H-1’), 7.81 (1H, d, J= 1.2 Hz, H-6), 8.04 (1H, s, H-
5”), 11.33 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.24 (5-CH3), 24.61 (cyclopentyl), 31.07 (CH2), 31.91 (cyclopentyl), 
37.06 (C-2’), 58.88 (C-5’), 60.90 (C-3’), 83.83 (C-1’), 84.47 (C-4’), 109.60 (C-5), 121.63 (C-5”), 136.25 
(C-6), 146.71 (C-4”), 150.43 (C-2), 163.72 (C-4). 
 
Exact Mass (ESI-MS) for C18H26N5O4 [M+H]+ found: 376.1975, calcd: 376.1979. 
 
3’-[4-(p-Chlorophenyl)-1,2,3-triazol-1-yl]-3’-deoxy-β-D-thymidine (1.53) 
 
O N
HO
N
NH
N
N
O
O
Cl  
 
Reaction of compound 1.6 (70 mg, 0.26 mmol) with 1-chloro-4-ethynylbenzene (72 mg, 0.52 mmol) 
following the general procedure for the synthesis of 4”-substituted 3’-deoxy-3’-(1,2,3-triazol-1-yl)-β-D-
thymidine derivatives yielded compound 1.53 (15 mg, 14%) as a light-gray powder. 
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1H NMR (300 MHz, DMSO-d6): δ 1.82 (3H, d, J= 1.2 Hz, 5-CH3), 2.63-2.85 (2H, m, H-2’a and H-2’b), 
3.60-3.74 (2H, m, H-5’a and H-5’b), 4.22-4.32 (1H, m, H-4’), 5.28-5.34 (1H, m, 5’-OH), 5.36-5.44 (1H, 
m, H-3’), 6.42 (1H, app t, J= 6.6 Hz, H-1’), 7.52-7.56 (2H, m, Ph), 7.83 (1H, d, J= 1.2 Hz, H-6), 7.86-
7.91 (2H, m, Ph), 8.83 (1H, s, H-5”), 11.33 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.26 (5-CH3), 37.13 (C-2’), 59.47 (C-5’), 60.76 (C-3’), 83.89 (C-1’), 
84.41 (C-4’), 109.71 (C-5), 121.38 (C-5”), 126.86, 128.81, 129.03, 129.33, 129.49, and 132.42 (4-
chlorophenyl), 136.25 (C-6), 145.49 (C-4”), 150.44 (C-2), 163.73 (C-4). 
 
Exact Mass (ESI-MS) for C18H19ClN5O4 [M+H]+ found: 404.1129, calcd: 404.1120. 
 
3’-[4-(3,4-Dichlorophenyl)-1,2,3-triazol-1-yl]-3’-deoxy-β-D-thymidine (1.54) 
 
O N
HO
N
NH
N
N
O
O
Cl
Cl
 
 
Reaction of compound 1.6 (67 mg, 0.25 mmol) with 3,4-dichlorophenylacetylene (88 mg, 0.50 mmol) 
following the general procedure for the synthesis of 4”-substituted 3’-deoxy-3’-(1,2,3-triazol-1-yl)-β-D-
thymidine derivatives afforded compound 1.54 (25 mg, 25%) as a white powder. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.82 (3H, d, J= 0.9 Hz, 5-CH3), 2.71-2.80 (2H, m, H-2’a and H-2’b), 
3.64-3.77 (2H, m, H-5’a and H-5’b), 4.25-4.29 (1H, m, H-4’), 5.32 (1H, t, J= 5.1 Hz, 5’-OH), 5.37-5.43 
(1H, m, H-3’), 6.42 (1H, app t, J= 6.9 Hz, H-1’), 7.72 (1H, d, J= 8.7 Hz, 3,4-dichlorophenyl), 7.82-7.87 
(2H, m, 3,4-dichlorophenyl), 8.08 (1H, d, J= 1.8 Hz, H-6), 8.93 (1H, s, H-5”).  
 
13C NMR (75 MHz, DMSO-d6): δ 12.26 (5-CH3), 37.06 (C-2’), 59.60 (C-5’), 60.76 (C-3’), 83.89 (C-1’), 
84.43 (C-4’), 109.66 (C-5), 122.08 (C-5”), 125.18, 126.78, 130.26, 131.27, 131.32, and 131.77 (3,4-
dichlorophenyl), 136.23 (C-6), 144.37 (C-4”), 150.44 (C-2), 163.73 (C-4). 
 
Exact Mass (ESI-MS) for C18H18Cl2N5O4 [M+H]+ found: 438.0745, calcd: 438.0730. 
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3’-Deoxy-3’-[4-(pyridin-2-yl)-1,2,3-triazol-1-yl]-β-D-thymidine (1.55) 
 
O N
HO
N
NH
N
N
O
O
N
 
 
Reaction of compound 1.6 (74 mg, 0.28 mmol) with 2-ethynylpyridine (57 mg, 0.55 mmol) following the 
general procedure for the synthesis of 4”-substituted 3’-deoxy-3’-(1,2,3-triazol-1-yl)-β-D-thymidine 
derivatives gave compound 1.55 (22 mg, 21%) as a light gray powder. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.82 (3H, d, J= 1.2 Hz, 5-CH3), 2.64-2.73 (1H, m, H-2’a), 2.79-2.88 
(1H, m, H-2’b), 3.64-3.80 (2H, m, H-5’a and H-5’b), 4.27-4.32 (1H, m, H-4’), 5.34-5.25 (1H, m, 5’-OH), 
5.43-5.52 (1H, m, H-3’), 6.46 (1H, app t, J= 6.9 Hz, H-1’), 7.34-7.39 (1H, m, pyridin-2-yl), 7.84 (1H, d, 
J=1.2 Hz, H-6), 7.88-7.94 (1H, m, pyridin-2-yl), 8.04-8.07 (1H, m, pyridin-2-yl), 8.60-8.63 (1H, m, 
pyridin-2-yl), 8.83 (1H, s, H-5”), 11.31 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.26 (5-CH3), 37.14 (C-2’), 59.46 (C-5’), 60.73 (C-3’), 83.88 (C-1’), 
84.40 (C-4’), 109.65 (C-5), 119.47 (pyridin-2-yl), 122.94 (C-5”), 123.11 (pyridin-2-yl), 136.30 (C-6), 
137.27 (pyridin-2-yl), 147.46 (C-4”), 149.72 (pyridin-2-yl), 150.45 (C-2), 163.74 (C-4). 
 
Exact Mass (ESI-MS) for C17H19N6O4 [M+H]+ found: 371.1461, calcd: 371.1462. 
 
General procedure for the synthesis of 5”-substituted 3’-deoxy-3’-(1,2,3-triazol-1-yl)-β-D-
thymidine derivatives 1.56-1.57 
 
The appropriate alkyne (2 equiv) and Cp*RuCl(PPh3)2 (0.02 equiv) were added to a solution of 
compound 1.6 (1 mmol, 1 equiv) in THF. The mixture was stirred at 65 °C, and after 24 hours the 
reaction was stopped. The solvent was removed and the residue dissolved in CH2Cl2, washed with 
water (3 x 10 mL), dried over MgSO4, and evaporated in vacuo. Purification with column 
chromatography afforded the corresponding 5-substituted triazole. 
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3’-Deoxy-3’-(5-phenyl-1,2,3-triazol-1-yl)-β-D-thymidine (1.56) 
 
O N
HO
N
NH
O
N
N
O
 
 
Reaction of compound 1.6 (66 mg, 0.25 mmol) with phenylacetylene (50 μL, 0.50 mmol) following the 
general procedure for the synthesis of 5”-substituted 3’-deoxy-3’-(1,2,3-triazol-1-yl)-β-D-thymidine 
derivatives afforded compound 1.56 (26 mg, 29%) as a white powder. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.77 (3H, d, J= 1.2 Hz, 5-CH3), 2.56-2.63 (2H, m, H-2’a and H-2’b), 
3.47-3.53 (1H, m, H-5’a), 3.54-3.64 (1H, m, H-5’b), 4.39 (1H, app dt, J= 3.6 Hz, H-4’), 5.14-5.19 (1H, 
m, H-3), 5.22-5.27 (1H, m, 5’-OH), 6.56 (1H, app t, J= 6.3 Hz, H-1’), 7.53-7.63 (5H, m, Ph), 7.77 (1H, 
d, J= 1.2 Hz, H-6), 7.92 (1H, s, H-4”), 11.35 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.45 (5-CH3), 38.00 (C-2’), 58.57 (C-5’), 61.50 (C-3’), 84.97 (C-1’), 
85.12 (C-4’), 110.03 (C-5), 126.49, 129.44, and 129.90 (Ph), 133.16 (C-5”), 136.45 (C-6), 138.22 (C-
4”), 150.65 (C-2), 163.96 (C-4). 
 
Exact Mass (ESI-MS) for C18H20N5O4 [M+H]+ found: 370.1512, calcd: 370.1510. 
 
3’-[5-(p-Chlorophenyl)-1,2,3-triazol-1-yl]-3’-deoxy-β-D-thymidine (1.57) 
 
O N
HO
N
NH
O
N
N
O
Cl  
 
The reaction of compound 1.6 (52 mg, 0.19 mmol) with 1-chloro-4-ethynylbenzene (55 mg, 0.40 mmol) 
following the general procedure for the synthesis of 5”-substituted 3’-deoxy-3’-(1,2,3-triazol-1-yl)-β-D-
thymidine derivatives yielded compound 1.57 (19 mg, 20%) as a white solid. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.78 (3H, app s, 5-CH3), 2.44-2.65 (2H, m, H-2’a and H-2’b), 3.46-
3.52 (1H, m, H-5’a), 3.57-3.63 (1H, m, H-5’b), 4.37-4.41 (1H, m, H-4’), 5.11-5.14 (1H, m, H-3’), 5.19-
5.25 (1H, m, 5’-OH), 6.54 (1H, app t, J= 6.6 Hz, H-1’), 7.56-7.66 (4H, m, Ph), 7.76 (1H, app s, H-6), 
7.95 (1H, s, H-4”), 11.35 (1H, s, 3-NH). 
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13C NMR (75 MHz, DMSO-d6): δ 12.94 (5-CH3), 38.41 (C-2’), 59.06 (C-5’), 62.03 (C-3’), 85.33 (C-1’), 
85.51 (C-4’), 110.39 (C-5), 125.98, 129.86, and 131.83 (4-chlorophenyl), 133.84 (C-5”), 135.22 (C-4”), 
136.80 (C-6), 137.53 (4-chlorophenyl), 151.13 (C-2), 164.34 (C-4). 
 
Exact Mass (ESI-MS) for C18H19ClN5O4 [M+H]+ found: 404.1120, calcd: 404.1120;  
 
3’-Amino-3’-deoxy-5’-O-triphenylmethyl-β-D-thymidine (1.58) 
 
O N
TrO
H2N
NH
O
O
 
 
A solution of compound 1.47 (113 mg, 0.22 mmol) in methanol (6 mL) was hydrogenated under 
atmospheric pressure for 5 h in the presence of 10% Pd/C. The catalyst was removed by filtration 
through Celite and the filtrate was evaporated in vacuo. The residue was mixed with water and 
extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were dried with MgSO4 and 
evaporated under reduced pressure. The resulting residue was purified by column chromatography 
(CH2Cl2/MeOH 95:5) to obtain pure compound 1.58 (79 mg, 73%) as a white solid. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.49 (3H, app s, 5-CH3), 1.90-2.08 (1H, m, H-2’a), 2.17-2.52 (1H, m, 
H-2’b), 3.22-3.27 (2H, m, H-5’a and H-5’b), 3.47-3.53 (1H, app dd, J= 6.6 Hz, J= 13.5 Hz, H-3’), 3.67-
3.70 (1H, m, H-4’), 6.14 (1H, dd, J= 5.4 Hz, J= 6.8 Hz, H-1’), 7.25-7.42 (15H, m, Tr), 7.49 (1H, d, J= 
0.9 Hz, H-6). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.56 (5-CH3), 41.34 (C-2’), 52.23 (C-3’), 64.55 (C-5’), 84.28 (C-1’), 
86.21 (C-4’), 86.92 (Tr), 109.97 (C-5), 127.81, 128.64 and 128.97 (Tr), 136.51 (C-6), 144.30 (Tr), 
151.05 (C-2), 164.42 (C-4). 
 
Exact Mass (ESI-MS) for C29H29N3NaO4 [M+Na]+ found: 506.2050, calcd: 506.2057. 
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N-(3’-Deoxy-5’-O-triphenylmethyl-β-D-thymidin-3’-yl)-N’-(4-chloro-3-(trifluoromethyl)phenyl)-
thiourea (1.59) 
O N
TrO
HN
NH
O
O
HN
S
Cl
CF3
 
 
To a suspension of compound 1.58 (2.36 g, 4.88 mmol) in DMF (44 mL) was added 4-chloro-3-
(trifluoromethyl)phenyl isothiocyanate (1.0 mL, 6.35 mmol) in 58 mL DMF at 0 °C. The reaction was 
stirred at room temperature for 3 h. The solvent was evaporated to dryness and the residue purified by 
column chromatography (CH2Cl2/MeOH 97:3) affording thiourea 1.59 as a white foam (3.44 g, 98%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.46 (3H, d, J= 0.9 Hz, 5-CH3), 2.26-2.34 (1H, m, H-2’a), 2.48-2.58 
(1H, m, H-2’b), 3.18 (2H, d, J= 4.8 Hz, H-5’a and H-5’b), 4.07-4.12 (1H, m, H-4’), 5.21 (1H, app br s, 
H-3’), 6.28 (1H, app t, J= 6.6 Hz, H-1’), 7.24-7.44 (15H, m, Tr), 7.60-7.71 (3H, m, subs Ph), 8.03 (1H, 
s, H-6), 8.62 (1H, d, J= 6.3 Hz, 3’-NH), 9.84 (1H, s, N’H), 11.37 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.45 (5-CH3), 37.52 (C-2’), 54.98 (C-5’), 64.69 (C-3’), 83.67 (C-1’), 
84.31 (C-4’), 87.20 (Tr), 110.36 (C-5), 121.57 (CF3), 125.19 (subs Ph), 126.78, 127.19, 127.59, 
127.85, 128.40, 128.65, 128.80, and 128.99 (subs Ph and Tr), 132.37 and 136.24 (subs Ph), 139.71 
(C-6), 144.13 (Tr), 151.06 (C-2), 164.35 (C-4), 181.32 (C=S). 
 
Exact Mass (ESI-MS) for C37H32ClF3N4NaO4S [M+Na]+ found: 743.1677, calcd: 743.1675. 
 
(E)-5-(2-Bromovinyl)-2’-deoxy-5’-O-triphenylmethyl-β-D-uridine (1.60) 
 
O N
TrO
HO
NH
O
O
Br
7
8
6 5
4
3
21
 
 
To a solution of (E)-5-(2-bromovinyl)-2’-deoxyuridine (BVDU, 1.10) (467 mg, 1.40 mmol) in anhydrous 
pyridine (3 mL) was added trityl chloride (0.460 g, 1.65 mmol). The mixture was heated to 65 °C and 
stirred overnight. The reaction mixture was then diluted with CH2Cl2 (3 mL), washed with saturated 
aqueous NaHCO3 (3 x 10 mL), and dried over anhydrous MgSO4. The solvent was removed under 
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reduced pressure, and the resulting residue was purified by column chromatography (CH2Cl2/MeOH 
94:6), affording 1.60 as a white foam (482 mg, 65%). 
 
1H NMR (300 MHz, DMSO-d6): δ 2.12-2.31 (2H, m, H-2’a and H-2’b), 3.13-3.24 (2H, m, H-5’a and H-
5’b), 3.86-3.90 (1H, m, H-4’), 4.24-4.27 (1H, m, H-3’), 5.32 (1H, d, J= 4,7 Hz, 3’-OH), 6.16 (1H, app t, 
J= 6,7 Hz, H-1’), 6.45 (1H, d, J= 13,5 Hz, H-8), 7.18 (1H, d, J= 13,5 Hz, H-7), 7.22-7.38 (15H, m, Tr), 
7.72 (1H, s, H-6) 11.60 (1H, br s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 38.69 (C-2’), 64.00 (C-5’), 70.06 (C-3’), 84.36 (C-1’), 85.47 (C-4’), 
86.24 (Tr), 106.97 (C-5), 109.95 (C-8), 123.91, 127.16, 127.97, 128.56, and 128.26 (Tr), 129.68 (C-7), 
139.32 (C-6), 148.52 (Tr), 149.26 (C-2), 161.68 (C-4). 
 
Exact Mass (ESI-MS) for C30H28BrN2O5 [M+H]+ found: 575.1118, calcd: 575.1176. 
 
2,3’-O-Anhydro-(E)-5-(2-bromovinyl)-2’-deoxy-5’-O-triphenylmethyl-β-D-uridine (1.62) 
 
O N
TrO
N O
Br
O
 
 
To an ice-cooled solution of compound 1.60 (482 mg, 0.84 mmol) in pyridine (3 mL) was added 
methanesulfonyl chloride (0.20 mL, 2.51 mmol). The reaction mixture was stirred for 2 h, quenched 
with NaHCO3, and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried over 
MgSO4 and evaporated to dryness. The residue was dissolved in 10 mL of ethanol and dry Et3N (0.68 
mL, 4.88 mmol) was added. The mixture was heated, under reflux, for 18 h. The reaction was cooled, 
extracted with CH2Cl2 (3 x 10 mL), and the combined organic layers were dried over MgSO4 and 
evaporated to dryness. The resulting residue was purified by column chromatography (CH2Cl2/MeOH 
96:4), yielding compound 1.62 as a white foam (351 mg, 75%). 
 
1H NMR (300 MHz, DMSO-d6): δ 2.43-2.67 (2H, m, H-2’a and H-2’b), 3.11-3.13 (2H, m, H-5’a and H-
5’b), 4.43-4.49 (1H, m, H-4’), 5.38 (1H, app s, H-3’), 5.92 (1H, app d, J= 3.5 Hz, H-1’), 6.86 (1H, d, J= 
13.5 Hz, H-8), 7.20-7.41 (15H, m, Tr), 7.54 (1H, d, J= 13.5 Hz, H-7), 7.96 (1H, s, H-6). 
 
13C NMR (75 MHz, DMSO-d6): δ 32.73 (C-2’), 62.32 (C-5’), 77.55 (C-3’), 83.57 (C-1’), 86.39 (Tr), 
87.57 (C-4’), 109.31 (C-5), 115.17 (C-8), 127.06, 127.92, and 128.16 (Tr), 130.17 (C-7), 139.62 (C-6), 
143.22 (Tr), 152.29 (C-2), 168.07 (C-4). 
 
Exact Mass (ESI-MS) for C30H26BrN2O [M+H]+ found: 557.1061, calcd: 557.1070. 
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3’-Azido-(E)-5-(2-bromovinyl)-2’,3’-dideoxy-5’-O-triphenylmethyl-β-D-uridine (1.63) 
 
O N
TrO
N3
NH
O
O
Br
 
 
p-Nitrophenyl alcohol (114 mg, 0.82 mmol) first and then NaN3 (267 mg, 4.12 mmol) were added to a 
suspension of anhydronucleoside 1.62 (229 mg, 0.41 mmol) in dry DMF (5 mL) under N2. The solution 
was stirred for 7 h at 110 °C. The reaction was quenched with 5 mL water and extracted with CH2Cl2 
(3 x 5 mL). The combined organic layers were dried over MgSO4 and evaporated to dryness. The 
resulting residue was purified by column chromatography (CH2Cl2/MeOH 96:4), affording compound 
1.63 as a yellow oil (195 mg, 79%). 
 
1H NMR (300 MHz, DMSO-d6): δ 2.35-2.58 (2H, m, H-2’a and H-2’b), 3.25-3.40 (2H, m, H-5’a and H-
5’b), 3.85-3.92 (1H, m, H-4’), 4.58 (1H, dt, J= 7.5 Hz, H-3’), 6.15 (1H, dd, J= 4.5 Hz, J= 7.2 Hz, H-1’), 
6.64 (1H, d, J= 13.5 Hz, H-8), 7.23-7.44 (16H, m, H-7 and Tr), 7.79 (1H, s, H-6). 
 
13C NMR (75 MHz, DMSO-d6): δ 35.90 (C-2’), 59.16 (C-5’), 62.81 (C-3’), 82.11 (C-1’), 83.79 (C-4’), 
86.37 (Tr), 110.12 (C-5), 115.79 (C-8), 126.19, 127.05, 127.20, 127.86, 127.99, and 128.22 (Tr), 
129.71 (C-7), 139.59 (C-6), 143.38 (Tr), 149.23 (C-2), 161.63 (C-4). 
 
Exact Mass (ESI-MS) for C30H27BrN5O4 [M+H]+ found: 600.1274, calcd: 600.1241. 
 
3’-Azido-(E)-5-(2-bromovinyl)-2’,3’-dideoxy-β-D-uridine (1.64) 
 
O N
HO
N3
NH
O
O
Br
 
 
Compound 1.63 (260 mg, 0.43 mmol) was dissolved in a mixture of ZnBr2 (1.59 g, 7.05 mmol) in 
CH2Cl2/iPrOH (7 mL, 85:15) and stirred overnight at room temperature. The reaction was quenched 
with water and extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were dried over 
MgSO4 and evaporated to dryness. The resulting residue was purified by column chromatography 
(CH2Cl2/MeOH 98:2), affording compound 1.64 (139 mg, 90%) as a yellow-brown oil. 
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1H NMR (300 MHz, DMSO-d6): δ 2.31-2.44 (2H, m, H-2’a and H-2’b), 3.60-3.71 (2H, m, H-5’a and H-
5’b), 3.80-3.86 (1H, m, H-4’), 4.38-4.44 (1H, m, H-3’), 5.30 (1H, app s, 5’-OH), 6.05-6.09 (1H, m, H-1’), 
6.84 (1H, d, J= 13.8 Hz, H-8), 7.25 (1H, d, J= 13.5 Hz, H-7), 8.04 (1H, s, H-6). 
 
13C NMR (75 MHz, DMSO-d6): δ 36.67 (C-2’), 54.92 (C-5’), 60.36 (C-3’), 84.12 (C-1’), 84.37 (C-4’), 
106.60 (C-5), 109.71 (C-8), 129.83 (C-7), 139.38 (C-6), 149.24 (C-2), 168.25 (C-4).  
 
Exact Mass (ESI-MS) for C11H13BrN5O4 [M+H]+ found: 358.0119, calcd: 358.0145. 
 
(E)-5-(2-Bromovinyl)-2’,3’-dideoxy-3’-(4-phenyl-1,2,3-triazol-1-yl)-β-D-uridine (1.65) 
 
O N
HO
N
NH
O
N
N
O
Br
 
 
Reaction of compound 1.64 (64 mg, 0.18 mmol) with phenylacetylene (39 μL, 0.36 mmol) was 
performed as described in the general procedure for the synthesis of 4”-substituted 3’-deoxy-3’-(1,2,3-
triazol-1-yl)-β-D-thymidine derivatives. Compound 1.65 was obtained as a white solid in 6% yield (5 
mg). 
 
1H NMR (300 MHz, DMSO-d6): δ 2.73-2.80 (1H, m, H-2’a), 2.86-2.95 (1H, m, H-2’b), 3.66-3.70 (1H, m, 
H-5’a), 3.76-3.80 (1H, m, H-5’b), 4.32-4.34 (1H, m, H-4’), 5.34-5.48 (2H, m, 5’-OH and H-3’), 6.42 (1H, 
app t, J= 6.9 Hz, H-1’), 6.90 (1H, d, J= 13.2 Hz, H-8), 7.28 (1H, d, J= 13.5 Hz, H-7), 7.33-7.38 (1H, m, 
Ph), 7.44-7.50 (2H, m, Ph), 7.85 (2H, d, J= 5.1 Hz, Ph), 8.25 (1H, s, H-6), 8.77 (1H, s, H-5”). 
 
13C NMR (75 MHz, DMSO-d6): δ 39.95 (C-2’), 55.47 (C-5’), 63.77 (C-3’), 84.66 (C-1’), 4.80 (C-4’), 
108.00 (C-5), 109.92 (C-8), 122.28 (C-5”), 126.89 (Ph), 129.77 (C-7), 130.87, 131.58, and 133.20 
(Ph), 139.02 (C-6), 144.25 (C-4”), 148.71 (C-2), 160.16 (C-4). 
 
Exact Mass (ESI-MS) for C19H19BrN5O4 [M+H]+ found: 460.0637, calcd: 460.0615. 
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(E)-5-(2-Bromovinyl)-3’-[4-(p-chlorophenyl)-1,2,3-triazol-1-yl]-2’,3’-dideoxy-β-D-uridine (1.66) 
 
O N
HO
N
NH
O
N
N
O
Br
Cl  
 
Reaction of compound 1.65 (69 mg, 0.19 mmol) with 1-chloro-4-ethynylbenzene (52 mg, 0.38 mmol) 
was performed as described in the general procedure for the synthesis of 4”-substituted 3’-deoxy-3’-
(1,2,3-triazol-1-yl)-β-D-thymidine derivatives, affording compound 1.66 (6 mg) in a 6% yield.  
 
1H NMR (300 MHz, DMSO-d6): δ 2.73-2.80 (1H, m, H-2’a), 2.85-2.94 (1H, m, H-2’b), 3.64-3.71 (1H, m, 
H-5’a), 3.75-3.81 (1H, m, H-5’b), 4.32-4.35 (1H, m, H-4’), 5.36-5.46 (2H, m, 5’-OH and H-3’), 6.41 (1H, 
app t, J= 6.9 Hz, H-1’), 6.89 (1H, d, J= 13.5 Hz, H-8), 7.28 (1H, d, J= 13.5 Hz, H-7), 7.52-7.56 (2H, m, 
Ph), 7.86-7.90 (2H, m, Ph), 8.21 (1H, s, H-6), 8.82 (1H, s, H-5”), 11.65 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 37.18 (C-2’), 55.73 (C-5’), 61.79 (C-3’), 84.59 (C-1’), 84.83 (C-4’), 
107.44 (C-5), 109.90 (C-8), 121.37 (C-5”), 126.89, 129.06, and 129.47 (4-chlorophenyl), 129.83 (C-7), 
132.461 (4-chlorophenyl), 139.54 (C-6), 145.51 (C-4”), 149.32 (C-2), 160.16 (C-4). 
 
Exact Mass (ESI-MS) for C19H18BrClN5O4 [M+H]+ found: 494.0219, calcd: 494.0225.  
 
3-[3-Azido-2,3-dideoxy-5-O-triphenylmethyl-β-D-ribofuranosyl)]-2,3-dihydrofuro-[2,3-
d]pyrimidin-2-one (1.67) 
O N
TrO N
N3
O
O
1
2
3
4
5 6
7
8
 
 
NaN3 (1.21 g, 18.57 mmol) was added to a suspension of anhydronucleoside 1.62 (1.04 g, 1.86 mmol) 
in dry DMF (25 mL) under N2. The solution was stirred overnight at 110 °C. The reaction was 
quenched with 25 mL water and extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were 
dried over MgSO4 and evaporated to dryness. The resulting residue was purified by column 
chromatography (CH2Cl2/MeOH 97:3), affording compound 1.67 as a brown foam (600 mg, 54 %).  
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1H NMR (300 MHz, DMSO-d6): δ 2.53-2.65 (2H, m, H-2’a and H-2’b), 3.30-3.40 (2H, m, H-5’a and H-
5’b), 4.02-4.08 (1H, m, H-4’), 4.56 (1H, app dd, J= 7.2 Hz, J= 14.1 Hz, H-3’), 6.09-6.14 (2H, m, H-1’ 
and H-5), 7.23-7.43 (15H, m, Tr), 7.71 (1H, d, J= 3.0 Hz, H-6), 8.71 (1H, s, H-4). 
  
13C NMR (75 MHz, DMSO-d6): δ 37.77 (C-2’), 58.40 and 62.13 (C-3’ and C-5’), 83.08 (C-4’), 86.83 
(Tr), 87.08 (C-1’), 104.63 and 104.70 (C-5 and C-7), 127.30, 128.11 and 128.24 (Tr), 138.67 (C-4), 
143.78 (Tr), 145.00 (C-6), 153.63 (C-2), 171.33 (C-8). 
 
Exact Mass (ESI-MS) for C30H25N5NaO4 [M+Na]+ found: 542.1792, calcd: 542.1799. 
 
3-[3-Azido-2,3-dideoxy-β-D-ribofuranosyl]-2,3-dihydrofuro-[2,3-d]pyrimidin-2-one (1.68) 
 
O N
HO N
N3
O
O
 
 
Compound 1.67 (98 mg, 0.19 mmol) was dissolved in a mixture of ZnBr2 (678 mg, 3.01 mmol) in 
CH2Cl2/iPrOH (3 mL, 85:15) and stirred overnight at room temperature. The reaction was quenched 
with water and extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were dried over MgSO4 
and evaporated to dryness. The resulting residue was purified by column chromatography 
(CH2Cl2/MeOH 95:5) yielding compound 1.68 ( 20 mg, 39%) as a yellow powder.  
 
1H NMR (300 MHz, DMSO-d6): δ 2.37-2.45 (1H, m, H-2’a), 2.53-2.60 (1H, m, H-2’b), 3.64-3.78 (2H, m, 
H-5’a and H-5’b), 3.97-4.01 (1H, m, H-4’), 4.35 (1H, app dd, J= 6.3 Hz, J= 12.6 Hz, H-3’), 5.38 (1H, 
app br s, 5’-OH), 6.08-6.12 (1H, m, H-1’), 6.82 (1H, d, J= 2.7 Hz, H-5), 7.75 (1H, d, J= 2.7 Hz, H-6), 
8.88 (1H, s, H-4). 
 
13C NMR (75 MHz, DMSO-d6): δ 37.95 (C-2’), 58.78 and 60.03 (C-3’ and C-5’), 85.17 (C-4’), 87.16 (C-
1’), 104.71 and 105.26 (C-5 and C-7), 139.04 (C-4), 144.88 (C-6), 153.74 (C-2), 171.35 (C-8). 
 
Exact Mass (ESI-MS) for C11H11N5NaO4 [M+Na]+ found: 300.0713, calcd: 300.0703. 
2.7.2 Experimental Assays  
Radiochemicals  
 
The radiolabeled substrate [CH3-3H]dThd (70 Ci/mmol) was obtained from Moravek Biochemicals 
(Brea, CA).  
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Thymidine Kinase Assay Using [CH3-3H]dThd as the Natural Substrate 
 
The activity of recombinant TK-1, TK-2, herpes simplex virus-1 TK, varicella zoster virus TK, and the 
multifunctional deoxynucleoside kinase of Drosophila melanogaster and the 50% inhibitory 
concentration of the test compounds were assayed in a 50 μL reaction mixture containing 50 mM 
Tris/HCl, pH 8.0, 2.5 mM MgCl2, 10 mM dithiothreitol, 0.5 mM CHAPS, 3 mg/mL bovine serum 
albumin, 2.5 mM ATP, 1 μM [methyl-3H]dThd, and enzyme. The samples were incubated at 37 °C for 
30 min in the presence or absence of different concentrations (5-fold dilutions) of the test compounds. 
At this time point, the enzyme reaction still proceeded linearly. Aliquots of 45 μL of the reaction 
mixtures were spotted on Whatman DE-81 filter paper disks (Whatman, Clifton, NJ). The filters were 
washed three times for 5 min each in 1 mM ammonium formate, once for 1 min in water, and once for 
5 min in ethanol. The radioactivity was determined by scintillation counting. To determine the Km (for 
dThd or ATP) and Ki values (for the inhibitors), varying concentrations of dThd (ranging between 0.4 
and 5 μM) were used at saturating concentrations of ATP (2.5 mM) or varying concentrations of ATP 
(ranging between 5 and 100 μM) at saturating concentrations of dThd (20 μM). The kinetic values 
were derived from Lineweaver-Burk plots.  
 
Cytostatic Assay 
 
Human osteosarcoma cells (OST TK-) that had been transduced by the Drosophila melanogaster 
deoxynucleoside kinase gene were seeded in 48-well plates at 20000 cells/1 mL well in DMEM 
supplemented with 10% fetal calf serum, 10 mM HEPES, 1 mM Na pyruvate, and 2 mM L-glutamine. 
The cells were incubated at 37 °C in the presence of 10 or 4 μM compound 1.66. One day later, serial 
dilutions of BVDU (1.10) and 5FdUrd (1.69) were added to the cell cultures. At day 4, cell number was 
counted using a Coulter particle counter model Z1, enabling the calculation of the 50% inhibitory 
concentrations of BVDU and 5FdUrd in the presence or absence of compound 1.66. 
 
Molecular Modeling 
 
The thymine ring of compound 1.53 was manually docked into the substrate-binding site of the 
previously reported59 homology-based model of human TK-2 in complex with ATP and Mg2+, and the 
two alternative locations for the phenyl triazole substituent were explored. Energy refinement of the 
resulting complexes and subsequent molecular dynamics simulations were carried out essentially as 
described59 using the AMBER 10.0 suite of programs.77  
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3 SYNTHESIS AND BIOLOGICAL EVALUATION OF 3’-
GUANIDINE-SUBSTITUTED THYMIDINE AND BVDU 
DERIVATIVES 
3.1 OBJECTIVES 
Modeling studies on the binding of compound 1.43 to human TK-2 suggested that the nitrogen atoms 
of the thiourea urea group of 1.43 could interact favorably with the oxygens of the γ-phosphate of the 
co-substrate ATP,59 whereas for 1.53 a binding mode involving a water-mediated interaction with the 
side chain of the central glutamate in the EEE LID region of the enzyme was proposed (Figure I.27).73 
To further expand the array of hydrogen-bonding functionalities at the 3’ position and to identify those 
that are optimal for TK-2 inhibition, we decided to synthesize a series of novel thymidine and BVDU 
analogues containing a substituted amine or guanidine group instead of a thiourea at the 3’ position or 
a 1,5-disubstituted tetrazole linker. 
 
O N
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NH
NH
O
NH
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Cl
F3C
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O N
HO
N
NH
O
N
N
O
1.43
TK-2: IC50 = 0.15 µM
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1.53
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TK-1: IC50 = 71 µM
Cl
 
 
Figure I.27
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3.2 CHEMISTRY 
3.2.1 Synthesis of 3’-Benzylamino Analogues of Thymidine 
A small series of 3’-benzylamino analogues of thymidine (1.80-1.82) was synthesized by treatment of 
amine 1.58 with different aldehydes followed by in situ reduction of the resulting imines with NaBH4 
and final detritylation (Scheme I.6).78 
 
O N
TrO
H2N
NH
O
1.58
a
O
O HN
TrO
HN
O
b
O
R1
R2
1.77-1.79
O N
HO
HN
NH
O
O
R1
R2
1.80: R1 = H, R2 = H
1.81: R1 = H, R2 = Cl
1.82: R1 = CF3, R2 = Cl  
 
Scheme I.6. Reagents and conditions: a) (i) suitable benzaldehyde, dry MeOH, rt, 24 h; (ii) NaBH4, rt, 30 min, 
16-88% over 2 steps; b) ZnBr2, CH2Cl2/iPrOH 85:15, rt, overnight, 34-58%. 
3.2.2 Synthesis of 3’-Guanidine and 3’-Aminotetrazole Analogues of Thymidine 
The guanidine analogues 1.86-1.88 were synthesized by an HgCl2-promoted guanylation79 of the 3’-
thiourea precursor 1.59 which was prepared from the 3’-amino analogue 1.58, followed by final 
detritylation (Scheme I.7). 
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Scheme I.7. Reagents and conditions: a) suitable amine or 7N NH3, Et3N, HgCl2, DMF, 0 °C → rt, 20 h, 56-
57%; b) HCOOH/Et2O 7:3, rt, 1 h, 64–71%.  
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Interestingly, upon replacement in the above mentioned guanylation conditions of the amine by 
sodium azide, thiourea 1.59 was converted into 5-aminotetrazole 1.89 by spontaneous 
electrocyclization of an intermediate guanyl azide (Scheme I.8).80 The observed selectivity of the 
electrocyclization step is in accordance with earlier results, leading to the regioisomer in which the 
tetrazole is conjugated with the phenyl ring.81 Two typical methods for the removal of the trityl 
protecting group of 1.89 were explored.66,82 Surprisingly, treatment with ZnBr2 resulted in a 9:1-mixture 
of both tetrazole isomers 1.90 and 1.91, which were separated using preparative HPLC. In our view, 
ZnBr2 may promote the observed isomerization by catalyzing opening of the tetrazole ring followed by 
a non-specific ring closure. This isomerization could be prevented by performing the deprotection with 
formic acid in ether (Scheme I.8). 
 
 
O N
HN
NH
O
O
1.89
TrO
N
N N
N
O N
HN
NH
O
O
1.90
HO
O N
N
NH
O
O
1.91
HO
N
N N
N
N
N
N NH
a b
1.89 1.90
c
Cl
F3C
Cl
Cl
CF3
F3C
O N
TrO
HN
NH
O
O
HN
S
Cl
CF3
1.59
 
 
Scheme I.8. Reagents and conditions: a) NaN3, DMF, Et3N, HgCl2, 0 °C → rt, 6 h, 31%; b) ZnBr2, 
CH2Cl2/iPrOH (85:15), rt, overnight, 32%; c) HCOOH/Et2O 7:3, rt, 1 h, 45%. 
 
A possible mechanism for the formation of compound 1.89 is depicted in Scheme I.9, displacement by 
sodium azide of a mercury(II)-activated thiourea I generates an intermediate guanyl azide II, which 
upon electrocyclization, forms the corresponding 5-aminotetrazole 1.89.80  
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Scheme I.9. Mechanism for the formation of aminotetrazole analogue 1.89 starting from thiourea 1.59. 
 
An IR spectrum (performed at the Laboratory of Drug Quality and Registration, UGent) of compound 
1.90 proved that the molecule represented the 1,5-aminotetrazole and not the uncyclisized azide form. 
Absorption in the 2100-2270 cm-1 region, due to azide stretching, is not present whereas the 
emergence of peaks in the 1400-1500 cm–1 region confirms the formation of a tetrazole ring (Figure 
I.28). 
 
Figure I.28. IR spectra of compound 1.90 
 
In the case of the benzylthiourea analogue 1.92, competitive cyclization of the guanyl azide afforded a 
1:2.2-mixture of the tetrazoles 1.93 and 1.94. This isomer ratio was only slightly affected after further 
trityl deprotection with ZnBr2 (1:2.6-mixture of isomers 1.95 and 1.96). Identification of each isomer 
was based on the multiplicity of 3’-NH and 5’’-NH (e.g., 1.95: 3’-NH, d, J= 6.9 Hz; 1.96: 5’’-NH, t, J= 
5.7 Hz) (Scheme I.10). 
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Scheme I.10. Reagents and conditions: a) benzyl isothiocyanate, DMF, 0 °C → rt, 3 h, 99%; b) NaN3, DMF, 
Et3N, HgCl2, 0 °C → rt, 6 h, 52%; c) ZnBr2, CH2Cl2/iPrOH (85:15), rt, overnight, 54%. 
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3.2.3 Synthesis of 3’-Aminotetrazole Analogues of BVDU 
Application of an identical reaction sequence used for 1.59 on the BVDU thiourea analogue 1.98 
afforded 1.100 and 1.101 (3:1) in moderate yields (Scheme I.11). 
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Scheme I.11. Reagents and conditions: a) PPh3, THF, H2O, rt, overnight, 71%; b) 4-chloro-3-
(trifluoromethyl)phenyl isothiocyanate, DMF, 0 °C → rt, 3 h, 82%; c) NaN3, HgCl2, Et3N, DMF, 0 °C → rt, 6 h, 
75%; d) ZnBr2, CH2Cl2/iPrOH (85:15), rt, overnight, 32%. 
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3.3 BIOLOGICAL EVALUATION 
All compounds were evaluated for their ability to inhibit dThd phosphorylation by recombinant purified 
human cytosolic TK-1, human mitochondrial TK-2, HSV-1 TK, VZV-TK and Dm-dNK under the 
guidance of Prof. Dr. Jan Balzarini at the Laboratory of Virology and Chemotherapy, Rega Institute, 
K.U.Leuven (Table I.4). The 3’-benzylamino analogues demonstrated modest inhibitory activity on TK-
2. This activity was influenced by the nature of the substituents at the phenyl ring. Derivatives 
containing either the unsubstituted (1.80) or a 4-chloro-substituted (1.81) phenyl gave micromolar 
inhibition, while the analogue possessing a 3-CF3-4-Cl-substituted phenyl (1.82) displayed significantly 
improved TK-2 inhibitory activity. In addition, all the 3’-aminobenzyl derivatives showed poor inhibitory 
activity against TK-1 (IC50 values, 442 to ≥ 500 μM). dThd phosphorylation by TK-2 was also inhibited 
by the substituted guanidine analogues (compounds 1.86-1.88), which yielded IC50 values ranging 
from 0.43 to 1.3 μM. The anti-TK-2 activity was influenced by the nature of the third substituent on the 
guanidine moiety. The “unsubstituted” analogue 1.86 and the iPr-substituted analogue 1.88 afforded 
appreciable potency and excellent selectivity over TK-1 (Table I.4). In the 1,5-aminotetrazole series, 
the anti-TK-2 activity was clearly influenced by a) the type of isomer, b) the substituent at position N-1 
of the tetrazole ring, and c) the substituent on position 5 of the base. In all cases, the isomer in which 
the tetrazole ring is attached to C-3’ via a NH bridge (1.90, 1.95 and 1.100), showed the best inhibitory 
activity against TK-2 (IC50s in the 0.014-0.90 mM range). The benzyl substituted analogue 1.95 gave 
submicromolar inhibition, while introduction of an electron-withdrawing 3-CF3-4-Cl phenyl substituent 
significantly improved the inhibitory activity (1.90), which matches with that of the earlier described 3’-
(4-(3,4-dichlorophenyl)-1,2,3-triazol-1-yl) analogue. Combination of this favorable 3’-modification with 
a 5’-O-trityl substituent led, as expected,73 to an analogue (1.89) that was completely devoid of TK-2 
inhibitory activity (IC50s > 500 μM for all kinases tested). On the other hand, introduction of an 
additional 5-(2-bromovinyl) group (1.100), known to be a privileged substituent for TK-2 recognition, 
proved to be compatible with the 3’-modification (IC50 TK-2: 0.014 μM). This 5-(2-bromovinyl) 
substituent improved the TK-2 inhibitory activity by 2- to 3-fold, and it further caused an increase in the 
selectivity for TK-2 versus TK-1, resulting in the complete lack of inhibitory effect against TK-1-
catalyzed dThd phosphorylation. A similar effect had previously been observed in the triazole series.73 
To the best of our knowledge, compound 1.100 is the most potent and selective inhibitor of TK-2 
reported to date. The isomeric aminotetrazole analogues in which the similar substituted tetrazole 
group is connected directly to the sugar ring were markedly less inhibitory to TK-2 activity: 1.101 
showed an IC50 value of 0.40 μM, that is, at least 25-fold higher than the IC50 value observed for 1.100 
(Table I.4). 
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Table I.4. Inhibitory effects of thymidine and BVDU analogues on 1 μM [CH3-3H]dThd phosphorylation by 
deoxyribonucleoside kinases from different origins. 
 
O N
HO
HN
NH
O
O
R1
R2
O N
HO
HN
NH
O
O
HN
N
Cl
CF3
R1
O N
HN
NH
O
O
R2
HO
N
N N
NR1
O N
N
NH
O
O
R2
HO
N
N
N NH
1.80-1.82 1.86-1.88 1.91, 1.96 and 1.1011.90, 1.95 and 1.100
R1
 
 
Cmpd R1 R2 
IC50a (μM) 
TK-1 TK-2 HSV-1 TK VZV TK Dm-dNK 
1.80 H H > 500 4.6 ± 0.3 > 500 99 ± 74 48 ± 3 
1.81 H Cl ≥ 500 3.3 ± 0.2 > 500 35 ± 5 41 ± 4 
1.82 CF3 Cl 442 ± 37 0.33 ± 0.04 492 ± 12 28 ± 1 4.8 ± 0.2 
1.86 H - 355 ± 69 0.43 ± 0.02 > 500 41 ± 3 11 ± 6 
1.87 Bn - 468 ± 12 1.3 ± 0.5 372 ± 39 41 ± 1 7.7 ± 4.1 
1.88 iPr - ≥ 500 0.58 ± 0.29 > 500 277 ± 35 12 ± 4 
1.90 3-CF3,4-ClPh CH3 382 ± 52 0.035 ± 0.007 316 ± 39 63 ± 26 1.2 ± 0.0 
1.91 3-CF3, 4-ClPh CH3 29 ± 1 0.59 ± 0.19 40 ± 0 5.5 ± 2.3 3.6 ± 0.7 
1.95 Bn CH3 > 500 0.90 ± 0.01 > 500 144 ± 42 10 ± 6 
1.96 Bn CH3 222 ± 112 2.6 ± 1.2 39 ± 1 3.2 ± 0.5 31 ± 4 
1.100 3-CF3, 4-ClPh Bromovinyl > 500 0.014 ± 0.001 34 ± 3 26 ± 3 0.41 ± 0.04 
1.101 3-CF3, 4-ClPh Bromovinyl > 500 0.40 ± 0.04 26 ± 4 6.1 ± 1.6 3.6 ± 0.2 
aIC50 is the 50% inhibitory concentration of the test compounds, which was measured as the concentration 
required to inhibit 1 μM [CH3-3H]dThd phosphorylation by 50%. Data are the mean of at least 2 to 3 independent 
experiments (± S.D.). 
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Interestingly, a close relationship for the inhibitory concentration of the test compounds was observed 
between TK-2 and Dm-dNK (r = 0.951) but not between TK-2 and HSV-1 TK (r = -0.229) (Table I.4, 
Figure I.29).  
 
Figure I.29. Correlation between the IC50 values of the inhibitors shown in Table I.4 against TK-2 and Dm-dNK. 
3.4 MOLECULAR MODELING 
Gago et al. used the previously reported homology-built model of ATP-bound TK-2 (Part I, chapter 2) 
and the same methodology59,73 to provide a rationale for the present findings in atomic detail. In the 
case of 1.90, the tetrazole moiety is proposed to establish a non-water mediated interaction with the 
guanidinium of Arg167 whereas the amino group can establish a hydrogen bond with the hydroxyl 
group of Tyr177 (Figure. I.30). Interestingly, whereas Arg167 in TK-2 is positionally equivalent to 
Arg169 in Dm-dNK and Arg222 in HSV-1 TK, the structural equivalent of Tyr177 in TK-2 is also a 
tyrosine (Tyr179) in Dm-dNK but a methionine (Met231) in HSV-1 TK. This latter amino acid cannot 
establish a hydrogen bond with the amino group of 1.90 and this may contribute to the fact that these 
compounds are much better inhibitors against TK-2 and Dm-dNK than against HSV-1 TK. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.30. (left) Detail of the substrate binding site in the refined complex of 1.90 with ATP-bound human TK-2. 
Inhibitor, protein and ATP carbon atoms are colored blue, grey and green, respectively. The magenta sphere 
represents the catalytic Mg2+ ion. Some of the protein side-chains relevant to the discussion are labeled and 
shown as sticks. Note the non-water mediated interaction between the tetrazole moiety and the guanidinium of 
Arg167 and the hydrogen bond between the amino group and the hydroxyl group of Tyr177. (right) Contact 
surface of the enzyme with inhibitor 1.90 (colored in green).  
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3.5 CONCLUSIONS 
Our ongoing efforts to identify potent and selective inhibitors of mitochondrial thymidine kinase 2, led 
us to synthesize new 3’-modified thymidines related to the recently discovered 3’-[4-aryl-(1,2,3-triazol-
1-yl)]-3’-deoxythymidine analogues. Replacement of the triazole linkage by a basic amine or 
guanidine, as possible interaction partners of the γ-phosphate group of the ATP cosubstrate, generally 
led to a drop in inhibitory activity. Interestingly, treatment of a 3’-arylthiourea-substituted 5’-O-tritylated 
thymidine precursor with HgCl2 and sodium azide exclusively afforded tetrazole 1.89 containing an 
amino group between C-3’ of the deoxyribose and the tetrazole, while the same reaction performed on 
a 3’-benzylthiourea congener mainly gave rise to the regioisomer with the tetrazole ring directly 
connected to the sugar. In the resulting 1,5-aminotetrazole series, the isomers in which the tetrazole 
ring is attached to C-3’ via a NH bridge exhibit the best anti-TK-2 activity, with a 3-CF3-4-Cl phenyl 
substituent at position N-1 of the tetrazole ring affording the best TK-2-inhibition profile. Further 
introduction of a 5-(2-bromovinyl) substituent gave derivative 1.100, which emerged as the most 
potent and selective TK-2 inhibitor reported so far. A TK-2 homology model allowed to assess the 
binding mode of both tetrazole isomers. In the case of regioisomer 1.90, modeling studies indicated a 
contributing role of the tetrazole ring and the amino bridge to the overall affinity for TK-2. 
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3.6 EXPERIMENTAL PART 
3.6.1 Synthesis 
General procedure for the synthesis of substituted 3’-benzylamino-3’-deoxy-5’-O-
triphenylmethyl-β-D-thymidine analogues 1.77-1.79 
 
To a suspension of amine 1.58 (1.0 equiv.) in dry MeOH was added a suitable benzaldehyde (1.05 
equiv.). After 24 h stirring at room temperature, NaBH4 (1.5 equiv.) was added and 30 min later the 
mixture was quenched with 1M NaOH. The reaction mixture was extracted with CH2Cl2 and the 
organic layer washed with brine and dried over MgSO4, filtered and evaporated to dryness. The 
residue was purified by column chromatography affording 3’-benzylamino analogues 1.77-1.79 in 
moderate yield. 
 
3’-Benzylamino-3’-deoxy-5’-O-triphenylmethyl-β-D-thymidine (1.77)  
 
O N
TrO
HN
NH
O
O
 
 
Reaction of compound 1.58 (88 mg, 0.18 mmol), benzaldehyde (17 mL, 0.17 mmol) in 0.7 mL MeOH 
was performed as described in the general procedure for the synthesis of 3’-benzylamino-3’-deoxy-5’-
O-triphenylmethyl-β-D-thymidine analogues affording 1.77 as a colourless solid (17 mg, 16%).  
 
1H NMR (300 MHz, CDCl3): δ 1.47 (3H, d, J= 1.2 Hz, 5-CH3), 2.29 (2H, app t, J= 6.0 Hz, H-2’a and H-
2’b), 3.33-3.47 (2H, m, H-5’a and H-5’b), 3.57 (1H, app dd, J= 6.3 Hz, J= 12.3 Hz, H-3’), 3.74 (2H, app 
q, J= 13.2 Hz, Bn), 3.91-3.93 (1H, m, H-4’), 6.26 (1H, app t, J= 6.0 Hz, H-1’), 7.20-7.40 (20H, m, Tr 
and Bn), 7.52 (1H, d, J= 0.9 Hz, H-6).  
 
13C NMR (75 MHz, CDCl3): δ 12.10 (5-CH3), 39.60 (C-2’), 52.29 (Bn), 57.53 (C-3’), 63.80 (C-5’), 84.68 
(C-1’), 85.11 (C-4’), 87.45 (Tr), 110.96 (C-5), 127.42, 127.51, 128.15, 128.71, 128.81 (Bn and Tr), 
135.70 (C-6), 139.60 (Bn), 143.50 (Tr), 150.29 (C-2), 163.77 (C-4).  
 
Exact Mass (ESI-MS) for C36H36N3O4 [M+H]+ found: 574.2770, calcd: 574.2700. 
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3’-(4-Chlorobenzylamino)-3’-deoxy-5’-O-triphenylmethyl-β-D-thymidine (1.78) 
 
O N
TrO
HN
NH
O
O
Cl  
 
Reaction of compound 1.58 (82 mg, 0.17 mmol), 4-chlorobenzaldehyde (23 mg, 0.16 mmol) in 0.6 mL 
MeOH was performed as described in the general procedure for the synthesis of 3’-benzylamino-3’-
deoxy-5’-O-triphenylmethyl-β-D-thymidine analogues affording 1.78 as a colourless solid (91 mg, 
88%).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.43 (3H, d, J= 0.9 Hz, 5-CH3), 2.13-2.27 (2H, m, H-2’a and H-2’b), 
3.16-3.24 (2H, m, H-5’a and H-5’b), 3.39 (1H, app dt, J= 5.7 Hz, H-3’), 3.67 (2H, app q, J= 14.1 Hz, 
subs Bn), 3.87-3.91 (1H, m, H-4’), 6.19 (1H, app t, J= 6.3 Hz, H-1’), 7.24-7.37 (19H, m, Tr and subs 
Bn), 7.51 (1H, d, J= 0.9 Hz, H-6), 11.32 (1H, s, 3-NH).  
 
13C NMR (75 MHz, DMSO-d6): δ 11.75 (5-CH3), 37.44 (C-2’), 49.98 (subs Bn), 56.83 (C-3’), 64.04 (C-
5’), 83.26 (C-1’), 83.91 (C-4’), 86.30 (Tr), 109.38 (C-5), 127.14, 127.93, 128.01, 128.24, 129.70, 
131.06 (Tr and subs Bn), 135.66 (C-6), 139.60 (subs Bn), 143.48 (Tr), 150.34 (C-2), 163.67 (C-4).  
 
Exact Mass (ESI-MS) for C36H35ClN3O4 [M+H]+ found: 608.2357, calcd: 608.2311. 
 
3’-[4-Chloro-(3-trifluoromethyl)benzylamino]-3’-deoxy-5’-O-triphenylmethyl-β-D-thymidine (1.79) 
 
O N
TrO
HN
NH
O
O
CF3
Cl  
 
Reaction of compound 1.58 (108 mg, 0.22 mmol), 4-chloro-3-(trifluoromethyl)benzaldehyde (51 mg, 
0.24 mmol) in 0.8 mL MeOH was performed as described in the general procedure for the synthesis of 
3’-benzylamino-3’-deoxy-5’-O-triphenylmethyl-β-D-thymidine analogues affording 1.79 as a colourless 
solid (103 mg, 68%). 
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1H NMR (300 MHz, DMSO-d6): δ 1.44 (3H, d, J= 0.9 Hz, 5-CH3), 2.18-2.26 (2H, m, H-2’a and H-2’b), 
3.19 (2H, d, J= 3.6 Hz, H-5’a and H-5’b), 3.30-3.38 (1H, m, H-3’), 3.74 (2H, app q, J= 14.1 Hz, Bn), 
3.88-3.89 (1H, m, H-4’), 6.18 (1H, app t, J= 6.6 Hz, H-1’), 7.24-7.34 (15H, m, Tr), 7.50 (1H, d, J= 1.5 
Hz, H-6), 7.55-7.63 (2H, m, Bn), 7.76 (1H, d, J= 1.5 Hz, Bn), 11.31 (1H, s, 3-NH).  
 
13C NMR (75 MHz, DMSO-d6): δ 11.79 (5-CH3), 37.29 (C-2’), 49.49 (Bn), 57.09 (C-3’), 59.74 (C-5’), 
83.22 (C-1’), 83.87 (C-4’), 86.28 (Tr), 109.38 (C-5), 121.15, 124.77, 126.93-128.22, 128.63 (Tr and 
subs Bn), 131.28 and 133.47 (subs Bn), 135.70 (C-6), 140.99 (subs Bn), 143.49 (Tr), 150.34 (C-2), 
163.67 (C-4).  
 
Exact Mass (ESI-MS) for C37H34ClF3N3O4 [M+H]+ found: 676.2194, calcd: 676.2184. 
 
3’-Benzylamino-3’-deoxy-β-D-thymidine (1.80) 
 
O N
HO
HN
NH
O
O
 
 
Compound 1.77 (94 mg, 0.16 mmol) was dissolved in a mixture of ZnBr2 (592 mg, 2.63 mmol) in 
CH2Cl2/iPrOH (2.6 mL, 85:15) and stirred overnight at room temperature. The reaction was quenched 
with water and extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were dried over MgSO4 
and evaporated to dryness. The resulting residue was purified by column chromatography 
(CH2Cl2/MeOH 95:5), to yield compound 1.80 (18.2 mg, 34%) as a colourless oil. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.77 (3H, m, 5-CH3), 1.99-2.14 (2H, m, H-2’a and H-2’b), 3.27-3.33 
(1H, m, H-3’), 3.53-3.71 (4H, m, H-5’a, H-5’b and Bn), 3.76-3.80 (1H, m, H-4’), 4.10 (1H, app br s, 3’-
NH), 5.01 (1H, app br s, 5’-OH), 6.15 (1H, app t, J= 6.3 Hz, H-1’), 7.19-7.32 (5H, m, Bn), 7.74 (1H, d, 
J= 1.2 Hz, H-6), 11.25 (1H, s, 3-NH).  
 
13C NMR (75 MHz, DMSO-d6): δ 12.27 (5-CH3), 37.55 (C-2’), 51.10 (Bn), 57.39 (C-3’), 61.75 (C-5’), 
83.96 (C-1’), 85.32 (C-4’), 109.14 (C-5), 126.56, 127.96 and 128.09 (Bn), 136.25 (C-6), 140.78 (Bn), 
150.42 (C-2), 163.77 (C-4).  
 
Exact Mass (ESI-MS) for C17H22N3O4 [M+H]+ found: 332.1613, calcd: 332.1605. 
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3’-(4-Chlorobenzylamino)-3’-deoxy-β-D-thymidine (1.81) 
 
O N
HO
HN
NH
O
O
Cl  
 
Compound 1.81 (14 mg, 56%, colourless solid) was synthesized from compound 1.78 (40 mg, 0.066 
mmol) using the same procedure as described for the synthesis of 1.80.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.76 (3H, d, J= 1.0 Hz, 5-CH3), 2.04-2.10 (2H, m, H-2’a and H-2’b), 
3.24-3.40 (1H, m, H-3’), 3.51-3.66 (2H, m, H-5’a and H-5’b), 3.69 (2H, d, J= 3.3 Hz, subs Bn), 3.75-
3.79 (1H, m, H-4’), 5.02 (1H, app br s, 5’-OH), 6.14 (1H, app t, J= 6.5 Hz, H-1’), 7.37 (4H, app s, subs 
Bn), 7.73 (1H, d, J= 1.3 Hz, H-6), 11.25 (1H, s, 3-NH).  
 
13C NMR (75 MHz, DMSO-d6): δ 12.35 (5-CH3), 37.58 (C-2’), 50.30 (subs Bn), 57.33 (C-3’), 61.77 (C-
5’), 84.03 (C-1’), 85.35 (C-4’), 109.27 (C-5), 128.12, 129.88 and 131.12 (subs Bn), 136.35 (C-6), 
139.95 (subs Bn), 150.51 (C-2), 163.90 (C-4). 
 
Exact Mass (ESI-MS) for C17H21ClN3O4 [M+H]+ found: 366.1215, calcd: 366.1215. 
 
3’-[4-Chloro-3-(trifluoromethyl)benzylamino]-3’-deoxy-β-D-thymidine (1.82) 
 
O N
HO
HN
NH
O
O
CF3
Cl  
 
Compound 1.82 (80 mg, 58%, colourless solid) was synthesized from compound 1.79 (97 mg, 0.14 
mmol) using the same procedure as described for the synthesis of 1.80.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.77 (3H, d, J= 1.2 Hz, 5-CH3), 2.05-2.12 (2H, m, H-2’a and H-2’b), 
3.25-3.33 (1H, m, H-3’), 3.52-3.67 (2H, m, H-5’a and H-5’b), 3.73-3.84 (3H, m, H-4’ and subs Bn), 4.07 
(1H, app br s, 3’-NH), 5.01 (1H, app br s, 5’-OH), 6.15 (1H, app t, J= 6.3 Hz, H-1’), 7.67 (2H, app s, 
subs Bn), 7.73 (1H, d, J= 0.9 Hz, H-6), 7.84 (1H, app s, subs Bn), 11.25 (1H, s, 3-NH). 
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13C NMR (75 MHz, DMSO-d6): δ 12.25 (5-CH3), 37.43 (C-2’), 49.63 (subs Bn), 57.24 (C-3’), 61.62 (C-
5’), 83.88 (C-1’), 85.22 (C-4’), 109.15 (C-5), 124.83, 126.06-128.57, 131.30 and 133.59 (subs Bn), 
136.21 (C-6), 141.23 (subs Bn), 150.41 (C-2), 163.76 (C-4). 
 
Exact Mass (ESI-MS) for C18H20ClF3N3O4 [M+H]+ found: 434.1114, calcd: 434.1089. 
 
General procedure for the synthesis of N-(3’-deoxy-5’-O-triphenylmethyl-β-D-thymidin-3’-yl)-N’-
(4-chloro-3-(trifluoromethyl)phenyl)guanidine analogues 1.83-1.85 
 
To a solution of thiourea 1.59 (1.0 equiv.) in dry DMF were added the appropriate amine (1.0 equiv.), 
Et3N (2.0 equiv.) and HgCl2 (1.0 equiv.) at 0 °C under N2 atmosphere. The resulting black reaction 
mixture was stirred for several hours at room temperature until TLC indicated complete consumption 
of starting material. The suspension was filtered through a pad of Celite, washing with CH2Cl2. The 
filtrate was diluted with water and extracted with CH2Cl2. The combined organic layers were dried over 
MgSO4, filtered and concentrated under reduced pressure. The resulting residue was purified by silica 
gel chromatography (CH2Cl2/MeOH 90:10 or 80:20) to give the appropriate guanidine in moderate 
yield. 
 
N-(3’-Deoxy-5’-O-triphenylmethyl-β-D-thymidin-3’-yl)-N’-[4-chloro-3-(trifluoromethyl)phenyl]-
guanidine (1.83) 
O N
TrO
HN
NH
O
O
HN
N
Cl
CF3
H
 
 
Reaction of compound 1.59 (232 mg, 0.32 mmol) with 10 mL 7N NH3 following the procedure as 
described above, yielded compound 1.83 (128 mg, 57%) as a white powder. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.50 (3H, app s, 5-CH3), 2.29-2.34 (1H, m, H-2’a), 2.49-2.52 (1H, m, 
H-2’b), 3.26-3.39 (2H, m, H-5’a and H-5’b), 4.00-4.02 (1H, m, H-4’), 4.64-4.66 (1H, m, H-3’), 6.21 (1H, 
app t, J= 5.7 Hz, H-1’), 7.23-7.61 (19H, m, Tr, subs Ph and H-6), 11.34 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 11.87 (5-CH3), 37.24 (C-2’), 50.90 (C-3’), 62.94 (C-5’), 82.65 (C-1’), 
83.35 (C-4’), 86.39 (Tr), 109.50 (C-5), 122.39, 124.59, 125.95, 126.73, 127.05, 127.16, 127.90, 
127.97, 128.29, 132.21 (CF3, subs Ph and Tr), 135.79 (C-6), 143.46 (Tr), 150.37 (C-2), 153.18 (C=N), 
163.74 (C-4). 
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Exact Mass (ESI-MS) for C37H34ClF3N5O4 [M+H]+ found: 704.2241, calcd: 704.2246. 
 
N-(3’-Deoxy-5’-O-triphenylmethyl-β-D-thymidin-3’-yl)-N’-[4-chloro-3-(trifluoromethyl)phenyl]-
benzylguanidine (1.84) 
O N
TrO
HN
NH
O
O
HN
N
Cl
CF3
 
 
Reaction of compound 1.59 (87 mg, 0.12 mmol) with benzylamine (13 μL, 0.12 mmol) following the 
procedure as described above, afforded compound 1.84 (54 mg, 56%) as a white solid.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.43 (3H, d, J= 0.9 Hz, 5-CH3), 2.20-2.28 (1H, m, H-2’a), 2.31-2.41 
(1H, m, H-2’b), 3.23-3.32 (2H, m, H-5’a and H-5’b), 3.92-3.95 (1H, m, H-4’), 4.26 (2H, d, J= 5.7 Hz, 
Bn), 4.60-4.63 (1H, m, H-3’), 6.13-6.26 (3H, m, H-1’ and Bn), 6.73 (1H, d, J= 8.4 Hz, 3’-NH), 6.91 (1H, 
s, N’H), 7.19-7.41 (21H, m, Tr, Bn and subs Ph), 7.54 (1H, d, J= 0.9 Hz, H-6).  
 
13C NMR (75 MHz, DMSO-d6): δ 11.81 (5-CH3), 37.32 (C-2’), 44.48 (Bn), 54.91 (C-3’), 63.42 (C-5’), 
83.46 (C-1’), 86.26 (C-4’ and Tr), 109.31 (C-5), 119.81, 126.63, 127.02, 127.06, 127.89, 128.11, 
128.26, 131.62 (CF3, subs Ph, Tr and Bn), 135.73 (C-6), 140.03 (Bn), 143.56 (Tr), 151.33 (C-2), 
151.49 (C=N), 163.70 (C-4). 
 
Exact Mass (ESI-MS) for C44H40ClF3N5O4 [M+H]+ found: 794.2727, calcd: 794.2715. 
 
N-(3’-Deoxy-5’-O-triphenylmethyl-β-D-thymidin-3’-yl)-N’-[4-chloro-3-(trifluoromethyl)phenyl]-
isopropylguanidine (1.85) 
O N
TrO
HN
NH
O
O
HN
N
Cl
CF3
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Reaction of compound 1.59 (232 mg, 0.32 mmol) with isopropylamine (27 μL, 0.32 mmol) following the 
procedure as described above, afforded compound 1.85 (128 mg, 57%) as a white powder.  
 
1H NMR (300 MHz, DMSO-d6): δ 0.97-1.06 (6H, m, iPr), 1.42 (3H, s, 5-CH3), 2.26-2.35 (2H, m, H-2’a 
and H-2’b), 3.24-3.35 (2H, m, H-5’a and H-5’b), 3.66 (1H, app sex, J= 6.9 Hz, iPr), 3.95-3.96 (1H, m, 
H-4’), 4.64 (1H, app d, J= 5.4 Hz, H-3’), 5.29 (1H, d, J= 5.4 Hz, 3’-NH), 6.08 (1H, br s, N’H), 6.20 (1H, 
app t, J= 6.3 Hz, H-1’), 6.76 (1H, d, J= 8.7 Hz, subs Ph), 6.94 (1H, s, subs Ph), 7.21-7.42 (16H, m, Tr 
and subs Ph), 7.56 (1H, d, J= 1.2 Hz, H-6), 11.32 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 11.74 (5-CH3), 22.65 (iPr), 37.20 (C-2’), 42.73 (iPr), 50.48 (C-3’), 
63.51 (C-5’), 83.48 (C-1’), 83.75 (C-4’), 86.27 (Tr), 109.34 (C-5), 119.34, 121.30, 124.92, 126.42, 
126.81, 127.07, 127.42, 127.87, 128.27, 128.54, 131.63 (CF3, subs Ph and Tr), 135.72 (C-6), 143.54 
(Tr), 150.33 (C-2), 151.32 (C=N), 163.68 (C-4). 
 
Exact Mass (ESI-MS) for C40H40ClF3N5O4 [M+H]+ found: 746.2717, calcd: 746.2715. 
 
N-(3’-Deoxy-β-D-thymidin-3’-yl)-N’-[4-chloro-3-(trifluoromethyl)phenyl]guanidine (1.86) 
 
O N
HO
HN
NH
O
O
HN
N
Cl
CF3
H
 
 
A solution of compound 1.83 (108 mg, 0.15 mmol) in 3.0 mL HCOOH/Et2O 7:3 (v:v) reacted for 45 min 
at room temperature. The reaction was quenched with EtOAc and water, washed with sat. NaHCO3 
and extracted with EtOAc (3 x 5mL). The combined organic layers were dried over MgSO4 and the 
solvent evaporated. The residue was purified by column chromatography (CH2Cl2/MeOH 80:20) to 
yield compound 1.86 (50 mg, 71%) as a yellow/brown solid. Treatment with a 4N HCl solution in 1,4-
dioxane gave the appropriate salt.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.78 (3H, d, J= 0.9 Hz, 5-CH3), 2.16-2.36 (2H, m, H-2’a and H-2’b), 
3.59-3.72 (2H, m, H-5’a and H-5’b), 3.81-3.84 (1H, m, H-4’), 4.29 (1H, app dd, J= 6.0 Hz, J= 12.9 Hz, 
H-3’), 5.76 (1H, app br s, 5’-OH), 6.16 (1H, app t, J= 6.3 Hz, H-1’), 7.12 (1H, d, J= 7.5 Hz, subs Ph), 
7.25 (1H, s, subs Ph), 7.50 (1H, d, J= 8.4 Hz, subs Ph), 7.75 (1H, d, J= 1.2 Hz, H-6). 
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13C NMR (75 MHz, DMSO-d6): δ 12.29 (5-CH3), 37.33 (C-2’), 50.93 (C-3’), 61.17 (C-5’), 83.34 (C-1’), 
85.37 (C-4’), 109.26 (C-5), 126.65, 127.06, 128.26 and 131.97 (subs Ph), 136.08 (C-6), 147,39 (C-2), 
150.42 (C=N), 163.76 (C-4).  
 
Exact Mass (ESI-MS) for C18H20ClF3N5O4 [M+H]+ found: 462.1132, calcd: 462.1150. 
 
N-(3’-Deoxy-β-D-thymidin-3’-yl)-N’-[4-chloro-3-(trifluoromethyl)phenyl]benzylguanidine (1.87) 
 
O N
HO
HN
NH
O
O
HN
N
Cl
CF3
 
 
Compound 1.87 (15 mg, 68%) was synthesized from compound 1.84 (33 mg, 0.041 mmol) using the 
same procedure as described for the synthesis of 1.86. Treatment with a 4N HCl solution in 1,4-
dioxane gave the appropriate salt.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.76 (3H, d, J= 0.6 Hz, 5-CH3), 2.23 (2H, app t, J= 6.9 Hz, H-2’a and 
H-2’b), 3.51-3.3.57 (1H, m, H-5’a), 3.62-3.67 (1H, m, H-5’b), 3.77-3.81 (1H, m, H-4’), 4.27-4.32 (3H, m, 
H-3’ and Bn), 6.14 (1H, app t, J= 6.3 Hz, H-1’), 6.35 (1H, app br s, 5’-OH), 6.93 (1H, app dd, J= 2.4 
Hz, J= 8.7 Hz, subs Ph), 7.02-7.03 (1H, m, subs Ph), 7.20-7.35 (5H, m, Bn), 7.41 (1H, d, J= 8.7 Hz, 
subs Ph), 7.73 (1H, d, J= 1.2 Hz, H-6).  
 
13C NMR (75 MHz, DMSO-d6): δ 12.27 (5-CH3), 37.32 (C-2’), 44.59 (Bn), 51.01 (C-3’), 60.98 (C-5’), 
83.32 (C-1’), 85.17 (C-4’), 109.18 (C-5), 120.07, 121.28, 121.52, 121.60, 124.90, 126.56, 126.70, 
126.96, 127.13, 127.86, 128.18, 131.82, (CF3, subs Ph and Bn), 136.18 (C-6), 140.01 (Bn), 150.40 (C-
2), 152.17 (C=N), 163.77 (C-4).  
 
Exact Mass (ESI-MS) for C25H26ClF3N5O4 [M+H]+ found: 552.1620, calcd: 552.1620. 
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N-(3’-Deoxy-β-D-thymidin-3’-yl)-N’-[4-chloro-3-(trifluoromethyl)phenyl]isopropylguanidine (1.88) 
 
O N
HO
HN
NH
O
O
HN
N
Cl
CF3
 
 
Compound 1.88 (54 mg, 0.11 mmol, 64%) was synthesized from compound 1.85 (123.7 mg, 0.17 
mmol) using the same procedure as described for the synthesis of 1.86. Treatment with a 4N HCl 
solution in 1,4-dioxane gave the appropriate salt.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.07-1.09 (6H, m, iPr), 1.77 (3H, d, J= 1.2 Hz, 5-CH3), 2.28 (2H, app 
t, J= 7.2 Hz, H-2’a and H-2’b), 3.56-3.84 (4H, m, H-4’, H-5’a, H-5’b and iPr), 4.32 (1H, app dd, J= 6.6 
Hz, J= 12.3 Hz, H-3’), 5.90 (1H, app br s, 5’-OH), 6.18 (1H, app t, J= 6.6 Hz, H-1’), 7.06 (1H, app dd, 
J= 2.4 Hz, J= 8.7 Hz, subs Ph), 7.19 (1H, d, J= 2.1 Hz, subs Ph), 7.47 (1H, d, J= 8.7 Hz, subs Ph), 
7.71 (1H, d, J= 1.2 Hz, H-6).  
 
13C NMR (75 MHz, DMSO-d6): δ 12.25 (5-CH3), 22.59 (iPr), 36.96 (C-2’), 43.23 (iPr), 51.64 (C-3’), 
61.14 (C-5’), 83.30 (C-1’), 85.08 (C-4’), 109.36 (C-5), 120.86, 121.21, 121.41, 124.83, 126.64, 127.05, 
127.57, 131.97 (CF3 and subs Ph), 136.13 (C-6), 150.42 (C-2), 152.10 (C=N), 163.74 (C-4). 
 
Exact Mass (ESI-MS) for C21H26ClF3N5O4 [M+H]+ found: 504.1644, calcd: 504.1620. 
 
General procedure for the synthesis of substituted 1,5-aminotetrazole analogues 1.89, 1.93, 
1.94 and 1.99 
 
To a suspension of a suitable thiourea (1.0 equiv.), sodium azide (3.0 equiv.) and HgCl2 (1.1 equiv.) in 
dry DMF was added Et3N (3.0 equiv.) at 0 °C under N2 atmosphere. The resulting suspension was 
stirred for several hours at room temperature until TLC indicated complete consumption of starting 
material. The suspension was filtered through a pad of Celite, washing with CH2Cl2. The filtrate was 
diluted with water and extracted with CH2Cl2. The combined organic layers were dried over MgSO4, 
filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel 
chromatography (EtOAc/hexane 95:5 or CH2Cl2/MeOH 98:2) to give the appropriate tetrazole. 
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5-(3’-Amino-3’-deoxy-5’-O-triphenylmethyl-β-D-thymidin-3’N-yl)-1-(4-chloro-3-(trifluoromethyl)-
phenyl)tetrazole (1.89) 
O N
HN
NH
O
O
TrO
N
N N
NCl
F3C  
 
Reaction of compound 1.59 (189 mg, 0.26 mmol), NaN3 (51 mg, 0.79 mmol), HgCl2 (78 mg, 0.29 
mmol) and Et3N (105 μL, 0.76 mmol) yielded compound 1.89 (58 mg, 31%) as a yellow/brown solid.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.51 (3H, s, 5-CH3), 2.33-2.42 (1H, m, H-2’a), 2.46-2.53 (1H, m, H-
2’b), 3.27-3.33 (1H, m, H-5’a), 3.41-3.46 (1H, m, H-5’b), 4.09-4.13 (1H, m, H-4’), 4.55-4.60 (1H, m, H-
3’), 6.31 (1H, app t, J= 6.6 Hz, H-1’), 7.23-7.42 (15H, m, Tr), 7.50 (1H, d, J= 7.2 Hz, 3’-NH), 7.60 (1H, 
d, J= 1.2 Hz, H-6), 7.90-8.05 (3H, subs Ph), 11.36 (1H, s, 3-NH).  
 
13C NMR (75 MHz, DMSO-d6): δ 11.82 (5-CH3), 36.68 (C-2’), 59.74 (C-3’), 64.09 (C-5’), 82.60 (C-1’), 
83.70 (C-4’), 86.44 (Tr), 109.73 (C-5), 120.36, 123.99, 124.96, 125.03, 127.17-127.67, 127.95-128.27, 
128.51, 130.86, 131.90, 132.21, 133.21 (CF3, subs Ph and Tr), 135.83 (C-6), 143.49 (Tr), 150.39 (C-
2), 154.54 (C=N), 163.66 (C-4).  
 
Exact Mass (ESI-MS) for C37H31ClF3N7O4Na [M+Na]+ found: 752.006, calcd: 752.1970. 
 
5-(3’-Amino-3’-deoxy-β-D-thymidin-3’N-yl)-1-(4-chloro-3-(trifluoromethyl)phenyl)tetrazole (1.90) 
 
O N
HN
NH
O
O
HO
N
N N
NCl
F3C  
 
A solution of compound 1.89 (34 mg, 0.047 mmol) in 1.0 mL HCOOH/Et2O 7:3 (v:v) reacted for 45 
min. EtOAc and water were added to the mixture which was then washed with saturated NaHCO3 and 
extracted with EtOAc (3 x 5 mL). The combined organic layers were dried over MgSO4 and the solvent 
evaporated. The residue was purified by column chromatography (CH2Cl2/MeOH 95:5) to yield 
compound 1.90 (10.0 mg, 0.021 mmol, 45%) as a white solid.  
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1H NMR (300 MHz, DMSO-d6): δ 1.80 (3H, s, 5-CH3), 2.29-2.34 (2H, m, H-2’a and H-2’b), 3.65-3.73 
(2H, m, H-5’a and H-5’b), 3.97-4.01 (1H, m, H-4’), 4.35-4.41 (1H, m, H-3’), 5.19 (1H, app br s, 5’-OH), 
6.25 (1H, app t, J= 6.9 Hz, H-1’), 7.81 (1H, d, J= 0.9 Hz, H-6), 7.96-8.03 (2H, m, subs Ph), 8.17 (1H, s, 
subs Ph).  
 
13C NMR (75 MHz, DMSO-d6): δ 12.30 (5-CH3), 37.05 (C-2’), 54.46 (C-3’), 61.51 (C-5’), 83.63 (C-1’), 
84.66 (C-4’), 109.45 (C-5), 124.06-133.14 (subs Ph), 136.18 (C-6), 150.49 (C-2), 154.84 (C=N), 
163.79 (C-4).  
 
Exact Mass (ESI-MS) for C18H18ClF3N7O4 [M+H]+ found: 488.1070, calcd: 488.1055. 
 
5-(3’-Amino-3’-deoxy-β-D-thymidin-3’N-yl)-1-(4-chloro-3-(trifluoromethyl)phenyl)tetrazole (1.90) 
and 5-[(4-chloro-3-(trifluoromethyl)phenyl)amino]-1-(3’-deoxy-β-D-thymidin-3’-yl)tetrazole (1.91) 
 
O N
N
NH
O
O
HO
N
N
N NH
Cl
CF3
1.91
O N
HN
NH
O
O
HO
N
N N
NCl
F3C
1.90
 
 
Compound 1.89 (80 mg, 0.11 mmol) was dissolved in a mixture of ZnBr2 (394 mg, 1.75 mmol) in 
CH2Cl2/iPrOH (1.8 mL, 85:15) and stirred overnight at room temperature. The reaction was quenched 
with water and extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were dried over MgSO4 
and evaporated to dryness. The resulting residue was purified using RP-HPLC (Phenomenex Luna C-
18, 250 x 21.10 mm 5 mm, H2O-CH3CN, 90:10 → 0:100 in 29 min, flow: 17.5 mL min-1), affording 
isomers 1.90 and 1.91 as white powders (17 mg, 32%, 9:1).  
 
Compound 1.91: 
 
1H NMR (300 MHz, DMSO-d6): δ 1.83 (3H, app s, 5-CH3), 2.50-2.2.62 (2H, m, H-2’a and H-2’b), 3.65-
3.76 (3H, m, H-4’, H-5’a and H-5’b), 4.25 (1H, app s, H-3’), 5.43 (1H, br s, 5’-OH), 6.46 (1H, app t, J= 
6.6 Hz, H-1’), 7.55-7.58 (1H, d, J= 8.1 Hz, subs Ph), 7.80-7.96 (2H, m, subs Ph), 8.15 (1H, app s, H-
6).  
 
13C NMR (175 MHz, DMSO-d6): δ 12.73 (5-CH3), 61.68 (C-5’), 84.32 and 84.54 (C-1’ and C-4’), 110.20 
(C-5), 127.97-134.08 (subs Ph), 136.59 (C-6), 150.94 (C-2), (C=N not visible), 164.19 (C-4). 
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Exact Mass (ESI-MS) for C18H18ClF3N7O4 [M+H]+ found: 488.1063, calcd: 488.1055. 
 
N-(3’-Deoxy-5’-O-triphenylmethyl-β-D-thymidin-3’-yl)-N’-benzylthiourea (1.92) 
 
O N
HN
NH
O
O
HN
S
TrO
 
 
Reaction of compound 1.58 (364 mg, 0.75 mmol) with benzyl isothiocyanate (114 mg, 0.75 mmol) was 
performed as described for the synthesis of compound 1.59 affording compound 1.92 in a 99% yield 
(471 mg, white foam).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.42 (3H, s, 5-CH3), 2.18-2.26 (1H, m, H-2’a), 2.45-2.55 (1H, m, H-
2’b), 3.18-3.22 (1H, m, H-5’a), 3.38-3.43 (1H, m, H-5’b), 4.03 (1H, app s, H-4’), 4.68 (2H, app s, Bn), 
5.10 (1H, app br s, H-3’), 6.21 (1H, app t, J= 6.6 Hz, H-1’), 7.21-7.42 (20H, m, Tr and Bn), 7.55 (1H, 
app s, 6-H), 7.80-7.92 (1H, m, 3’-NH), 8.02 (1H, m, N’H), 11.35 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 11.79 (5-CH3), 30.80 (Bn), 35.81 (C-2’), 47.04 (C-3’), 63.76 (C-5’), 
83.63 (C-1’ and C-4’), 86.51 (Tr), 109.55 (C-5), 126.86, 127.17, 127.23, 128.01, 128.27, 128.32 (Tr 
and Bn), 135.51 (Bn), 139.13 (C-6’), 143.47 (Tr), 150.38 (C-2), 162.34 (C-4).  
 
Exact Mass (ESI-MS) for C37H37N4O4S [M + H]+ found: 633.2505, calcd: 633,2530. 
 
5-(3’-Amino-3’-deoxy-5’-O-triphenylmethyl-β-D-thymidin-3’N-yl)-1-benzyltetrazole (1.93) and 5-
(benzylamino)-1-(3’-deoxy-5’-O-triphenylmethyl-β-D-thymidin-3’-yl)tetrazole (1.94) 
 
O N
N
NH
O
O
TrO
N
N
N NH
1.94
O N
HN
NH
O
O
TrO
N
N N
N
1.93
 
 
Reaction of compound 1.92 (207 mg, 0.33 mmol), NaN3 (64 mg, 0.98 mmol), HgCl2 (98 mg, 0.36 
mmol) and Et3N (136 μL, 0.98 mmol) in 1.3 mL DMF was performed as described in the general 
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synthesis of substituted 1,5-aminotetrazole analogues. A mixture of compounds 1.93 and 1.94 (1:2.2) 
was obtained as a white solid (108 mg, 52%).  
 
1H NMR (300 MHz, CDCl3): δ 1.33 (isomer 1: 5-CH3, s), 1.49 (isomer 2: 5-CH3, s), 2.40-2.50 (isomer 
1: H-2’a and H-2’b, m), 2.79-2.88 (isomer 2: H-2’a and H-2’b, m), 3.34-3.45 (isomer 2: H-5’a and H-
5’b, m), 3.48-3.54 (isomer 1: H-5’a and H-5’b, m), 4.07-4.10 (isomer 1:H-4’, m), 4.33-4.47 (isomer 2: 
CH2Ph, m), 4.51-4.56 (isomer 2: H-4’, m), 4.69-4.71 (isomer 1: H-3’, m), 5.07-5.15 (isomer 2: H-3’, m), 
5.32 (isomer 1: Bn, s), 6.09 (isomer 2: H-1’, app t, J= 5.4 Hz), 6.18 (isomer 1: H-1’ and isomer 2: N’H, 
app t, J= 6.0 Hz), 6.57 (isomer 1: 3’-NH, d, J= 7.2Hz), 7.07-7.56 (20H, m, Tr, Bn & 6-H), 10.15 (isomer 
1: 3-NH, s), 10.27 (isomer 2: 3-NH, s).  
 
13C NMR (75 MHz, CDCl3): δ 11.72 and 12.13 (5-CH3), 37.66 (C-2’), 48.15 and 48.72 (Bn), 54.31 and 
55.24 (C-3’), 62.59 (C-5’), 82.25 (C-1’), 84.17 (C-4’), 87.48 and 87.69 (Tr), 110.69 and 111.54 (C-5), 
127.36-128.90 (Tr), 133.91 (Bn), 135.75 and 136.72 (C-6), 137.86 (Bn), 143.15 and 143.34 (Tr), 
150.70 and 151.04 (C-2), 154.92 and 155.81 (C=N), 164.04 (C-4).  
 
Exact Mass (ESI-MS) for C37H36N7O4 [M + H]+ found: 642.2827, calcd: 642,2823. 
 
5-(3’-Amino-3’-deoxy-β-D-thymidin-3’N-yl)-1-(benzyl)tetrazole (1.95) and 5-(benzylamino)-1-(3’-
deoxy-β-D-thymidin-3’-yl)tetrazole (1.96) 
 
O N
N
NH
O
O
HO
N
N
N NH
O N
HN
NH
O
O
HO
N
N N
N 1.95 1.96
 
 
Reaction of a mixture of compounds 1.93 and 1.94 (199 mg, 0.31 mmol) under the same conditions as 
described for the synthesis of 1.90 and 1.91 and purification on a RP-HPLC (Phenomenex Luna C-18, 
H2O/0.1% HCOOH in CH3CN, 90:10 → 0:100 in 29 min, flow: 17.5 mL min-1) afforded compounds 
1.95 and 1.96 as white powders (17 mg, 54%, 1:3).  
 
Compound 1.95: 
 
1H NMR (300 MHz, DMSO-d6): δ 1.79 (3H, d, J= 0.9 Hz, 5-CH3), 2.22-2.40 (2H, m, H-2’a and H-2’b), 
3.62-3.72 (2H, m, H-5’a and H-5’b), 3.97 (1H, app dt, J= 3.3 Hz, H-4’), 4.30-4.36 (1H, m, H-3’), 5.19 
(1H, app br s, 5’-OH), 5.43 (2H, s, Bn), 6.29 (1H, t, J= 6.9 Hz, H-1’), 7.22-7.25 (2H, m, Bn), 7.30-7.41 
(3H, m, Bn), 7.51 (1H, d, J= 6.9 Hz, 3’-NH), 7.81 (1H, d, J= 0.9 Hz, 6-H).  
PART I - Chapter 3: 3’-Guanidine-Substituted Thymidine and BVDU Derivatives  
78 
 
13C NMR (75 MHz, DMSO-d6): δ 12.30 (5-CH3), 37.08 (C-2’), 47.66 (Bn), 54.26 (C-3’), 61.56 (C-5’), 
83.62 (C-1’), 84.89 (C-4’), 109.48 (C-5), 127.42, 127.97, 128.77 and 135.30 (Bn), 136.09 (C-6), 
150.53 (C-2), 154.95 (C=N), 163.82 (C-4). 
 
Exact Mass (ESI-MS) for C18H22N7O4 [M + H]+ found: 400.1738, calcd: 400,1728.  
 
Compound 1.96: 
 
1H NMR (300 MHz, DMSO-d6): δ 1.81 (3H, d, J= 0.9 Hz, 5-CH3), 2.52-2.60 (2H, m, H-2’a and H-2’b), 
3.68 (2H, app dq, J= 3.0 Hz, J= 11.9 Hz, H-5’a and H-5’b), 4.32 (1H, app q, J= 3.6 Hz, H-4’), 4.51 (2H, 
d, J= 5.7 Hz, Bn), 5.10-5.16 (1H, m, H-3’), 5.39 (1H, app br s, 5’-OH), 6.39 (1H, t, J= 6.6 Hz, H-1’), 
7.23-7.40 (5H, m, Bn), 7.60 (1H, t, J= 5.7 Hz, 5’’-NH), 7.81 (1H, d, J= 1.5 Hz, 6-H), 11.35 (1H, s, 3-
NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.36 (5-CH3), 36.66 (C-2’), 46.87 (Bn), 55.04 (C-3’), 60.90 (C-5’), 
83.60 (C-4’), 84.03 (C-1’), 109.51 (C-5), 127.08, 127.40 and 128.32 (Bn), 136.05 (C-6), 138.92 (Bn), 
150.45 (C-2), 155.40 (C=N), 163.76 (C-4).  
 
Exact Mass (ESI-MS) for C18H22N7O4 [M + H]+ found: 400.1709, calcd: 400.1728. 
 
3’-Amino-(E)-5-(2-bromovinyl)-2’,3’-dideoxy-5’-O-triphenylmethyl-β-D-uridine (1.97) 
 
O N
TrO
H2N
NH
O
O
Br
 
 
Water (40 μL) and triphenylphosphine (318 mg, 1.21 mmol) were added to a solution of compound 
1.63 (154 mg, 0.26 mmol) in THF (6.6 mL). The solution was stirred for 24 h at room temperature. 
Then the solvent was evaporated and the crude residue was purified by column chromatography 
(CH2Cl2/MeOH 93:7) affording compound 1.97 as a yellow solid (104 mg, 71%).  
 
1H NMR (300 MHz, DMSO-d6): δ 2.03-2.12 (1H, m, H-2’a), 2.21-2.29 (1H, m, H-2’b), 3.17-3.29 (2H, m, 
H-5’a and H-5’b), 3.46 (1H, app dt, J= 7.2 Hz, H-3’), 3.69-3.74 (1H, m, H-4’), 4.09 (1H, br s, 3’-NH), 
6.13 (1H, dd, J= 4.5 Hz, J= 6.9 Hz, H-1’), 6.53 (1H, d, J= 13.2 Hz, H-8), 7.19-7.42 (16H, m, H-7 and 
Tr), 7.74 (1H, s, 6-H).  
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13C NMR (75 MHz, DMSO-d6): δ 51.34 (C-3’), 63.94 (C-5’), 84.20 (C-1’), 85.70 (C-4’), 86.11 (Tr), 
106.80 (C-8), 109.73 (C-5), 127.09, 127.93, 128.27, 129.85 (C-7 and Tr), 139.45 (C-6), 143.63 (Tr), 
149.23 (C-2), 161.70 (C-4).  
 
Exact Mass (ESI-MS) for C30H28BrN3NaO4 [M+Na]+ found: 596.1162, calcd: 596.1155. 
 
N-[(E)-5-(2-Bromovinyl)-2’,3’-dideoxy-5’-O-triphenylmethyl-β-D-uridin-3’-yl]-N’-[4-chloro-3-
(trifluoromethyl)phenyl]thiourea (1.98) 
 
O N
TrO
HN
NH
O
O
Br
HN
Cl
CF3
S
 
 
Reaction of compound 1.97 (104 mg, 0.18 mmol) with 4-chloro-3-(trifluoromethyl)phenyl 
isothiocyanate (37 μL, 0.24 mmol) was performed as described for the synthesis of compound 1.58 
affording compound 1.98 in a 82% yield (119 mg, colourless solid).  
 
1H NMR (300 MHz, DMSO-d6): δ 2.27-2.33 (1H, m, H-2’a), 2.49-2.60 (1H, m, H-2’b), 3.27-3.32 (1H, m, 
H-5’a), 3.41-3.46 (1H, m, H-5’b), 4.12-4.13 (1H, m, H-4’), 5.08 (1H, app br s, H-3’), 6.25 (1H, app t, J= 
6.6 Hz, H-1’), 6.41 (1H, d, J= 13.8 Hz, H-8), 7.19-7.42 (16H, m, H-7 and Tr), 7.63-7.70 (2H, m, subs 
Ph), 7.85 (1H, s, 6-H), 8.02 (1H, s, subs Ph), 8.62 (1H, m, 3’-NH), 9.94 (1H, s, N’H), 11.65 (H, s, 3-
NH).  
 
13C NMR (75 MHz, DMSO-d6): δ 36.83 (C-2’), 54.23 (C-3’), 64.18 (C-5’), 83.07 (C-1’), 84.35 (C-4’), 
86.40 (Tr), 107.12 (C-8), 110.02 (C-5), 120.88, 121.60, 124.50, 124.74, 125.29, 126.56, 127.17, 
127.96, 128.28, 129.51, 130.42, 131.67 (CF3, C-7, subs Ph and Tr), 139.14 (C-6), 143.39 (Tr), 149.24 
(C-2), 161.67 (C-4), 180.57 (C=S).  
 
Exact Mass (ESI-MS) for C38H31BrClF3N4NaO4S [M + H]+ found: 833.0752, calcd: 833.0782. 
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5-(3’-Amino-(E)-5-(2-bromovinyl)-2’,3’-dideoxy-5’-O-triphenylmethyl-β-D-uridin-3’N-yl)-1-[4-
chloro-3-(trifluoromethyl)phenyl]tetrazole (1.99) 
 
O N
TrO
HN
NH
O
O
Br
N
N N
NCl
F3C  
 
Reaction of compound 1.98 (90 mg, 0.11 mmol), NaN3 (22 mg, 0.34 mmol), HgCl2 (33 mg, 0.12 mmol) 
and Et3N (45 μL, 0.32 mmol) in 0.5 mL DMF was performed as described in the general synthesis of 
substituted 1,5-aminotetrazole analogues. Compound 1.99 was obtained as white foam (68 mg, 75%).  
 
1H NMR (300 MHz, DMSO-d6): δ 2.36-2.45 (1H, m, H-2’a), 2.49-2.58 (1H, m, H-2’b), 3.27-3.32 (1H, m, 
H-5’a), 3.43-3.48 (1H, m, H-5’b), 4.14 (1H, ddd, J= 2.7 Hz, J= 5.4 Hz, J= 5.4 Hz, H-4’), 4.43-4.55 (1H, 
m, H-3’), 6.29 (1H, app t, J= 6.9 Hz, H-1’), 6.50 (1H, m, J= 13.5 Hz, H-8), 7.21-7.46 (17H, m, H-7 and 
3’-NH and Tr), 7.87-7.91 (2H, m, subs Ph), 8.00 (1H, s, 6-H), 8.03-8.04 (1H, subs Ph), 11.65 (1H, s, 3-
NH).  
 
13C NMR (75 MHz, DMSO-d6): δ 36.65 (C-2’), 54.40 (C-3’), 64.28 (C-5’), 82.75 (C-1’), 84.35 (C-4’), 
86.36 (Tr), 107.11 (C-8), 110.13 (C-5), 120.36, 123.98, 124.93, 127.15, 127.68, 127.93-128.26, 
129.53, 130.83, 131.89, 132.19 and 133.23 (CF3, C-7, subs Ph and Tr), 139.42 (C-6), 143.49 (Tr), 
149.24 (C-2), 154.48 (C=N), 161.63 (C-4).  
 
Exact Mass (ESI-MS) for C38H30BrClF3N7NaO4 [M + Na]+ found: 842.1042, calcd: 842.1076. 
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5-(3’-Amino-(E)-5-(2-bromovinyl)-2’,3’-dideoxy-β-D-uridin-3’N-yl)-1-[4-chloro-3-
(trifluoromethyl)phenyl]tetrazole (1.100) and 5-[(4-chloro-3-(trifluoromethyl)phenyl)amino]-1-
[(E)-5-(2-bromovinyl)-2’,3’-dideoxy-β-D-uridin-3’-yl]tetrazole (1.101) 
 
O N
HO
HN
NH
O
O
Br
N
N N
NCl
F3C
O N
HO
N
NH
O
O
Br
N
N
N NH
Cl
CF3
1.100 1.101
 
 
Reaction of compound 1.99 (80 mg, 0.11 mmol) under the same conditions as described for the 
synthesis of 1.90 and 1.91 and purification on a RP-HPLC (Phenomenex Luna C-18, H2O/0.1% 
HCOOH in CH3CN, 90:10 → 0:100 in 29 min, flow: 17.5 mL min-1) afforded compounds 1.100 and 
1.101 as white powders (17 mg, 32%, 3:1).  
 
Compound 1.100: 
 
1H NMR (300 MHz, DMSO-d6): δ 2.38 (2H, app t, J= 6.6 Hz, H-2’a and H-2’b), 3.67-3.77 (2H, m, H-5’a 
and H-5’b), 4.02-4.06 (1H, m, H-4’), 4.40 (1H, app dd, J= 5.7 Hz, J= 6.0 Hz, H-3’), 5.23 (1H, app br s, 
5’-OH), 6.22 (1H, app t, J= 6.9 Hz, H-1’), 6.86 (1H, d, J= 13.5 Hz, H-8), 7.26 (1H, d, J= 13.5 Hz, H-7), 
7.95-8.09 (2H, m, subs Ph), 8.13-8.14 (1H, m, subs Ph), 8.19 (1H, s, H-6).  
 
13C NMR (75 MHz, DMSO-d6): δ 37.36 (C-2’), 54.06 and 61.27 (C-3’ and C-5’), 84.43 (C-1’), 84.91 (C-
4’), 106.59 (C-5), 109.79 (C-8), 124.03-133.20 (CF3, C-7 and subs Ph), 139.49 (C-6), 149.29 (C-2), 
154.67 (C=N), 161.68 (C-4).  
 
Exact Mass (ESI-MS) for C19H17BrClF3N7O4 [M+H]+ found: 578.0168, calcd: 578,0161. 
 
Compound 1.101: 
 
1H NMR (300 MHz, DMSO-d6): δ 2.65-2.71 (2H, m, H-2’a and H-2’b), 3.70-3.3.74 (2H, m, H-5’a and H-
5’b), 3.90-4.03 (1H, m, H-4’), 4.34-4.40 (1H, m, H-3’), 5.55-5.57 (1H, m, 5’-OH), 6.42 (1H, app t, J= 6.3 
Hz, H-1’), 6.93 (1H, d, J= 13.8 Hz, H-8), 7.29 (1H, d, J= 13.5 Hz, H-7), 7.69 (2H, d, J= 8.7 Hz, subs 
Ph), 7.99-8.01 (1H, m, subs Ph), 8.22 (1H, s, H-6). 
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13C NMR (175 MHz, DMSO-d6): δ 56.70 and 61.46 (C-3’ and C-5’), 84.80 (C-1’), 85.25 (C-4’), 110.49 
(C-5), 116.92-132.73 (CF3, C-7, C-8 and subs Ph), 139.91 (C-6), 149.78 (C-2), 162.16 (C-4).  
 
Exact Mass (ESI-MS) for C19H17BrClF3N7O4 [M+H]+ found: 578.0173, calcd: 578,0161. 
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1 INTRODUCTION 
Tuberculosis (TB), a contagious infection caused by Mycobacterium tuberculosis, has troubled 
humankind since its inception. It has been a leading cause of death throughout the world (± 2 million 
people annually), mainly in developing and underdeveloped countries. Currently, one third of the world 
population is latently infected. In 2009, there were an estimated 9.4 million incident cases of TB 
globally, with much of the burden falling on the young and middle aged between 15-49 years old.83 
Most occur in Asia (55%) and Africa (30%), smaller proportions in the Eastern Mediterranean Region 
(7%), the European Region (4%) and the Region of the Americas (3%) (Figure II.1).84  
 
 
Figure II.1. Estimated TB incidence rates by country, 200984 
 
HIV infection accounts for much of the recent increase in the global tuberculosis burden. In 2009, an 
estimated 12% of the 9.4 million incident cases were HIV-positive. Of these HIV-positive TB cases, 
approximately 80% were in the African Region. HIV-associated TB (HIV-TB) remains a major 
challenge to global health, and the epidemic is one of the major hurdles to attain the 2015 Millennium 
Development Goals for TB control (United Nations 2008).84 
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In the early 1980’s, the great majority of patients with tuberculosis could be cured by treatment with 
short-course curative chemotherapy that was possible as a consequence of several newly introduced 
anti-TB drugs. Unfortunately, the huge success of this drug treatment has been the catalyst for the 
emergence of a new wave of drug resistance. While wealthy industrialized countries with good public 
health care systems are expected to keep TB under control, in much of the developing world a 
catastrophe awaits. To avoid the risk of losing the battle against TB, it is crucially important to support 
research efforts devoted to (i) developing an effective TB vaccine, (ii) improving the diagnosis of TB 
and (iii) creating new, highly effective anti-TB medications.  
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1.1 TUBERCULOSIS 
1.1.1 Causative Organisms 
Human tuberculosis is an infection caused by the rod-shaped, Gram positive, aerobic bacterium 
Mycobacterium tuberculosis. Other human pathogens belonging to the Mycobacterium genus and 
causing TB include Mycobacterium bovis (usually in cows and rarely in humans) and Mycobacterium 
avium. Mycobacteria typically have a unique cell wall structure crucial to their survival. The well 
developed cell wall contains a considerable amount (± 50%) of a fatty acid, mycolic acid, covalently 
attached to the underlying peptidoglycan-bound polysaccharide arabinogalactan, providing an 
extraordinary lipid barrier (Figure II.2). This unique hydrophobic layer is an extremely efficient 
permeability barrier protecting the cell from toxic compounds and is generally thought to be the major 
determinant of the intrinsic resistance of mycobacteria to most common antibiotics, chemotherapeutic 
agents and chemical disinfectants.85  
 
One of the major hurdles in the search for new anti-TB agents is their uptake into the bacillus. So far, a 
few pathways for transport across the cell wall are suggested: (i) penetration of hydrophobic 
compounds by temporarily dissolving in the lipid bilayer and (ii) diffusion through water-filled protein 
channels (= porins) for small and hydrophilic compounds.85 Nevertheless, further research is 
indispensable to facilitate the development of new antituberculosis drugs. 
 
  
Figure II.2. Schematic representation of the cell envelope of Mycobacterium tuberculosis.86,87 
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1.1.2 Transmission  
Mycobacterium tuberculosis is spread by small airborne droplets, generated by the coughing, 
sneezing, talking or singing of a person with pulmonary or laryngeal tuberculosis. Because of their 
small size, 1-5 μm in diameter, these particles can remain airborne for minutes to hours after 
expectoration.88 Introduction of M. tuberculosis into the lungs can lead to infections of the respiratory 
system, however, the organism can spread to other organs, such as the lymphatics, pleura, 
bones/joints, or meninges, and cause extrapulmonary tuberculosis.89 The risk of infection following 
exposure depends on several factors, including the concentration of bacteria in the air, the duration of 
exposure, the virulence of the organism and the immunocompetence of the exposed individual.90 
1.1.3 Pathophysiology 
Once inhaled, the infectious droplets settle throughout the airways. The majority of the bacilli are 
trapped in the upper parts of the airways where the mucus-secreting goblet cells exist. The mucus 
produced catches foreign substances, and the cilia on the surface of the cells constantly beat the 
mucus and its entrapped particles upwards for removal. This system provides the body with an initial 
physical defense that prevents infection in most persons exposed to TB.89 
 
Bacteria in droplets that bypass the mucociliary system and reach the alveoli are quickly surrounded 
and engulfed by alveolar macrophages, the most abundant immune effector cells present in alveolar 
spaces. The macrophages, are part of the innate immune system and provide an opportunity for the 
body to destroy the invading mycobacteria and prevent infection. The subsequent phagocytosis by 
macrophages initiates a cascade of events resulting in either successful control of the infection, 
followed by latent tuberculosis, or progression to active disease, called primary progressive 
tuberculosis. The risk of development of active disease varies according to time since infection, age 
and host immunity.88  
 
After being ingested by alveolar macrophages, M. tuberculosis replicates slowly but continuously and 
spreads via the lymphatic system to the hilar lymph nodes. In most infected individuals, cell-mediated 
immunity develops 2-8 weeks after infection. For persons with intact cell-mediated immunity, the next 
defensive step is the formation of granulomas around M. tuberculosis organisms. These nodular-type 
of lesions, coming from an accumulation of macrophages and lymphocytes, create a micro-
environment that limits replication and the spread of the mycobacteria. This environment destroys 
macrophages and produces early solid necrosis at the center of the lesion, however, the bacilli are 
able to survive. By 2 or 3 weeks, the necrotic environment resembles cheese, often referred to 
caseous necrosis, and is characterized by low oxygen levels, low pH and limited nutrients restricting 
further growth, thereby establishing latency. Lesions in persons with an adequate immune system 
generally undergo fibrosis and calcification, successfully controlling the infection. For less 
immunocompetent persons, granuloma formation is unsuccessful in capturing the bacilli. The necrotic 
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tissue undergoes liquefaction, and the fibrous wall loses structural integrity. The semi-liquid material 
can then drain into a bronchus or nearby blood vessel. If discharge into a vessel occurs, 
extrapulmonary tuberculosis is likely to occur. Bacilli can also drain into the lymphatic system and 
collect in the tracheobronchial lymph nodes of the affected lung, where the organism can form new 
caseous granulomas.89 
 
Although, an effective host immune response can initially suppress M. tuberculosis, several factors 
can trigger subsequent development of active disease from reactivation of the latent infection. HIV is 
the greatest single risk factor for progression to active disease in adults. Other medical conditions that 
can compromise the immune system and predispose to development of active disease include poorly 
controlled diabetes mellitus, renal failure, chemotherapy, extensive corticosteroid therapy and 
malnutrition.88  
1.1.4 Symptoms 
Tuberculosis, although quite a serious disease, does not produce any symptoms in most of the cases 
where the infection has entered the body. Many individuals may host the bacteria but remain 
unaffected by their presence. Persons with latent tuberculosis have no signs or symptoms and are not 
infectious. 
 
Primary pulmonary tuberculosis is often asymptomatic, so that the results of diagnostic tests are the 
only evidence of the disease. In some cases patients suffer from fever, paratracheal lymphadenopathy 
or dyspnea. In this stage the infection may be only subclinical and may not advance to active disease. 
 
Primary progressive TB develops in 5-10% of persons exposed to M. tuberculosis. When a patient 
progresses to active tuberculosis, early signs and symptoms are often nonspecific including 
progressive fatigue, malaise, weight loss and a low-grade fever accompanied by chills and night 
sweats. Other symptoms of active TB involve wasting, finger clubbing, coughing, hemoptysis, pleuritic 
chest pain and dyspnea or orthopnea. 
 
Although the pulmonary system is the most common location for tuberculosis, extrapulmonary disease 
occurs in more than 20% of immunocompetent patients and the risk for extrapulmonary disease 
increases with immunosuppression. Most devastating is TB of the central nervous system, where 
infection may result in meningitis or space-occupying tuberculomas. If not treated, tubercular 
meningitis is fatal in most cases. 
 
Another fatal form of extrapulmonary TB is infection of the bloodstream by mycobacteria (= 
disseminated or miliary tuberculosis). The bacilli can then spread throughout the body, leading to 
multi-organ involvement. Miliary TB progresses rapidly and can be difficult to diagnose because of its 
systemic and nonspecific signs and symptoms such as fever, weight loss and weakness. Lymphatic 
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TB is the most common extrapulmonary tuberculosis. Other possible locations include bones, joints, 
pleura and genitourinary system.89 
1.1.5 Diagnosis 
People who are suspected of having active TB may be given a number of different tests to confirm the 
damage caused by the infection or to identify the organisms responsible for the infection.  
1.1.5.1 Microscopy 
Worldwide, the most common diagnostic test used to detect tuberculosis is the microscopic 
examination of sputum or other clinical materials. For the smear, the sample is spread thinly onto a 
glass slide, treated with Ziehl-Neelsen stain, decolorized using acid alcohol and counterstained with 
methylene blue. Acid-fast organisms appear to be red, other tissue elements will be blue.  
 
Microscopy is cheap to perform, specific enough to indicate treatment in countries where TB is 
prevalent and can be completed within hours if necessary. However, microscopy requires a large 
number of bacilli (5000 - 10 000 per mL sputum) to be present in order for the result to be positive.90  
1.1.5.2 Culture  
Bacteriological culture, considered as a the diagnostic gold standard, can identify the M. tuberculosis 
organism in >80% of TB cases with a specificity of >98%. As few as 10 - 100 viable bacilli per mL may 
be detected, although the sensitivity of cultures varies substantially depending on the specimen-
processing method and the culture medium used. 
 
Compared to the smear microscopy method, culture technique is more sensitive but its also more 
expensive and requires highly trained personnel. Nevertheless, it allows detection of more forms of 
disease, including less advanced cases. As M. tuberculosis grows slowly, conventional culture with 
visual detection of bacterial colony formation usually requires 2 to 6 weeks.90  
1.1.5.3 Tuberculin Skin Test (= Mantoux test) 
This method has been used in the clinic for many years primarily to detect latent infection, although it 
has also been applied inappropriately for detecting active disease in adults. Tuberculin or purified 
protein derivative (PPD) is composed of proteins from heat killed M. tuberculosis. Injection of PPD 
under the forearm skin will cause a hypersensitivity reaction in people with prior TB infection. This 
reaction presents as skin thickening at the site of injection after 24-48 hours. Unfortunately, its 
application is problematic due to the frequency of false-positive (e.g., BCG vaccine) and false negative 
(e.g., immunodefiency) skin reactions. Despite these shortcomings, the test is manufactured around 
the globe and applied broadly in almost all countries.89,90  
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1.1.5.4 Radiographic Methods 
It is still widely believed that tuberculosis of the lung can be diagnosed by chest X-ray. However, 
practical experience and numerous studies have shown that no radiographic pattern is diagnostic of 
tuberculosis. Many diseases of the lung have a similar radiographic appearance that can easily mimic 
TB. Similarly, the lesions of pulmonary tuberculosis can take almost any form on a radiographic 
picture. In developed countries where facilities and resources permit, patients with signs and 
symptoms of pulmonary TB are screened by chest X-ray. However, to establish the tubercular etiology 
of an abnormality, further examination is necessary and only bacteriology can provide the necessary 
proof.90  
1.1.5.5 NAATs 
Nucleic acid amplification tests constitutes a rapidly evolving improvement in the detection and 
identification of M. tuberculosis. Bacterial DNA (or ribosomal RNA transcribed into DNA) is 
enzymatically amplified and detected with an appropriate reading system via a signal-generating 
probe. Although the test can provide rapid confirmation of M. tuberculosis in sputum specimens 
positive for acid-fast bacilli, it has limitations including high cost, low sensitivity in smear-negative, 
culture positive specimens and low availability.90  
1.1.6 Prevention and Control 
The fundamental strategies for the prevention and control of TB include:91 
 
- early and accurate detection, diagnosis, and reporting of TB cases, leading to initiation and 
completion of treatment, 
- identification of contacts of patients with infectious TB and treatment of those at risk with an 
effective drug regimen, 
- identification of other persons with latent TB infection at risk for progression to TB disease, 
and treatment of those persons with an effective drug regimen, 
- identification of settings in which a high risk exists for transmission of M. tuberculosis and 
application of effective infection control measures. 
 
Interestingly, BCG vaccination is not recommended world wide as a routine strategy for TB control. 
1.1.6.1 DOTS 
To control tuberculosis, WHO and IUATLD (International Union Against Tuberculosis and Lung 
Diseases) recommend the DOTS strategy. Directly Observed Treatment Short course is a highly 
efficient and cost-effective strategy which is based on a five point policy package: political 
commitment, diagnosis primarily by sputum-smear microcopy, short-course anti-TB treatment, regular 
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drug supply and systematic monitoring to assess outcomes of every treated patient. Standard short-
course regimens can cure more than 95% of cases of new, drug-susceptible tuberculosis.88  
 
DOTS produces superior treatment completion rates to those achieved by non-supervised 
interventions (DOTS: 79-81% vs. non-supervised: 61%). When implemented over a long period, there 
will be a huge reduction in sources of infection and transmission.92 
1.1.6.2 BCG Vaccination 
BCG (Bacille Calmette-Guérin) was developed at the start of this century and is the most widely used 
vaccine in the world. It was developed by attenuation of M. bovis, which is closely related to M. 
tuberculosis (> 90% DNA homology). It is given in a single dose following a negative tuberculin skin 
test. The most controversial aspect of BCG is the variable efficacy found in different clinical trials. 
Generally speaking, trials conducted in the 1940s and 1950s in developed countries such as the UK, 
Denmark and North America demonstrated the vaccine to be highly efficient (70-80%), whereas more 
recent trials demonstrated no detectable protection against pulmonary TB. Several explanations for 
this variation in protective efficacy have been suggested, such as differences in strains and doses, 
genetic variability in the population studied, … . The most accepted hypothesis attributes this variation 
to higher levels of exposure to environmental mycobacteria in the areas where the vaccine affords no 
protection. Nevertheless, based on available information concerning the effectiveness of BCG vaccine 
in preventing serious forms of TB in children, WHO recommends BCG vaccination of children as soon 
as possible after birth in countries with a high TB prevalence.93,94 
1.1.7 Treatment 
1.1.7.1 Chemotherapy 
Mycobacteria are intrinsically resistant to most antibiotics due to several reasons (e.g., slow growth 
dormant stage, lipid-rich mycobacterial cell wall, …). Normally, the response of mycobacterial 
infections to chemotherapy is slow, and treatment must be administered for months to years, 
depending on which drugs are used. According to their therapeutic relevance and side effects, one 
can distinguish primary and second-line drugs. First-line drugs are common for patients without drug 
resistance strains or strains resistant to one or two drugs (other than isoniazid and rifampicin) and 
second line drugs are used in cases of multi-drug resistant infections, in combination with first-line 
drugs. These second line drugs are often less effective, have more side effects and are more 
expensive compared to the standard drugs. 
 
 
 
  
a) First-line antituberculosis drugs (Table II.1). 
 
 
Table II.1 First-line anti-tuberculosis drugs 
 
 Isoniazid95,96 Rifampicin96,97 Pyrazinamide96,98 Ethambutol98,99 Streptomycin96,98 
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b) Second-line antituberculosis drugs (Table II.2)  
 
Table II.2 Second-line anti-tuberculosis drugs 
 
 
Thioamides96,100 
(e.g., ethionamide, 
prothionamide) 
Aminoglycosides96 
(kanamycin, amikacin) 
Peptides96,98,101 (capreomycin, 
viomycin) 
Fluoroquinolones96,98 
(ciprofloxacin, ofloxacin) D-Cycloserine
98 
p-Amino-
salicylic 
acid102 
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c) WHO recommended regimens 
 
According to the World Health Organization, treatment of active tuberculosis is dependent on whether 
the disease has become drug resistant or not. 
 
- Standard first-line TB treatment requires a patient to take a combination of four drugs 
(isoniazid, rifampicin, pyrazinamide and ethambutol or streptomycin) for a minimum of six 
months. An unfinished treatment course can lead to treatment failure and the emergence of 
drug resistance.88,103  
 
- TB patients returning after defaulting or relapsing from their first treatment course may receive 
the retreatment regimen combining five drugs for a period of 8 months. During the whole 
period, isoniazid, rifampicine and ethambutol are administered, combined with pyrazinamide 
during the first three months and streptomycin during the first two months. The vast majority of 
the patients will be cured with this retreatment regimen. Failures are generally due to the use 
of an incorrect regimen and/or failure to ensure that the regimen is fully administered and 
directly observed.103  
 
- Multidrug resistance makes regimens with first-line drugs much less effective. Initiation of 
MDR treatment with second-line drugs gives a better chance of cure and prevents the 
development and spread of further resistance. Unfortunately, these agents are more 
expensive and cause more side effects compared to the standard drugs. Treatment regimens 
should consist of at least four drugs with either certain, or almost certain, effectiveness.103  
1.1.7.2 Surgery 
Surgery is rarely used to treat tuberculosis (TB), although it may be used to treat extensively drug-
resistant TB (XDR-TB) or to treat complications of an infection in the lungs or other parts of the body. 
1.1.8 Resistance 
1.1.8.1 Drug Resistant Tuberculosis 
Resistance to anti-TB drugs arises as a result of spontaneous mutations in the genome of M. 
tuberculosis. These mutations occur at predictable rates for each anti-tuberculosis drug (e.g., isoniazid 
10-6, rifampicin 10-8). Thus, in patients with active tuberculosis disease, subpopulations of resistant 
mycobacteria spontaneously arise, and can emerge as the dominant strain in the presence of drug-
selection pressure. Resistance to additional tuberculosis drugs can be added in a step-wise manner to 
create tuberculosis strains that are resistant to several drugs. This process is referred to as acquired 
resistance (= secondary resistance, figure II.3) and is the rationale for the adage “never add a single 
drug to a failing regimen”.104 
PART II - Chapter 1: Introduction   
98 
 
 
Figure II.3. Acquisition of resistance104 
Once created, drug-resistant strains can be transmitted, giving rise to drug-resistant tuberculosis in 
individuals never previously exposed to anti-TB drugs (= primary resistance, Figure II.4). The global 
epidemic of drug-resistant tuberculosis is due to a combination of acquired resistance and primary 
transmission. 
 
 
 
 
Figure II.4. Mechanisms in the development of resistance.104 
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1.1.8.2 Multidrug Resistant (MDR) - Extensively Drug Resistant (XDR) Tuberculosis 
A particularly dangerous form of drug-resistant TB is multidrug-resistant TB, which is defined as the 
disease caused by TB bacilli resistant to at least isoniazid and rifampicin, the two most powerful anti-
TB drugs. MDR-TB is not limited to the developing world. During the late 1980s and early 1990s, 
outbreak of MDR-TB in North America and Europe killed more than 80% of those who contracted the 
disease. In 2008, an estimated 440 000 cases of multidrug-resistant TB emerged. The WHO 
estimates that MDR-TB makes up greater than 10 percent of all new TB cases in Eastern Europe, the 
region most affected by the disease.84,104 Nevertheless, drug-resistant TB is generally treatable 
although it requires extensive chemotherapy (up to two years of treatment) with second-line anti-TB 
drugs, which are more costly than first-line drugs and which produce adverse drug reactions that are 
more severe, though manageable. 
 
Extensively drug resistant is emerging as an even more ominous threat. XDR-TB is caused by M. 
tuberculosis that is resistant to rifampicin and isoniazid, any fluoroquinolone, and one of the three 
injectable drugs, capreomycin, kanamycin and amikacyn. In March 2006, the Centers for Disease 
Control and Prevention (CDC) released the first known data on XDR-TB. The CDC and the WHO 
surveyed TB strains from a global network of TB laboratories and identified XDR-TB cases in all 
regions of the world. In the worst affected areas, an average of 10% of MDR-TB cases were found to 
be XDR-TB.105 
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1.2 THYMIDINE MONOPHOSPHATE KINASE (TMPK) 
Thymidine monophosphate kinase (TMPK, also called ATP:dTMP phosphotransferase or thymidylate 
kinase) belongs to the nucleoside monophosphate kinase (NMPKs) family.106 It catalyses the 
reversible phosphorylation of thymidine monophosphate (dTMP) to thymidine diphosphate (dTDP) 
utilizing ATP as its preferred phosphoryl donor.  
 
dTMP   +   ATP dTDP   +   ADP
TMPKmt
 
 
TMPK lies at the junction of the de novo and salvage pathway for the synthesis of thymidine 
triphosphate (dTTP). Because its crucial role in thymidine metabolism and in view of its low (22%) 
sequence identity with the human isoenzym (TMPKh), it represents an attractive target for blocking 
mycobacterial DNA synthesis. 
1.2.1 Structure of TMPKmt 
In 2001, de la Sierra et al. reported the X-ray structure of TMPK from M. tuberculosis (TMPKmt) bound 
to its natural substrate.107 TMPKmt has a molecular mass of 24 kDa and consists of 214 amino acid 
residues. It is a homodimer, each monomer being composed of nine α-helices surrounding a five-
stranded β-sheet core. This global folding is similar to that of other TMPKs, despite the low similarity of 
their primary sequences: 26%, 25% and 22% sequence identity over about 200 aligned residues with 
TMPKec (E. coli), TMPKy (yeast) and TMPKh respectively. 
 
The essential residues for the function of the enzyme can be found in three regions: 
 
- The P-loop, a highly conserved motif, controls the positioning of the phosphoryl groups of the 
phosphate donor. It binds and positions the α- and β-phosphoryl groups of ATP through 
interactions with amide backbone hydrogens. Unique for TMPKs is an interaction between the 
P-loop and the phosphoryl acceptor dTMP achieved through interaction between the 3’-
hydroxyl group of dTMP and a carboxylic acid residue at position X2 of the P-loop motif (Asp9 
in TMPKmt). Although the exact function of Asp9 is still unclear, it seems to play a key role in 
the catalytic mechanism of TMPK as any mutation of this residue in either the yeast, human or 
E. coli enzyme abolishes the phosphoryl transfer activity.108  
 
- The DR(Y/H/F)-motif is a strictly conserved Arg residue acting as a clip to orient the 
phosphoryl donor and acceptor via an interaction with the phosphate group of dTMP and the 
γ-phosphate of ATP. 
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- The LID region closes as a flexible stretch upon binding of the phosphoryl donor to the 
enzyme. Phosphoryl groups of both substrates interact with Arg side chains of the LID region, 
revealing the importance of these amino acids in catalyzing phosphoryl transfer.107 
 
NMPKs, including TMPKmt, are highly flexible molecules that undergo large conformational changes 
upon substrate binding. One can distinguish between (i) the open conformation, observed without 
substrate, (ii) the partially closed conformation with a single substrate and (iii) the fully closed and 
active conformation, observed in the presence of both substrates (dTMP and ATP).107 
 
Another unique feature of TMPKmt is that, for catalysis, it requires the transient binding of a 
magnesium ion to coordinate the phosphate acceptor. The observed Mg2+ is not reported for the yeast 
or E. coli enzyme and for the human enzyme, one magnesium binding site has been reported but is 
located further away along the ATP-binding site, between the β- and γ-phosphate groups. Three water 
molecules, an oxygen atom from the phosphoryl of dTMP and the carboxylate oxygen atoms of Asp9 
and Glu166 coordinate the Mg2+ in an octahedral configuration.107 Fioravanti et al. suggest that this 
cation neutralizes the electrostatic repulsion between the anionic substrates and optimizes their proper 
alignment.109  
1.2.1.1 The dTMP-binding Site 
Examination of the X-ray structure of TMPKmt reveals that the main binding forces between dTMP 
(2.1) and the enzyme are (Figure II.5):110 
 
- a stacking interaction between the pyrimidine ring and Phe70, 
 
- a hydrogen bond between O4 of thymidine and the Arg74 side-chain which results in a 
preference for thymidine over cytosine, 
 
- a hydrogen bond between Asn100 and N3 of the thymidine ring, 
 
- a hydrogen bond between the 3’-hydroxyl of dTMP and the terminal carboxyl of Asp9, that in 
turns interacts with Mg2+, responsible for positioning the phosphate oxygen of dTMP, 
 
- hydrogen bonds between the 5’-O-phosphoryl group and Tyr39 and Phe36, 
 
- ionic interactions between the 5’-O-phosphoryl group and Arg95 and Mg2+.  
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Figure II.5. Schematic representation of the most important amino acid residues of TMPKmt interacting with 
dTMP (in black) + structure and atom numbering of dTMP110 
1.2.2 Known TMPKmt Inhibitors 
1.2.2.1 Close Analogues of the dTMP Substrate     
Initially, effort were made to obtain TMPK inhibitors by modifying the structure of the substrate.111 
 Base modifications 
The 5-methyl group of dTMP was replaced by several halogen atoms. All these compounds behaved 
as substrates for TMPKmt, the best one being 5-Br-dUMP with a slight decrease in Km and Vm 
compared to dTMP. Substitution by an iodine (5-I-dUMP) or a fluorine (5-F-dUMP) drastically 
decreased the affinity for the enzyme. Upon removal of the methyl group (dUMP), the affinity 
drastically decreased (50-fold) as well as the reaction rate (3-fold). Modification at the 2-position of the 
pyrimidine ring resulted in 5-methyl-iso-dCMP which acted as a competitive inhibitor with a Ki of 130 
μM.111  
 
Because a 5-bromine (5-Br-dUMP) was well accepted by the enzyme, analogs with sterically 
demanding substituents at the 5-position (e.g., hydroxymethyl, ethyl, bromovinyl, furanyl, thienyl or 
benzyloxymethyl) were investigated as TMPKmt inhibitors and found less potent indicating that the 
cavity near the 5-position cannot be stretched too much.112  
O N
O
HO
NH
O
O
P
O
O
O
2.1 (dTMP)
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 3’-modifications 
 
The first reported selective competitive inhibitor for TMPKmt is AZTMP in which the 3’-hydroxyl of the 
natural substrate is substituted by an azido group. While AZTMP behaves as a substrate for TMPKec 
and TMPKy, it showed a Ki of 20 μM for TMPKmt. X-ray structures of TMPKmt in complex with dTMP 
and AZTMP provide structural evidence that AZTMP inhibits TMPKmt by excluding the Mg2+ ion, 
essential for catalysis.110  
 
Due to the unique behavior of AZTMP towards TMPKmt in comparison to other TMPKs, 3'-
modifications in particular were considered to have potential for finding good and selective inhibitors. 
3’-Amino-3’-deoxythymidine monophosphate, intended to establish an ionic interaction with Asp9, 
showed a 20-fold higher Ki value compared to AZTMP indicating that the 3’-amino group does not 
interact with Asp9 as strongly as AZTMP.113  
 
In the X-ray structure, near the 3’-positition, one could observe a cavity with the potential of 
accommodating larger substituents, which led Vanheusden et al. to prepare a series of 3’-C-branched-
chain nucleotides (the 3’-C-hydroxymethyl (2.2), 3’-C-azidomethyl (2.3), 3’-C-aminomethyl (2.4) and 
3’-C-fluoromethyl (2.5) derivatives of dTMP). 2’-Deoxy-3’-branched chain analogues proved to be 
potent inhibitors of TMPKmt: within the series 3’-CH2NH2 (2.4), 3’-CH2N3 (2.3) and 3’-CH2F (2.5) 
nucleotides exhibited the highest affinities with Ki values of 10.5, 12 and 15 μM, respectively (Figure 
II.6).110 
O N
R2
NH
O
O
R1
2.2: R1 = OH, R2 = OPO32-
2.3: R1 = N3, R2 = OPO32-
2.4: R1 = NH2, R2 = OPO32-
2.5: R1 = F, R2 = OPO32-
2.6: R1 = OH, R2 = OH
2.7: R1 = N3, R2 = OH
2.8: R1 = NH2, R2 = OH
2.9: R1 = F, R2 = OH  
Figure II.6 
Interestingly, the parent nucleosides (2.6-2.9) generally exhibited affinities for TMPKmt in the same 
order of magnitude and displayed a superior selectivity profile versus human TMPK.110 A main 
disadvantage of 5’-O-phosphorylated analogues concerned their uptake in cells, generally accepted to 
be very difficult. Normally, nucleosides cross the cell membrane barrier in the non-phosphorylated 
form and are then phosphorylated by intracellular kinases. However, in this particular case, 
intracellular activation is not possible, as no gene coding for TK could be identified in the M. 
tuberculosis genome. The inhibitory activities of 2.6-2.9 indicated the possibility of the enzyme to 
accommodate non-phosphorylated thymidine analogues and directed further research toward the 
synthesis of non-phosphorylated TMPKmt inhibitors. 
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 Bicyclic and dimeric nucleoside inhibitors 
 
In an effort to further optimize the inhibitory potency of 3'-C-branched-chain nucleosides, Vanheusden 
et al. serendipitously obtained 3 potent and selective TMPKmt inhibitors 2.10-2.12 (Figure II.7).114 
O T
HO
O
S
HN
2.10 (Ki = 3.5 µM)
O T
HO
O
O
HN
O T
HO
OT
OH
HN NH
O
2.11 (Ki = 13.5 µM) 2.12 (Ki = 37 µM)  
Figure II.7 
1.2.2.2 Optimization of the Branched-Chain Nucleosides 
Due to the lack of a binding site for a second nucleoside at the 3'-position, the Ki value of 2.12 (37 µM) 
was most unexpected. Modeling studies on the binding mode of dinucleoside 2.12 to its target 
suggested that the second monomer binds to the area where normally the phosphoryl donor binds, in 
this way forcing the sugar ring to tilt over 180° compared to the natural substrate dTMP (Figure II.8).114 
 
 
 
Figure II.8. Comparison of the binding mode of dTMP with the binding mode of compound 2.12. (A) dTMP as 
observed in the X-ray structure with TMPKmt.107 (B) Predicted binding mode of 2.12 with TMPKmt. Hydrogen 
bonds are drawn as dashed lines from 2.12 to residues Asp9, Arg14, Asn100 and Glu166. Residues whose 
atoms make hydrophobic contact with 2.12 are Lys13, Ala35, Tyr39, Phe36, Phe70, Arg95, Asn100, Tyr103 and 
Tyr165.114  
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These results encouraged Van Daele et al. to explore if the binding site, which accommodates the 
second thymidine residue of 2.12, could be occupied with different aryl moieties connected to 3’-C-
branched thymidine via a thiourea moiety.69 This resulted in several analogs with excellent affinity for 
TMPKmt, e.g., 2.13 (Ki = 5 µM, Figure II.9). 
 
O T
HO
NHNH
S
Cl
F3C
2.13
 
 
Figure II.9 
 
In a next step, Van Daele et al. explored if an alternative sugar scaffold could be used to impose the 
favorable relative orientation of the thymine and the phenylthiourea moieties for TMPKmt inhibition.69 It 
was hypothesized that an α-nucleoside in which the 5’-position served as the thiourea anchor might 
show potential towards this end (Figure II.10). This hypothesis was supported by the discovery that α-
thymidine 5’-monophosphate (α-dTMP) was accepted by TMPKmt as a substrate (Km = 15 µM), 
indicating that inversion of configuration at the anomeric position does not prevent the 5’-OP(O)(OH)2 
moiety from being favorably oriented in order to operate as a phosphate acceptor.69 
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Figure II.10. Suggested inverse sugar binding of 3’-C-arylthiourea-modified β-thymidine and anticipated similar 
relative orientation of the colored moieties in 5’-deoxy-5’-arylthiourea modified α-thymidines. 
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From a small library of 5’-N-arylthiourea α-dT derivatives, compound 2.14 (Figure II.11) emerged as 
the most potent TMPKmt inhibitor (Ki = 0.6 µM).69 Based on the observation that the 3’-deoxy and the 
3'-deoxy-2',3'-didehydro analogs of 2.14 exhibit slightly higher Ki values (2.3 and 3.8 µM), the 3’-OH 
group is assumed to contribute to the overall affinity of 2.14 to TMPKmt. 
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Figure II.11 
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2 SYNTHESIS AND INHIBITORY ACTIVITY OF 
THYMIDINE ANALOGUES TARGETING TMPKmt  
2.1 OBJECTIVES 
Based on the interesting TMPKmt inhibitory activities previously discovered in both series of thiourea-
modified nucleosides represented by 2.13 and 2.14 (Figure II.12), the present synthetic work was 
directed towards structural variations of these compounds to gain further insight into the S.A.R. 
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N
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N
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Cl
F3C
2.14 (Ki = 0.6 µM)
O N
HO
NHNH
S
Cl
F3C
2.13 (Ki = 5 µM)
NH
O
O
N NH
O
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Figure II.12 
 
First, we decided to investigate unbranched 3’-modified analogues of β-thymidine that are synthetically 
easier accessible than 2.13. Analogues 1.43 and 2.15 represent close analogues of 3’-C-arylthiourea 
2.13, in which the methylene group between C-3’ and the (thio)urea group has been omitted.59 
Analogues 1.50, 1.51, and 1.53, derived from AZT (1.6), were selected to investigate if a 1,4-
disubstituted 1,2,3-triazole motif can act as a bioisostere for the 3’-C-thiourea linker of 2.13 as 
previously found to be the case for TK-2 inhibition.73 The aminotetrazole isomers 1.90 and 1.96 were 
synthesized in the context of TK-2 inhibition115 and are also characterized by the presence of a 
heterocyclic linker to connect the aromatic moiety to position 3 of the 2-deoxyribofuranose ring (Figure 
II.13).  
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Figure II.13 
 
Compounds 2.22-2.24 are derived from 5’-azido-5’-deoxy-α-D-thymidine (2.21) and synthesized in an 
effort to improve the activity of compound 2.14 (Figure II.14).  
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Figure II.14 
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To further investigate the influence of the relative orientation between the aryl moiety and the 
nucleobase, compound 2.26, which is the α-analogue of 1.53, was synthesized and evaluated (Figure 
II.15). 
2.26
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O N
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1.53
N NH
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Figure II.15 
 
To assess the inhibitory activity of anomeric variants of 2.14, its β-anomer 2.18, as well as two 
heterocyclic analogues, 2.19 and 2.20, are included in this study (Figure II.16).  
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Figure II.16 
 
Based on earlier reports of 4-thiothymidine analogues showing promising antimycobacterial potency 
against M. bovis and M. tuberculosis in vitro and thus capable of entering the bacillus,116 several 
analogues were synthesized in which the 4-oxygen of the thymine moiety was replaced by a more 
lipophilic sulfur atom (e.g., 2.16, 2.17, 2.22 and 2.23) to probe the influence of this modification on the 
inhibitor uptake in the bacillus.  
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2.2 CHEMISTRY 
With the exception of compounds 2.16-20, 2.22-24 and 2.26, the chemical synthesis of all other final 
compounds has been reported before.59,69,73,115,117 
2.2.1 Synthesis of 3’-Modified 4-Thio-β-Thymidine Analogues 
For the preparation of 4-thio-AZT (2.16, Scheme II.1), AZT (1.6) was first protected using acetic 
anhydric.117 Subsequent treatment of compound 2.27 with Lawesson’s reagent118 generated 4-thio 
pyrimidine 2.28 which was hydrolysed under basic conditions.119  
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N NH
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N NH
S
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2.162.28
1.6 2.27
 
 
Scheme II.1. Reagents and conditions: (a) Ac2O, DMAP, rt, 3 h, 99%; (b) Lawesson's reagent, toluene, 80 °C, 
overnight, 20%; (c) 7N NH3 in MeOH, rt, 6 h, 42%. 
 
A CuAAC reaction (see PART I - chapter 2) between 2.27 and 1-chloro-4-ethynylbenzene, followed by 
thionation of the resulting 1,4-disubstituted 1,2,3-triazole 2.29 gave analogue 2.17 after final 
deprotection (Scheme II.2).  
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Scheme II.2. Reagents and conditions: (a) 1-chloro-4-ethynylbenzene, CuSO4·5H2O, sodium ascorbate, H2O/t-
BuOH 2:1, rt, 24 h, 41%; (b) Lawesson's reagent, toluene, 80 °C, overnight, 49%; (c) 7N NH3 in MeOH, rt, 6 h, 
66%. 
2.2.2 Synthesis of 5’-Modified β-Thymidine Analogues 
The synthesis of a series of 5’-substituted thymidine analogues started from β-thymidine which was 
converted into 5’-azido-5’-deoxy 2.32 as depicted in Scheme II.3.69 Protection of azide 2.32 followed 
by catalytic hydrogenation and coupling of amine 2.34 with 4-chloro-3-(trifluoromethyl)phenyl 
isothiocyanate gave thiourea derivative 2.35 which was deprotected using TBAF in THF.120 A 
mercury(II)-promoted reaction of 2.35 with NaN3 and Et3N gave access to aminotetrazole 2.19 after 
final desilylation.  
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Scheme II.3. Reagents and conditions: (a) MsCl, pyridine, -78 °C → 0 °C, 1 h, 63%; (b) NaN3, DMF, 60 °C, 
overnight, 38%; (c) TBDMSCl, imidazole, pyridine, rt, 1 h, 100%; (d) H2, Pd/C, MeOH, rt, overnight, 95%; (e) 4-
chloro-3-(trifluoromethyl)phenyl isothiocyanate, DMF, 0 °C → rt, 1 h, 76%; (f) 1M TBAF in THF, THF, rt, 1 h, 53-
60%; (g) NaN3, HgCl2, Et3N, DMF, 0 °C → rt, overnight, 83%.  
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“Click chemistry” followed by HPLC purification allowed to isolate enough pure material of 2.20 for 
testing (Scheme II.4). 
 
O N
N3
HO
NH
O
O N
N
HO
NH
O
N
N
Cl
2.32 2.20
a
O O
 
 
Scheme II.4. Reagents and conditions: (a) 1-chloro-4-ethynylbenzene, CuSO4·5H2O, sodium ascorbate, H2O/t-
BuOH (1:2), rt, 7 d, 2%. 
2.2.3 Synthesis of 5’-Modified (4-Thio-)α-Thymidine Analogues 
For the synthesis of 5’-modified α-D-thymidine analogues 2.21-2.24, 3’,5’-O-diacetyl-β-D-thymidine 2.37 
was first anomerized to its α-anomer according to the procedure of Ward et al.121 (Scheme II.5). 
Compound 2.38 was then thionated using Lawesson’s reagent followed by deprotection and 
conversion into the monomesylate ester 2.41. Upon treatment with NaN3, 2.41 was converted into 
azide 2.42, which was reduced to afford 5’-amino-5’-deoxy-4-thio-α-D-thymidine 2.43. Final treatment 
of this amine with the appropriate isothiocyanate analogues afforded derivatives 2.22 and 2.23. 
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Scheme II.5. Reagents and conditions: (a) Ac2O, pyridine, rt, 2 h, 98%; (b) H2SO4, Ac2O, CH3CN, rt, 2 h, 45%; 
(c) Lawesson's reagent, dry 1,4-dioxane, reflux, 4 h; (d) 7N NH3 in MeOH, rt, 4 h, 37% over 2 steps; (e) MsCl, 
pyridine, -78 °C → 0 °C, 1 h, 70%; (f) NaN3, DMF, 60 °C, overnight, 89%; (g) PPh3, THF, H2O, rt, 1 d, 89%; (h) 
suitable isothiocyanate, DMF, 0 °C → rt, 3 h, 42-69%. 
 
After deprotection of compound 2.38 under basic conditions and conversion into azide 2.21,69 
compound 2.24 was synthesized using the same method as described for triazole 2.20 (Scheme II.6) 
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Scheme II.6. Reagents and conditions. (a) 7N NH3 in MeOH, rt, 16 h, 90%; (b) (i) MsCl, Pyridine, 0 °C, 1 h, 
62%; (ii) NaN3, DMF, 60 °C, 16 h, 65%; (c) 1-chloro-4-ethynylbenzene, CuSO4·5H2O, sodium ascorbate, H2O/t-
BuOH (2:1), rt, 4 d, 31%. 
2.2.4 Synthesis of 3’-Modified α-Thymidine Analogues 
The synthesis of 3’-modified α-D-thymidine analogues 2.25117 and 2.26 started with the anomerisation 
of 5’-O-acetylated AZT 2.27. Deprotection of 2.45 followed by CuAAC with 1-chloro-4-ethynylbenzene 
afforded triazole 2.26 in moderate yield (Scheme II.7). 
 
O N
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Scheme II.7. Reagents and conditions: (a) acetic anhydride, H2SO4, CH2Cl2, rt, 2 h, 20% (b) 7N NH3 in MeOH, 
rt, overnight, 72%, (c) 1-chloro-4-ethynylbenzene, CuSO4·5H2O, sodium ascorbate, H2O/t-BuOH (1:3), rt, 24 h, 
47%. 
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2.3 BIOLOGICAL EVALUATION 
Table II.3. Kinetic parameters of TMPKmt with compounds 1.43, 1.50, 1.51, 1.53, 1.90, 1.96 and 2.14-2.26. 
 
O
R
HO
O
HO
RO N
R
HO
NH
O
O
R
HO
N NH
X
O
1.43, 1.50, 1.51, 1.53, 1.90, 
1.96, 2.15-2.17
2.18-2.20 2.14, 2.21-2.24 2.25-2.26
O
N NH
X
O
N NH
O
O
 
Compd X R 
Ki (μM) 
TMPKmt 
Ki (μM) 
TMPKh 
SIc 
MIC99 
M. Bovis 
(μg/mL) 
2.14 O 3-CF3-4-Cl-phenylthiourea 0.6    
2.15 O 3-CF3-4-Cl-phenylurea 2.8 95 34  
1.43 O 3-CF3-4-Cl-phenylthiourea 9.9    
1.6 O N3 28    
2.16 S N3 >100    
1.50 O 4-(phenyl)-triazol-1-yl 4.2    
1.53 O 4-(p-chlorophenyl)-triazol-1-yl 2.1    
2.17 S 4-(p-chlorophenyl)-triazol-1-yl 15    
1.51 O 4-(benzyl)-triazol-1-yl 2.7 N.I.b >100  
1.90 O 1-(3-CF3-4-Cl-phenyl)-tetrazol-5-amine 45    
1.96 O 5-(aminobenzyl)-tetrazol-1-yl 2.3 N.I.b >100  
2.18 O 3-CF3-4-Cl-phenylthiourea 14.5    
2.19 O 1-(3-CF3-4-Cl-phenyl)-tetrazol-5-amine 73    
2.20 O 4-(p-chlorophenyl)-triazol-1-yl 201    
2.21 O N3 26.5    
2.22 S phenylthiourea N.I.a   >>100 
2.23 S 3-CF3-4-Cl-phenylthiourea 0.17 N.I.a >100 25 
2.24 O 4-(p-chlorophenyl)-triazol-1-yl 9    
2.25 O N3 6    
2.26 O 4-(p-chlorophenyl)-triazol-1-yl 35    
N.I.: no inhibition detected at a final concentration of (a) 0.05 mM and (b) 1 mM. 
SIc: Ki TMPKh/Ki TMPKmt 
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All compounds have been evaluated for TMPKmt inhibition under the supervision of Dr. Hélène 
Munier-Lehmann at the Institut Pasteur (Paris, France) as described in the Experimental Section. 
Replacement of the 3’-azido group of AZT (1.6) by a 3-CF3-4-Cl-phenylurea substituent (2.15) resulted 
in a 10-fold increased activity, while this trend was less pronounced with the thiourea analogue 1.43. 
In the 1,4-disubstituted 1,2,3-triazole series, the anti-TMPKmt activity was clearly influenced by the 
nature of the substituent at C-4 of the triazole. The click product of AZT and phenylacetylene (1.50) 
proved to be more potent than AZT itself. p-Chloro-substitution of the phenyl ring of 1.50 or 
introduction of a methylene between the triazole and the phenyl caused a moderate increase in 
activity (1.51 and 1.53). In this series of 3’-modified thymidine analogues, replacement of the oxygen 
at position 4 of the thymine moiety by a sulfur typically led to a significant drop in affinity for the target 
enzyme (compare couples 1.6/2.16 and 1.53/2.17). Compounds 1.90 and 1.96, both containing a 1,5-
disubstituted tetrazole significantly differed in their capacity to inhibit TMPKmt. The aminotetrazole 
analogue 1.96, in which the tetrazole ring is directly attached to the sugar ring, showed a significantly 
better activity compared to analogue 1.90 in which the tetrazole ring is connected to C-3’ via a NH-
bridge. Remarkably, an opposite trend was observed for these tetrazole analogues on mitochondrial 
thymidine kinase 2.  
 
The inhibitory activity of a series of 5’-modified β-thymidine analogues appeared to be weak. 
Introduction of a 3-CF3-4-Cl-phenylthiourea substituent (2.18) gave micromolar inhibition, while 
replacement of the thiourea by a 1-(3-CF3-4-Cl-phenyl)-tetrazol-5-amine (2.19) or a 4-(p-
chlorophenyl)-triazol-1-yl (2.20) caused a 5 and 14-fold drop in Ki value, respectively. Comparison of 
the anomeric couples 2.14/2.18 and 2.20/2.24 demonstrate that the α-anomers, which feature a trans 
orientation of the nucleobase and the 5’-substituent, exhibit superior TMPKmt inhibition compared to 
their β-epimers (factor 22-24). 
 
The 5’-modified α-thymidine analogues (2.14, 2.21-2.24) demonstrated moderate to excellent 
inhibitory activity for TMPKmt. Also in this small series, the activity is influenced by the nature of the 
substituent at the 5’-position. Derivative 2.21, containing an azide function, gave moderate inhibition 
with a strikingly comparable Ki value (26.5 μM) as its AZT counterpart (28 μM). As observed in the 3’-
modified series, conversion of the azide moiety by a 4-(4-chlorophenyl)-1,2,3-triazol-1-yl substituent 
improved the inhibitory activity, although to a lesser extent. Most interestingly and in contrast to what 
was observed in the 3’-modified series, substitution of the 4-oxygen of the original hit 2.14 by a 4-S, 
increased the activity by a factor 3, ranking it amongst the most potent TMPKmt inhibitor together with 
the (Z)-butenylthymines carrying a naphtholactam or naphthosultam moiety (Ki values of 0.42 and 0.27 
µM, respectively).122 
 
In addition, α-analogue 2.26, which was synthesized to further assess the influence of the relative 
orientation between the aryl moiety and the nucleobases, showed poor inhibitory activity against 
TMPKmt, indicating that the preferred trans-orientation of the base and the aromatic substituent also 
holds for the 3’-modified analogues.  
 
Compound 2.23 was evaluated for its in vitro inhibitory activity against Mycobacterium bovis BCG. It 
showed 100% inhibition of bacterial growth at a concentration of 25 μg/mL.  
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2.4 MOLECULAR DOCKING 
In an effort to rationalize the threefold increase in affinity upon replacement of the 4-O of the original 
hit 2.14 by a 4-S (2.23), both compound were docked into the substrate binding site of the TMPKmt 
enzyme (Figure II.17). For inhibitor 2.14, the interactions of the base moiety with the surrounding 
residues are similar to the ones with the natural substrate: a stacking with Phe70, a H-bond of base 
atom N3 with Asn100 and base atom O4 hydrogen bonding with Arg74. In compound 2.23 where the 
C(4)=O is replaced by a C(4)=S, the hydrogen bonds to Arg74 is lost. However, due to the bigger size 
of the sulfur atom, a better van der Waals interaction is seen with surrounding residues Phe70, Arg74 
and Asn100 which may explain a higher affinity for this inhibitor. 
 
 
Figure II.17. Compound 2.14 (left) and compound 2.23 (right) docked in the substrate binding site of TMPKmt. 
The carbon atoms of both inhibitors are colored green. The enzyme contact surface is colored cyan, and the 
contact surface with the 4S atom is colored magenta. 
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2.5 CONCLUSIONS 
On the basis of the structures of nucleosides 2.13 and 2.14, which were identified earlier as potent 
TMPKmt inhibitors, this chapter described the synthesis and biological evaluation of a series of new 
thymidine analogues, including α- and β-derivatives. In both the 3’- and the 5’-derivatised analogues, 
the anomer that places the thymine base trans to the aromatic substituent showed the best TMPKmt 
inhibition. In addition, several analogues were synthesized in which the 4-oxygen was replaced by a 
more lipophilic sulfur atom to probe the influence of this modification on TMPKmt inhibitory activity. 
Remarkably, a 4-thio modification of the pyrimidine base was favorable for the 5’-modified α-
analogues, while it caused an opposite effect on the 3’-modified β-analogues. Several compounds 
showed an inhibitory potency in the low micromolar range, with the 5’-arylthiourea 4-thio-α-thymidine 
analogue 2.23 being the most active one (Ki = 0.17 μM). This compound is capable of inhibiting 
mycobacterial growth at a concentration of 25 μg/mL, promoting TMPKmt as an attractive target for 
further inhibitor design. 
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2.6 EXPERIMENTAL PART 
2.6.1 Synthesis 
5’-O-Acetyl-3’-azido-3’-deoxy-β-D-thymidine (2.27) 
 
O
N3
AcO
N NH
O
O
 
 
To a stirred suspension of 3’-azido-3’-deoxy-β-D-thymidine (1.6, AZT) (231 mg, 0.86 mmol) in acetic 
anhydride (5 mL), 4-dimethylaminopyridine (DMAP) (10 mg, 0.086 mmol) was added. The reaction 
mixture was stirred at room temperature for 3 h. Acetic anhydride was removed in vacuo and the 
residue was dissolved in EtOAc and washed with brine. The organic layer was dried over Na2SO4, 
evaporated and purified by column chromatography (CH2Cl2/MeOH 95:5) to afford compound 2.27 
(264 mg, 99%) as a white foam. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.78 (3H, d, J= 1.5 Hz, 5-CH3), 2.04 (3H, s, OAc), 2.27-2.36 (1H, m, 
H-2’a), 2.40-2.50 (1H, m, H-2’b), 3.95 (1H, app dd, J= 4.8 Hz, J= 10.2 Hz, H-4’), 4.22 (2H, app d, J= 
4.8 Hz, H-5’a an H-5’b), 4.42-4.48 (1H, m, H-3’), 6.07-6.13 (1H, m, H-1’), 7.44 (1H, d, J= 1.2 Hz, H-6), 
11.33 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.12 (5-CH3), 20.57 (OAc), 35.61 (C-2’), 60.06 (C-3’), 63.24 (C-5’), 
80.61 (C-4’), 83.60 (C-1’), 109.88 (C-5), 136.05 (C-6), 150.37 (C-2), 163.66 (C-4), 170.11 (OAc). 
 
Exact mass (ESI-MS) for C12H16N5O5 [M+H]+ found, 310.0837; calcd, 310.1146. 
 
5’-O-Acetyl-3’-azido-3’-deoxy-4-thio-β-D-thymidine (2.28) 
 
O
N3
AcO
N NH
S
O
 
 
Lawesson’s reagent (154 mg, 0.38 mmol) was added to a solution of compound 2.27 (111 mg, 0.36 
mmol) in 10 mL dry toluene. The mixture was refluxed overnight and the solvent was removed in 
vacuo. The residue was purified by column chromatography (CH2Cl2/ MeOH 95:5) to give compound 
2.28 as a brown-yellow solid (23 mg, 20%).  
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1H NMR (300 MHz, DMSO-d6): δ 1.99 (3H, d, J= 0.9 Hz, 5-CH3), 2.06 (3H, s, OAc), 2.34-2.43 (1H, m, 
H-2’a), 2.53-2.57 (1H, m, H-2’b), 3.99-4.04 (1H, m, H-4’), 4.21-4.32 (2H, m, H-5’a an H-5’b), 4.44-4.50 
(1H, m, H-3’), 6.07 (1H, dd, J= 5.7 Hz, J= 7.2 Hz, H-1’), 7.58 (1H, s, H-6), 12.75 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 16.78 (5-CH3), 20.58 (OAc), 35.96 (C-2’), 59.81 (C-3’), 63.09 (C-5’), 
81.10 (C-4’), 84.64 (C-1’), 117.95 (C-5), 133.32 (C-6), 147.67 (C-2), 171.92 (OAc), 190.95 (C-4). 
 
Exact mass (ESI-MS) for C12H16N5O4S [M+H]+ found, 326.0941; calcd, 326.0918. 
 
3’-Azido-3’-deoxy-4-thio-β-D-thymidine (2.16) 
 
O
N3
HO
N NH
S
O
 
 
Compound 2.28 (16 mg, 0.050 mmol) was dissolved in a 7N NH3 in MeOH solution (1 mL) and stirred 
at room temperature for 6 hours. The reaction mixture was concentrated in vacuo and the residue was 
purified on a silica gel column using CH2Cl2/MeOH (95:5) as the eluent to afford compound 2.16 as a 
yellow powder (6.0 mg, 42%). Spectroscopic data of 2.16 are in accordance with literature data.123 
 
1H NMR (300 MHz, DMSO-d6): δ 1.97 (3H, d, J= 0.6 Hz, 5-CH3), 2.29-2.38 (1H, m, H-2’a), 2.41-2.48 
(1H, m, H-2’b), 3.59-3.71 (2H, m, H-5’a and H-5’b), 3.83-3.87 (1H, m, H-4’), 4.40 (1H, app dd, J= 6.0 
Hz, J= 12.6 Hz, H-3’), 5.28 (1H, br s, 5’-OH), 6.04 (1H, app t, J= 5.7 Hz, H-1’), 7.86 (1H, s, H-6). 
 
13C NMR (75 MHz, DMSO-d6): δ 16.90 (5-CH3), 36.64 (C-2’), 59.44 (C-3’), 60.35 (C-5’), 84.32 and 
84.44 (C-4’ and C-1’), 117.63 (C-5), 133.34 (C-6), 147.71 (C-2), 190.76 (C-4). 
 
Exact mass (ESI-MS) for C10H14N5O3S [M+H]+ found, 326.284.0813; calcd, 284.0812. 
 
5’-O-Acetyl-3’-(4-(p-chlorophenyl)-1,2,3-triazol-1-yl)-3’-deoxy-β-D-thymidine (2.29) 
 
O
N
AcO
N NH
O
ON
N
Cl  
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Compound 2.27 (146 mg, 0.47 mmol), sodium ascorbate (5 mg, 0.024 mmol) and CuSO4͘͘∙5H2O (5 mg, 
0.019 mmol) were suspended in 9 mL of H2O/t-BuOH (2:1). 1-Chloro-4-ethynylbenzene (129 mg, 0.94 
mmol) was added after 15 minutes and the mixture was stirred at room temperature for 24 h. The 
reaction mixture was extracted with EtOAc and the combined organic phases were dried over 
anhydrous MgSO4 and evaporated to dryness. The crude product was purified using column 
chromatography (CH2Cl2/MeOH 95:5) to afford compound 2.29 (87 mg, 41 %) as a white powder. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.84 (3H, s, 5-CH3), 2.04 (3H, s, OAc), 2.73-2.94 (2H, m, H-2’a and 
H-2’b), 4.27-4.37 (2H, m, H-5’a and H-5’b), 4.43-4.49 (1H, m, H-4’), 5.47-5.54 (1H, m, H-3’), 6.45 (1H, 
t, J= 7.2 Hz, H-1’), 7.52-7.57 (2H, m, subs Ph), 7.63 (1H, d, J= 1.2 Hz, H-6), 7.85-7.90 (2H, m, subs 
Ph), 8.86 (1H, s, H-5”), 11.41 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.14 (5-CH3), 20.53 (OAc), 36.36 (C-2’), 59.50 and 63.29 (C-5‘ and 
C-3’), 80.85 (C-4’), 84.15 (C-1’), 110.00 (C-5), 121.34 (C-5”), 126.86, 129.07, 129.42 and 132.48 
(subs Ph), 136.39 (C-6), 145.54 (C-4”), 150.44 (C-2), 163.74 (C-4), 170.08 (OAc). 
 
Exact mass (ESI-MS) for C20H21ClN5O5 [M+H]+ found, 446.1238; calcd, 446.1226. 
 
5’-O-Acetyl-3’-(4-(p-chlorophenyl)-1,2,3-triazol-1-yl)-3’-deoxy-4-thio-β-D-thymidine (2.30) 
 
O
N
AcO
N NH
S
ON
N
Cl  
 
Lawesson’s reagent (158 mg, 0.39 mmol) was added to a solution of compound 2.29 (87 mg, 0.20 
mmol) in 10 mL dry toluene. The mixture was refluxed overnight and the solvent was removed in 
vacuo. The residue was purified by column chromatography (CH2Cl2/ MeOH 95:5) to give compound 
2.30 as a brown-yellow solid (44 mg, 49%).  
 
1H NMR (300 MHz, CDCl3): δ 2.00 (3H, s, 5-CH3), 2.05 (3H, s, OAc), 2.86-2.94 (1H, m, H-2’a), 3.17-
3.26 (1H, m, H-2’b), 4.35 (2H, d, J= 3.3 Hz, H-5’a and H-5’b), 4.59-4.65 (1H, m, H-4’), 5.49 (1H, app 
dd, J= 7.5 Hz, J= 15.3 Hz, H-3’),6.01-6.04 (1H, m, H-1’), 7.24 (1H, s, H-6), 7.32 (2H, d, J= 8.4 Hz, 
subs Ph), 7.68 (2H, d, J= 8.4 Hz, subs Ph), 7.93 (1H, s, H-5”), 11.10 (1H, s, 3-NH). 
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13C NMR (75 MHz, CDCl3): δ 17.41 (5-CH3), 21.00 (OAc), 38.16 (C-2’), 60.31 and 63.45 (C-5‘ and C-
3’), 82.99 (C-4’), 89.57 (C-1’), 120.21 and 120.71 (C-5 and C-5”), 127.23, 128.77, 129.39, 134.01 and 
134.47 (C-6 and subs Ph), 147.20 and 148.49 (C-4” and C-2), 170.66 (OAc), 190.91 (C-4). 
 
Exact mass (ESI-MS) for C20H21ClN5O4S [M+H]+ found, 462.1042; calcd, 462.0997. 
 
3’-(4-(p-Chlorophenyl)-1,2,3-triazol-1-yl)-3’-deoxy-4-thio-β-D-thymidine (2.17) 
 
O
N
HO
N NH
S
ON
N
Cl  
 
Compound 2.30 (42 mg, 0.090 mmol) was dissolved in a 7N NH3 in MeOH solution (1 mL) and stirred 
at room temperature for 6 hours. The reaction mixture was concentrated in vacuo and the residue was 
purified on a silica gel column using CH2Cl2/MeOH (95:5) as the eluent to afford compound 2.17 as a 
yellow powder (25.2 mg, 66%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, d, J= 0.9 Hz, 5-CH3), 1.96 (1H, app dt, J= 3.6 Hz, J= 14.1 
Hz, H-2’a), 2.45-2.55 (1H, m, H-2’b), 4.28 (1H, app s, H-3’), 4.47-4.64 (3H, m, H-4’, H-5’a and H-5’b), 
5.63 (1H, s, 5’-OH), 6.18 (1H, dd, J= 3.9 Hz, J= 7.5 Hz, H-1’), 7.49-7.54 (2H, m, subs Ph), 7.72 (1H, d, 
J= 1.2 Hz, H-6), 7.86-7.91 (2H, m, subs Ph), 8.62 (1H, s, H-5”).  
 
13C NMR (75 MHz, DMSO-d6): δ 16.94 (5-CH3), 37.51 (C-2’), 59.02 (C-3’), 60.41 (C-5‘), 84.80 and 
84.90 (C-4’ and C-1’), 117.81 (C-5), 121.40 (C-5”), 126.87, 129.03, 129.47, 132.44 and 133.50 (C-6 
and subs Ph), 145.49 and 147.79 (C-4” and C-2), 190.90 (C-4).  
 
Exact mass (ESI-MS) for C18H19ClN5O3S [M+H]+ found, 420.0915; calcd, 420.0892. 
 
5’-O-Methanesulfonyl-β-D-thymidine (2.31) 
 
O N
MsO
HO
NH
O
O
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To a solution of β-thymidine (3 g, 12 mmol) in pyridine (45 mL) was added methanesulfonyl chloride 
(0.86 mL, 11 mmol) at -78 °C. The reaction mixture was stirred for 1 h at 0 °C. The reaction was 
quenched with saturated aq. NaHCO3 and extracted with CH2Cl2 three times, dried over MgSO4 and 
evaporated. The residue was purified by column chromatography (CH2Cl2/MeOH 95:5) to give 
compound 2.31 (2.5 g, 63%) as a white solid. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.78 (3H, d, J= 1.2 Hz, 5-CH3), 2.10-2.20 (2H, m, H-2’a and H-2’b), 
3.23 (3H, s, CH3SO2), 3.95-4.00 (1H, m, H-4’), 4.24-4.29 (1H, m, H-3’), 4.32-4.43 (2H, m, H-5’a and H-
5’b), 6.23 (1H, app t, J= 7.5 Hz, H-1’), 7.48 (1H, d, J= 1.2 Hz, H-6). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.04 (5-CH3), 36.73 (C-2’), (CH3SO2 under DMSO peak), 69.62 (C-
5’), 70.14 (C-5’), 83.38 (C-4’), 83.98 (C-1’), 109.88 (C-5), 135.82 (C-6), 150.46 (C-2), 163.67 (C-4). 
 
Exact mass (ESI-MS) for C11H17N2O7S [M+H]+ found, 321.0119; calcd, 321.0751. 
 
5’-Azido-5’-deoxy-β-D-thymidine (2.32) 
 
O N
N3
HO
NH
O
O
 
 
A solution of compound 2.31 (2.5 g, 7.8 mmol) and NaN3 (5.07 g, 78 mmol) in DMF (140 mL) was 
stirred at 60 °C overnight. The reaction mixture was evaporated in vacuo. The residue was dissolved 
in CH2Cl2 and washed with H2O. The organic layer was dried over MgSO4, evaporated and purified by 
column chromatography (CH2Cl2/MeOH 95:5) to afford compound 2.32 (793 mg, 38%) as white 
crystals. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.77 (3H, d, J= 1.2 Hz, 5-CH3), 2.03-2.10 (1H, m, H-2’a), 2.19-2.28 
(1H, m, H-2’b), 3.54 (2H, app d, J= 5.1 Hz, H-5’a and H-5’b), 3.80-3.85 (1H, m, H-4’), 4.15-4.19 (1H, 
m, H-3’), 5.39 (1H, br s, 3’-OH), 6.18 (1H, app t, J= 6.9 Hz, H-1’), 7.47 (1H, d, J= 1.2 Hz, H-6), 11.30 
(1H, s, 3-NH).  
 
13C NMR (75 MHz, DMSO-d6): δ 12.10 (5-CH3), 38.08 (C-2’), 51.70 (C-5’), 70.73 (C-3’), 83.87 (C-4’), 
84.56 (C-1’), 109.82 (C-5), 136.08 (C-6), 150.49 (C-2), 163.67 (C-4).  
 
Exact mass (ESI-MS) for C10H14N5O4 [M+H]+ found, 268.1055; calcd, 268.1040. 
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5’-Azido-3’-O-tert-butyldimethylsilyl-5’-deoxy-β-D-thymidine (2.33) 
 
O N
N3
TBDMSO
NH
O
O
 
 
To a stirred solution of compound 2.32 (296 mg, 1.11 mmol) in anhydrous pyridine (16 mL), tert-
butyldimethylsilyl chloride (627 mg, 4.16 mmol) and imidazole (359 mg, 5.27 mmol) were added. After 
stirring for 1 h at room temperature, solvents were removed under reduced pressure and the crude 
was purified over silica gel (CH2Cl2/MeOH 95:5) affording compound 2.33 (450 mg, 100%) as a brown 
solid. 
 
1H NMR (300 MHz, CDCl3): δ 0.089 (6H, s, TBDMS), 0.89-0.91 (9H, m, TBDMS), 1.95 (3H, s, 5-CH3), 
2.15-2.29 (2H, m, H-2’a and H-2’b), 3.50 (1H, dd, J= 3.6 Hz, J= 13.5 Hz, H-5’a), 3.71 (1H, dd, J= 3.0 
Hz, J= 13.2 Hz, H-5’b), 3.92-3.95 (1H, m, H-4’), 4.34-4.37 (1H, m, H-3’), 6.26 (1H, app t, J= 6.3 Hz, H-
1’), 7.32 (1H, s, H-6), 9.46 (1H, s, 3-NH). 
 
13C NMR (75 MHz, CDCl3): δ -4.65, -4.41 and -3.33 (TBDMS), 12.91 (5-CH3), 18.17 (TBDMS), 25.93 
(TBDMS), 40.91 (C-2’), 51.98 (C-5’), 71.90 (C-3’), 85.02 and 85.10 (C-4’ and C-1’), 111.62 (C-5), 
135.64 (C-6), 150.68 (C-2), 164.16 (C-4). 
 
Exact mass (ESI-MS) for C16H28N5O4Si [M+H]+ found, 382.1879; calcd, 382.1905. 
 
5’-Amino-3’-O-tert-butyldimethylsilyl-5’-deoxy-β-D-thymidine (2.34) 
 
O N
H2N
TBDMSO
NH
O
O
 
 
A solution of compound 2.33 (458 mg, 1.20 mmol) in methanol (5 mL) was hydrogenated under 
atmospheric pressure overnight in the presence of 10% Pd/C. The catalyst was removed by filtration 
through Celite and the filtrate was evaporated in vacuo to obtain pure compound 2.34 (403 mg, 95%) 
as a white foam. 
 
1H NMR (300 MHz, CDCl3): δ 0.077 (6H, s, TBDMS), 0.89-0.91 (9H, m, TBDMS), 1.92 (3H, s, 5-CH3), 
2.10-2.30 (2H, m, H-2’a and H-2’b), 2.86 (1H, dd, J= 6.3 Hz, J= 13.8 Hz, H-5’a), 3.05 (1H, dd, J= 3.3 
Hz, J= 13.5 Hz, H-5’b), 3.77-3.82 (1H, m, H-4’), 4.25-4.30 (1H, m, H-3’), 6.25 (1H, app t, J= 6.6 Hz, H-
1’), 7.30 (1H, s, H-6). 
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13C NMR (75 MHz, CDCl3): δ -4.69, -4.45 and -3.38 (TBDMS), 12.83 (5-CH3), 18.08 and 18.19 
(TBDMS), 25.87 (TBDMS), 40.82 (C-2’), 43.42 (C-5’), 72.18 (C-3’), 84.67 (C-1’), 87.57 (C-4’), 111.37 
(C-5), 135.74 (C-6), 151.40 (C-2), 165.16 (C-4). 
 
Exact mass (ESI-MS) for C16H30N3O4Si [M+H]+ found, 356.2004; calcd, 356.2000. 
 
N-(3’-O-tert-Butyldimethylsilyl-5’-deoxy-β-D-thymidin-5’-yl)-N’-(4-chloro-3-trifluoromethyl-
phenyl)thiourea (2.35) 
O N
N
H
TBDMSO
NH
O
N
H
S
Cl
F3C
O
 
 
To a solution of compound 2.34 (403 mg, 1.13 mmol) in DMF (4 mL) was added a solution of 4-chloro-
3-(trifluoromethyl)phenyl isothiocyanate (0.18 mL, 1.13 mmol) in DMF (2 mL) at 0 °C. The reaction 
mixture was stirred for 1 h. The solvents were evaporated to dryness and the residue was purified by 
column chromatography (CH2Cl2/MeOH 98:2) affording compound 2.35 as a colourless solid (510 mg, 
76%). 
 
1H NMR (300 MHz, DMSO-d6): δ 0.098 (6H, s, TBDMS), 0.87-0.88 (9H, m, TBDMS), 1.80 (3H, s, 5-
CH3), 2.02-2.10 (1H, m, H-2’a), 2.24-2.34 (1H, m, H-2’b), 3.55-3.65 (1H, m, H-4’), 3.98-3.99 (2H, m, H-
5’a and H-5’b), 4.45-4.47 (1H, m, H-3’), 6.15-6.19 (1H, m, H-1’), 7.52 (1H, s, subs Ph), 7.62-7.72 (2H, 
m, subs Ph and H-6), 7.96 (1H, subs Ph), 8.12 (1H, s, 5’-NH), 9.93 (1H, s, N’H), 11.33 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ -4.99 and -4.93 (TBDMS), 11.95 (5-CH3), 17.57 (TBDMS), 25.57 
(TBDMS), (C-2’ under DMSO peak), 45.74 (C-5’), 72.80 (C-3’), 83.98 and 84.19 (C-1’ and C-4’), 
109.74 (C-5), 124.50-139.00 (subs Ph, CF3 and C-6), 150.36 (C-2), 163.56 (C-4), 180.77 (C=S). 
 
Exact mass (ESI-MS) for C24H33ClF3N4O4Si [M+H]+ found, 593.1643; calcd, 593.1627. 
 
N-(5’-Deoxy-β-D-thymidin-5’-yl)-N’-(4-chloro-3-trifluoromethylphenyl)thiourea (2.18) 
 
O N
N
H
HO
NH
O
N
H
S
Cl
F3C
O
 
 
Compound 2.35 (84 mg, 0.14 mmol) was dissolved in THF (0.9 mL). A solution of 1M tetra-n-
butylammonium fluoride in THF (0.31 mL) was added. After 1 h at room temperature the reaction was 
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completed. The solvent was evaporated and the dry residue was purified by column chromatography 
(CH2Cl2/MeOH 95:5) to give pure compound 2.18 (40 mg, white solid) in 60% yield.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.79 (3H, s, 5-CH3), 2.05-2.13 (1H, m, H-2’a), 2.17-2.27 (1H, m, H-
2’b), 3.59-3.66 (1H, m, H-4’), 3.87-3.96 (2H, m, H-5’a and H-5’b), 4.23-4.24 (1H, m, H-3’), 5.38 (1H, d, 
J= 4.2 Hz, 3’-OH), 6.18-6.22 (1H, m, H-1’), 7.51-7.7.75 (3H, m, subs Ph and H-6), 8.17-8.22 (2H, m, 
subs Ph and 5’-NH), 9.99 (1H, s, N’H), 11.32 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.73 (5-CH3), (C-2’ under DMSO peak), 46.95 (C-5’), 71.97 (C-3’), 
84.56 and 84.69 (C-1’ and C-4’), 110.54 (C-5), 121.59-139.91 (subs Ph, CF3 and C-6), 151.18 (C-2), 
164.38 (C-4), 181.44 (C=S). 
 
Exact mass (ESI-MS) for C18H19ClF3N4O4 [M+H]+ found, 479.0778; calcd, 479.0762. 
 
1-(4-Chloro-3-trifluoromethylphenyl)-5-(5’-amino-3’-O-tert-butyldimethylsilyl-5’-deoxy-β-D-
thymidin-5’N-yl)tetrazole (2.36) 
O N
NH
OTBDMS
NH
O
NN
N N
Cl
CF3
O
 
 
To a suspension of compound 2.35 (504 mg, 0.85 mmol), sodium azide (166 mg, 2.55 mmol) and 
HgCl2 (253 mg, 0.93 mmol) in dry DMF (3.3 mL) was added Et3N (0.36 mL, 2.55 mmol) under N2 
atmosphere. The resulting black suspension was stirred overnight at room temperature. The mixture 
was filtered through a pad of Celite, washing with CH2Cl2. The filtrate was diluted with water and 
extracted with CH2Cl2. The combined organic layers were dried over MgSO4, filtered and concentrated 
under reduced pressure. The resulting residue was purified by silica gel chromatography 
(CH2Cl2/MeOH 98:2) affording compound 2.36 (424 mg, 83%) as a colourless solid. 
 
1H NMR (300 MHz, DMSO-d6): δ 0.029-0.042 (6H, m, TBDMS), 0.84-0.86 (9H, m, TBDMS), 1.78 (3H, 
s, 5-CH3), 2.00-2.07 (1H, m, H-2’a), 2.23-2.33 (1H, m, H-2’b), 3.48-3.62 (2H, m, H-5’a and H-5’b), 
3.94-3.99 (1H, m, H-4’), 4.42-4.45 (1H, m, H-3’), 6.10-6.14 (1H, m, H-1’), 7.41 (1H, t, J= 6.0 Hz, 5’-
NH), 7.53 (1H, d, J= 1.2 Hz, H-6), 7.88-8.03 (3H, m, subs Ph), 11.31 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ -5.06 and -4.91 (TBDMS), 11.92 (5-CH3), 17.56 (TBDMS), 25.56 
(TBDMS), (C-2’ under DMSO peak), 45.82 (C-5’), 72.90 (C-3’), 84.07 and 84.58 (C-1’ and C-4’), 
109.61 (C-5), 128.00-136.27 (subs Ph, CF3 and C-6), 150.35 (C-2), 155.28 (C=N), 163.62 (C-4). 
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Exact mass (ESI-MS) for C24H32ClF3N7O4Si [M+H]+ found, 602.1910; calcd, 602.1920. 
 
1-(4-Chloro-3-trifluoromethylphenyl)-5-(5’-amino-5’-deoxy-β-D-thymidin-5’N-yl)tetrazole (2.19) 
 
O N
NH
HO
NH
O
NN
N N
Cl
CF3
O
 
 
Compound 2.36 (241 mg, 0.400 mmol) was dissolved in THF (2.5 mL). A solution of 1M tetra-n-
butylammonium fluoride in THF (0.88 mL) was added. After 1 h at room temperature the reaction was 
completed. The solvent was evaporated and the dry residue was purified by column chromatography 
(CH2Cl2/MeOH 95:5) to give pure compound 2.19 (104 mg, white solid) in 53% yield.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.76 (3H, d, J= 0.9 Hz, 5-CH3), 2.04-2.11 (1H, m, H-2’a), 2.14-2.24 
(1H, m, H-2’b), 3.49-3.65 (2H, m, H-5’a and H-5’b), 3.93-3.98 (1H, m, H-4’), 4.22-4.27 (1H, m, H-3’), 
5.32 (1H, d, J= 4.5 Hz, 3’-OH), 6.12-6.17 (1H, m, H-1’), 7.39 (1H, t, J= 5.7 Hz, 5’-NH), 7.50 (1H, d, J= 
1.5 Hz, H-6), 7.90-8.07 (3H, m, subs Ph), 11.29 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.02 (5-CH3), (C-2’ under DMSO peak), 46.16 (C-5’), 71.24 (C-3’), 
83.91 (C-1’), 84.28 (C-4’), 109.73 (C-5), 124.95-136.26 (subs Ph, CF3 and C-6), 150.47 (C-2), 155.42 
(C=N), 163.76 (C-4). 
 
Exact mass (ESI-MS) for C18H18ClF3N7O4 [M+H]+ found, 488.1052; calcd, 488.1055. 
 
5’-(4-(p-Chlorophenyl)-1,2,3-triazol-1-yl)-5’-deoxy-β-D-thymidine (2.20) 
 
O N
N
HO
NH
O
N
N
Cl
O
 
 
Compound 2.32 (56 mg, 0.21 mmol), sodium ascorbate (cat. amount) and CuSO4͘͘∙5H2O (cat. amount) 
were suspended in 3 mL of H2O/t-BuOH (1:2). 1-Chloro-4-ethynylbenzene (57 mg, 0.42 mmol) was 
added after 15 minutes and the mixture was stirred at room temperature for 7 days. The reaction 
                                                                PART II - Chapter 2: Thymidine Analogues Targeting TMPKmt 
  129 
 
mixture was extracted with EtOAc and the combined organic phases were dried over anhydrous 
MgSO4 and evaporated to dryness. Purification of the crude using RP-HPLC (Phenomenex Luna C-
18, H2O/0.1% HCOOH in CH3CN, 90:10 → 0:100 in 23 min, flow 17.5 mL/min) afforded compound 
2.20 (2.0 mg, 2%) as a white powder. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.68 (3H, s, 5-CH3), 2.02-2.24 (2H, m, H-2’a and H-2’b), 4.09-4.14 
(1H, m, H-4’), 4.28-4.31 (1H, m, H-3’), 4.64-4.80 (2H, m, H-5’a and H-5’b), 5.59 (1H, br s, 3’-OH), 6.18 
(1H, app t, J= 6.9 Hz, H-1’), 7.23 (1H, d, J= 1.2 Hz, H-6), 7.49-7.53 (2H, m, subs Ph), 7.85-7.90 (2H, 
m, subs Ph), 8.62 (1H, s, H-5”), 11.30 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 11.96 (5-CH3), 37.84 (C-2’), 51.13 (C-5’), 70.47 (C-3’), 83.66 (C-4’), 
83.77 (C-1’), 109.79 (C-5), 122.53-132.25 (subs Ph and C-5”), 135.96 (C-6), 145.26 (C-4”), 150.37 (C-
2), 163.56 (C-4). 
 
Exact mass (ESI-MS) for C18H19ClN5O4 [M+H]+ found, 404.1125; calcd, 404.1120.  
 
3’,5’-Di-O-acetyl-β-D-thymidine (2.37) 
 
O N
AcO
AcO
NH
O
O
 
 
β-thymidine (2.50 g, 10.32 mmol) was dissolved in pyridine (40 mL) and acetic anhydride (40 mL). The 
reaction mixture was stirred at room temperature during 2 h, evaporated to dryness, and co-
evaporated with toluene to obtain pure compound 2.37 in a 98% yield (3.30 g, white foam). 
 
1H NMR (300 MHz, CDCl3): δ 1.94 (3H, d, J= 1.2 Hz, 5-CH3), 2.11 (3H, s, OAc), 2.13 (3H, s, OAc), 
2.12 (1H, dd, J= 6.6 Hz, J= 8.4 Hz, H-2’a), 2.43-2.51 (1H, m, H-2’b), 4.24-4.28 (1H, m, H-4’), 4.35-4.45 
(2H, m, H-5’a and H-5’b), 5.21 (1H, dt, J= 2.1 Hz, J= 6.6 Hz, H-3’), 6.31 (1H, dd, J= 5.7 Hz, J= 8.7, H-
1’), 7.29 (1H, d, J= 1.2 Hz, H-6), 8.62 (1H, br s, 3-NH). 
 
Exact mass (ESI-MS) for C14H19N2O7 [M+H]+ found, 327.1194; calcd, 327.1192. 
 
3’,5’-Di-O-acetyl-α-D-thymidine (2.38) 
 
O
AcO
AcO
N NH
O
O  
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To a solution of compound 2.37 (3.30 g, 10.11 mmol) in 5 mL dry CH3CN, was added a freshly 
prepared solution, containing 17 μL H2SO4 and 0.66 mL acetic anhydride in 5 mL dry CH3CN. After 2 
h, the mixture was quenched with saturated NaHCO3-solution and extracted three times with EtOAc. 
After purification (CH2Cl2/MeOH 95:5), compound 2.38 was obtained in a 45% yield (1.51 g, white 
crystals).  
 
1H NMR (300 MHz, CDCl3): δ 1.95 (3H, d, J= 1.2 Hz, 5-CH3), 2.05 (3H, s, OAc), 2.12 (3H, s, OAc), 
2.21-2.28 (1H, m, H-2’a), 2.81 (1H, dt, J= 6.9 Hz, J= 15.1 Hz, H-2’b), 4.19-4.25 (2H, m, H-5’a and H-
5’b), 4.59-4.63 (1H, m, H-4’), 5.23 (1H, dt, J= 1.6 Hz, J= 6.4 Hz, H-3’), 6.26 (1H, dd, J= 2.4 Hz, J= 7.2 
Hz, H-1’), 7.30 (1H, d, J= 1.2 Hz, H-6), 8.62 (1H, br s, 3-NH). 
 
Exact mass (ESI-MS) for C14H19N2O5 [M+H]+ found, 327.1195; calcd, 327.1192. 
 
4-Thio-α-D-thymidine (2.40) 
 
O
HO
HO
N NH
S
O
 
 
Lawesson’s reagent (777 mg, 1.92 mmol) was added to a solution of compound 2.38 (519 mg, 1.59 
mmol) in 15 mL dry 1,4-dioxane. The mixture was refluxed for 4 hours. After the reaction mixture had 
been cooled, the solvent was removed in vacuo. The crude product thus obtained (compound 2.39) 
was treated with 8 mL of a 7N NH3 in MeOH solution and stirred at room temperature for 4 hours. The 
reaction mixture was concentrated in vacuo and the residue was purified on a silica gel column using 
CH2Cl2/MeOH (94:6) as the eluent to afford compound 2.40 as a yellow foam (150 mg, 37%).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, s, 5-CH3), 1.94-1.98 (1H, m, H-2’a), 2.51-2.57 (1H, m, H-
2’b), 3.40 (2H, t, J= 5.2 Hz, H-5’a and H-5’b), 4.23-4.25 (2H, m, H-3’ and H-4’), 4.86 (1H, t, J= 5.7 Hz, 
5’-OH), 5.26 (1H, d, J= 2.7 Hz, 3’-OH), 6.04 (1H, dd, J= 2.7 Hz, J= 7.5 Hz, H-1’), 7.81 (1H, d, J= 0.9 
Hz, H-6), 12.65 (1H, s, 3-NH).  
 
Exact mass (ESI-MS) for C10H15N2O4S [M+H]+ found, 259.0753; calcd, 259.0747.  
 
5’-O-Methanesulfonyl-4-thio-α-D-thymidine (2.41) 
 
O
HO
MsO
N NH
S
O
 
 
                                                                PART II - Chapter 2: Thymidine Analogues Targeting TMPKmt 
  131 
 
To a solution of 4-thio-α-D-thymidine 2.40 (146 mg, 0.57 mmol) in pyridine (5 mL) was added 
methanesulfonyl chloride (42 μL,0.54 mmol) at -78 °C. The reaction mixture was stirred for 1 h at 0 °C. 
The reaction was quenched with saturated aqueous NaHCO3-solution and extracted with CH2Cl2 three 
times, dried over MgSO4 and evaporated. The residue was purified by column chromatography 
(CH2Cl2/ MeOH 95:5) to give compound 2.41 as a yellow foam (133 mg, 70%).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.97 (3H, d, J= 0.6 Hz, 5-CH3), 1.99-2.04 (1H, m, H-2’a), 2.53-2.30 
(1H, m, H-2’b), 3.22 (3H, s, SO2CH3), 4.08-4.10 (2H, m, H-5’a and H-5’b), 4.16-4.30 (1H, m, H-3’), 
4.40-4.46 (1H, m, H-4’), 5.55 (1H, br s, 3’-OH), 6.09 (1H, dd, J= 3.6 Hz, J= 7.5 Hz, H-1’), 7.69 (1H, s, 
H-6).  
 
Exact mass (ESI-MS) for C11H17N2O6S2 [M+H]+ found, 337.0533; calcd, 337.0523. 
 
5’-Azido-5’-deoxy-4-thio-α-D-thymidine (2.42) 
 
O
HO
N3 N NH
O
S  
 
A solution of compound 2.41 (129 mg, 0.38 mmol) and NaN3 (250 mg, 3.86 mmol) in DMF (7 mL) was 
heated overnight at 60 °C. The reaction mixture was evaporated in vacuo. The residue was dissolved 
in CH2Cl2 and washed with brine. The organic layer was dried over MgSO4, evaporated and purified by 
column chromatography (CH2Cl2/MeOH 95:5) affording compound 2.42 (97 mg, 89%) as a yellow oil. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.98 (3H, d, J= 0.9 Hz, 5-CH3), 2.04 (1H, t, J= 3.3 Hz, H-2’a), 2.56-
2.65 (1H, m, H-2’b), 3.40-3.44 (2H, m, H-5’a and H-5’b), 4.14-4.17 (1H, m, H-3’), 4.34-4.39 (1H, m, H-
4’), 5.47 (1H, br s, 3’-OH), 6.09 (1H, dd, J= 3.6 Hz, J= 7.5 Hz, H-1’), 7.78 (1H, s, H-6).  
 
Exact mass (ESI-MS) for C10H14N5O3S [M+H]+ found, 284.0813; calcd, 284.0812. 
 
5’-Amino-5’-deoxy-4-thio-α-D-thymidine (2.43)  
 
O
HO
H2N N NH
O
S  
 
Compound 2.42 (97 mg, 0.34 mmol) and PPh3 (187 mg, 0.71 mmol) were dissolved in THF (6 mL). 
After stirring for 10 minutes, H2O was added (883 μL) and the mixture was stirred for 1 day. The 
PART II - Chapter 2: Thymidine Analogues Targeting TMPKmt   
132 
 
reaction mixture was extracted with CH2Cl2 and the water phase lyophilized to give amine 2.43 (78 
mg, 89%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.96 (3H, d, J= 0.6 Hz, 5-CH3), 2.00 (1H, t, J= 3.6 Hz, H-2’a), 2.58-
2.68 (1H, m, H-2’b), 2.76-2.87 (1H, m, H-5’a), 2.96-3.04 (1H, m, H-5’b), 4.18-4.20 (1H, m, H-3’), 4.32 
(1H, dt, J= 3.3 Hz, J= 9.6 Hz, H-4’), 5.57 (1H, br s, 3’-OH), 6.15 (1H, dd, J= 3.3 Hz, J= 7.5 Hz, H-1’), 
7.77 (1H, s, H-6). 
 
Exact mass (ESI-MS) for C10H16N3O3S [M+H]+ found, 258.0907; calcd, 258.0907. 
 
N-(5’-Deoxy-4-thio-α-D-thymidin-5’-yl)-N’-phenylthiourea (2.22)  
 
O
HO
N
H
N
H
S
N NH
O
S  
 
For the synthesis of compound 2.22, amine 2.43 (26 mg, 0.10 mmol) was dissolved in DMF (1 mL). At 
0 °C, phenyl isothiocyanate (16 mg, 0.12 mmol) was added and the reaction mixture was allowed to 
stir at room temperature during 3 h. After completion of the reaction, the reaction mixture was 
evaporated to dryness and the residue was purified by column chromatography (CH2Cl2/MeOH 95:5) 
to obtain final compound 2.22 (27.0 mg, 69%) as a yellow powder.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.97 (3H, d, J= 0.9 Hz, 5-CH3), 2.01-2.03 (1H, m, H-2’a), 2.54-2.63 
(1H, m, H-2’b), 3.53-3.70 (2H, m, H-5’a and H-5’b), 4.21-4.24 (1H, m, H-3’), 4.42-4.46 (1H, m, H-4’), 
5.43 (1H, d, J= 2.7 Hz, 3’-OH), 6.12 (1H, dd, J= 2.7 Hz, J= 7.5 Hz, H-1’), 7.08-7.13 (1H, m, Ph), 7.29-
7.34 (2H, m, Ph), 7.43-7.47 (2H, m, Ph), 7.80 (1H, s, H-6).  
 
13C NMR (75 MHz, DMSO-d6): δ 17.03 (5-CH3), (C-2’ under DMSO peak), 45.49 (C-5’), 70.79 (C-3’), 
86.08 (C-1’), 86.78 (C-4’), 117.22 (C-5), 123.22, 124.30, 128.63 and 134.25 (Ph), 139.13 (C-6), 
147.87 (C-2), 180.74 (C=S), 190.56 (C-4).  
 
Exact mass (ESI-MS) for C17H21N4O3S2 [M+H]+ found,393.1053; calcd, 393.1050. 
 
N-(5’-Deoxy-4-thio-α-D-thymidin-5’-yl)-N’-(4-chloro-3-trifluoromethylphenyl)thiourea (2.23) 
 
O
HO
N
H
N
H
S
N NH
O
S
Cl
F3C
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Compound 2.23 was synthesized from amine 2.43 (52 mg, 0.20 mmol) and 4-chloro-3-
trifluoromethylphenyl isothiocyanate (57 mg,0.24 mmol) using the same procedure as described for 
the synthesis of compound 2.22. After purification by column chromatography (CH2Cl2/MeOH 95:5), 
compound 2.23 (41.7mg, 42%) was obtained as a yellow powder.  
 
1H NMR (300 MHz, DMSO-d6): δ 1.98 (3H, d, J= 0.6 Hz, 5-CH3), 2.06 (1H, t, J= 2.1 Hz, H-2’a), 2.57-
2.66 (1H, m, H-2’b), 3.56-3.59 (1H, m, H-5’a), 3.67-3.72 (1H, m, H-5’b), 4.25-4.26 (1H, m, H-3’), 4.44-
4.48 (1H, m, H-4’), 5.47 (1H, d, J= 3.0 Hz, 3’-OH), 6.14 (1H, dd, J= 2.7 Hz, J= 7.5 Hz, H-1’), 7.64 (2H, 
d, J= 8.7 Hz, subs Ph), 7.74 (2H, dd; J= 2.1 Hz, J= 8.4 Hz, subs Ph), 7.83 (1H, d, J= 0.9 Hz, H-6).  
 
13C NMR (75 MHz, DMSO-d6): δ 17,11 (5-CH3), (C-2’ under DMSO peak), 45.62 (C-5’), 70.95 (C-3’), 
86.18 and 86.55 (C-4’ and C-1’), 117.22 (C-5), 124.61, 127.50, 131.77 and 134.28 (CF3 and subs Ph), 
139.23 (C-6), 148.00 (C-2), 180.95 (C=S), 190.70 (C-4).  
 
Exact mass (ESI-MS) for C18H19ClF3N4O3S2 [M+H]+ found,495.0508; calcd, 495.0534. 
 
α-D-Thymidine (2.44) 
O
HO
HO
N NH
O
O  
 
Compound 2.38 (1.1 g, 3.37 mmol) was dissolved in a 7N solution of NH3 in MeOH (35 mL). The 
reaction mixture was stirred overnight at room temperature. The solvent was evaporated in vacuo and 
the residue was dissolved in EtOAc and extracted three times with water. The organic layer was dried 
over MgSO4, filtered and concentrated under reduced pressure, yielding 0.73 g of pure compound 
2.44 (90%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.78 (3H, d, J= 1.2 Hz, 5-CH3), 1.84-1.91 (1H, m, H-2’a), 2.48-2.60 
(1H, m, H-2’b), 3.39 (2H, app t, J= 5.2 Hz, H-5’a and H-5’b), 4.13-4.17 (1H, m, H-3’), 4.23-4.26 (1H, m, 
H-4’), 4.81 (1H, t, J= 5.7 Hz, 5’-OH), 5.30 (1H, d, J= 3.0 Hz, 3’-OH), 6.12 (1H, dd, J= 3.3 Hz, J= 7.5 
Hz, H-1’), 7.75 (1H, d, J= 1.2 Hz, H-6), 11.20 (1H, br s, 3-NH). 
 
Exact mass (ESI-MS) for C10H15N2O5 [M+H]+ found, 243.0975; calcd, 243.0981. 
 
5’-Azido-5’-deoxy-α-D-thymidine (2.21) 
 
O
HO
N3 N NH
O
O  
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To a solution of α-D-thymidine 2.44 (0.45 g, 1.86 mmol) in pyridine (7 mL) was added methanesulfonyl 
chloride (130 μL, 0.21 mmol) at -78 °C. The reaction mixture was stirred for 1 h at 0 °C. The reaction 
was quenched with a saturated aqueous NaHCO3-solution and extracted with CH2Cl2 three times, 
dried over MgSO4 and evaporated. The residue was purified by column chromatography 
(CH2Cl2/MeOH 98:2) to give the mesylated compound as a white solid (0.37 g, 62%).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, s, 5-CH3), 1.95-2.05 (1H, m, H-2’a), 2.55-2.68 (1H, m, H-
2’b), 3.19 (3H, s, CH3SO2), 4.12-4.34 (3H, m, H-5’a, H-5’b and H-3’), 4.33-4.36 (1H, m, H-4’), 5.58 
(1H, br s, 3’-OH), 6.12 (1H, dd, J= 4.4 Hz, J= 7.6 Hz, H-1’), 7.73 (1H, s, H-6), 11.27 (1H, br s, 3-NH). 
 
Exact mass (ESI-MS) for C11H17N2O7S [M+H]+ found, 321.0759; calcd, 321.0756. 
 
A solution of 5’-mesylated α-D-thymidine (370 mg, 1.16 mmol) and NaN3 (755 g, 11.71 mmol) in DMF 
(20 mL) was stirred overnight at 60 °C. The reaction mixture was evaporated in vacuo. The residue 
was dissolved in CH2Cl2 and washed with H2O. The organic layer was dried over MgSO4, evaporated 
and purified by column chromatography (CH2Cl2/MeOH 95:5) to afford compound 2.21 as a white solid 
(200 mg, 65%). Spectroscopic data of 2.21 are in accordance with literature data.69 
 
1H NMR (300 MHz, DMSO-d6): 1.76 (3H, s, 5-CH3), 1.93-2.02 (1H, m, H-2’a), 2.51-2.60 (1H, m, H-
2’b), 3.49-3.60 (2H, m, H-5’a and H-5’b), 4.12-4.16 (1H, m, H-3’), 4.24-4.27 (1H, m, H-4’), 5.50 (1H, br 
s, 3’-OH), 6.13 (1H, dd, J= 4.5 Hz, J= 7.5 Hz, H-1’), 7.72 (1H, s, H-6), 11.26 (1H, br s, 3-NH). 
 
Exact mass (ESI-MS) for C10H14N5O4 [M+H]+ found, 268.1045; calcd, 268.1046. 
 
5’-(4-(p-Chlorophenyl)-1,2,3-triazol-1-yl)-5’-deoxy-α-D-thymidine (2.24) 
 
O
HO
NNN
Cl
N NH
O
O
 
 
Compound 2.21 (85 mg, 0.32 mmol), sodium ascorbate (3 mg, 0.016 mmol) and CuSO4͘͘∙5H2O (3 mg, 
0.013 mmol) were suspended in 3 mL of H2O/t-BuOH (2:1). 1-Chloro-4-ethynylbenzene (87 mg, 0.64 
mmol) was added after 15 minutes and the mixture was stirred at room temperature for 4 days. Water 
was added and the triazole product precipitated. Filtration of the mixture afforded pure compound 2.24 
(40.0 mg, 31%) as a white powder. 
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1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, d, J= 1.2 Hz, 5-CH3), 1.94 (1H, app t, J= 3.9 Hz, H-2’a), 
1.99 (1H, app t, J= 3.9 Hz, H-2’b), 4.22-4.32 (1H, m, H-4’), 4.43-4.66 (3H, m, H-3’, H-5’a and H-5’b), 
5.65 (1H, br s, 3’-OH), 6.18 (1H, dd, J= 4.2 Hz, J= 7.5 Hz, H-1’), 7.49-7.54 (2H, m, subs Ph), 7.72 (1H, 
d, J= 1.2 Hz, H-6), 7.86-7.91 (2H, m, subs Ph), 8.62 (1H, s, H-5”), 11.26 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.15 (5-CH3), 51.20 (C-5’), 70.53 (C-4’), 84.72 (C-1’), 85.37 (C-3’), 
108.81 (C-5), 122.41 (C-5”), 126.73, 128.83, 129.45 and 132.15 (subs Ph), 136.64 (C-6), 145.12 (C-
4”), 150.29 (C-2), 163.65 (C-4). 
 
Exact mass (ESI-MS) for C18H19ClN5O4 [M+H]+ found, 404.1129; calcd, 404.1120. 
 
5’-O-Acetyl-3’-azido-3’-deoxy-α-D-thymidine (2.45) 
 
O
N3
AcO
N NH
O
O  
 
To a solution of compound 2.27 (642 mg, 2.08 mmol) in 1 mL dry CH2Cl2, was added a freshly 
prepared solution containing 34 μL H2SO4 and 140 μL acetic anhydride in 1 mL dry CH2Cl2. After 2 h, 
the mixture was quenched with a saturated NaHCO3-solution and extracted three times with EtOAc. 
Purification of the crude on a silica gel column (EtOAc/hexane 9:1) yielded compound 2.45 as a white 
foam (126 mg, 20%).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.80 (3H, d, J= 0.9 Hz, 5-CH3), 2.06 (3H, s, OAc), 2.15-2.22 (1H, m, 
H-2’a), 2.70-2.75 (1H, m, H-2’b), 4.11-4.14 (2H, m, H-5’a and H-5’b), 4.34-4.39 (1H, m, H-3’), 4.42-
4.45 (1H, m, H-4’), 6.07 (1H, dd, J= 6.0 Hz, J= 6.9 Hz, H-1’), 7.59 (1H, d, J= 1.2 Hz, H-6), 11.32 (1H, 
s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.15 (5-CH3), 20.62 (OAc), 36.23 (C-2’), 60.43 (C-3), 63.68 (C-5’), 
81.46 (C-4’), 84.93 (C-1’), 109.38 (C-5), 136.25 (C-6), 150.36 (C-2), 163.80 (C-4), 170.15 (OAc).  
 
Exact mass (ESI-MS) for C12H16N5O5 [M+H]+ found, 310.1164; calcd, 310.1146. 
 
3’-Azido-3’-deoxy-α-D-thymidine (2.25) 
 
O
N3
HO
N NH
O
O  
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Compound 2.45 (146 mg, 0.47 mmol) was dissolved in a 7N NH3 in MeOH solution (2.6 mL) and 
stirred at room temperature for 6 hours. The reaction mixture was concentrated in vacuo and the 
residue was purified on a silica gel column using EtOAc/hexane (8:2) as the eluent to afford 
compound 2.25 as a colourless solid (91 mg, 72%). Spectroscopic data of 2.25 are in accordance with 
literature data.117 
 
1H NMR (300 MHz, CDCl3): δ 1.95 (3H, d, J= 0.9 Hz, 5-CH3), 2.12-2.17 (1H, m, H-2’a), 2.82-2.91 (1H, 
m, H-2’b), 3.08 (1H, t, J= 5.4 Hz, 5’-OH), 3.65-3.72 (1H, m, H-5’a), 3.81-3.85 (1H, m, H-5’b), 4.27-4.35 
(2H, m, H-3’ and H-4’), 6.29 (1H, dd, J= 4.2 Hz, J= 6.9 Hz, H-1’), 7.32 (1H, d, J= 1.5 Hz, H-6), 9.48 
(1H, s, 3-NH). 
 
13C NMR (75 MHz, CDCl3): δ 12.67 (5-CH3), 38.22 (C-2’), 60.83 (C-3), 62.62 (C-5’), 85.93 and 86.02 
(C-4’ and C-1’), 111.24 (C-5), 135.35 (C-6), 150.72 (C-2), 164.03 (C-4).  
 
Exact mass (ESI-MS) for C10H14N5O4 [M+H]+ found, 268.1020; calcd, 268.1040. 
 
3’-(4-(p-Chlorophenyl)-1,2,3-triazol-1-yl)-3’-deoxy-α-D-thymidine (2.26) 
 
O
N
HO
N
N
Cl
N NH
O
O
 
 
Compound 2.25 (72 mg, 0.27 mmol), sodium ascorbate (3 mg, 0.024 mmol) and CuSO4͘͘∙5H2O (3 mg, 
0.011 mmol) were suspended in 3 mL of a H2O/t-BuOH (1:2) mixture. 1-Chloro-4-ethynylbenzene (74 
mg, 0.54 mmol) was added after 15 minutes and the mixture was stirred at room temperature for 24 h. 
The reaction mixture was extracted with EtOAc and the combined organic phases were dried over 
MgSO4 and evaporated to dryness. The crude product was purified using column chromatography 
(EtOAc/hexane 8:2) to obtain compound 2.26 (50.8 mg, 47%) as a white powder. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.75 (3H, s, 5-CH3), 2.71-2.80 (1H, m, H-2’a), 2.98-3.07 (1H, m, H-
2’b), 3.54-3.70 (2H, m, H-5’a and H-5’b), 4.65-4.70 (1H, m, H-4’), 5.12 (1H, t, J= 5.4 Hz, 5’-OH), 5.29-
5.36 (1H, m, H-3’), 6.26 (1H, app t, J= 6.6 Hz, H-1’), 7.50-7.54 (2H, m, subs Ph), 7.63 (1H, d, J= 1.2 
Hz, H-6), 7.84-7.87 (2H, m, subs Ph), 8.82 (1H, s, H-5”), 11.29 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 12.18 (5-CH3), 37.12 (C-2’), 59.23 (C-3), 61.12 (C-5’), 83.89 (C-4’), 
84.43 (C-1’), 109.58 (C-5), 121.38 (C-5”), 126.88-132.47 (subs Ph), 136.07 (C-6), 145.49 (C-4”), 
150.46 (C-2), 163.78 (C-4).  
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Exact mass (ESI-MS) for C18H19ClN5O4 [M+H]+ found, 404.1156; calcd, 404.1120. 
2.6.2 Biological Assays  
Spectrophotometric Binding Assay 
 
TMPKmt activities were determined using the coupled spectrophotometric assay described by Blondin 
et al.124 using an Eppendorf ECOM 6122 photometer and a wavelength of 334 nm. The reaction 
medium (0.5 mL final volume) contained 50 mM Tris-HCl, pH 7.4, 50 mM KCl, 2 mM MgCl2, 0.2 mM 
NADH, 1 mM phosphoenol pyruvate, and 2 units each of lactate dehydrogenase, pyruvate kinase and 
nucleoside diphosphate kinase. The concentrations of ATP and dTMP were kept constant at 0.5 and 
0.05 mM, respectively, whereas the concentrations of analogues varied between 0.01 and 2 mM.  
 
Biological Assays on Mycobacterium bovis (BCG) 
 
Compound 2.23 was assayed for its inhibitory potency on Mycobacterium bovis growth in vitro.125 A 
micro-method of culture was performed in 7H9 Middlebrook broth medium containing 0.2% glycerol 
and 0.5% Tween-80. Serial 2-fold dilutions of each compound were prepared directly in 96-well plates. 
The bacterial inoculum was prepared previously at a concentration in the range of 107 bacteria (M. 
bovis BCG 1173P2) in 7H9 medium and stored at -80 °C until used. The bacteria, adjusted at 105 per 
mL, were delivered in 100 μL per well. The covered plates were sealed with parafilm and incubated at 
37 °C in plastic boxes containing a humidified normal atmosphere. At day 8 of incubation, 30 μL of a 
resazurin (Sigma) solution at 0.01% (wt/vol) in water was added to each well. After an overnight 
incubation at 37 °C, the plates were assessed for color development using the optical density 
difference at 570 and 630 nm on a microplate reader. The change from blue to pink indicates 
reduction of resazurin and therefore bacterial growth. The lowest compound concentration that 
prevented the color change determined the MIC for the assayed compound. 
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1 INTRODUCTION 
1.1 PURINERGIC RECEPTORS 
Extracellular nucleotides, such as ATP, ADP, UTP and UDP are important signaling molecules that 
mediate diverse biological effects via cell-surface receptors termed purinergic receptors.126 These 
receptors were first formally recognized by Burnstock in 1978, when he proposed that these could be 
divided into two classes termed “P1-purinoceptors”, at which adenosine is the principal natural ligand, 
and “P2-purinoceptors”, recognizing ATP, ADP, UTP and UDP.127 Although P1 and P2 receptors are 
now characterized primarily according to their distinct molecular structures, supported by evidence of 
distinct effector systems, pharmacological profiles, and tissue distributions, this major division remains 
a fundamental part of purine receptor classification. In addition, receptors for pyrimidines are now 
included within the P2 receptor family.128 
 
P1 receptors have been further subdivided, according to convergent molecular, biochemical, and 
pharmacological evidence into four subtypes: A1, A2A, A2B and A3.126 All are members of the rhodopsin 
family of G protein-coupled receptors and are coupled principally to adenylate cyclase.129  
 
Based on differences in molecular structure and signal transduction mechanisms, P2 receptors divide 
naturally into two families of ligand-gated ion channels and G protein-coupled receptors termed P2X 
and P2Y receptors, respectively. To date seven mammalian P2X receptors (P2X1–7) and at least eight 
different P2Y receptor subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14) have been 
cloned, characterized and accepted as valid members of the P2 receptor family (Figure III.1).130 
 
 
 
Figure III.1. Purinergic receptor superfamily tree.
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1.2 THE P2Y RECEPTOR FAMILY 
1.2.1 Biochemistry of P2Y Receptors 
The cloning of the first two members of the P2Y receptor family, P2Y1 and P2Y2, has been reported in 
1993131,132 and up to now, eight distinct subtypes are cloned and pharmacologically characterized: 
P2Y1,2,4,6,11,12,13,14. The missing numbers belong to non-mammalian receptors, which may be orthologs 
of mammalian subtypes, or receptors that do not appear to be bona-fide P2Y receptor family 
members.130 
 
The P2Y receptors belong to the rhodopsin family of GPCRs and show the typical features of G-
protein-coupled receptors consisting of seven hydrophobic transmembrane regions (TM) connected by 
three intracellular and three extracellular loops (EL) (Figure III.2). The peptides of the human P2Y 
receptors consist of 328 (P2Y6) to 377 (P2Y2) amino acids corresponding to a predicted molecular 
mass 41 to 53 kDa after glycosylation. The biochemical analysis of the P2Y-receptor proteins has 
shown that P2Y-receptors expressed at the level of the cell membrane are in fact modified by N-linked 
glycosylation. For the P2Y12-receptor, it has recently been demonstrated that N-linked glycosylation of 
the receptor protein is essential for signal transduction, but not for ligand binding or cell surface 
expression.133  
 
 
Figure III.2. Predicted secondary structure of the human P2Y12 receptor. The dashed lines show predicted 
disulfide bridges. 134 
 
The degree of relationship among the members of human P2Y receptors is 20 to 50%, indicating a 
relative high diversity in the amino acid composition.135 For comparison, the hP2Y1 receptor and the 
hP2Y2,4,6 receptors share 38, 44 and 46% sequence identity, respectively, and the hP2Y1 receptor 
and the hP2Y12 receptor, which have similarities in their pharmacological profile, share only 24%. 
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Interestingly, all known P2Y receptor subtypes possess at their extracellular domains 4 cysteine 
residues, which are likely to form 2 disulfide bridges, the first one between the N-terminal domain and 
EL3 and the second bridge between EL1 and EL2 (Figure III.2).136,137 
1.2.2 P2Y Receptor Subtypes and Their Signaling  
From a phylogenetic and structural point of view, two distinct P2Y receptor subgroups have been 
identified both characterized by a relatively high level of sequence divergence. The first subgroup 
includes the P2Y1,2,4,6,11 receptors and the second group encompasses the P2Y12,13,14 subtypes. 
 
P2Y1,2,4,6 receptors act via Gq proteins resulting in phospholipase C (PLC) stimulation leading to the 
formation of IP3 and mobilization of intracellular Ca2+. In addition, activation of the P2Y11 receptor by 
ATP leads to a rise in both cAMP and IP3, whereas activation by UTP produces calcium mobilization 
without IP3 or cAMP increase.129 The second group of P2Y receptors couples via Gi proteins leading to 
the inhibition of adenylate cyclase followed by a decrease in intracellular cAMP levels (Figure III.3).130 
 
The response time of P2Y receptors is longer than the rapid responses mediated by P2X receptors 
because it involves second-messenger systems and/or ionic conductances mediated by G protein 
coupling.126  
 
Figure III.3. Schematic diagram of the cAMP (left) and PLC (right) signal transduction pathways.138 
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1.3 THE P2Y2 RECEPTOR 
The P2Y2 receptor is the most widely studied uracil nucleotide receptor. It is broadly distributed 
throughout the body and is most prominently expressed in the lung, heart, skeletal muscle, spleen, 
kidney and liver.134,139,140  
 
P2Y2 receptors have been cloned and pharmacologically characterized from human, rat, mouse, 
canine and porcine cells or tissues. The human receptor exhibits 89% identity in amino acid sequence 
to the mouse receptor. 
 
As mentioned above, P2Y2 receptor signaling is linked to PLC. Ligand and receptor binding triggers 
the GDP-GTP exchange of Gq proteins and the dissociation of the α-subunit. The latter activates 
phospholipase C which will hydrolyze phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-
triphosphate (IP3) and diacylglycerol (DAG). Formation of IP3 results in an intracellular Ca2+ 
mobilization from internal stores. Additionally, DAG activates protein kinase C which in turn 
phosphorylates cellular proteins.138  
1.3.1 P2Y2 Receptor Agonists 
The P2Y2 receptor is unique among the human pyrimidine nucleotide receptors in that it is activated by 
two structurally different nucleotides, ATP and UTP, which contain a different base moiety. Other 
naturally occurring bases, e.g., guanine and cytosine are not tolerated.  
 
The P2Y2 receptor is activated equipotently by both UTP (3.1, Figure III.4) and ATP (1.4). The human 
P2Y4 receptor is selectively activated by UTP, and ATP is a potent competitive antagonist at this 
receptor. However, the P2Y4 receptor of several other species is activated by both UTP and 
ATP.141,142,143 The high dependence of the human P2Y4 receptor on uridine nucleotides for activation 
makes it difficult to find UTP analogues that are P2Y2 receptor selective. However, in controlled clinical 
studies, UTP is used in preference to ATP as P2Y2 receptor agonist because of the expected higher 
selectivity of pyrimidine nucleotides versus the other P2 receptors and because active ATP 
metabolites such as adenosine may interact with the P1 receptors leading to undesirable side 
effects.144 
 
When tested under conditions excluding enzymatic conversion of nucleotides, UDP and ADP did not 
activate the P2Y2 receptor, indicating that the receptor is selective for nucleoside triphosphates.145 The 
phosphate groups of nucleotides are deprotonated at physiological pH (pKa1 ≈ 1, pKa2 ≈ 6),146 thus, the 
nucleoside triphosphates are tetra-anions, while the diphosphates exhibit a tri-anionic form. Under 
physiological conditions, the anions may form complexes with divalent cations, such as Ca2+ or Mg2+. 
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There is some evidence that the tetra-anionic forms of ATP and UTP and not the complexed forms 
bind to P2Y2 receptors, and this may be true for all nucleotide receptors.147 
 
A lot of efforts have been made to synthesize highly potent and selective agonists for the P2Y2 
receptor. The most important results towards this goal are summarized below. 
1.3.1.1 Phosphate Chain Modifications 
UTPγS (3.2, Figure III.4), a phosphate chain modified nucleotide, is a relatively potent P2Y2 receptor 
agonist and is more stable against hydrolyzing enzymes compared to UTP.148 The same modification 
in ATP resulted in a 75-fold decrease in activity.149  
 
The phosphate chain in UTP has also been modified by replacement of the β,γ-oxygen bridge by NH 
(3.3), CH2 (3.4) or CF2 (3.5) (Figure III.4). All these modifications resulted in a decrease in activity at 
P2Y2 receptors (rank order of potency: O > NH > CF2 > CH2). Exchange of the β,γ-oxygen in ATP had 
similar effects.  
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Figure III.4 
 
In order to obtain metabolic stable agonists, Cosyn et al.150 decided to replace the α-phosphate group 
of UTP by an isosteric phosphonate group (3.6). Unfortunately 3.6 exhibited nearly quantitative 
hydrolysis to the corresponding 5’-phosphonate 3.7 during the receptor binding experiments (Figure 
III.5). Surprisingly, when tested in its pure form, 3.7 showed partial P2Y2 agonist activity while being 
inactive at the P2Y4 receptor.  
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Figure III.5 
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1.3.1.2 Dinucleotides 
Diadenosine polyphosphates are relatively potent agonists at P2Y2 receptors but are physiologically 
unstable and are quickly degraded to ATP, ADP, AMP and mainly to adenosine.151 The most potent 
dinucleotide, Ap4A (3.8, Figure III.6), contains four phosphate groups which connect two adenosine 
residues. Ap4A is only 3-fold less potent than ATP but also interacts with P2Y4 and P2X receptor 
subtypes.  
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Figure III.6 
 
Diuridine polyphosphates have the advantage of being more P2Y2 selective than adenine 
dinucleotides since they do not or only weakly interact with other purine nucleotide sensitive P2 
receptor subtypes. In addition, they are not degraded to adenosine, which may activate P1 purinergic 
receptors. Up4U (diquafosol, INS-365, 3.9, Figure III.6) is the most potent P2Y2 agonist in this group, 
exhibiting similarly high activity as UTP.152,153  
 
A synthetic mixed dinucleotide consisting of 2'-deoxycytidine and uridine connected via their 5'-
positions by a tetraphosphate chain (denufosol, Up4dC, INS-37217, 3.10, Figure III.6), is a potent, 
selective, and highly stable P2Y2 agonist that has been tested as an inhalable drug in a number of 
clinical trials for the treatment of cystic fibrosis.154,155 
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1.3.1.3 Uracil Modifications  
From a series of UTP derivatives in which the oxygen in position 4 of the uracil moiety was replaced 
by various substituents the sulfur-containing 4-thioUTP (3.11) showed the most promising P2Y2 
activity, while all other variations (methoxy, hexyloxy, methylthio, amino, morpholino, hexylamino and 
cyclopentylamino) caused significant loss in P2Y2 activity in comparison with UTP.135 In addition, 2-
thioUTP (3.12) behaved as a very potent P2Y2 receptor agonist with increased selectivity versus P2Y4 
receptors (Figure III.7).  
 
A bromine atom has been introduced in the 5-position (3.13, Figure III.7) of UTP. This modification led 
to a 15-fold decrease in activity. 5-Alkyl-substituted UTP derivatives were found to be full agonists at 
P2Y2 receptors of NG108-15 cells, but less potent than UTP. The activity decreased with increasing 
size of the 5-substituent: H > methyl > ethyl > isopropyl > propyl > butyl.156 
 
The N3-hydrogen does not appear to be essential since compound 3.14, which is lacking the 3-NH, is 
still quite active. Replacement (3.15) or reorientation (3.16) of the uracil ring resulted in less potent 
analogues (Figure III.7).157  
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Figure III.7 
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1.3.1.4 Ribose Modifications 
Removal of the 2’- or 3’-hydroxyl group of UTP caused a significant loss in P2Y2 receptor activity. The 
2',3'-dideoxy derivative of UTP was inactive. 2’-Amino-2’-deoxy UTP (3.17) and the arabino isomer of 
UTP (3.18) were equipotent to ATP at the P2Y2 receptor and showed a moderate selectivity over the 
P2Y4 receptor, while other 2’-modifications decreased the P2Y2 receptor potency (Figure III.8).  
 
Replacement of the sugar by a bicyclo[3.1.0]hexane system, which mimics a ribofuranose rigidified in 
the northern conformation, was well tolerated by the P2Y2 receptor. (N)-methanocarba-UTP (3.19, 
Figure III.8) was almost equipotent to UTP.158 
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Figure III.8 
 
1.3.1.5 Combined Modifications  
Combination of a 2-thiouracil modification with a β-D-arabinofuranose (3.20) demonstrated moderately 
potent and highly selective agonist activity at the P2Y2 receptor, while the 2’-amino-2’-deoxy ribose 
analogue (3.21) was 6 times more potent than the natural ligand UTP and 300-fold selective in 
activation of the P2Y2 receptor in comparison with the P2Y4 receptor. The potency of 3.21 is greatly 
reduced upon acetylation (3.22) and reduced to a lesser degree upon trifluoroacetylation (3.23) 
(Figure III.9).  
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In vitro pharmacological data for the most potent P2Y2 receptor agonists currently known are 
presented in Table III.1. EC50 values represent the half maximal effective concentration in an assay of 
P2Y2 and P2Y4 receptor-stimulated phospholipase C activity. The structure-activity relationship of the 
different phosphate chain, uracil and ribose UTP modifications is summarized in Figure III.10. 
 
Table III.1. In vitro pharmacological data for the most potent P2Y2 receptor agonists currently known. 
Compound Name 
EC50 (P2Y2) 
nM 
EC50 (P2Y4) 
nM 
1.4 ATP 85 Antagonist 
3.1 UTP 49 73 
3.2 UTPγS 240 1600 
3.8 Ap4A 180 Inactive 
3.9 Up4U (diquafosol) 60 200 
3.10 Up4dC (denufosol) 220 800 
3.11 4-thioUTP 26 23 
3.12 2-thioUTP 35 350 
3.17 2’-amino-2’-deoxyUTP 62 1200 
3.18 arabino-UTP 87 710 
3.19 (N)-methanocarba-UTP 85 91 
3.21 2’-amino-2’-deoxy-2-thioUTP 8 2400 
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Figure III.10. Structure-activity relationship of UTP derivatives as P2Y2 agonists. 
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1.3.2 Therapeutic Potential of P2Y2 Receptor Agonists 
1.3.2.1 Cystic Fibrosis 
Cystic fibrosis (CF) is a recessive genetic disease caused by mutations in the cystic fibrosis 
transmembrane regulator gene (CFTR). A deletion of phenylalanine at position 508 (ΔF508) accounts 
for more than 70% of all cases of CF. The disease generally has multiple manifestations like 
pancreatic dysfunction, diabetes mellitus, ileus and male infertility. Depending on the mutation there 
are more or less severe symptoms. The most prominent manifestation accounting for 90% of mortality 
is pulmonary disease, characterized by desiccated mucus, impaired mucociliary clearance and 
secondary bacterial infections. Mutated CFTR in lung epithelium causes decreased chloride secretion 
and excessive sodium absorption, leading to a reduction in airway surface liquid (ASL). Depletion of a 
specific part of the ASL, the periciliary liquid, leads to defective ciliary function and cough clearance. 
Subsequently, thickened mucus plaques adhere to the airway surface, generating hypoxic regions and 
promoting bacterial infections. CF has affected approximately 80 000 individuals worldwide and their 
main life expectancy is currently about 37 years.159 
 
In healthy people, airway hydration is regulated by CFTR proteins, the so called cystic fibrosis 
transmembrane conductance regulator Cl- channels (Figure III.11). Activation of these Cl- channels, 
via P2Y2 or A2B, results in an increased Cl- secretion and a decreased Na+ absorption due to the 
downregulation of the epithelial Na+ channels (ENaC). However, in cystic fibrosis, mutations in de 
CFTR gene result in a decreased function or expression of the CFTR proteins. Consequently, the 
ENaC activity is up-regulated (Na+ influx ↑) and the cell depends only on the Ca2+ activated Cl- 
channels (CaCC) for Cl- secretion. As a result, Cl- secretion is limited and airway epithelia will be 
dehydrated with reduced mucociliary clearance and a propensity for chronic infection of the respiratory 
tract with resulting inflammation, progressive airway damage and bronchiectasis.160,161 
 
Figure III.11. Regulation of the ASL volume homeostasis by ATP release. (a) Normal airway epithelia exhibit 
ATP-mediated P2Y2 receptor regulation and ADO-mediated A2B receptor regulation of CFTR; (b) Normal airway 
epithelia balance: Na+ absorption against Cl- secretion to maintain ASL homeostasis; (c) CF airway epithelia do 
not (or less) express functional CFTR proteins resulting in an A2B mediated activation of ENaC; (d) CF airway 
epithelia balance: increased salt and water absorption leading to a reduction in ASL.162 
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Studies using in vitro models of airway epithelia have shown the important role of the P2Y2 receptor in 
regulating ion transport in epithelial cells. Activation of ion transport by P2Y2 receptors in both normal 
and CF airway epithelia leads to liquid secretion (Figure III.11).163 Taken this into account, the 
impaired ion transport in the bronchi of CF patients can be bypassed by stimulation of P2Y2 receptors. 
Subsequently, it was found that UTP stimulated mucin secretion from goblet cells164 and increased the 
beat frequency of cilia in isolated normal and CF epithelial cells.165 A knockout study confirmed 
previous pharmacological data and identified P2Y2 receptors as the crucial luminal P2 receptor in 
respiratory epithelium.166  
 
The natural ligand UTP, has high potency, but limited metabolic stability and thus has a relatively short 
duration of action when administered via inhalation. Therefore, Inspire Pharmaceuticals, Inc. has 
developed a series of new, highly selective and potent P2Y2 receptor agonists with enhanced 
metabolic stability. Some of the most promising compounds were used in clinical studies evaluating 
the effects of inhaled P2Y2 agonists on sputum expectoration and mucociliary clearance in smokers 
and patients with a variety of airway disorders, including CF.163 Denufosol (3.10, Up4dC, INS37217) 
received fast-track and orphan drug status in US and orphan drug status in Europe as a treatment for 
CF. A first phase III trial of denufosol in CF (TIGER-I) demonstrated an improved lung function versus 
placebo in patient having minimally impaired to normal baseline lung function characteristic of early 
CF lung disease. However, results from a second phase III trial (TIGER-II) were disappointing and did 
not confirm the promising result from TIGER-I.167  
1.3.2.2 Dry Eye Syndrome 
P2Y2 receptors can be found on the ocular surface (e.g., cornea, conjunctiva, …) where they play an 
important role in the regulation of conjunctival mucin and Cl- secretion. Activation of the P2Y2 receptor 
stimulates chlorine and water secretion from conjunctival epithelial cells, leading to a better 
lubrification of the ocular surface.168,169 In 1999, Inspire Pharmaceuticals, Inc. started to test diquafosol 
(3.9, Up4U) for the treatment of dry eye syndrome. Unfortunately, diquafosol failed in late phase III 
trial. 
1.3.2.3 Cancer 
P2Y1 and P2Y2 receptors are, perhaps, the most widely studied purinoceptor subtypes in cancer.170 
Whereas the role of P2Y1 receptors in cancer is to decrease cellular proliferation, the P2Y2 receptor 
usually increases cell numbers. Indeed, in most physiological conditions, activation of human P2Y2 
receptors causes an increase in cell proliferation. This is reflected in some cancer types such as 
melanoma and lung cancer.171,172 However, in other cancer types such as esophageal cancer and 
some colorectal cancers, activation of P2Y2 receptors causes a decrease in cellular proliferation. For 
these types of cancer, P2Y2 receptor agonists have been suggested as novel therapeutics.173,174 
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1.3.2.4 Antihypertensiva 
Studies performed in various species have showed that systemic activation of P2Y2 receptors lowers 
blood pressure and inhibits renal Na+ reabsorption. Based on these effects, it is suggested that P2Y2 
receptor agonists may have potential in the treatment of hypertension.175 
1.3.2.5 Vaginal Humidifier 
Due to the fact that P2Y2 receptors are expressed in cervical and vaginal tissues, it is thought that 
P2Y2 receptor agonists may be an alternative and effective therapy to alleviate postmenopausal 
symptoms of vaginal dryness by increasing mucin production as well as by enhancing pelvic blood 
flow.176 
1.3.3 P2Y2 Receptor Antagonists 
Studies with antagonists are important to elucidate the physiological roles of receptors. Unfortunately, 
subtype-selective P2-receptor antagonists are not available. All known P2-receptor antagonists block 
several subtypes of P2-receptors. Nevertheless, the combined use of subtype preferential agonists 
and antagonists may allow the pharmacological characterization of different P2Y-subtypes.134 
1.3.3.1 Standard P2 Antagonists  
The standard P2 receptor antagonists Reactive Blue 2 (RB-2, 3.24) and suramin (3.25) block the 
human P2Y2 receptor with moderate potency (Figure III.12). Both appear to be competitive 
antagonists. RB-2 is one of the most potent P2Y2 receptor antagonists known to date (IC50 ~ 1 μM). It 
is an anthraquinone derivative that bears three negatively charged sulfonate groups and may be meta- 
or para-sulfonated or a mixture of both isomer.130 Suramin, a polysulfonated naphthalene derivative of 
relatively high molecular weight, exhibits an IC50 value of ca. 50 μM. When given at high micromolar 
concentrations, suramin affects all nucleotide-sensitive P2Y receptors with the exception of the P2Y4 
receptor.  
 
In addition to P2Y2-antagonistic activity, RB-2 and suramin interact with a number of other receptors 
and proteins, including other P2Y receptor subtypes, P2X receptors,177 ectonucleotidases,178 kinases 
(RB-2),179 and G proteins (suramin).180 The promiscuity of these molecules limits their usefulness as 
pharmacological tools. 
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Figure III.12 
1.3.3.2 Anthraquinones 
In 2007, Müller and coworkers synthesized a series of simplified RB-2 analogues. Compound 3.26 
(PSB-716, Figure III.13) appeared to be a relatively potent P2Y2 antagonist with an IC50 value of 9 μM. 
In contrast to RB-2, 3.26 seems to be selective versus other P2Y subtypes as well as nucleotide-
metabolizing enzymes.181  
1.3.3.3 Thiouracil Derivative AR-C118925 
The natural ligand UTP served as a lead compound for the development of new P2Y2 receptor 
antagonists. Structural modifications to eliminate efficacy and to improve the pharmacokinetic 
properties led to the development of thiouracil derivative AR-C118925 (3.27, Figure III.13). This 
analogue contains a heterocyclic substituent in the 5 position and a substituent at N-1 that mimics the 
ribose triphosphate group. AR-C118925 appears to be a selective and competitive P2Y2 receptor 
antagonist and showed an IC50 value of ca. 1 μM.130 
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1.3.3.4 Flavonoids 
Flavonoids are secondary plant metabolites found in fruits, vegetables, bark and flowers of many 
higher plants. A series of 40 flavonoids was investigated at P2Y2 receptors and several flavones were 
found to block P2Y2 receptors in the low micromolar range. The post potent compounds were 
kaempferol (3.28), tangeretin (3.29) and heptamethoxyflavone (3.30) (Figure III.14).182  
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Figure III.14 
1.3.4 Therapeutic Potential of P2Y2 Receptor Antagonists 
1.3.4.1 Inflammation 
P2Y2 receptors are expressed by endothelial cells and cells of the immune system (e.g., T-cells, 
neutrophils, eosinophils and macrophages), and thus appear to play a role in defense mechanisms 
and inflammatory processes. Antagonists are considered to have potential anti-inflammatory 
properties.147  
1.3.4.2 Coronary Vasospastic Disorders 
P2Y2 receptor antagonists are though as potential therapeutics of coronary vasospastic disorders 
since stimulation of P2Y2, besides P2X receptors, mediates contraction of human coronary arteries.183 
1.3.4.3 Neuroprotective Agents 
P2 receptor antagonists, including RB-2, have been reported to exhibit neuroprotective properties. 
They may be useful for the treatment of epileptic seizures, strokes and neurodegenerative diseases, 
such as Alzheimer’s and Parkinson’s disease.147 
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1.3.5 Molecular Modeling of the P2Y2 Receptor 
The first site-directed mutagenesis and molecular modeling of transmembrane helical domains 6 and 
7 (TMs 6 and 7) of the P2Y2 receptor were reported by Erb et al.184 In 2006, a molecular model was 
provided by a molecular dynamics simulation in a phospholipidic and aqueous environment. In 
contrast with the earlier one, this model contained not only seven TMs but also all extracellular and 
intracellular hydrophilic loops.185 Recently, Hillman et al. published a more detailed and refined model 
generated in homology to the crystal structure of bovine rhodopsin.186  
 
A binding pocket could be determined in the upper third part of the receptor molecule (Figure III.15). 
So far, the structure of this pocket is rather unclear but amino acids from the sixth (TM6) and seventh 
transmembrane (TM7) helices and from the second extracellular loop (EL2) have shown to be 
involved. An entry channel between TM5 and TM6 was found to lead to this binding site. In addition, 
this channel provides a binding pocket for larger ligands like dinucleotides.  
 
 
Figure III.15. Computer generated model of the P2Y2 receptors embedded in a lipid bilayer with Ap4A into the 
binding site.186 
 
Binding of ATP and UTP led to an induced fit of the receptor protein. UTP induced a larger protein 
rearrangement than ATP because the protein has to adapt itself more strongly to the smaller UTP 
molecule, resulting in the formation of more stable hydrogen bonds in the UTP-P2Y2 complex 
compared to that of the ATP-P2Y2 complex. As a consequence, UTP is a slightly more potent and 
efficacious agonist than ATP. 
 
On the other hand, for the large dinucleotide Ap4A (3.8), a lower degree of induced fit by the protein is 
observed, and the ligand has to adapt its conformation in order to fit into the binding site. Although the 
dinucleotides (being large molecules) can have more interactions with the receptor protein than the 
mononucleotides, their potency is lower. This may be explained by their suboptimal fit into the receptor 
binding site. As seen in Figure III.15, part of the dinucleotide Ap4A sticks out of the receptor protein. 
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Dinucleotide binding would result in reduced flexibility of the receptor protein, including EL2, which is 
part of the binding pocket for mononucleotides.186  
 
The homology model of the P2Y2 receptor has allowed to identify the amino acid residues with 
important roles as gate keepers in ligand binding and in activating and stabilizing the receptor. Since 
our work does not rely on the available structural information of the P2Y2 receptor, we prefer not go in 
too much detail about available models and refer the interested reader to the original papers.184,185,186 
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2 URIDINE 5’-PHOSPHONATE ANALOGUES 
2.1 OBJECTIVES 
The major limitations associated with known agonists for the P2Y2 receptor are (i) the lack of selectivity 
vs. closely related P2Y receptor subtypes and (ii) their fast degradation by nucleotide-hydrolyzing 
ecto-enzymes, which results in a relative short duration of action.130 In that context, it was recently 
explored to what extent replacement of the α-phosphate group of UTP (3.1) by an isosteric 
phosphonate affected P2Y2 receptor activity.150 Since the carbon-phosphorus bond cannot be 
hydrolyzed, this analogue was expected to exhibit prolonged metabolic stability. While Cosyn et al. 
initially focused on a diphosphophosphonate mimic of UTP (3.6), it was fortuitously discovered that its 
synthetic precursor 3.7 was also capable of activating the P2Y2 receptor, while being inactive at the 
P2Y4 receptor (Figure III.16).150  
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Figure III.16. 
 
In this chapter, we explore the influence of further modifications of the 5’-methylene phosphonate 3.7 
on activity at the P2Y2 receptor. A preliminary report from Astra-Zeneca indicated that incorporation of 
large semiplanar, hydrophobic aromatic rings at position 5 of thiouridine triphosphate may be 
accommodated by the P2Y2 receptor but tend to preclude the conformational change required for 
receptor activation.187 Therefore, we introduced several (hetero)aromatic substituents at the 5-position 
of the 5’-methylene phosphonate analogue 3.7. In addition, we also envisaged replacement of the 2’-
OH group of 3.7 with a 2’-chloro and a 2’-amino group. In the case of UTP, the latter modification was 
associated with increased P2Y2 selectivity while maintaining excellent potency.  
 
Finally, another phosphonate bio-isostere of uridine 5’-monophosphate (UMP), obtained by the 
inversion of the 4’-CH2-O group of UMP, was also explored. 
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2.2 CHEMISTRY 
2.2.1 Synthesis of 5-Modified 5’-Methylene Phosphonate Uridine Analogues 
Different methods for the preparation of isosteric phosphonate analogues of nucleoside phosphates 
have been reported. Most often these involve a Wittig-type188 or an Arbuzov189 reaction. In addition, 
Barton et al.190 published a radical approach for the introduction of the carbon-phosphorous bond. We 
decided to follow the method described by Xu et al.191 in which the isosteric analogue was prepared by 
treatment of a suitable protected uridine 5’-aldehyde with a stabilized [Ph3P=CHPO(OEt)2] ylide 
(Scheme III.1). Starting from uridine (3.31), 5’,6’-vinyl phosphonate 3.33 was synthesized by oxidation 
of 2’,3’-O-isopropylidene-uridine 3.32 to an 5’-aldehyde intermediate, which was immediately reacted 
with freshly prepared [(diethoxyphosphinyl)methylidene] triphenylphosphorane 3.72.191 Catalytic 
hydrogenation of the obtained olefin in the presence of palladium on carbon gave access to the 
corresponding saturated phosphonate ester 3.34.  
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Scheme III.1. Reagents and conditions. (a) 2,2-dimethoxypropane, p-toluenesulfonic acid, acetone, 5 h, 80%; 
(b) (i) IBX, CH3CN, 80 °C, 6 h; (ii) [(Diethoxyphosphinyl)methylidene] triphenylphosphorane (3.72), DMSO, rt, 
overnight, 59% over 2 steps; (c) H2, Pd/C, MeOH, rt, overnight, 76%.  
 
C-5 selective NBS-mediated bromination116 of phosphonate 3.34 followed by a Suzuki-Miyaura 
coupling with a number of commercial aryl and heteroaryl boronic acids gave access to a series of C-5 
substituted analogues. The latter transformation took place in a DMF-H2O solution and was catalyzed 
by Pd(PPh3)4. Sodium carbonate was used for the activation of the boronic acids.192 One-pot 
deprotection of the phosphonate diester and the 2’,3’-O-isopropylidene group by consecutive 
treatment with TMSBr and TFA afforded the desired phosphonates 3.44-3.51 in variable yields 
(Scheme III.2).193 
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Scheme III.2. Reagents and conditions. (a) NBS, DMF, rt, overnight, 79%; (b) R-B(OH)2, Na2CO3, Pd(PPh3)4, 
DMF, H2O, reflux, 4 h, 39-76%; (c) (i) TMSBr, CH2Cl2, rt, overnight; (ii) 50% aq. TFA, H2O, rt, 4 h, 11-78%. 
2.2.2 Synthesis of 2’-Amino and 2’-Chloro 5’-Methylene Phosphonate Uridine 
Analogues 
The synthesis of 2’-amino 5’-methylene phosphonate 3.56 started from intermediate 3.34 and is 
depicted in Scheme III.3. After deprotection of the 2’ and 3’ hydroxyl groups of 3.34, 2’,2-O-anhydro 
analogue 3.53 was formed using diphenyl carbonate, NaHCO3 in DMF or thionyl chloride in CH3CN 
followed by the addition of NaOAc.194 Introduction of the azide group at the 2’ position was 
accomplished via opening of 3.53 with NaN3 in DMF.195 Interestingly, these conditions caused 
concomitant incomplete hydrolysis of the phosphonate ester to afford 3.54. Azide-mediated 
conversion of a phosphonate diester to its mono-ester was previously reported by Holy.196 Staudinger 
reduction197 of the azide followed by deprotection of mono ethylphosphonate 3.55 resulted in the 
desired 2’-amino uridine 5’-phosphonate analogue 3.56.198 
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Scheme III.3. Reagents and conditions. (a) 50% aq. HCOOH, rt, 4.5 h, 57% or 50% aq. TFA, 0 °C → rt, 2 h, 
64%; (b) (i) SOCl2, CH3CN, rt, 2 h; (ii) NaOAc, DMF, 85 °C, 3 h, 92% over 2 steps or (PhO)2CO, NaHCO3, DMF, 
reflux, 1.5 h, 65 %; (c) NaN3, DMF, 130 °C, overnight, quant. yield; (d) PPh3, THF, H2O, rt, overnight, quant. yield; 
(e) TMSBr, CH2Cl2, rt, overnight, 78%. 
 
Similarly, treatment of 3.53 with a 2N HCl in diethylether solution followed by the hydrolysis of the 
phosphonate diester resulted in the 2’-chloro analogue 3.58 (Scheme III.4).113 
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Scheme III.4. Reagents and conditions. (a) 2N HCl in Et2O, dioxane, rt, overnight, 54%; (b) TMSBr, CH2Cl2, rt, 
overnight, 58%. 
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2.2.3 Synthesis of 4’-O-CH2 Phosphonate Analogue 3.68 
The formation of 4’-O-CH2 phosphonate 3.68 started with the synthesis of glycal 3.64 (Scheme III.5). 
Since the direct oxidation of 2’-deoxyuridine into 2’-deoxyuridine-5’-carboxylic acid using 
TEMPO/BAIB199 and PDC failed, 2’-deoxyuridine was first tritylated followed by the silyl protection of 
3’-OH. After removal of the trityl group, the 5’-OH group was oxidized with TEMPO/BAIB to furnish 
carboxylic acid 3.62. Treatment of compound 3.62 with NH4F in MeOH200 followed by a 
decarboxylative elimination201 afforded glycal 3.64 in moderate yield. 
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Scheme III.5. Reagents and conditions. (a) TEMPO, BAIB, CH3CN, H2O, rt, 16 h, 78% for 3.61 → 3.62; (b) trityl 
chloride, pyridine, 65 °C, overnight, 61%; (c) TBDPSCl, imidazole, DMF, rt, overnight, 100%; (d) ZnBr2, 
CH2Cl2/iPrOH (85:15), rt, overnight, 60%; (e) NH4F, MeOH, rt, overnight, 100%; (f) dimethylformamide 
dineopentyl acetal, DMF, 130 °C, 20 min, 46%.  
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Treatment of glycal 3.64 with phenylselenyl chloride at -70 °C followed by the addition of silver 
perchlorate in the presence of diethyl(hydroxymethyl)phosphonate afforded phosphonate 3.65 in 35% 
overall yield.202 Compound 3.65 was further transformed into olefin 3.66 via sodium periodate 
oxidation of selenium and subsequent elimination.202 OsO4-promoted dihydroxylation in the presence 
of N-methylmorpholine-N-oxide203 followed by TMSBr hydrolysis of the phosphonate ester groups 
provided compound 3.68 in moderate yield. A positive NOE was observed between the H-1’ and H-4’ 
of compound 3.66, confirming the cis stereo-arrangement of the uracil base and the 
phosphonomethoxy side chain (Scheme III.6). 
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Scheme III.6. Reagents and conditions. (a) (i) PhSeCl, CH2Cl2, -70 °C, 1 h; (ii) HOCH2PO(OEt)2, AgClO4, 
CH2Cl2, CH3CN, -70 °C → 0 °C, 15 min, 35% over 2 steps; (b) NaIO4, NaHCO3, MeOH, rt , 1 h then 80 °C, 75 
min, 68%; (c) OsO4, NMO, acetone-water (5:1), rt, 48 h, 60%; (d) TMSBr, 2,6-lutidine, DMF, 0 °C → rt, overnight, 
50%. 
 
Assignment of the stereochemical arrangement in 3.65 was based on mechanistic considerations as 
depicted in Figure III.17.202 The sterically favored α side approach of the electrophile generated the 
energetically more stable selenium and/or oxonium transition intermediate I in preference to the less 
favorable II. 
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Figure III.17 
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2.3 PHARMACOLOGICAL EVALUATION 
Activities of analogues at the P2Y2 receptor were determined measuring PLC-dependent 
phosphoinositide hydrolysis in 1321N1 human astrocytoma cells stably expressing the human P2Y2 
receptor (performed under the guidance of Prof. Dr. Kendall Harden at the Department of 
Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA).204,205 
Neither UTP nor any of the phosphonate analogues promoted inositol phosphate accumulation in wild-
type 1321N1 cells (Fig. III.18A). In contrast, quantification of inositol phosphate accumulation in P2Y2 
receptor-expressing 1321N1 cells revealed that the newly synthesized 5’-methylene-phosphonate 
analogues are P2Y2 receptor agonists (Fig III.18B). 
 
 
Figure III.18. Inositol phosphate production in (A) wild type 1321N1 human astrocytoma cells and (B) 1321N1 
cells stably expressing the human P2Y2 receptor. 
 
None of the analogues produced maximal effects as great as UTP when tested at 100 μM 
concentration. Therefore, full concentration effect curves were carried out with each of the analogues 
to more clearly assess their maximal effects relative to UTP and to establish their relative potencies as 
P2Y2 receptor agonists. To enhance clarity of comparison of the relative activities of these analogues, 
the data are arbitrarily presented in four separate panels (Fig. III.19). 
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Figure III.19. Concentration dependent activation of the P2Y2 receptor by phosphonate nucleotide derivatives. 
 
The 5-modified uridine 5’-phosphonate analogues activated the P2Y2 receptor with a range of 
apparent potencies, and the maximal effect observed with each of these molecules was only 30-40% 
of that observed with UTP. Preferred modifications at position 5 of the uracil moiety of compound 3.7 
included phenyl (3.44), 1-naphthyl (3.45), 4-fluorophenyl (3.46), 2-furanyl (3.49) and p-tolyl (3.48) (Fig. 
III.19). The most potent agonist was the 5-(4-fluorophenyl) analogue (3.46), which activated the 
receptor with a slightly higher potency (EC50 = 170 ± 100 nM) than analogue 3.49 (EC50 = 560 ± 240 
nM).  
 
Both 2’-modified analogues (3.56 and 3.58) were essentially inactive at the P2Y2 receptor. The 
negative impact of the replacement of a 2’-OH by a 2’-NH2 group, may indicate that these 
phosphonates have a different mode of binding to the P2Y2 receptor, since a similar modification on 
UTP was well tolerated.  
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Compound 3.68 was significantly less potent than the lead phosphonate indicating that replacement of 
the 5’-CH2 group by an oxygen tends to reduce agonist activity.  
 
The activities of the two most potent new compounds 3.46 and 3.49 were directly compared to the 5-
unsubstituted parent compound 3.7 (Fig. III.20). Both analogues produced maximal effects at the P2Y2 
receptor that were similar to that of 3.7, but were approximately 10-fold more potent than 3.7. 
 
 
 
Figure III.20. Comparison of the concentration dependence of the most potent phosphonates for activation of the 
P2Y2 receptor. 
 
The idea that these modified uridine 5’-phosphonate analogues are orthosteric ligands that exhibit less 
intrinsic efficacy than UTP was examined by assessing their capacity at high concentrations to inhibit 
the effect of a near-maximal concentration of UTP (Fig. III.21A). No inhibitory effect on the action of 
UTP was observed with any of these phosphonate analogues. Concentration effect curves for UTP 
also were carried out in the absence and presence of a high (100 μM) concentration of 3.46 or 3.49 to 
determine whether the activity of these molecules was consistent with that of agonists acting at the 
orthosteric or an allosteric site of the P2Y2 receptor. The data presented in Figure III.21 are consistent 
with the idea that these uridine 5’-phosphonate analogues act at an allosteric site rather than the 
orthosteric binding pocket to produce their effect on P2Y2 receptor activity. 
 
A possible binding site for the agonists might be a site that is close to the terminal end of the 
dinucleotides, i.e. the far site U of Up4U (3.8). If this should be true then the behavior in combination 
with UTP should be very different from the combination with Up4U. To test this hypothesis, an 
experiment in which the capacity of different C-5 modified uridine 5’-phosphonates to lower the IP3 
concentration produced by Up4U stimulation will be done in the near future. 
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Figure III.21. Effect of high concentrations of phosphonate analogues on the P2Y2 receptor-mediated activity of 
UTP. (A) Lack of effect of the broad range of phosphonate analogues on response to UTP. The effects of 100 μM 
concentrations of the indicated phosphonates were tested in the presence of 100 nM UTP in 1321N1-P2Y2 cells 
as described in Methods. (B) Concentration dependent effects of UTP in the presence of the most potent 
phosphonate analogues. 1321N1-P2Y2 cells were incubated with various concentrations UTP in the absence or 
presence of 100 μM 3.46 or 3.49. 
 
Interestingly, compound 3.69, a regioisomer of 3.44, with a 6-phenyl substituent,193 exhibited clearly 
lower apparent efficacy and potency in activating the P2Y2 receptor (Figure III.22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.22. Comparison of the concentration dependent activation of the P2Y2 receptor by the 5-, and 6-phenyl 
substituted 5’-methylene phosphonate analogues 3.44 and 3.69. 
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2.4 CONFORMATIONAL ANALYSIS 
The conformational behavior of nucleosides is considered to be of great importance for their 
interactions with target proteins and thus for their biological activity. The complete definition of the 
conformation of a nucleoside involves the determination of three principal structural parameters:1) the 
glycosyl torsion angle χ, which determines the relative position of the base to the sugar moiety (syn or 
anti); 2) the torsion angle γ, which determines the orientation of the 5’-OH group with respect to C3’; 
and 3) the puckering of the furanose ring and its deviation from planarity.206 
 
The sugar puckering of natural ribo- and deoxyribonucleosides in solution appears as a dynamic 
equilibrium between two major conformers, the North (N) and the South (S), with a very low energy 
barrier between the two states (Figure III.23).206,207  
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Figure III.23. Rapidly equilibrium North and South conformation of nucleosides. 
 
Davies et al.208 derived the following equations that relate the fraction of the North conformer XN with 
the values of the vicinal three scalar couplings that can be measured between the protons of the ring: 
 
JH1’,H2’ = 9.3 (1-XN) 
JH2’,H3’ = 4.6XN + 5.3 (1-XN) 
JH3’,H4’ = 9.3XN 
 
To assess the impact of the presence of a substituent at the C-5 position of the uracil base on the 
relative proportions of Northern and Southern conformers, these scalar couplings were measured at 
five different temperatures for the 5-phenyl substituted uridine phosphonate 3.44, while the same was 
done for the non C-5 substituted uridine phosphonate 3.7. The fraction of the N-type conformer was 
obtained by minimizing the sum of square difference between the experimental couplings and those 
calculated from the above equations. The results are shown in Table III.2. 
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Table III.2. 1H-NMR derived mole fraction of the N-type conformer of 3.7 and 3.44 at different temperatures 
(Measurements are performed under the supervision of Prof. Dr. José Martens at the NMR and Structure Analysis 
Unit, Department of Organic Chemistry, UGent).  
 
 XN 
T [°C] 3.7 3.44 
20 55.5 52.9 
27 54.8 53.1 
35 54.4 54.1 
42 54.1 53.8 
50 54.0 53.0 
 
For analogue 3.7, the Northern and Southern conformers are nearly equally present, with a small 
preference for the Northern. From Table III.2, it appears that 3.44 has similar North/South populations 
as 3.7. It can therefore be concluded that the implantation of a phenyl group at the C-5 position 
appears to have no effect on the conformational state of the ribofuranose ring. Interestingly, this is in 
contrast to the effect of implanting a phenyl ring at C-6 of the base (3.69) as was published recently by 
Nencka et al.,193 that clearly shows an enhanced preference for the Northern conformation.  
 
As mentioned above, another aspect of the conformation is the orientation of the base relative to the 
ring structure, which is assumed to be either syn (with the oxygen at position C-2 lying immediately 
above the furanose ring) or anti (with the oxygen at position C-2 pointing away from the furanose ring). 
The NOESY spectrum of compound 3.7 showed clear cross-peaks from the H-6 proton to the H-3’ and 
both H-5’ protons, confirming that the anti rotamer could be adopted. When a bulky group is implanted 
at the C-5 position, it is positioned further away from the ribose ring and the conformational 
implications for the five ring appeared to be negligible. 
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2.5 PHOTOPHYSICAL EVALUATION 
The application of fluorescent nucleoside analogues as molecular probes provides a new tool for 
studying the uptake and metabolism of the corresponding analogues as described in PART I - Chapter 
2. In the phosphonate series 3.44-3.51, several phosphonate analogues showed fluorescence 
properties. A photophysical evaluation (performed in the Laboratory of General Biochemistry and 
Physical Pharmacy, UGent) of compound 3.46 is depicted in Figure III.24. The 5-(4-
fluorophenyl)uridine 5’-phosphonate analogue showed an excitation maximum of 328 nm and an 
emission maximum of 360 nm.  
 
 
 
Figure III.24. Excitation and emission spectrum of compound 3.46. 
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2.6 CONCLUSIONS 
In this study we explored the influence of modifications of uridine 5’-methylene phosphonate (3.7) on 
the activity at the human P2Y2 receptor. A Suzuki–Miyaura coupling of a suitable 5-bromo precursor 
with aryl and heteroaryl boronic acids allowed to generate a small series of C-5 substituted analogues 
of 3.7. All 5-modified analogues caused P2Y2-dependent IP3 accumulation. Interestingly, none of the 
phosphonate analogues had the same maximal activity as UTP. Within this series, a 5-(2-furanyl) 
modification (3.49) gave the highest efficacy, while 5-(4-fluorophenyl) substitution (3.46) afforded the 
highest potency. Remarkably, these analogues failed to inhibit activity of UTP down to the level of 
activity seen with the 5-modified analogues alone as would be expected for classical partial agonists. 
A possible explanation for this phenomenon is that these phosphonates are producing their effects by 
interacting with a receptor site distinct from the orthosteric site. Phosphonate 3.49 may become a 
useful, metabolically stable tool compound for further pharmacological characterization of the P2Y2 
receptor. 
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2.7 EXPERIMENTAL PART 
2.7.1 Synthesis 
2’,3’-O-Isopropylidene-β-D-uridine (3.32) 
 
O N
HO
O O
NH
O
O
 
 
p-Toluenesulfonic acid (300 mg, 1.52 mmol) was added to a suspension of uridine (3.71 g, 15.19 
mmol) in dry action (150 mL) and 2,2-dimethoxypropane (10 mL). The reaction was stirred at room 
temperature for 5 h. The mixture was concentrated in vacuo and the residue dissolved in EtOAc. The 
organic phase was washed with sat. aq. NaHCO3, dried with MgSO4, filtered and evaporated to 
dryness. Purification on a silica gel column (CH2Cl2/MeOH 95:5) afforded compound 3.32 as a white 
solid (3.45 g, 80%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.29 (3H, s, CH3), 1.49 (3H, s, CH3), 3.57 (1H, dd, J= 4.5 Hz, J= 8.7 
Hz, H-5’a), 4.06 (1H, dd, J= 4.2 Hz, J= 8.1 Hz, H-5’b), 4.73-4.76 (1H, m, H-4’), 4.89 (1H, dd, J= 2.7 
Hz, J= 6.6 Hz, H-3’), 5.08 (1H, app t, J= 4.8 Hz, H-2’), 5.63 (1H, d, J= 8.1 Hz, CH=CH), 5.83 (1H, d, J= 
2.7 Hz, H-1’), 7.79 (1H, d, J= 8.1 Hz, CH=CH). The spectrum is accordance with the literature 
report.209 
 
13C NMR (75 MHz, DMSO-d6): δ 25.19 (CH3), 27.06 (CH3), 61.27 (C-5’), 80.48 (C-3’), 83.68 (C-4’), 
86.52 (C-2’), 91.12 (C-1’), 101.74 (C-5), 112.96 (isopropylidene), 141.92 (C-6), 150.34 (C-2), 163.18 
(C-4). 
 
Exact mass (ESI-MS) for C12H17N2O6 [M+H]+ found, 285.1086; calcd, 285.1081. 
 
1-[5,6-Dideoxy-6-(diethoxyphosphinyl)-2,3-O-isopropylidene-β-D-ribo-hex-5-enofuranosyl]uracil 
(3.33) 
O N
O O
NH
O
P
O
EtO
EtO
O
 
 
IBX (3.23 g, 11.49 mmol) was added to a solution of 3.32 (2.18 g, 7.66 mmol) in CH3CN (60 mL) and 
the resulted suspension was stirred at 80 °C for 6 h. After cooling in an ice bath (15 min), the solid was 
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removed by filtration and washed with cold CH3CN. The solvent was evaporated and the residue was 
co-distilled with toluene. The residue was dissolved in anhydrous DMSO (20 mL) and freshly prepared 
3.72 in DMSO (20 mL) was added. After 20 h, the mixture was poured into water and extracted with 
CH2Cl2. The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The 
residue was lyophilized to remove the remaining DMSO and purified on a silica gel column 
(CH2Cl2/MeOH 95:5 and acetone/pentane 50:50) yielding 1.88 g mg (59%) of 3.33 as a foam. 
   
1H NMR (300 MHz, DMSO-d6): δ 1.22 (6H, t, J= 6.9 Hz, 2 x OCH2CH3), 1.30 (3H, s, CH3), 1.50 (3H, s, 
CH3), 3.88-4.01 (4H, m, 2 x OCH2CH3), 4.58-4.61 (1H, m, H-4’), 4.84 (1H, dd, J= 4.5 Hz, J= 6.6 Hz, H-
3’), 5.13 (1H, dd, J= 1.5 Hz, J= 6.3 Hz, H-2’), 5.63 (1H, d, J= 8.1 Hz, CH=CH), 5.82 (1H, d, J= 1.5 Hz, 
H-1’), 5.93-6.05 (1H, m, H-6’), 6.62-6.77 (1H, m, H-5’), 7.73 (1H, d, J= 8.1 Hz, CH=CH), 11.43 (1H, s, 
3-NH). The spectrum is accordance with the literature report.150 
 
Exact mass (ESI-MS) for C17H26N2O8P [M+H]+ found, 417.1442; calcd, 417.1421. 
 
1-[5,6-Dideoxy-6-(diethoxyphosphinyl)-2,3-O-isopropylidene-β-D-ribo-hexofuranosyl]uracil 
(3.34) 
O N
O O
NH
O
P
O
EtO
EtO
O
 
 
To a solution of compound 3.33 (921 mg, 2.21 mmol) in MeOH (15 mL) was added 10% Pd/C. The 
reaction mixture was stirred under hydrogen atmosphere overnight. The catalyst was removed by 
filtration through Celite and the filtrate was evaporated to yield pure compound 3.34 (707 mg, 76%) as 
a colourless solid. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.22 (6H, t, J= 7.1 Hz, 2 x OCH2CH3), 1.29 (3H, s, CH3), 1.48 (3H, s, 
CH3), 1.72 (4H, m, H-5’a,b and H-6’a,b), 3.92-4.02 (5H, m, 2 x OCH2CH3 and H-4’), 4.64 (1H, dd, J= 
4.7 Hz, J= 6.5 Hz, H-3’), 5.00 (1H, dd, J= 2.3 Hz, J= 6.5 Hz, H-2’), 5.64 (1H, dd, J= 2.0 Hz, J= 7.9 Hz, 
CH=CH), 5.75 (1H, d, J= 2.9 Hz, H-1’), 7.70 (1H, d, J= 7.9 Hz, CH=CH), 11.40 (1H, s, 3-NH). The 
spectrum is accordance with the literature report.150 
 
Exact mass (ESI-MS) for C17H28N2O8P [M+H]+ found, 419.1605; calcd, 419.1578. 
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1-[5,6-Dideoxy-6-(diethoxyphosphinyl)-2,3-O-isopropylidene-β-D-ribo-hexofuranosyl]-5-
bromouracil (3.35) 
O N
O O
NH
O
P
O
EtO
EtO
O
Br
 
 
To a solution of compound 3.34 (399 mg, 0.95 mmol) in DMF (8 mL) was added N-bromosuccinimide 
(NBS, 187 mg, 1.05 mmol) under N2. The reaction mixture was stirred at room temperature for 16 
hours. DMF was removed in vacuo and the residue was purified by column chromatography 
(CH2Cl2/MeOH 95:5) to afford compound 3.35 (376 mg, 79%) as a colourless oil. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.20-1.28 (9H, m, 2 x OCH2CH3 and CH3), 1.47 (3H, s, CH3), 1.69-
1.92 (4H, m, H-5’a,b and H-6’a,b), 3.90-4.04 (5H, m, 2 x OCH2CH3 and H-4’), 4.64-4.67 (1H, m, H-3’), 
5.04 (1H, dd, J= 2.1 Hz, J= 6.6 Hz, H-2’), 5.73 (1H, d, J= 2.1 Hz, H-1’), 8.23 (1H, s, H-6), 11.91 (1H, s, 
3-NH). 
 
31P NMR (DMSO-d6): δ 31.53. 
 
13C NMR (75 MHz, DMSO-d6): δ 16.25 (OCH2CH3), 16.32 (OCH2CH3), 19.89 (C-6’), 21.76 (C-5’), 
25.24 (CH3), 27.00 (CH3), 60.91 (OCH2CH3), 61.00 (OCH2CH3), 82.61 (C-3’), 83.38 (C-2’), 85.65 (C-4’, 
d, J= 17.9 Hz), 91.77 (C-1’), 96.12 (C-5), 113.49 (isopropylidene), 142.53 (C-6), 149.56 (C-2), 159.23 
(C-4). 
 
Exact mass (ESI-MS) for C17H27BrN2O8P [M+H]+ found, 497.0697; calcd, 497.0683. 
 
General procedure for the synthesis of 5-modified nucleoside phosphonates via Suzuki-
Miyaura coupling  
 
A mixture of compound 3.35 (1 equiv.), aryl boronic acid (2 equiv.), Pd(PPh3)4 (0.1 equiv.) and Na2CO3 
(3.3 equiv.) in DMF and degassed H2O was heated (± 130 °C, oil bath) under argon for 6 h or until 
TLC indicated consumption of all starting material. The mixture was then concentrated and co-distilled 
with toluene. The residue was purified by column chromatography affording 5-modified analogues in 
moderate yield. 
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1-[5,6-Dideoxy-6-(diethoxyphosphinyl)-2,3-O-isopropylidene-β-D-ribo-hexofuranosyl]-5-
phenyluracil (3.36) 
O N
O O
NH
O
P
O
EtO
EtO
O
 
 
Reaction of compound 3.35 (78 mg, 0.16 mmol) with phenylboronic acid (39 mg, 0.32 mmol), 
Pd(PPh3)4 (18 mg, 0.016 mmol) and Na2CO3 (55 mg, 0.52 mmol) in DMF (4 mL) and degassed H2O 
(0.5 mL) was performed as described in the general procedure for the synthesis of 5-modified 
phosphonates. Purification of the crude on a silica gel column (CH2Cl2/MeOH 95:5) afforded 
compound 3.36 as a colourless oil (33 mg, 43%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.18-1.23 (6H, m, 2 x OCH2CH3), 1.30 (3H, s, CH3), 1.49 (3H, s, 
CH3), 1.74-1.89 (4H, m, H-5’a,b and H-6’a,b), 3.91-4.02 (5H, m, 2 x OCH2CH3 and H-4’), 4.67-4.71 
(1H, m, H-3’), 5.14 (1H, dd, J= 2.4 Hz, J= 6.6 Hz, H-2’), 5.85 (1H, d, J= 2.1 Hz, H-1’), 7.29-7.41 (3H, 
m, Ph), 7.52-7.55 (2H, m, Ph), 7.91 (1H, s, H-6), 11.62 (1H, s, 3-NH). 
 
31P NMR (DMSO-d6): δ 31.55. 
 
13C NMR (75 MHz, DMSO-d6): δ 16.22 (OCH2CH3), 16.30 (OCH2CH3), 19.88 (C-6’), 21.74 (C-5’), 
25.26 (CH3), 27.03 (CH3), 60.89 (OCH2CH3), 61.02 (OCH2CH3), 82.76 (C-3’), 83.42 (C-2’), 85.55 (C-4’, 
d, J= 17.9 Hz), 91.96 (C-1’), 113.44 and 113.85 (isopropylidene and C-5), 127.39, 128.05, 128.27, 
132.69 and 140.40 (Ph and C-6), 149.70 (C-2), 162.21 (C-4). 
 
Exact mass (ESI-MS) for C23H32N2O8P [M+H]+ found, 495.1891; calcd, 495.1891. 
 
1-[5,6-Dideoxy-6-(diethoxyphosphinyl)-2,3-O-isopropylidene-β-D-ribo-hexofuranosyl]-5-
(naphthalen-1-yl)uracil (3.37) 
O N
O O
NH
O
P
O
EtO
EtO
O
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Reaction of compound 3.35 (63 mg, 0.13 mmol) with naphthalene-1-boronic acid (45 mg, 0.25 mmol), 
Pd(PPh3)4 (15 mg, 0.013 mmol) and Na2CO3 (44 mg, 0.42 mmol) in DMF (3 mL) and degassed H2O 
(0.4 mL) was performed as described in the general procedure for the synthesis of 5-modified 
phosphonates. Purification of the crude on a silica gel column (CH2Cl2/MeOH 96:4) afforded 
compound 3.37 as a colourless solid (42 mg, 61%).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.19 (6H, dt, J= 1.5 Hz, J= 7.2 Hz, 2 x OCH2CH3), 1.31 (3H, s, CH3), 
1.50 (3H, s, CH3), 1.74-1.91 (4H, m, H-5’a,b and H-6’a,b), 3.90-4.04 (5H, m, 2 x OCH2CH3 and H-4’), 
4.71 (1H, dd, J= 4.5 Hz, J= 6.3 Hz, H-3’), 5.18 (1H, dd, J= 2.4 Hz, J= 6.6 Hz, H-2’), 5.87 (1H, d, J= 2.1 
Hz, H-1’), 7.49-7.55 (2H, m, naphthalene), 7.69 (1H, dd, J= 1.8 Hz, J= 8.4 Hz, naphthalene), 7.90-7.95 
(3H, m, naphthalene), 8.06 (1H, s, H-6), 8.12 (1H, d, J= 1.2 Hz, naphthalene), 11.69 (1H, s, 3-NH). 
 
31P NMR (DMSO-d6): δ 31.58. 
 
13C NMR (75 MHz, DMSO-d6): δ 16.21 (OCH2CH3), 16.28 (OCH2CH3), 19.87 (C-6’), 21.74 (C-5’), 
25.30 (CH3), 27.05 (CH3), 61.01 (2 x OCH2CH3), 82.80 (C-3’), 83.47 (C-2’), 85.56 (C-4’), 92.28 (C-1’), 
113.40 and 113.66 (isopropylidene and C-5), 126.09, 126.19, 126.49, 126.82, 127.28, 127.42, 127.94, 
130.42, 132.12, 132.78 and 140.89 (naphthalene and C-6), 149.80 (C-2), 162.51 (C-4). 
 
Exact mass (ESI-MS) for C27H34N2O8P [M+H]+ found, 545.2076; calcd, 545.2047. 
 
1-[5,6-Dideoxy-6’-(diethoxyphosphinyl)-2,3-O-isopropylidene-β-D-ribo-hexofuranosyl]-5-(4-
fluorophenyl)uracil (3.38) 
O N
O O
NH
O
P
O
EtO
EtO
O
F
 
 
Reaction of compound 3.35 (78 mg, 0.16 mmol) with 4-fluorophenylboronic acid (44 mg, 0.31 mmol), 
Pd(PPh3)4 (18 mg, 0.016 mmol) and Na2CO3 (54 mg, 0.51 mmol) in DMF (4 mL) and degassed H2O 
(0.5 mL) was performed as described in the general procedure for the synthesis of 5-modified 
phosphonates. Purification of the crude on a silica gel column (CH2Cl2/MeOH 95:5) afforded 
compound 3.38 as a colourless solid (56 mg, 70%). 
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1H NMR (300 MHz, DMSO-d6): δ 1.18 (6H, dt, J= 0.9 Hz, J= 7.2 Hz, 2 x OCH2CH3), 1.27 (3H, s, CH3), 
1.47 (3H, s, CH3), 1.72-1.89 (4H, m, H-5’a,b and H-6’a,b), 3.92-4.02 (5H, m, 2 x OCH2CH3 and H-4’), 
4.69 (1H, dd, J= 4.8 Hz, J= 6.6 Hz, H-3’), 5.14 (1H, dd, J= 2.4 Hz, J= 6.9 Hz, H-2’), 5.83 (1H, d, J= 2.4 
Hz, H-1’), 7.19-7.25 (2H, m, subs Ph), 7.57-7.63 (2H, m, subs Ph), 7.92 (1H, s, H-6), 11.64 (1H, s, 3-
NH). 
 
31P NMR (DMSO-d6): δ 31.56. 
 
13C NMR (75 MHz, DMSO-d6): δ 16.22 (OCH2CH3), 16.29 (OCH2CH3), 19.89 (C-6’), 21.75 (C-5’), 
25.27 (CH3), 27.03 (CH3), 61.03 (2 x OCH2CH3), 82.77 (C-3’), 83.40 (C-2’), 85.56 (C-4’, d, J= 17.9 Hz), 
92.01 (C-1’), 112.89, 113.46, 114.74 and 115.02 (subs Ph, isopropylidene and C-5), 129.08, 130.24 
and 130.35 (subs Ph), 140.45 (C-6), 149.71 (C-2), 159.94 (subs Ph), 162.26 (C-4). 
 
Exact mass (ESI-MS) for C23H31FN2O8P [M+H]+ found, 513.1815; calcd, 513.1797. 
 
1-[5,6-Dideoxy-6-(diethoxyphosphinyl)-2,3-O-isopropylidene-β-D-ribo-hexofuranosyl]-5-
styryluracil (3.39) 
O N
O O
NH
O
P
O
EtO
EtO
O
 
 
Reaction of compound 3.35 (91 mg, 0.18 mmol) with trans-2-phenylvinylboronic acid (56 mg, 0.37 
mmol), Pd(PPh3)4 (21 mg, 0.018 mmol) and Na2CO3 (64 mg, 0.60 mmol) in DMF (4 mL) and degassed 
H2O (0.5 mL) was performed as described in the general procedure for the synthesis of 5-modified 
phosphonates. Purification of the crude on a silica gel column (CH2Cl2/MeOH 95:5) afforded 
compound 3.39 as a colourless solid (72 mg, 76%).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.18 (6H, app dt, J= 1.2 Hz, J= 6.9 Hz, 2 x OCH2CH3), 1.28 (3H, s, 
CH3), 1.48 (3H, s, CH3), 1.71-1.88 (4H, m, H-5’a,b and H-6’a,b), 3.90-4.01 (5H, m, 2 x OCH2CH3 and 
H-4’), 4.68 (1H, dd, J= 4.8 Hz, J= 6.6 Hz, H-3’), 5.06 (1H, dd, J= 2.4 Hz, J= 6.6 Hz, H-2’), 5.80 (1H, d, 
J= 2.4 Hz, H-1’), 6.88 (1H, d, J= 16.2 Hz, styrene), 7.20-7.25 (1H, m, styrene), 7.33 (2H, d, J= 7.8 Hz, 
styrene), 7.43-7.48 (3H, m, styrene), 7.94 (1H, H-6).  
 
31P NMR (DMSO-d6): δ 31.51. 
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13C NMR (75 MHz, DMSO-d6): δ 16.22 (OCH2CH3), 16.30 (OCH2CH3), 19.90 (C-6’), 21.76 (C-5’), 
25.29 (CH3), 27.02 (CH3), 60.99 (2 x OCH2CH3), 82.64 (C-3’), 83.49 (C-2’), 85.41 (C-4’, d, J= 17.6 Hz), 
91.34 (C-1’), 111.22 (C-5), 113.54 (isopropylidene), 120.83, 125.99, 127.42, 128.32, 128.74 and 
137.43 (styrene), 140.09 (C-6), 149.26 (C-2), 162.21 (C-4). 
 
Exact mass (ESI-MS) for C25H34N2O8P [M+H]+ found, 521.2049; calcd, 521.2047. 
 
1-[5,6-Dideoxy-6-(diethoxyphosphinyl)-2,3-O-isopropylidene-β-D-ribo-hexofuranosyl]-5-(p-
tolyl)uracil (3.40) 
O N
O O
NH
O
P
O
EtO
EtO
O
 
 
Reaction of compound 3.35 (63 mg, 0.13 mmol) with 4-methylphenylboronic acid (36 mg, 0.25 mmol), 
Pd(PPh3)4 (15 mg, 0.013 mmol) and Na2CO3 (45 mg, 0.42 mmol) in DMF (3 mL) and degassed H2O 
(0.4 mL) was performed as described in the general procedure for the synthesis of 5-modified 
phosphonates. Purification of the crude on a silica gel column (CH2Cl2/MeOH 97:3) afforded 
compound 3.40 as a colourless solid (29 mg, 46%).  
 
1H NMR (300 MHz, CDCl3): δ 1.24-1.33 (9H, m, 2 x OCH2CH3 and CH3) 1.54 (3H, s, CH3), 1.72-2.07 
(4H, m, H-5’a,b and H-6’a,b), 2.71 (3H, s, p-tolyl), 4.01-4.13 (5H, m, 2 x OCH2CH3 and H-4’), 4.64 (1H, 
dd, J= 4.5 Hz, J= 6.3 Hz, H-3’), 5.04 (1H, dd, J= 2.1 Hz, J= 6.3 Hz, H-2’), 5.67 (1H, d, J= 2.4 Hz, H-1’), 
7.16-7.79 (4H, m, p-tolyl), 8.00 (1H, H-6). 
 
31P NMR (CDCl3): δ 31.27. 
 
13C NMR (75 MHz, CDCl3): δ 16.62 (OCH2CH3), 16.70 (OCH2CH3), 25.46 (C-6’), 27.27 (C-5’), 29.82 
(CH3), 31.48 (CH3), 38.38 (p-tolyl), 59.75 (OCH2CH3), 62.14 (OCH2CH3), 83.60 (C-3’), 84.56 (C-2’), 
86.95 (C-4’), 94.17 (C-1’), 115.12 and 115.97 (isopropylidene and C-5), 128.36, 129.12, 129.50, 
138.40 and 139.41 (p-tolyl and C-6), 149.83 (C-2), 162.71 (C-4). 
 
Exact mass (ESI-MS) for C24H34N2O8P [M+H]+ found, 509.2076; calcd, 509.2047. 
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1-[5,6-Dideoxy-6-(diethoxyphosphinyl)-2,3-O-isopropylidene-β-D-ribo-hexofuranosyl]-5-(furan-2-
yl)uracil (3.41) 
O N
O O
NH
O
P
O
EtO
EtO
O
O
 
 
Reaction of compound 3.35 (93 mg, 0.19 mmol) with furan-2-boronic acid (42 mg, 0.37 mmol), 
Pd(PPh3)4 (22 mg, 0.019 mmol) and Na2CO3 (65 mg, 0.62 mmol) in DMF (4.5 mL) and degassed H2O 
(0.6 mL) was performed as described in the general procedure for the synthesis of 5-modified 
phosphonates. Purification of the crude on a silica gel column (CH2Cl2/MeOH 95:5) afforded 
compound 3.41 as a brown solid (36 mg, 40%).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.16-1.28 (6H, m, 2 x OCH2CH3) 1.28 (3H, s, CH3), 1.48 (3H, s, 
CH3), 1.76-1.81 (4H, m, H-5’a,b and H-6’a,b), 3.82-4.07 (5H, m, 2 x OCH2CH3 and H-4’), 4.58-4.68 
(1H, m, H-3’), 5.03-5.13 (1H, m, H-2’), 5.84-5.86 (1H, m, H-1’), 6.50-6.54 (1H, m, furan), 6.83-6.88 
(1H, m, furan), 7.61-7.66 (1H, m, furan), 8.02 (1H, app d, J= 4.8 Hz, H-6). 
 
31P NMR (DMSO-d6): δ 31.63. 
 
13C NMR (75 MHz, DMSO-d6): δ 16.29 (OCH2CH3), 16.37 (OCH2CH3), 20.00 (C-6’), 21.98 (C-5’), 
25.31 (CH3), 27.07 (CH3), 60.99 and 61.11 (2 x OCH2CH3), 82.83 (C-3’), 83.74 (C-2’), 85.89 (C-4’, d, 
J= 17.6 Hz), 92.37 (C-1’), 105.72 and 108.40 (furan), 111.73 (C-5), 113.46 (isopropylidene), 128.83 
and 131.55 (furan), 141.79 (C-6), 149.24 (C-2), 160.37 (C-4). 
 
Exact mass (ESI-MS) for C21H30N2O9P [M+H]+ found, 485.1708; calcd, 485.1683. 
 
1-[5,6-Dideoxy-6-(diethoxyphosphinyl)-2,3-O-isopropylidene-β-D-ribo-hexofuranosyl]-5-
(thiophen-2-yl)uracil (3.42) 
O N
O O
NH
O
P
O
EtO
EtO
S
O
 
 
Reaction of compound 3.35 (81 mg, 0.16 mmol) with thiophene-2-boronic acid (42 mg, 0.33 mmol), 
Pd(PPh3)4 (19 mg, 0.016 mmol) and Na2CO3 (57 mg, 0.54 mmol) in DMF (4 mL) and degassed H2O 
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(0.5 mL) was performed as described in the general procedure for the synthesis of 5-modified 
phosphonates. Purification of the crude on a silica gel column (CH2Cl2/MeOH 95:5) afforded 
compound 3.42 as a colourless solid (32 mg, 39%).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.1-1.22 (6H, m, 2 x OCH2CH3) 1.28 (3H, s, CH3), 1.48 (3H, s, CH3), 
1.68-1.91 (4H, m, H-5’a,b and H-6’a,b), 3.90-3.97 (5H, m, 2 x OCH2CH3 and H-4’), 4.67-4.69 (1H, m, 
H-3’), 5.13-5.15 (1H, m, H-2’), 5.82 (1H, m, H-1’), 7.05-7.07 (1H, m, thiophene), 7.46-7.47 (2H, m, 
thiophene), 8.20 (1H, s, H-6). 
 
31P NMR (DMSO-d6): δ 31.64. 
 
13C NMR (75 MHz, DMSO-d6): δ 16.25 (OCH2CH3), 16.33 (OCH2CH3), (C-6 and C-5’ not visible), 
25.31 (CH3), 27.07 (CH3), 60.99 (2 x OCH2CH3), 82.87 (C-3’), 83.57 (C-2’), 85.86 (C-4’), 93.79 (C-1’), 
108.56 (C-5), 113.40 (isopropylidene), 128.73-138.33 (thiophene), (C-6, C-2 and C-4 not visible). 
 
Exact mass (ESI-MS) for C21H30N2O8PS [M+H]+ found, 501.1453; calcd, 501.1455. 
 
1-[5,6-Dideoxy-6-(diethoxyphosphinyl)-2,3-O-isopropylidene-β-D-ribo-hexofuranosyl]-5-
(benzothiophen-3-yl)uracil (3.43) 
 
O N
O O
NH
O
P
O
EtO
EtO
S
O
 
 
Reaction of compound 3.35 (105 mg, 0.21 mmol) with 1-benzothiophen-3-yl-boronic acid (77 mg, 0.42 
mmol), Pd(PPh3)4 (24 mg, 0.021 mmol) and Na2CO3 (74 mg, 0.70 mmol) in DMF (5 mL) and degassed 
H2O (0.7 mL) was performed as described in the general procedure for the synthesis of 5-modified 
phosphonates. Purification of the crude on a silica gel column (CH2Cl2/MeOH 95:5) afforded 
compound 3.43 as a brown solid (49 mg, 42%). 
 
1H NMR (300 MHz, CDCl3): δ 1.25-1.32 (9H, m, 2 x OCH2CH3 and CH3), 1.55 (3H, s, CH3), 1.77-1.93 
(2H, m, H-6’a and H-6’b), 1.98-2.08 (2H, m, H-5’a and H-5’b), 4.02-4.12 (5H, m, 2 x OCH2CH3 and H-
4’), 4.61 (1H, t, J= 5.7 Hz, H-3’), 5.00 (1H, app d, J= 6.6 Hz, H-2’), 5.70 (1H, app s, H-1’), 7.32-7.41 
(2H, m, benzothiophene), 7.46-7.48 (1H, m, benzothiophene), 7.54 (1H, s, H-6), 7.67 (1H, d, J= 7.8 
Hz, benzothiophenyl), 7.86 (1H, d, J= 7.8 Hz, benzothiophene), 9.53 (1H, br s, 3-NH). 
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31P NMR (DMSO-d6): δ 31.01. 
 
13C NMR (75 MHz, CDCl3): δ 16.52 (OCH2CH3), 16.60 (OCH2CH3), 21.04 (C-6’), 22.94 (C-5’), 25.48 
(CH3), 27.31 (CH3), 61.81 (OCH2CH3), 83.43 (C-3’), 84.41 (C-2’), 86.64 (C-4’, d, J= 17.9 Hz), 93.79 
(C-1’), 110.69 and 115.11 (C-5 and isopropylidene), 122.48, 123.08, 124.65, 124.71, 126.86, 126.94 
and 137.70 (benzothiophene), 140.15 and 140.39 (C-6 and benzothiophene), 149.54 (C-2), 162.12 (C-
4). 
 
Exact mass (ESI-MS) for C25H32N2O8PS [M+H]+ found, 551.1620; calcd, 551.1612. 
 
General procedure for the deprotection of 5-modified nucleoside phosphonates  
 
The phosphonic ester (1 equiv.) was dissolved in dry CH2Cl2 under argon. TMSBr (2 equiv.) was 
added and the resulting solution was stirred overnight. The solvents were evaporated and the residue 
was co-distilled with toluene. Then, water was added followed by TFA (50%) and the mixture was 
stirred for 4 h. The solvent was evaporated and subsequently portioned between EtOAc/Et2O (1:1) 
and water. The organic phase was washed with water and the water layers were combined and 
lyophilized. Purification of the crude using RP-HPLC (Phenomenex Luna C-18, H2O/0.1% HCOOH in 
CH3CN, 90:10 → 0:100 in 23 min, flow 17.5 mL/min) afforded compounds 3.44-3.51 in moderate yield. 
 
1-[5,6-Dideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-phenyluracil (3.44) 
 
O N
HO OH
NH
O
P
O
HO
HO
O
 
 
Reaction of compound 3.36 (32 mg, 0.068 mmol) with TMSBr (18 μL, 1.35 mmol) in dry CH2Cl2 (1.4 
mL) followed by reaction with 1.4 mL 50% aq. TFA in water (0.7 mL) as described in the general 
procedure for the deprotection of 5-modified nucleoside phosphonates, afforded compound 3.44 as a 
white powder (14.1 mg, 55%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.40-1.43 (2H, m, H-6’a and H-6’b), 1.80-1.84 (2H, m, H-5’a and H-
5’b), 3.82-3.83 (2H, m, H-3’ and H-4’), 4.19 (1H, t, J= 5.1 Hz, H-2’), 5.72 (1H, d, J= 4.5 Hz, H-1’), 7.26-
7.40 (3H, m, Ph), 7.51-7.54 (2H, m, Ph), 7.64 (1H, s, H-6). 
 
31P NMR (DMSO-d6): δ 25.89. 
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13C NMR (75 MHz, DMSO-d6): δ (C-6’ not visible), 26.89 (C-5’), 72.46 (C-3’), 72.52 (C-2’), 83.48 (C-4’, 
d, J= 15.9 Hz), 89.54 (C-1’), 113.97 (C-5), 127.36, 128.16, 128.22 and 132.80 (Ph), 138.34 (C-6), 
150.11 (C-2), 162.07 (C-4). 
 
Exact mass (ESI-MS) for C16H18N2O8P [M-H]- found, 397.0815; calcd, 397.0806. 
 
1-[5,6-Dideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(naphthalen-1-yl)uracil (3.45) 
 
O N
HO OH
NH
O
P
O
HO
HO
O
 
 
Reaction of compound 3.37 (70 mg, 0.073 mmol) with TMSBr (19 μL, 1.46 mmol) in dry CH2Cl2 (1.5 
mL) followed by reaction with 1.5 mL 50% aq. TFA in water (0.7 mL) as described in the general 
procedure for the deprotection of 5-modified nucleoside phosphonates, afforded compound 3.45 as a 
white powder (22.6 mg, 39%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.60 (2H, app br s, H-6’a and H-6’b), 1.78-1.84 (2H, m, H-5’a and H-
5’b), 3.77-3.85 (2H, m, H-3’ and H-4’), 4.25 (1H, t, J= 5.4 Hz, H-2’), 5.73 (1H, d, J= 4.8 Hz, H-1’), 7.29-
7.41 (3H, m, naphthalene), 7.52-7.69 (2H, m, naphthalene), 7.69 (1H, s, H-6), 11.57 (1H, s, 3-NH). 
 
31P NMR (DMSO-d6): δ 25.71. 
 
13C NMR (75 MHz, DMSO-d6): δ 23.80 (C-6’), 27.04 (C-5’), 72.56 (C-3’), 72.62 (C-2’), 83.52 (C-4’), 
89.83 (C-1’), 113.94 (C-5), 126.19, 126.27, 126.58, 126.78, 127.50, 128.22, 130.51, 132.23 and 
132.91 (naphthalene), 138.95 (C-6), 150.21 (C-2), 162.32 (C-4). 
 
Exact mass (ESI-MS) for C20H20N2O8P [M-H]- found, 447.0969; calcd, 447.0963. 
 
1-[5,6-Dideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(4-fluorophenyl)uracil (3.46) 
 
O N
HO OH
NH
O
P
O
HO
HO
O
F
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Reaction of compound 3.38 (56 mg, 0.11 mmol) with TMSBr (29 μL, 2.20 mmol) in dry CH2Cl2 (2.2 
mL) followed by reaction with 2.2 mL 50% aq. TFA in water (1.1 mL) as described in the general 
procedure for the deprotection of 5-modified nucleoside phosphonates, afforded compound 3.46 as a 
white powder (26.1 mg, 57%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.62 (2H, app br s, H-6’a and H-6’b), 1.79 (2H, app br s, H-5’a and 
H-5’b), 3.77-3.84 (2H, m, H-3’ and H-4’), 4.26 (1H, t, J= 5.1 Hz, H-2’), 5.73 (1H, d, J= 4.8 Hz, H-1’), 
7.21 (2H, t, J= 8.7 Hz, subs Ph), 7.56-7.60 (2H, m, subs Ph), 7.70 (1H, s, H-6), 11.59 (1H, s, 3-NH). 
 
31P NMR (DMSO-d6): δ 26.17. 
 
13C NMR (75 MHz, DMSO-d6): δ (C-6’ not visible), 27.05 (C-5’), 72.57 (C-3’), 72.60 (C-2’), 83.65 (C-
4’), 89.67 (C-1’), 113.11 (C-5), 114.92, 115.20, 129.21, 129.25, 130.29 and 130.40 (subs Ph), 138.44 
(C-6), 150.18 (C-2), 160.01 (subs Ph), 162.17 (C-4). 
 
Exact mass (ESI-MS) for C16H17FN2O8P [M-H]- found, 415.0722; calcd, 415.0712. 
 
1-[5,6-Dideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-styryluracil (3.47) 
 
O N
HO OH
NH
O
P
O
HO
HO
O
 
 
Reaction of compound 3.39 (72 mg, 0.14 mmol) with TMSBr (36 μL, 2.75 mmol) in dry CH2Cl2 (2.8 
mL) followed by reaction with 2.8 mL 50% aq. TFA in water (1.4 mL) as described in the general 
procedure for the deprotection of 5-modified nucleoside phosphonates, afforded compound 3.47 as a 
white powder (6.5 mg, 11%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.60 (2H, br s, H-6’a and H-6’b), 1.87 (2H, br s, H-5’a and H-5’b), 
3.78-3.86 (2H, m, H-3’ and H-4’), 4.15 (1H, app s, H-2’), 5.75-5.76 (1H, m, H-1’), 6.98 (1H, d, J= 16.2 
Hz, styrene), 7.15-7.57 (6H, m, styrene), 7.78 (1H, s, H-6). 
31P NMR (DMSO-d6): δ 24.42. 
 
13C NMR (175 MHz, DMSO-d6): δ 24.35 (C-6’), 27.07 (C-5’), 72.35 (C-3’), 72.72 (C-2’), 83.48 (C-4’), 
88.68 (C-1’), 111.27 (C-5), 121.28, 125.97, 127.27, 128.20, 128.57 and 137.57 (styrene), 138.78 (C-
6), 149.62 (C-2), 162.04 (C-4). 
 
                                                                      PART III - Chapter 2: Uridine 5’-Phosphonate Analogues 
  185 
 
Exact mass (ESI-MS) for C18H20N2O8P [M-H]- found, 423.0954; calcd, 423.0963. 
 
1-[5,6-Dideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(p-tolyl)uracil (3.48) 
 
O N
HO OH
NH
O
P
O
HO
HO
O
 
 
Reaction of compound 3.40 (29 mg, 0.058 mmol) with TMSBr (15 μL, 1.15 mmol) in dry CH2Cl2 (1.2 
mL) followed by reaction with 1.2 mL 50% aq. TFA in water (0.6 mL) as described in the general 
procedure for the deprotection of 5-modified nucleoside phosphonates, afforded compound 3.48 as a 
white powder (4.3 mg, 18%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.40-1.99 (4H, m, H-6’a,b and H-5’a,b), 2.34 (3H, s, p-tolyl), 3.77-
3.82 (2H, m, H-3’ and H-4’), 4.22 (1H, m, H-2’), 5.73 (1H, d, J= 4.5 Hz, H-1’), 7.19 (2H, d, J= 7.5 Hz, p-
tolyl), 7.42 (2H, d, J= 7.8 Hz, p-tolyl), 7.62 (1H, s, H-6). 
 
31P NMR (DMSO-d6): δ 25.55. 
 
13C NMR (75 MHz, DMSO-d6): δ 20.61 (p-tolyl), (C-6’ not visible), 27.00 (C-5’), 72.33 (C-3’), 72.42 (C-
2’), 83.64 (C-4’), 89.28 (C-1’), 113.74 (C-5), 127.85, 128.58, 129.71 and 136.47 (p-tolyl), 137.58 (C-6), 
149.92 (C-2), 161.95 (C-4). 
 
Exact mass (ESI-MS) for C17H20N2O8P [M-H]- found, 411.0970; calcd, 411.0963. 
 
1-[5,6-Dideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(furan-2-yl)uracil (3.49) 
 
O N
HO OH
NH
O
P
O
HO
HO
O
O
 
 
Reaction of compound 3.41 (32 mg, 0.067 mmol) with TMSBr (18 μL, 1.34 mmol) in dry CH2Cl2 (1.4 
mL) followed by reaction with 1.4 mL 50% aq. TFA in water (0.7 mL) as described in the general 
procedure for the deprotection of 5-modified nucleoside phosphonates, afforded compound 3.49 as a 
white powder (5.8 mg, 22%). 
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1H NMR (300 MHz, DMSO-d6): δ 1.61 (2H, br s, H-6’a and H-6’b), 1.83-1.91 (2H, m, H-5’a and H-5’b), 
3.80-3.82 (2H, m, H-3’ and H-4’), 4.12 (1H, s, H-2’), 5.73 (1H, d, J= 3.9 Hz, H-1’), 6.51 (1H, d, J= 1.8 
Hz, furan), 6.87 (1H, d, J= 3.3 Hz, furan), 7.66 (1H, s, furan), 7.82 (1H, s, H-6). 
 
31P NMR (DMSO-d6): δ 25.08. 
 
13C NMR (75 MHz, DMSO-d6): δ (C-6’ not visible), 27.12 (C-5’), 72.58 and 73.34 (C-2’ and C-3’), 83.56 
(C-4’), 89.56 (C-1’), 105.69, 108.10 and 111.56 (C-5 and furan), 134.25 (C-6), 141.81 and 146.08 
(furan), 149.42 (C-2), 160.07 (C-4). 
 
Exact mass (ESI-MS) for C14H16N2O9P [M-H]- found, 387.0604; calcd, 387.0599. 
 
1-[5,6-Dideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(thiophen-2-yl)uracil (3.50) 
 
O N
HO OH
NH
O
P
O
HO
HO
S
O
 
 
Reaction of compound 3.42 (32 mg, 0.063 mmol) with TMSBr (17 μL, 1.26 mmol) in dry CH2Cl2 (1.3 
mL) followed by reaction with 1.2 mL 50% aq. TFA in water (0.6 mL) as described in the general 
procedure for the deprotection of 5-modified nucleoside phosphonates, afforded compound 3.50 as a 
white powder (9.3 mg, 37%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.61 (2H, br s, H-6’a and H-6’b), 1.75-1.91 (2H, m, H-5’a and H-5’b), 
3.80-3.85 (2H, m, H-3’ and H-4’), 4.22-4.28 (1H, m, H-2’), 5.71 (1H, d, J= 4.5 Hz, H-1’), 7.02-7.10 (1H, 
m, thiophene), 7.46 (1H, d, J= 5.1 Hz, thiophene), 7.50 (1H, s, thiophene), 7.96 (1H, s, H-6). 
 
31P NMR (DMSO-d6): δ 25.42. 
 
13C NMR (175 MHz, DMSO-d6): δ 24.21 (C-6’), 26.99 (C-5’), 72.36 (C-3’), 72.73 (C-2’), 83.68 (C-4’), 
89.80 (C-1’), 108.63 (C-5), 123.20, 125.80, 126.54 and 133.39 (thiophene), 135.82 (C-6), 149.48 (C-
2), 161.30 (C-4). 
 
Exact mass (ESI-MS) for C14H16N2O8PS [M-H]- found, 403.0343; calcd, 403.0371. 
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1-[5,6-Dideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(benzothiophen-3-yl)uracil 
(3.51) 
O N
HO OH
NH
O
P
O
HO
HO
S
O
 
 
Reaction of compound 3.43 (49 mg, 0.088 mmol) with TMSBr (23 μL, 1.76 mmol) in dry CH2Cl2 (1.8 
mL) followed by reaction with 1.8 mL 50% aq. TFA in water (0.9 mL) as described in the general 
procedure for the deprotection of 5-modified nucleoside phosphonates, afforded compound 3.51 as a 
white powder (31.5 mg, 78%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.59 (2H, br s, H-6’a and H-6’b), 1.76-1.80 (2H, m, H-5’a and H-5’b), 
3.76-3.83 (2H, m, H-3’ and H-4’), 4.21-4.4.24 (1H, m, H-2’), 5.77 (1H, d, J= 4.8 Hz, H-1’), 7.36-7.44 
(2H, m, benzothiophene), 7.63-7.66 (1H, m, benzothiophene), 7.78 (2H, app d, J= 7.2 Hz, 
benzothiophene and H-6), 7.98-8.02 (1H, m, benzothiophene), 11.66 (1H, s, 3-NH). 
 
31P NMR (DMSO-d6): δ 26.13. 
 
13C NMR (75 MHz, DMSO-d6): δ (C-6’ not visible), 26.65 (C-5’), 72.49 (C-3’), 72.44 (C-2’), 83.47 (C-
4’), 89.37 (C-1’), 109.30 (C-5), 123.05, 124.28, 124.39, 126.65, 128.23, 138.02, 139.14 and 139.68 
(benzothiophenyl and C-6), 150.29 (C-2), 162.00 (C-4). 
 
Exact mass (ESI-MS) for C18H18N2O8PS [M-H]- found, 453.0531; calcd, 453.0527. 
 
1-[5,6-Dideoxy-6-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]uracil (3.52) 
 
O N
HO
NH
O
P
O
EtO
EtO
OH O  
 
1st Method: A solution of 3.34 (428 mg, 1.02 mmol) and 50% aqueous HCOOH (10 mL) was stirred for 
4,5 h at room temperature. The mixture was evaporated in vacuo and purified on a silica column using 
CH2Cl2/MeOH (90:10) as a solvent. Compound 3.52 was obtained as a colourless solid (220 mg, 
57%). 
 
2nd Method: Compound 3.34 (340 mg, 0.81 mmol) was dissolved in 50% aqueous TFA at 0 °C. After 
stirring for 2 hours at room temperature, the mixture was evaporated to dryness. The crude was 
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purified using column chromatography (CH2Cl2/MeOH 95:5 → 90:10) yielding compound 3.52 as a 
colourless solid (198 mg, 64%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.23 (6H, t, J= 6.9 Hz, 2 x OCH2CH3), 1.72-1.86 (4H, m, H-5’a,b and 
H-6’a,b), 3.32-3.83 (2H, m, H-3’ and H-4’), 3.93-4.11 (5H, m, 2 x OCH2CH3 and H-2’), 5.12 (1H, d, J= 
5.7 Hz, 3’-OH), 5.35 (1H, d, J= 5.7 Hz, 2’-OH), 5.63 ‘1H, d, J= 8.1 Hz, CH=CH), 5.68 (1H, d, J= 5.1 
Hz, H-1’), 7.59 (1H, d, J= 8.1 Hz, CH=CH), 11.34 (1H, s, 3-NH). 
 
31P NMR (DMSO-d6): δ 31.86. 
 
13C NMR (75 MHz, DMSO-d6): δ 16.26 and 16.33 (2 x OCH2CH3), 19.99 (C-6’), 21.85 (C-5’), 61.95 (2 
x OCH2CH3), 72.40 and 72.57 (C-2’ and C-3’), 82.65 (C-4, d, J= 17.3 Hz), 88.93 (C-1’), 102.06 (C-5), 
141.42 (C-6), 150.61 (C-2), 163.03 (C-4). 
 
Exact mass (ESI-MS) for C14H24N2O8P [M+H]+ found, 379.1262; calcd, 379.1265. 
 
1-[2,2-Anhydro-5,6-dideoxy-6-(diethoxyphosphinyl)-β-D-arabino-hexofuranosyl]uracil (3.53) 
 
O N
HO
N
O
P
O
EtO
EtO
O  
 
1st Method: Compound 3.52 (205 mg, 0.54 mmol) was dissolved into a mixed solution of thionyl 
chloride (0.17 mL) and CH3CN (1.4 mL) with vigorously stirring at room temperature. After 2 h, the 
mixture was poured into water and extracted with CH2Cl2. The combined organic layers were dried 
over MgSO4, filtered and concentrated in vacuo. Without further purification, the 2,3-sulfonyl derivative 
of 3.52 and sodium acetate (223 mg, 2.72 mmol) were heated in DMF at about 85 °C. After stirring for 
3 h, solvents were removed in vacuo and the crude purified on a silica gel column (CH2Cl2/MeOH 
(95:5 → 80:20)) yielding 180 mg (92%) of 3.53 as a white foam.  
 
2nd Method: Diphenyl carbonate (33 mg, 0.15 mmol) and sodium bicarbonate (1 mg, 0.012 mmol) 
were added to the DMF (0.7 mL) solution of 3.52 (53 mg, 0.14 mmol). The mixture was heated to 
reflux, and carbon dioxide was generated. After 1.5 hour, the darkened solution was concentrated in 
vacuo and the crude purified on a silica gel column (CH2Cl2/MeOH 90:10) affording 3.53 in a 65% 
yield. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.14-1.23 (7H, m, 2 x OCH2CH3 and H-5’a), 1.59-1.68 (3H, m, H-5’b 
and H-6’a,b), 3.84-3.94 (4H, m, 2 x OCH2CH3), 4.00-4.10 (1H, m, H-4’), 4.32 (1H, app s, H-3’), 5.19 
(1H, d, J= 5.7 Hz, H-2’), 5.87 (1H, d, J= 7.5 Hz, CH=CH), 6.30 (1H, d, J= 5.7 Hz, H-1’), 7.91 (1H, d, J= 
7.5 Hz, CH=CH). 
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31P NMR (DMSO-d6): δ 31.02. 
 
13C NMR (75 MHz, CDCl3): δ 16.45 and 16.53 (2 x OCH2CH3), 21.08 (C-6’), 22.99 (C-5’), 62.14 and 
62.23 (2 x OCH2CH3), (C3’ under CDCl3 peak), 87.72 (C-4’, d, J= 16.7 Hz), 89.49 (C-2’), 90.31 (C-1’), 
109.94 (C-5), 136.16 (C-6), 160.19 (C-2), 172.90 (C-4). 
 
Exact mass (ESI-MS) for C14H22N2O7P [M+H]+ found, 361.1157; calcd, 361.1159. 
 
1-[2-Azido-2,5,6-trideoxy-6-(ethoxyhydroxyphosphinyl)-β-D-ribo-hexofuranosyl]uracil (3.54) 
 
O N
HO N3
NH
O
P
O
EtO
HO
O
 
 
A suspension of compound 3.53 (33 mg, 0.092 mmol) and NaN3 (37 mg, 0.56 mmol) in 0.7 mL DMF 
was heated overnight at 150 °C. The mixture was cooled to room temperature and evaporated in 
vacuo. The crude was dissolved in CH2Cl2/MeOH (8:2) and filtrated. Solvents were removed to afford 
compound 3.54 in quantitative yield (yellow oil). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.08-1.20 (3H, m, OCH2CH3), 1.48-1.70 (2H, m, H-6’a,b), 1.76-1.91 
(2H, m, H-5’a,b), 3.75-3.89 (3H, m, OCH2CH3 and H-2’), 4.13-4.17 (1H, m, H-4’), 4.24-4.26 (1H, m, H-
3’), 5.66-5.74 (2H, m, H-1’ and CH=CH), 7.94-8.02 (1H, m, CH=CH). 
 
31P NMR (DMSO-d6): δ 25.36. 
 
Exact mass (ESI-MS) for C12H19N5O7P [M+H]+ found, 376.0997; calcd, 376.1017. 
 
1-[2-Amino-2,5,6-trideoxy-6-(ethoxyhydroxyphosphinyl)-β-D-ribo-hexofuranosyl]uracil (3.55) 
 
O N
HO NH2
NH
O
P
O
EtO
HO
O
 
 
Compound 3.54 (24 mg, 0.065 mmol) and PPh3 (34 mg, 0.13 mmol) were dissolved in THF (1 mL). 
After stirring for 10 minutes, H2O was added (17 μL). After stirring overnight, the volatiles were 
removed in vacuo. The residue dissolved in water, washed with EtOAc/Et2O (1:1) and lyophilized. 
Compound 3.55 was obtained in quantitative yield (light yellow solid). 
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1H NMR (300 MHz, DMSO-d6): δ 1.02-1.15 (3H, m, OCH2CH3), 1.21-1.52 (2H, m, H-6’a,b), 1.76 (2H, 
br s, H-5’a,b), 3.56-3.77 (3H, m, OCH2CH3 and H-2’), 4.04-4.10 (1H, m, H-4’), 4.22 (1H, app s, H-3’), 
5.83-5.88 (1H, m, CH=CH), 6.27 (1H, app d, J= 5.4 Hz, H-1’), 7.91-7.93 (1H, d, J= 7.5 Hz, CH=CH). 
 
31P NMR (D2O-d6): δ 26.76. 
 
Exact mass (ESI-MS) for C12H19N3O7P [M-H]- found, 348.0954; calcd, 348.0966. 
 
1-[2-Amino-2,5,6-trideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]uracil (3.56) 
 
O N
HO NH2
NH
O
P
O
HO
HO
O
 
 
To a solution of compound 3.55 (24 mg, 0.067 mmol) in CH2Cl2 (1.9 mL) was added TMSBr (89 μL, 
0.67 mmol). After stirring overnight, the volatiles were removed in vacuo. The residue was dissolved in 
water, washed with EtOAc/Et2O (1:1) and lyophilized. The crude was purified using flash 
chromatography (iPrOH/NH4OH/H2O 6:3:1) yielding compound 3.56 (18.6 mg, 78%) as a light yellow 
powder. Compound 3.56 was isolated in the bis ammonium salt form. 
 
1H NMR (300 MHz, D2O): δ 1.61-1.78 (2H, m, H-6’a,b), 1.89-1.95 (2H, m, H-5’a,b), 4.00-4.01 (1H, m, 
H-2’), 4.12-4.18 (1H, m, H-4’), 4.34-4.37 (1H, m, H-3’), 5.93 (1H, d, J= 7.8 Hz, CH=CH), 6.06 (1H, app 
d, J= 6.6 Hz, H-1’), 7.73 (1H, d, J= 8.4 Hz, CH=CH). 
 
31P NMR (D2O-d6): δ 24.03. 
 
13C NMR (75 MHz, D2O): δ 24.10 (C-6’, d, J= 133.9 Hz), 27.29 (C-5’, d, J= 3.5 Hz), 55.79 (C-2’), 71.65 
(C-3’), 86.20 (C-4’, d, J= 17.3 Hz), 87.27 (C-1’), 102.90 (C-5), 141.67 (C-6), 151.88 (C-2), 166.21 (C-
4). 
 
Exact mass (ESI-MS) for C10H15N3O7P [M-H]- found, 320.0646; calcd, 320.0653. 
 
1-[2-Chloro-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]uracil (3.57) 
 
O N
HO Cl
NH
O
P
O
EtO
EtO
O
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To a solution of compound 3.53 (76 mg, 0.21 mmol) in dry DMF (0.5 mL) was added 2N HCl in 
diethylether (1.4 mL). After stirring overnight, the mixture was concentrated in vacuo and the residue 
purified on a silica gel column (CH2Cl2/MeOH 90:10) affording 3.57 as a colourless solid (45 mg, 
54%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.23 (6H, t, J= 7.2 Hz, 2 x OCH2CH3), 1.65-1.98 (4H, m, H-5’a,b and 
H-6’a,b), 3.87-3.89 (1H, m, H-4’), 3.94-4.02 (5H, m, 2 x OCH2CH3 and H-3’), 4.73 (1H, app t, J= 6.0 
Hz, H-2’), 5.69 (1H, d, J= 8.1 Hz, CH=CH), 5.89 (1H, d, J= 5.1 Hz, 3’-OH), 5.96 (1H, d, J= 6 Hz, H-1’), 
7.63 (1H, d, J= 8.4 Hz, CH=CH), 11.45 (1H, s, 3-NH). 
 
31P NMR (DMSO-d6): δ 32.03. 
 
13C NMR (75 MHz, DMSO-d6): δ 16.43 and 16.50 (2 x OCH2CH3), 20.06 (C-6’), 21.92 (C-5’), 61.12, 
61.16 and 61.23 (C-2’ and 2 x OCH2CH3), 71.93 (C-3’), 83.57 (C-4’, d, J= 16.8 Hz), 88.83 (C-1’), 
102.62 (C-5), 140.71 (C-6), 150.69 (C-2), 163.07 (C-4). 
 
Exact mass (ESI-MS) for C14H23ClN2O7P [M+H]+ found, 397.0942; calcd, 397.0926. 
 
1-[2-Chloro-2,5,6-trideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]uracil (3.58) 
 
O N
HO Cl
NH
O
P
O
HO
HO
O
 
 
To a solution of 3.57 (41 mg, 0.10 mmol) in CH2Cl2 (1.5 mL) was added TMSBr (27 μL, 0.20 mmol). 
After stirring overnight, the volatiles were removed in vacuo. The residue was dissolved in water, 
washed with EtOAc/Et2O (1:1) and lyophilized. The crude was purified using flash chromatography 
(iPrOH/NH4OH/H2O 6:3:1) yielding 58% of compound 3.58 (21.8 mg, white powder). Compound 3.58 
was isolated in the bis ammonium salt form. 
 
1H NMR (300 MHz, D2O): δ 1.60-1.82 (2H, m, H-6’a and H-6’b), 1.94-2.05 (2H, m, H-5’a and H-5’b), 
4.13-4.19 (1H, m, H-4’), 4.27 (1H, app t, J= 5.4 Hz, H-3’), 4.66 (1H, app t, J= 5.1 Hz, H-2’), 5.92 (1H, 
d, J= 8.4 Hz, CH=CH), 6.08 (1H, d, J= 4.8 Hz, H-1’), 7.71 (1H, d, J= 8.1 Hz, CH=CH). 
 
31P NMR (D2O): δ 24.24. 
 
13C NMR (75 MHz, D2O): δ 24.17 (C-6’, d, J= 133.6 Hz), 27.08 (C-5’, d, J= 3.8 Hz), 61.39 (C-2’), 72.56 
(C-3’), 84.25 (C-4’, d, J= 17.9 Hz), 90.27 (C-1’), 102.73 (C-5), 141.52 (C-6), 151.69 (C-2), 166.25 (C-
4). 
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Exact mass (ESI-MS) for C10H13ClN2O7P [M-H]- found, 339.0154; calcd, 339.0154. 
 
2’-Deoxy-5’-O-triphenylmethyl-β-D-uridine (3.59) 
 
O N
TrO
HO
NH
O
O
 
 
To a solution of 2’-deoxyuridine (5.30 g, 23.22 mmol) in anhydrous pyridine (50 mL) was added 
triphenylmethyl chloride (7.28 g, 26.11 mmol). The mixture was heated to 65 °C and stirred overnight. 
Then it was diluted with CH2Cl2 (50 mL), washed with saturated aqueous NaHCO3 (3 x 100 mL), and 
dried over anhydrous MgSO4. The solvent was removed under reduced pressure and the resulting 
residue was purified by column chromatography (CH2Cl2/MeOH 96:4), affording compound 3.59 (6.65 
g, 61%) as a white foam. 
 
1H NMR (300 MHz, DMSO-d6): δ 2.18 (1H, app t, J= 6.6 Hz, H-2’a and H-2’b), 3.15-3.20 (1H, m, H-
5’a), 3.24-3.33 (1H, m, H-5’b), 3.86-3.90 (1H, m, H-4’), 4.25-4.30 (1H, m, H-3’), 5.34-5.40 (2H, m, 3’-
OH and CH=CH), 6.15 (1H, app t, J= 6.3 Hz, H-1’), 7.25-7.41 (15H, m, Tr), 7.63 (1H, d, J= 8.4 Hz, 
CH=CH), 11.33 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 63.82 (C-5’), 70.04 (C-3’), 84.26 and 85.40 (C-1’ and C-4’), 86.47 
(Tr), 101.72 (C-5), 127.29, 128.11 and 128.43 (Tr), 140.56 (C-6), 143.60 (Tr), 150.48 (C-2), 163.18 (C-
4). 
 
Exact mass (ESI-MS) for C28H27N2O5 [M+H]+ found, 471.1919; calcd, 471.1915. 
 
3’-O-tert-Butyldiphenylsilyl-2’-deoxy-5’-O-triphenylmethyl-β-D-uridine (3.60) 
 
O N
TrO
TBDPSO
NH
O
O
 
 
To a solution of compound 3.59 (6.65 g, 14.13 mmol) in DMF (50 mL) were added imidazole (4.62 g, 
67.82 mmol) and tert-butyldiphenylchlorosilane (5.8 mL, 22.61 mmol) at rt. The mixture was stirred at 
the same temperature overnight. After being quenched with water, the mixture was extracted with 
Et2O three times and dried over MgSO4. The solvents were evaporated and the residue was purified 
on a silica gel column (CH2Cl2/MeOH 99:1) to give compound 3.60 (10.02 g, 100%) as a white foam. 
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1H NMR (300 MHz, DMSO-d6): δ 0.97 (9H, s, TBDPS), 2.02-2.09 (1H, m, H-2’a), 2.19-2.27 (1H, m, H-
2’b), 3.03-3.08 (2H, m, H-5’a and H-5’b), 4.01-4.05 (1H, m, H-4’), 4.39-4.43 (1H, m, H-3’), 5.30 (1H, 
dd, J= 1.8 Hz, J= 8.1 Hz, CH=CH), 6.18 (1H, app t, J= 6.3 Hz, H-1’), 7.20-7.57 (25H, m, Tr and 
TBDPS), 7.67-7.70 (1H, m, CH=CH), 11.30 (1H, s, 3-NH). 
 
Exact mass (ESI-MS) for C44H45N2O5Si [M+H]+ found, 709.3094; calcd, 709.3092. 
 
3’-O-tert-Butyldiphenylsilyl-2’-deoxy-β-D-uridine (3.61) 
 
O N
HO
TBDPSO
NH
O
O
 
 
Compound 3.60 (10.02 g, 14.14 mmol) was dissolved in a mixture of ZnBr2 (51.83 g, 230.16 mmol) in 
CH2Cl2/iPrOH (230 mL, 195:35) and stirred overnight at room temperature. The reaction was 
quenched with water and extracted with CH2Cl2 (3 x 100 mL). The combined organic layers were dried 
over MgSO4 and evaporated to dryness. The resulting residue was purified by column 
chromatography (CH2Cl2/MeOH 96:4), affording compound 3.61 (3.97 g, 60%) as a white solid. 
 
1H NMR (300 MHz, DMSO-d6): δ 1.05 (9H, s, TBDPS), 1.92-2.02 (1H, m, H-2’a), 2.10-2.17 (1H, m, H-
2’b), 3.15-3.22 (1H, m, H-5’a), 3.30-3.41 (1H, m, H-5’b), 3.92-3.93 (1H, m, H-4’), 4.41-4.43 (1H, m, H-
3’), 4.95 (1H, app t, J= 5.1 Hz, 5’-OH), 5.61 (1H, app dd, J= 2.1 Hz, J= 8.1 Hz, CH=CH), 6.26-6.31 
(1H, m, H-1’), 7.42-7.53 (6H, m, TBDPS), 7.59-7.63 (4H, m, TBDPS), 7.78 (1H, d, J= 8.1 Hz, CH=CH), 
11.30 (1H, s, 3-NH).   
 
13C NMR (75 MHz, DMSO-d6): δ 18.99 (TBDPS), 27.04 (TBDPS), 61.42 (C-5’), 74.32 (C-3’), 84.71 (C-
4’), 88.11 (C-1’), 102.30 (C-5’), 128.41, 128.43, 130.55, 133.24, 135.62 and 136.64 (TBDPS), 140.83 
(C-6), 150.84 (C-2), 163.74 (C-4).  
 
Exact mass (ESI-MS) for C25H31N2O5Si [M+H]+ found, 467.1992; calcd, 467.1997.  
 
3’-O-tert-Butyldiphenylsilyl-2’-deoxy-β-D-uridine-5’-carboxylic acid (3.62) 
 
O N
HO
TBDPSO
NH
OO
O
 
 
Alcohol 3.61 (1.12 g, 2.39 mmol) was dissolved in CH3CN (20 mL). BAIB (1.69 g, 5.25 mmol) was 
added followed by water (20 mL). The mixture was then treated with TEMPO (78 mg, 0.48 mmol) and 
stirred for 16 h. The reaction mixture was concentrated under reduced pressure and the crude purified 
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on a silica gel column (CH2Cl2/MeOH 95:5 → 80:20) yielding compound 3.62 as a white foam (0.90 g, 
78%). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.06 (9H, s, TBDPS), 1.87-1.96 (1H, m, H-2’a), 2.12-2.19 (1H, m, H-
2’b), 4.50 (1H, app s, H-4’), 4.65 (1H, d, J= 3.9 Hz, H-3’), 5.69 (1H, app dd, J= 2.1 Hz, J= 8.1 Hz, 
CH=CH), 6.45 (1H, dd, J= 5.4 Hz, J= 9.3, H-1’), 7.42-7.53 (6H, m, TBDPS), 7.62-7.65 (4H, m, 
TBDPS), 8.10 (1H, d, J= 7.8 Hz, CH=CH), 11.36 (1H, app d, J= 1.8 Hz, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ 18.69 (TBDPS), 26.63 (TBDPS), 76.48 (C-3’), 84.37 (C-4’), 85.68 (C-
1’), 102.09 (C-5’), 128.00, 128.05, 130.17, 130.21, 132.33, 132.46, 135.26 and 135.28 (TBDPS), 
140.40 (C-6), 150.49 (C-2), 163.04 (C-4), 171.71 (C-5’).   
 
Exact mass (ESI-MS) for C25H29N2O6Si [M+H]+ found, 481.1795; calcd, 481.1789. 
 
2’-Deoxy-β-D-uridine-5’-carboxylic acid (3.63) 
 
O N
HO
HO
NH
OO
O
 
 
A solution of compound 3.62 (273 mg, 0.57 mmol) and NH4F (42 mg, 1.14 mmol) in MeOH (2 mL) was 
stirred overnight at room temperature. The reaction mixture was evaporated and the residue dissolved 
in water, washed with EtOAc and lyophilized to obtain pure compound 3.63 as a white solid (140 mg, 
100%). 
 
1H NMR (300 MHz, D2O): δ 1.99-2.08 (1H, m, H-2’a), 2.23-2.30 (1H, m, H-2’b), 4.26 (1H, d, J= 1.5 Hz, 
H-4’), 4.49-4.54 (1H, m, H-3’), 5.80 (1H, d, J= 8.1 Hz, CH=CH), 6.30 (1H, dd, J= 5.7 Hz, J= 8.7 Hz, H-
1’), 8.36 (1H, d, J= 8.1 Hz, CH=CH). (The 1H NMR spectrum is accordance with the literature 
report.201) 
 
Exact mass (ESI-MS) for C9H9N2O6 [M-H]- found, 241.0470; calcd, 241.0466. 
 
(2R)-1-[(2,3-Dihydrofuran-2-yl]uracil (3.64) 
 
O N NH
O
O  
 
2’-Deoxyuridine-5’-carboxylic acid 3.63 (120 mg, 0.50 mmol) and dimethylformamide dineopentyl 
acetal (0.44 mL, 1.59 mmol) in DMF (5 mL) were heated at 130 °C. After 20 min the reaction mixture 
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was cooled and evaporated in vacuo. The crude was dissolved in CH2Cl2 and extracted with brine. 
The organic layer was dried over MgSO4, filtered and concentrated. Purification using silica column 
chromatography (CH2Cl2/MeOH 96:4) afforded compound 3.64 (41 mg, 46%) as a colourless solid. 
 
1H NMR (300 MHz, DMSO-d6): δ 2.55-2.64 (1H, m, H-2’a), 3.02-3.13 (1H, m, H-2’b), 5.14 (1H, app q, 
J= 2.4 Hz, H-3’), 5.64 (1H, d, J= 8.1 Hz, CH=CH), 6.54 (1H, app q, J= 4.2 Hz, H-1’), 6.60 (1H, app q, 
J= 3.0 Hz, H-4’), 7.33 (1H, d, J= 7.8 Hz, CH=CH), 11.35 (1H, s, 3-NH). (The 1H NMR spectrum is 
accordance with the literature report.201) 
 
13C NMR (75 MHz, DMSO-d6): δ 34.39 (C-2’), 84.13 (C-1’), 100.06 (C-3’), 102.90 (C-5), 140.01 (C-6), 
144.83 (C-4’), 150.24 (C-2), 163.10 (C-4).  
 
Exact mass (ESI-MS) for C8H9N2O3 [M+H]+ found, 181.0164; calcd, 181.0608. 
 
(2R,4S,5R)-1-[5-((Diethoxyphosphinyl)methoxy)-4-(phenylselenyl)tetrahydrofuran-2-yl]uracil 
(3.65) 
O N NH
PhSe
O
P
O
EtO
EtO
O
O
 
 
A solution of phenylselenyl chloride (44 mg, 0.23 mmol) in CH2Cl2 (0.1 mL) was added dropwise to a 
solution of glycal 3.64 (41 mg, 0.23 mmol) in CH2Cl2 (0.7 mL). After the mixture was stirred at -70 °C 
for 1 h, the solvent was removed under reduced pressure and the crude dissolved in CH2Cl2 (0.5 mL). 
Diethyl(hydroxymethyl)phosphonate (74 μL, 0.50 mmol) was added and the solution was cooled to -70 
°C. Over 3 minutes a solution of silver perchlorate (52 mg, 0.25 mmol) in CH3CN (0.1 mL) was added 
and the mixture was allowed to warm to 0 °C and poured into an aq. NaHCO3 solution. The organic 
phase was separated, dried over MgSO4 and evaporated in vacuo. The residual oil was purified on 
silica (CH2Cl2/MeOH 96:4) yielding compound 3.65 (40 mg, 35%) as a colourless solid.  
 
1H NMR (300 MHz, CDCl3): δ 1.26 (6H, app dt, J= 1.5 Hz, J= 7.2 Hz, 2 x OCH2CH3), 2.41-2.45 (2H, m, 
H-2’a and H-2’b), 3.59-3.67 (1H, m, H-5’a), 3.79-3.90 (2H, m, H-5’b and H-3’), 4.03-4.13 (4H, m, 2 x 
OCH2CH3), 5.09 (1H, app s, H-4’), 5.74 (1H, app dd, J= 2.4 Hz, J= 8.4 Hz, CH=CH), 6.48 (1H, app t, 
J= 7.2 Hz, H-1’), 7.23-7.33 (3H, m, Ph), 7.49-7.55 (2H, m, Ph), 7.61 (1H, d, J= 8.4 Hz, CH=CH), 8.51 
(1H, s, 3-NH).  
 
31P NMR (CDCl3): δ 20.12. 
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13C NMR (75 MHz, CDCl3): δ 16.65 and 16.72 (2 x OCH2CH3), 36.27 (C-2’), 43.79 (C-3’), 60.47 (C-5’), 
62.82 and 62.91 (2 x OCH2CH3), 86.53 (C-1’), 103.84 (C-4’), 110.04 (C-5), 127.36, 128.89, 129.73 
and 135.12 (Ph), 140.41 (C-6), 150.51 (C-2), 162.78 (C-4).  
Exact mass (ESI-MS) for C19H26N2O7PSe [M+H]+ found, 505.0630; calcd, 505.0637. 
 
(2R,5R)-1-[2,5-Dihydro-5-((diethoxyphosphinyl)methoxy)-furan-2-yl]uracil (3.66) 
 
O N NH
O
O
P
O
EtO
EtO
O  
 
To a solution of compound 3.65 (41 mg, 0.082 mmol) in MeOH (0.7 mL) was added dropwise a 
suspended solution of sodium bicarbonate (12 mg, 0.14 mmol) and sodium periodate (22 mg, 0.10 
mmol) in water (0.7 mL). After being stirred at rt for 1 h, the mixture was heated at 80 °C for 75 min. 
Volatiles were removed in vacuo and the residue was suspended in CH2Cl2, filtered through Celite and 
dried over MgSO4. After evaporation under reduced pressure, the crude was purified on a silica gel 
column (CH2Cl2/MeOH 96:4) to give compound 3.66 (19 mg, 68%) as a yellow oil. 
 
1H NMR (300 MHz, CDCl3): δ 1.31-1.36 (6H, m, 2 x OCH2CH3), 3.87-3.94 (1H, m, H-5’a), 4.03-4.22 
(5H, m, H-5’b and 2 x OCH2CH3), 5.71 (1H, d, J= 7.8 Hz, CH=CH), 5.80 (1H, app s, H-4’), 6.10 (1H, 
app d, J= 6.0 Hz, H-2’), 6.28-6.31 (1H, m, H-3’), 6.97 (1H, app s, H-1’), 7.39 (1H, d, J= 8.1 Hz, 
CH=CH), 9.21 (1H, s, 3-NH).  
 
31P NMR (CDCl3): δ 20.21. 
 
13C NMR (75 MHz, CDCl3): δ 16.18 and 16.25 (2 x OCH2CH3), 61.17, 62.36 and 63.41 (2 x OCH2CH3 
and C-5’), 87.77 (C-1’), 102.92 (C-5), 108.38 (C-4’), 130.11 (C-2’), 131.73 (C-3’), 139.77 (C-6), 150.21 
(C-2), 162.78 (C-4). 
 
Exact mass (ESI-MS) for C13H20N2O7P [M+H]+ found, 347.0999; calcd, 347.1003. 
 
(2R,3R,4S,5R)-1-[5-((Diethoxyphosphinyl)methoxy)-3,4-dihydroxy-tetrahydrofuran-2-yl]uracil 
(3.67) 
O N NH
O
O
P
O
EtO
EtO
HO OH O  
 
Compound 3.66 (37 mg, 0.11 mmol) was dissolved in a 5:1 acetone-water mixture (4 mL) and treated 
with osmium tetraoxide (0.19 mL [4 wt% solution], 0.032 mmol) and N-methylmorpholine-N-oxide (32 
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mg, 0.26 mmol). After stirring for 48 h, the mixture was quenched with a saturated solution of Na2S2O3 
(4 mL) and stirred for 30 min. The black mixture was extracted with EtOAc three times and the 
combined organic layers were dried over MgSO4 and evaporated. Chromatography of the residue on 
silica gel (CH2Cl2/MeOH 90:10) yielded diol 3.67 as a colourless solid (24 mg, 60%).  
 
1H NMR (300 MHz, DMSO-d6): δ 1.23 (6H, t, J= 6.9 Hz, 2 x OCH2CH3), 3.88-3.91 (3H, m, H-3’, H-5’a 
and H-5’b), 4.02-4.10 (4H, m, 2 x OCH2CH3), 4.93 (1H, app s, H-4’), 5.52 (1H, d, J= 6.0 Hz, 2’-OH), 
5.60 (1H, d, J= 4.2 Hz, 3’-OH), 5.65 (1H, d, J= 8.1 Hz, CH=CH), 6.06 (1H, d, J= 6.9 Hz, H-1’), 7.49 
(1H, d, J= 8.1 Hz, CH=CH).  
 
31P NMR (DMSO-d6): δ 20.55. 
 
13C NMR (75 MHz, DMSO-d6): δ 16.44 and 16.51 (2 x OCH2CH3), 59.50 (C-5’), 62.35 and 62.43 (2 x 
OCH2CH3), 73.07 (C-2’), 73.53 (C-3’), 87.78 (C-1’), 103.17 (C-5), 107.95 (C-4’), 140.47 (C-6), 151.13 
(C-2), 163.12 (C-4).  
 
Exact mass (ESI-MS) for C13H22N2O9P [M+H]+ found, 381.1035; calcd, 381.1057. 
 
(2R,3R,4S,5R)-1-[3,4-Dihydroxy-5-(phosphonomethoxy)-tetrahydrofuran-2-yl]uracil (3.68) 
 
OO N NH
O
P
O
HO
HO
HO OH O  
 
Compound 3.67 (23 mg, 0.061 mmol) was dissolved in dry DMF (3.8 mL) and cooled to 0 °C. The 
solution was then treated with 2,6-lutidine (71 μL, 0.61 mmol) followed by the dropwise addition of 
TMSBr (41 μL, 0.30 mmol). The mixture was allowed to warm to rt and stirred for 16 h. The solvent 
was evaporated and subsequently portioned between EtOAc/Et2O (1:1) and water. The organic phase 
was washed with water and the water layers were combined and lyophilized. The crude was purified 
using flash chromatography (iPrOH/NH4OH/H2O 6:3:1) yielding compound 3.68 (9.0 mg, 50%) as a 
white powder. Compound 3.68 was isolated in the bis ammonium salt form. 
 
1H NMR (300 MHz, CD3OD): δ 3.47-3.55 (1H, m, H-5’a), 3.80-3.87 (1H, m, H-5’b), 4.09 (1H, app d, J= 
4.2 Hz, H-3’), 4.40-4.44 (1H, m, H-2’), 4.96 (1H, app s, H-4’), 5.84 (1H, d, J= 8.1 Hz, CH=CH), 6.25 
(1H, d, J= 6.6 Hz, H-1’), 7.91 (1H, d, J= 7.8 Hz, CH=CH).  
 
31P NMR (CD3OD): δ 14.09. 
 
13C NMR (75 MHz, CD3OD): δ 64.88 (C-5’), 66.99 (C-2’), 73.62 (C-3’), 89.86 (C-1’), 104.15 (C-5), 
110.40 (C-4’), 143.28 (C-6), 152.96 (C-2), 166.08 (C-4). 
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Exact mass (ESI-MS) for C9H12N2O9P [M-H]- found, 323.0296; calcd, 323.0286. 
 
(Diethoxyphosphinyl)methyl triflate (3.70) 
 
P
O
EtO
OTf
EtO
 
 
To a stirred solution of diethyl(hydroxymethyl)phosphonate (4.17 g, 24.80 mmol) and 2,6-lutidine (3.59 
mL, 29.52 mmol) in anhydrous CH2Cl2 (40 mL), trifluoromethanesulfonic anhydride (5.0 mL, 28.52 
mmol) was added dropwise at -50 °C. The resulting mixture was allowed to warm to 0 °C over 3 h and 
was then diluted with diethylether. The ethereal solution was successively washed with water and 1N 
HCl and dried over MgSO4. After concentration in vacuo, compound 3.70 was obtained as a yellowish 
oil (6.07 g, 82%), which was used in the next step without purification. 
 
1H NMR (300 MHz, CDCl3): δ 1.38 (6H, t, J= 7.1 Hz, 2 x OCH2CH3), 4.19-4.29 (4H, m, 2 x OCH2CH3), 
4.63 (2H, d, J= 8.8 Hz, CH2). (The 1H NMR spectrum is accordance with the literature report.191) 
 
[(Diethoxyphosphinyl)methyl]triphenylphosphonium triflate (3.71) 
 
P
O
EtO
PPh3
EtO
OTf  
 
Compound 3.70 (6.07 g, 20.24 mmol) was added dropwise to a stirred solution of triphenylphosphine 
(6.11 g, 23.28 mmol) in 12 mL anhydrous CH2Cl2 at 0 °C. The mixture was allowed to warm to room 
temperature and then stirred overnight. The solvent was removed under reduced pressure and the 
crude purified on a silica gel column affording compound 3.71 (7.49 g, 66%) as a white solid. 
 
1H NMR (300 MHz, CDCl3): δ 1.12 (6H, t, J= 7.1 Hz, 2 x OCH2CH3), 3.91-4.06 (4H, m, 2 x OCH2 CH3), 
4.09-4.22 (2H, dd, J= 16.1 Hz and J= 20.2 Hz, CH2), 7.65-7.90 (15H, m, PPh3). (The 1H NMR 
spectrum is accordance with the literature report.191) 
 
[(Diethoxyphosphinyl)methyl]triphenylphosphorane (3.72) 
 
P
O
EtO
PPh3
EtO
 
 
To a stirred suspension of a NaH (60% dispersion in mineral oil, 257 mg, 6.42 mmol) in anhydrous 
THF (10 mL) was added triphenylphosphonium triflate salt 3.71 (1.53 g, 2.72 mmol) in anhydrous THF 
(10 mL) at 0 °C. The resulting mixture was stirred at 0 °C for 30 min. The solvent was removed under 
                                                                      PART III - Chapter 2: Uridine 5’-Phosphonate Analogues 
  199 
 
reduced pressure and the residue washed with anhydrous CH2Cl2 and filtered. After concentration of 
the extracts, a slightly yellow oil (compound 3.72) was obtained, that was used immediately as reagent 
for the synthesis of α,β-unsaturated phosphonate esters. 
 
1H NMR (300 MHz, CDCl3): δ 1.12 (6H, t, J= 7.1 Hz, 2 x OCH2CH3), 1.27 (1H, d, J= 7.5 Hz, CH), 3.81-
3.93 (4H, m, 2 x OCH2CH3), 7.40-7.74 (15H, m, PPh3). (The 1H NMR spectrum is accordance with the 
literature report.191) 
2.7.2 Experimental Assays 
Assay of PLC Activity Stimulated by the P2Y2 Receptor 
A stable cell line for study of the human P2Y2 receptor was generated by retroviral expression of the 
receptor in 1321N1 human astrocytoma cells, which do not natively express P2Y receptors. Agonist-
induced [3H]inositol phosphate production was measured in 1321N1 cells plated to 20,000 cells/well 
on 96-well plates two days prior to assay. Sixteen hours before the assay, the inositol lipid pool of the 
cells was radiolabeled by incubation in 100 μL of serum-free inositol-free Dulbecco's modified Eagle's 
medium, containing 1.0 μCi of myo-[3H]inositol. No changes of medium were made subsequent to the 
addition of [3H]inositol. On the day of the assay, cells were challenged with 25 μL of the five-fold 
concentrated solution of receptor agonists in 200 mM Hepes, pH 7.3 in HBSS, containing 50 mM LiCl 
for 30 min at 37 °C. Incubations were terminated by aspiration of the drug-containing medium and 
addition of 450 μL of ice-cold 50 mM formic acid. [3H]Inositol phosphate accumulation was quantified 
using scintillation proximity assay methodology as previously described in detail.205 
 
Data Analysis 
 
Agonist potencies (EC50 values) were determined from concentration-response curves by non-linear 
regression analysis using the GraphPad software package Prism (GraphPad, San Diego, CA). All 
experiments examining the activity of newly synthesized molecules also included full concentration 
effect curves for UTP at the P2Y2 receptor. Each concentration of drug was tested in triplicate assays, 
and concentration effect curves for each test drug were repeated in at least three separate 
experiments with freshly diluted molecule. The results are presented as mean ± SEM from multiple 
experiments or in the case of concentration effect curves from a single experiment carried out with 
triplicate assays that were representative of results from multiple experiments. 
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1 INTRODUCTION 
During the past two decades, antiviral drugs have become crucial in the management of several viral 
infections, including human HSV, HIV, HBV, HCV and cytomegalovirus (HCMV) infections. Prominent 
among these drugs are nucleoside analogues, which can act as potent antiviral agents owing to their 
ability to inhibit viral polymerases, which have key roles in the various viral life cycles.210 
1.1 2’-DEOXYPYRIMIDINES AS ANTIVIRAL AGENTS 
Many 2’-deoxypyrimidine derivatives have been synthesized and evaluated for their antiviral activities. 
Several analogues showed activity against DNA viruses (e.g., HSV, varicella zoster virus, Epstein-Barr 
virus (EBV) and HBV), however, some nucleosides of this class are cytotoxic to the host cells due to 
the poor selectivity of their triphosphate metabolites toward the viral DNA polymerases vs. the cellular 
host polymerases. 
1.1.1 5-Modified 2’-Deoxyuridine Analogues 
5-Iodo-2’-deoxyuridine (4.1, IdU), originally designed as a potential antitumor drug, was the first 2’-
deoxynucleoside which showed selective and potent anti-herpes activity. Subsequently, 5-
trifluoromethyl-2’-deoxyuridine (4.2, trifluridine) and 5-ethyl-2’-deoxyuridine (4.3, EdU) proved active 
against herpes simplex viruses and are currently used for the treatment of herpetic keratitis (Figure 
IV.1). IdU, trifluridine and EdU are phosphorylated to their monophosphates by virus-encoded 
thymidine kinases, followed by two phosphorylation steps by host kinases. Once converted into their 
active triphosphates, the latter act as selective inhibitors of HSV DNA polymerases.211 
 
Introduction of a (E)-5-(2-bromovinyl) moiety at position 5 of 2’-deoxyuridine resulted in analogue 1.10 
(Figure IV.1), which proved highly potent and active against herpes simplex virus 1 and VZV. BVDU 
has been used for many years, albeit at a limited scale, for the topical treatment of herpetic keratitis 
and for the oral treatment of VZV infections.212 
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O N
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HO
NH
O
4.1: R = I
4.2: R = CF3
4.3: R = Et
O N
HO
HO
NH
O
1.10
O
R
O
Br
 
 
Figure IV.1 
 
During the last decade, many publications have appeared on the synthesis and antiviral activity of 5-
modified 2’-deoxyuridine analogues. Several substituents have been introduced at C-5, including 
alkoxymethyl groups,213 azoles214 and alkyloximes.214 Several analogues proved moderately to highly 
active against HSV. These results showed that modification at position 5 of 2’-deoxyuridine represents 
an interesting approach in the search for new anti-herpes agents.  
1.1.2 Bicyclic Nucleoside Analogues (BCNs) 
Bicyclic nucleoside analogues with a furanopyrimidine base moiety (Figure IV.2) were discovered 
serendipitously as unwanted by-products from the Pd-catalyzed coupling of 5-iodo pyrimidine 
nucleosides with terminal alkynes. Bicyclic nucleoside analogue 4.4, which shows structural 
resemblance to compound 1.68, is inactive against HSV-1/2, CMV and VZV in vitro. However, several 
analogues containing a longer aliphatic chain (R = n-C8H17 to n-C10H21) substituted at position 6 of the 
furanopyrimidine base showed highly potent and specific activity against VZV. With an EC50 of 0.008-
0.01 μM, derivative 4.5 was the most potent compound in this series. Introduction of a substituted 
phenyl group at position 6 increased antiviral activity: compound 4.6 (FV 100) showed an EC50 value 
of 0.1-0.5 nM against VZV, being at least 1000 times more active than acyclovir.215,216  
 
O N
HO
HO
N
O
O
R
4.4: X = H
4.5: X = n-C8H17
4.6: X = 4-pentylphenyl  
 
Figure IV.2 
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1.1.3 Carba 2’-Deoxyuridine Analogues 
The carba analogs of some 2’-deoxypyrimidine nucleosides were tested for their antiviral potency and 
showed activity against HSV-1/2. Among them, carba-IdU (4.7) and carba-BVDU (4.8) showed 
comparable potency and selectivity against HSV-1/2 as their parent nucleosides (IdU and BVDU). 
Interestingly, also their (+)-enantiomers 4.9 and 4.10 were active against HSV-1 (Figure IV.3).217,218 
1.1.4 1,5-Anhydro-2,3-dideoxy-D-arabino-hexitol Analogues 
1,5-Anhydro-2,3-dideoxy-D-arabino-hexitol nucleosides (Figure IV.3) can be considered as ‘ring-
expanded’ 2’-deoxynucleoside analogs where a methyl group is inserted between the ring oxygen and 
the anomeric carbon atom. Among them, 1,5-anhydro-2,3-dideoxy-2-(5-iodouracil-1-yl)-D-arabino-
hexitol (4.11) and 1,5-anhydro-2,3-dideoxy-2-(5-trifluoromethyluracil-1-yl)-D-arabino-hexitol (4.12) 
showed potent activity against HSV-1 (EC50: 0.025 μg/mL for both) and HSV-2 (EC50: 0.5 μg/mL and 
0.38 μg/mL, respectively), comparable to acyclovir.219,220,221 
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Figure IV.3 
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1.1.5 Conformational Preference of 2’-Deoxypyrimidines as Antiviral Agents 
For antiviral 2’-deoxyribonucleosides, where the desired biological response is principally derived from 
the incorporation of the drug into DNA, the ability of the molecule to interact effectively with three 
activating kinases and the target cellular or viral DNA polymerase is of vital importance. Although the 
sugar ring of nucleosides is flexible and can adopt several conformations, two identifiable dynamically 
interconverting conformations have been observed in solution: North and South. When nucleosides 
bind to the active site of enzymes, one conformer interacts selectively with the enzyme. For this 
reason, locked nucleosides ((North)-methanocarbathymidine (N-MCT) and (South)-
methanocarbathymidine (S-MCT) (Figure IV.4)) have been used to probe the conformational 
preference of individual enzymatic steps. The herpes kinases showed a distinct bias for S-MCT, while 
DNA polymerases almost exclusively incorporate the N-MCT-5’-TP. As a result, only N-MCT 
demonstrated potent antiviral activity against herpes simplex viruses 1 and 2 and Kaposi’s sarcoma-
associated herpesvirus.222  
 
This differential conformational preference of the activating kinases and the target polymerases make 
the development of new antiviral nucleosides very challenging: for the activation into their active form 
the nucleoside analogues should adopt the Southern conformation, while for their antiviral activity 
against DNA polymerases the Northern conformation is preferred.222  
 
N NH
O
O
N
HO
H
NO
O
OH
HO
OH
N-MCT S-MCT  
 
Figure IV.4. Bicyclo[3.1.0]hexane nucleosides locked in two non-equilibrating North (N-MCT) and South (S-MCT) 
conformations.222 
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1.2 NUCLEOSIDE PHOSPHONATES AS ANTIVIRAL AGENTS 
Structural modifications, either on the base or the sugar moiety of a natural nucleoside is a commonly 
used method in the search for new antiviral agents. One should keep in mind that the viral nucleic acid 
biosynthesis can only be disturbed when the nucleoside analogue is converted into its corresponding 
triphosphate form.223 The first step in this process, the phosphorylation of the nucleoside analogue into 
its 5’-monophosphate counterpart by nucleoside kinases, is often rate limiting in the conversion to the 
active metabolite. One way to overcome this bottleneck is to devise prodrugs that are capable of 
delivering the nucleoside monophosphate intracellularly.224,225 Another approach to bypass the first 
phosphorylation step is to use phosphonate analogs, that, after intracellular conversion into their 
corresponding diphosphophosphonate forms, can exhibit antiviral activities.  
 
Currently, three acyclic nucleoside phosphonate prodrugs have been licensed for the treatment of viral 
infections: adefovir dipivoxil (4.13) for the treatment of chronic hepatitis B, tenofovir disoproxil 
fumarate (4.14) for the treatment of HIV & HBV infections and cidofovir (4.15) for the treatment of 
CMV retinitis in AIDS patients. Likewise, a few nucleoside phosphonates with a cyclic sugar moiety 
(e.g., 4.16, 4.17 and 4.18) were identified as potent antiviral agents without possessing cytotoxic 
activity (Figure IV.5).226 
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Figure VI.5 
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2 5-MODIFIED 2’-DEOXYURIDINE 5’-PHOSPHONATE 
ANALOGUES  
2.1 OBJECTIVES 
Modification of naturally occurring nucleosides is an important area in the development of new antiviral 
agents. A number of C-5 modified 2’-deoxypyrimidine analogues are known to possess potent and 
selective antiviral activity (cf. infra). However, relatively few examples of 5-(hetero)aryl-modified 
nucleosides with promising antiviral activity have been reported.227 This may be due to the fact that 
these nucleosides are not efficiently converted into their triphosphate form. This led us to investigate a 
small series of 2’-deoxyuridine analogues that combine different aromatic substituents at position 5 of 
the base with a 5’-methylene phosphonate group to bypass a possibly difficult first intracellular 
phosphorylation step. All compounds will be evaluated against a panel of different viruses. 
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2.2 CHEMISTRY 
2.2.1 Attempted Synthesis of 2’-Deoxyuridine 5’-Methylene Phosphonate 4.24 
The synthesis of the target phosphonate is depicted in Scheme IV.1 and started from 2’-deoxyuridine. 
After protection of the 3’- and 5’-OH as TBDMS ethers, the primary hydroxyl group was selectively 
deprotected using HF∙pyridine.228 Conversion of nucleoside 4.20 to the vinylic phosphonate 4.21 was 
accomplished following the same two-step procedure as described for 3.33. Catalytic hydrogenation of 
4.21 in the presence of Pd/C followed by the treatment of 4.22 with a 1M TBAF solution afforded 
phosphonate 4.23. Treatment of 4.23 with TMSBr in CH2Cl2 to deprotect the phosphonate ester 
caused concomitant anomerisation as revealed by 1H NMR analysis of the anomeric mixture. Attempts 
to separate 4.24 and 4.25 using flash chromatography and RP-HPLC were unsuccessful.  
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Scheme IV.1. Reagents and conditions. (a) TBDMSCl, imidazole, DMF, rt, 20 h, 100%; (b) HF∙pyridine, THF, 0 
°C → rt, 2 h, 43%; (c) (i) IBX, CH3CN, 80 °C, 6 h; (ii) 3.72, DMSO, rt, 20 h, 41% over 2 steps; (d) H2, Pd/C, 
MeOH, rt, overnight, 97%; (e) 1M TBAF in THF, rt, 3 h, 69%; (f) TMSBr, CH2Cl2, rt, overnight, 65%.  
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To avoid the anomerisation issue, we attempted to deprotect 4.23 in the presence of TMSBr under 
different reaction conditions. Following the reaction via 31P NMR, we observed anomerisation 
immediately after addition of TMSBr. Attempts at different temperatures learned that no reaction 
occurred under -20 °C, and that anomerisation started simultaneously with the phosphonate 
hydrolysis, even at low temperature. Also the addition of an acid scavenger (e.g., 
bis(trimethylsilyl)acetamide or 2,6-lutidine) could not prevent anomerisation.229  
 
Finally, we tried to obtain phosphonate 4.24 by removing the phosphonate protecting groups prior to 
desilylation of 3’-OH. Unfortunately, treatment of 4.22 with TMSBr in CH2Cl2 resulted again in a 
mixture of 4.24 and 4.25. Under these reaction conditions, the 3’-OH protecting group was removed as 
well. (Scheme IV.2). 
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Scheme IV.2. Reagents and conditions. (a) TMSBr, CH2Cl2, rt, overnight, 22%. 
2.2.2 Synthesis of 5-Modified 2’-Deoxyuridine 5’-Methylene Phosphonate Analogues  
A series of 5-modified 2’-deoxyuridine 5’-methylene phosphonate analogs could be obtained using the 
same strategy described for the synthesis of compounds 3.44-3.51. Starting from 4.22, selective 
bromination116 followed by a palladium-catalyzed cross-coupling192 with four commercial aryl and 
heteroaryl boronic acids gave access to a compounds 4.27-4.31 (Scheme IV.3). After removing the 
silyl protecting group with TBAF, deprotection of the phosphonate esters was performed using TMSBr 
in CH2Cl2. Except for the furan derivative, which degraded during the last step, final deprotection 
resulted in a 2:1 mixture of the α- and β-isomer, which could be separated using RP-HPLC.  
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Scheme IV.3. Reagents and conditions. (a) NBS, DMF, rt, overnight, 49%; (b) R-B(OH)2, Na2CO3, Pd(PPh3)4, 
DMF, H2O, reflux, 4 h, 75-91%; (c) 1M TBAF in THF, rt, 1 h, 32-71%; (d) TMSBr, CH2Cl2, rt, overnight, 4-19%. 
 
From a chemical point of view, it would have been interesting to investigate the influence of a 6 
modification on the anomerisation during phosphonate deprotection. We anticipate that introduction of 
a 6-substituent could have a bigger impact on this phenomenon than a 5 modification. Introduction of 
an electron withdrawing group is believed to reduce or prevent isomerisation whereas an electron 
donating group could facilitate isomerisation. Unfortunately, a shortage of time prevented us to explore 
this hypothesis. 
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2.3 STRUCTURE ANALYSIS 
To identify the α- and β-isomers of the 5-modified 2’-deoxyuridine 5’-methylene phosphonate 
analogues, a stereochemical assignment of compound 4.37 was performed in the NMR and Structure 
Analysis Unit of the Department of Organic Chemistry (UGent). The 2D ROESY spectrum of 
compound 4.37 is depicted in Figure IV.6. A clear rOe contact between H-4’ and H-2’b (proton down) 
and a much weaker interaction between H-6 and H-2’b proved that H-4’ and H-6 were not positioned 
at the same side of the furanose ring. The β-configuration of the nucleobase was further established 
by the presence of a strong interaction between H-6 and H-5’a,b (Figure IV.6).  
 
 
 
Figure IV.6. 2D ROESY (500.13 MHz, 298.0 K) spectrum of compound 4.37. 
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2.4 BIOLOGICAL EVALUATION 
All compounds were evaluated for their antiviral activity against a broad panel of viruses including 
HSV-1 (KOS), HSV-2 (G), vaccinia virus (VV), vesicular stomatitis virus (VSV), thymidine kinase 
deficient HSV-1 TK- (KOS ACVr), HCMV and VZV in HEL (human embryonic lung) cell cultures; and 
HIV-1 (IIIB) and HIV-2 (ROD) in human T-lymphocyte (CEM) cell cultures (performed in the Laboratory 
of Virology and Chemotherapy (Rega Institute, K.U.Leuven)) (Tables IV.1-IV.3). The activities of the 
compounds were compared with reference antiviral drugs: brivudin, cidofovir, acyclovir and 
ganciclovir.  
 
Table IV.1. Antiviral activity and cytotoxicity of 5-modified 2’-deoxyuridine phosphonate analogues against HSV-1, 
HSV-2, VV, VSV and HSV-1 TK- in HEL cell cultures.  
 
Compound 
EC50a (μM) 
MCCb (μM) HSV-1 
(KOS) 
HSV-2 (G) VV VSV 
HSV-1 TK- 
(KOS ACVr) 
4.37 > 100 > 100 > 100 > 100 > 100 > 100 
4.38 > 100 > 100 > 100 > 100 > 100 > 100 
4.39 > 100 > 100 > 100 > 100 > 100 > 100 
4.40 > 100 > 100 > 100 > 100 > 100 > 100 
4.41 > 100 > 100 > 100 > 100 > 100 > 100 
4.42 > 100 > 100 > 100 > 100 > 100 > 100 
4.43 > 100 > 100 > 100 > 100 > 100 > 100 
4.44 > 100 > 100 > 100 > 100 > 100 > 100 
Brivudin 0.4 250 10 > 250 250 > 250 
Cidofovir 2 1 10 > 250 2 > 250 
Acyclovir 0.2 0.2 > 250 > 250 112 > 250 
Ganciclovir 0.01 0.01 > 100 > 100 20 > 100 
a50%-Effective concentration or compound concentration required to reduce virus-induced cytopathogenicity by 
50%. 
bMinimum cytotoxic concentration or compound concentration required to cause a microscopically detectable 
alteration of normal cell morphology. 
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Table IV.2. Antiviral activity and cytotoxicity of 5-modified 2’-deoxyuridine phosphonate analogues against 
different HCMV and VZV strains in HEL cell cultures.  
 
Compound 
EC50a (μM)  Cytotoxicity (μM) 
HCMV AD-
169 
HCMV 
Davis 
VZV OKA 
VZV TK- 
07/1 
 Cell 
morphologyb 
(MCC) 
Cell 
growthc 
(CC50) 
4.37 > 100 > 100 > 100 > 100 
 
> 100  
4.38 45 45 100 100 
 
> 100 > 100 
4.39 > 20 41 > 20 > 20 
 
≥ 100 > 100 
4.40 55 63 > 100 > 100 
 
> 100 100 
4.41 > 100 > 100 > 100 > 100 
 
> 100  
4.42 45 > 20 100 100 
 
≥ 100 > 100 
4.43 > 100 > 100 > 100 > 100 
 
> 100  
4.44 > 100 > 100 > 100 > 100 
 
> 100  
Acyclovir   1.3 37 
 
> 440  
Brivudin   0.026 12 
 
> 300  
Ganciclovir 7.9 7.0   
 
≥ 394 141 
Cidofovir 0.67 0.95   
 
≥ 317 63 
aEffective concentration required to reduce virus-induced cytopathicity by 50%. Virus input was 100 plaque 
forming units (PFU). 
bMinimum cytotoxic concentration or compound concentration that caused a microscopically detectable alteration 
of cell morphology. 
c50%-Cytotoxic concentration or compound concentration required to reduce cell growth by 50%. 
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Table IV.3. Antiviral activity of 5-modified 2’-deoxyuridine phosphonate analogues in human T-lymphocyte (CEM) 
cell cultures. 
  
Compound 
EC50a(μM) 
CC50b (μM) 
HIV-1 HIV-2 
4.37 > 250 > 250 > 250 
4.38 > 50 > 50 > 250 
4.39 > 50 > 50 > 250 
4.40 > 50 > 50 > 250 
4.41 > 50 > 50 > 250 
4.42 > 50 > 50 > 250 
4.43 > 50 ≥ 50 > 250 
4.44 >50 > 50 > 250 
aEC50 = effective concentration or compound concentration required to protect CEM cells  
against the cytopathogenicity of HIV by 50% 
bCC50 = 50%-cytostatic concentration for the proliferation on T-lymphocyte CEM cells 
 
None of the tested compounds showed toxicity to any of the tested cell lines. However, the final 
compounds 4.37-4.40 and 4.41-4.44 failed to show antiviral activity against HSV-1, HSV-2, VV, VSV, 
HSV-1 TK- and different VZV strains (Tables IV.1 and IV.2). Also in the human T-lymphocyte (CEM) 
cell cultures (Table IV.3), none of these compounds showed activity against HIV-1 or HIV-2. Very 
weak antiviral activity was observed for the β-analogue 4.39 and the α-analogue 4.42 against HCMV 
Davies and HCMV AD-169, respectively, while compounds 4.38 and 4.40, showed weak antiviral 
activity against both HCMV strains. The most active compound of this series, analogue 4.38, was at 
least 6 or 50 times less active than ganciclovir and cidofovir, respectively.  
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2.5 CONCLUSIONS 
This chapter described the synthesis, stereochemical assignment and antiviral activity of a small 
series of 2’-deoxyuridine analogues that combined different aromatic substituents at position 5 of the 
base with a 5’-methylene phosphonate modification at the sugar moiety. All compounds were 
synthesized via an 8-step procedure, featuring a Wittig reaction and Suzuki-Miyaura coupling. An 
unexpected anomerisation during the last step of the synthesis allowed us to investigate the β- as well 
as the α-anomers of the corresponding phosphonates. None of these analogues exhibited significant 
antiviral activity. 
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2.6 EXPERIMENTAL PART 
2.6.1 Synthesis 
3’,5’-Di-O-tert-butyldimethylsilyl-2’-deoxy-β-D-uridine (4.19) 
 
O N
TBDMSO
TBDMSO
NH
O
O
 
 
2’-Deoxyuridine (5.64 g, 24.72 mmol) was dissolved in dry DMF (50 mL). Imidazole (7.41 g, 108.77 
mmol) and tert-butyldimethylsilyl chloride (9.32 g, 61.8 mmol) were added with stirring. After 20 h at rt, 
TLC in CH2C2/MeOH (95:5) showed a single spot. DMF was removed in vacuo and the residue was 
dissolved in CH2Cl2. The mixture was washed with a sat. aq. NaHCO3 solution, followed by brine. The 
organic layer was dried over MgSO4 and filtered. After evaporation, no further purification was needed 
to obtain pure compound 4.19 as a white foam (11.72 g, 100%). 
 
1H NMR (300 MHz, DMSO-d6): δ 0.071-0.092 (12H, m, 2 x TBDMS), 0.86-0.89 (18H, m, 2 x TBDMS), 
2.08-2.28 (2H, m, H-2’a and H-2’b), 3.67-3.81 (3H, m, H-4’, H-5’a and H-5’b), 4.35-4.39 (1H, m, H-3’), 
5.58 (1H, d, J= 8.1 Hz, CH=CH), 6.13 (1H, t, J= 6.6 Hz, H-1’), 7.28 (1H, d, J= 8.1 Hz, CH=CH), 11.33 
(1H, s, 3-NH).  
 
13C NMR (75 MHz, DMSO-d6): δ -5.58, -4.98 and -4.77 (TBDMS), 17.98 (TBDMS), 25.66 and 25.75 
(TBDMS), 62.36 (C-5’), 71.43 (C-3’), 84.05 (C-1’), 86.67 (C-4’), 101.70 (C-5), 140.20 (C-6), 150.36 (C-
2), 163.04 (C-4).   
 
Exact mass (ESI-MS) for C21H41N2O5Si2 [M+H]+ found, 457.2747 ; calcd, 457.2549. 
 
3’-O-tert-Butyldimethylsilyl-2’-deoxy-β-D-uridine (4.20) 
 
O N
HO
TBDMSO
NH
O
O
 
 
In a 250 mL polyethylene vial, compound 4.19 (1.41 g, 3.09 mmol) was dissolved in THF (32 mL). The 
vial was cooled to 0 °C and hydrogen fluoride-pyridine complex buffered with pyridine (19 mL of a 
stock solution made from 5 mL of pyridine, 12.5 mL of THF and 4.5 mL of hydrogen fluoride-pyridine) 
was added. The reaction mixture was stirred at 0 °C for 1 h and another hour at rt. Then it was 
carefully poured into a sat. NaHCO3 solution. The organic layer was separated and the aqueous layer 
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was extracted with EtOAc. The combined organic extracts were dried over MgSO4, filtered and 
concentrated. The crude residue was purified by flash chromatography over silica gel (CH2Cl2/MeOH 
97:3) to give 455 mg of compound 4.20 (white solid, 43%). 
 
1H NMR (300 MHz, DMSO-d6): δ 0.081 (6H, s, TBDMS), 0.87 (9H, s, TBDMS), 2.04-2.21 (2H, m, H-
2’a and H-2’b), 3.54 (2H, dd, J= 4.2 Hz, J= 9.0 Hz, H-5’a and H-5’b), 3.76 (1H, dd, J= 3.6 Hz, J= 6.6 
Hz, H-4’), 4.39-4.43 (1H, m, H-3’), 5.06 (1H, t, J= 5.4 Hz, 5’-OH), 5.63 (1H, d, J= 7.8 Hz, CH=CH), 
6.14 (1H, t, J= 7.5 Hz, H-1’), 7.81 (1H, d, J= 7.8 Hz, CH=CH), 11.29 (1H, s, 3-NH). 
 
13C NMR (75 MHz, DMSO-d6): δ -4.98 and -4.82 (TBDMS), 17.70 (TBDMS), 25.68 (TBDMS), 60.87 
(C-5’), 72.03 (C-3’), 83.98 (C-1’), 87.42 (C-4’), 101.86 (C-5), 147 (C-6), 150.48 (C-2), 163.35 (C-4).  
 
Exact mass (ESI-MS) for C15H27N2O5Si [M+H]+ found, 343.1707; calcd, 343.1684. 
 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-ribo-hex-5-
enofuranosyl]uracil (4.21) 
O N
TBDMSO
NH
O
P
O
EtO
EtO
O
 
 
IBX (550 mg, 1.97 mmol) was added to a solution of 4.20 (449 mg, 1.31 mmol) in CH3CN (12 mL) and 
the resulted suspension was stirred at 80 °C for 6 h. After cooling in an ice bath (15 min), the solid was 
removed by filtration and washed with cold CH3CN. The solvent was evaporated and the residue was 
co-distilled with toluene. The residue was dissolved in anhydrous DMSO (3.4 mL) and freshly 
prepared 3.72 in DMSO (3.4 mL) was added. After 20 h, the mixture was poured into water and 
extracted with CH2Cl2. The combined organic layers were dried over MgSO4, filtered and concentrated 
in vacuo. The residue was lyophilized to remove the remaining DMSO and purified on a silica gel 
column (CH2Cl2/MeOH 98:2) yielding 257 mg (41%) of 4.21 as a colourless solid. 
 
1H NMR (300 MHz, DMSO-d6): δ 0.070 (6H, s, TBDMS), 0.87 (9H, s, TBDMS), 1.23 (6H, app dt, J= 
1.5 Hz, J= 6.9 Hz, 2 x OCH2CH3), 2.13-2.22 (1H, m, H-2’a), 2.34-2.43 (1H, m, H-2’b), 3.92-4.03 (4H, 
m, 2 x OCH2CH3), 4.20-4.25 (1H, m, H-4’), 4.38-4.45 (1H, m, H-3’), 5.64 (1H, d, J= 7.8 Hz, CH=CH), 
5.96-6.09 (1H, m, H-6’), 6.16 (1H, dd, J= 6.0 Hz, J= 7.5 Hz, H-1’), 6.60-6.75 (1H, m, H-5’), 7.68 (1H, d, 
J= 8.4 Hz, CH=CH), 11.34 (1H, s, 3-NH). 
 
31P NMR (DMSO-d6): δ 17.21. 
 
13C NMR (75 MHz, DMSO-d6): δ -5.02 and -4.87 (TBDMS), 16.10 and 16.18 (2 x OCH2CH3), 17.60 
(TBDMS), 25.57 (TBDMS), 61.21 and 61.31 (2 x OCH2CH3), 74.36 (C-3’), 84.27 and 85.27 (C-1’ and 
C-4’), 102.07 (C-5), 118.48 (C-6’), 141.38 (C-6), 147.81 (C-5’), 150.29 (C-2), 162.98 (C-4). 
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Exact mass (ESI-MS) for C20H36N2O7PSi [M+H]+ found, 475.2035; calcd, 475.2024. 
 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]-
uracil (4.22) 
O N
TBDMSO
NH
O
P
O
EtO
EtO
O
 
 
To a solution of compound 4.21 (257 mg, 0.54 mmol) in MeOH (8 mL) was added 10% Pd/C. The 
reaction mixture was stirred under hydrogen atmosphere overnight. The catalyst was removed by 
filtration through Celite and the filtrate was evaporated to yield pure compound 4.22 (250 mg, 97%) as 
a colourless solid. 
 
1H NMR (300 MHz, DMSO-d6): δ 0.084 (6H, app d, J= 2.4 Hz, TBDMS), 0.87 (9H, s, TBDMS), 1.22 
(6H, t, J= 6.9 Hz, 2 x OCH2CH3), 1.65-1.86 (4H, m, H-5’a, H-5’b, H-6’a and H-6’b), 2.00-2.15 (1H, m, 
H-2’a), 2.22-2.31 (1H, m, H-2’b), 3.68-3.72 (1H, m, H-3’), 3.92-4.04 (4H, m, 2 x OCH2CH3), 4.23-4.29 
(1H, m, H-4’), 5.62 (1H, d, J= 8.1 Hz, CH=CH), 6.10 (1H, t, J= 6.6 Hz, H-1’), 7.59 (1H, d, J= 8.4 Hz, 
CH=CH), 11.32 (1H, s, 3-NH). 
 
31P NMR (DMSO-d6): δ 31.72. 
 
13C NMR (75 MHz, DMSO-d6): δ -5.04, -4.99 and -4.73 (TBDMS), 16.21 and 16.28 (2 x OCH2CH3), 
17.58 (TBDMS), 20.04 (C-6’), 21.90 (C-5’), 25.61 and 25.77 (TBDMS), 60.90 and 60.97 (2 x 
OCH2CH3), 73.84 (C-3’), 83.61 and 84.95 (C-1’ and C-4’), 102.10 (C-5), 141.03 (C-6), 150.40 (C-2), 
163.11 (C-4).   
 
Exact mass (ESI-MS) for C20H38N2O7PSi [M+H]+ found, 477.2119; calcd, 477.2180. 
 
1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]uracil (4.23) 
 
O N
HO
NH
O
P
O
EtO
EtO
O
 
 
Compound 4.22 (309 mg, 0.65 mmol) was dissolved in 4.1 mL THF and a TBAF solution in THF (1M, 
1.44 mL, 1.44 mmol) was added at rt. After stirring for 3 h the reaction mixture was evaporated in 
vacuo and poured on a silica column (CH2Cl2/MeOH 92:8) to give compound 4.23 (162 mg, 69%) as a 
colourless solid. 
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1H NMR (300 MHz, DMSO-d6): δ 1.23 (6H, t, J= 6.9 Hz, 2 x OCH2CH3), 1.68-1.82 (4H, m, H-5’a, H-
5’b, H-6’a and H-6’b), 2.04-2.24 (2H, m, H-2’a and H-2”), 3.66-3.68 (1H, m, H-4’), 3.92-4.08 (5H, m, 2 
x OCH2CH3 and H-3’), 5.30 (1H, d, J= 4.5 Hz, 3’-OH), 5.63 (1H, d, J= 8.7 Hz, CH=CH), 6.10 (1H, t, J= 
6.6 Hz, H-1’), 7.58 (1H, d, J= 7.8 Hz, CH=CH), 11.31 (1H, s, 3-NH). 
 
31P NMR (DMSO-d6): δ 31.89. 
 
13C NMR (75 MHz, DMSO-d6): δ 16.26 and 16.33 (2 x OCH2CH3), 20.14 (C-6’), 22.00 (C-5’), 60.89 
and 61.00 (2 x OCH2CH3), 72.52 (C-3’), 83.65 and 85.43 (C-1’ and C-4’), 102.08 (C-5), 140.79 (C-6), 
150.45 (C-2), 163.10 (C-4).   
 
Exact mass (ESI-MS) for C14H24N2O7P [M+H]+ found, 363.1308; calcd, 363.1316. 
 
1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]uracil (4.24) and 1-[2,5,6-
trideoxy-6-(dihydroxyphosphinyl)-α-D-ribo-hexofuranosyl]uracil (4.25) 
 
O N
HO
NH
O
P
O
HO
HO
4.24
O
HO
P
O
HO
HO
4.25
N NH
O
O
O
 
 
1st Method: To a solution of 4.23 (40 mg, 0.11 mmol) in CH2Cl2 (1.6 mL) was added TMSBr (29 μL, 
0.22 mmol). After stirring overnight, the volatiles were removed in vacuo. The residue was dissolved in 
water, washed with EtOAc/Et2O (1:1) and lyophilized. A 2:3 mixture of compounds 4.24 and 4.25 (25 
mg, 65%) was obtained as a yellow powder. 
 
2nd Method: To a solution of 4.22 (27 mg, 0.062 mmol) in CH2Cl2 (0.9 mL) was added TMSBr (16 μL, 
0.12 mmol). After stirring overnight, the volatiles were removed in vacuo. The residue was dissolved in 
water, washed with EtOAc/Et2O (1:1) and lyophilized. A 2:3 mixture of compounds 4.24 and 4.25 (4.1 
mg, 22%) was obtained as a yellow powder. 
 
1H NMR (300 MHz, D2O): δ 1.48-1.91 (4.4H, m, H-5’a, H-5’b, H-6’a, H-6’b and minor isomer H-2’a), 
2.12-2.17 (0.6H, major isomer, m, H-2’b), 2.34-2.38 (0.6H, major isomer, m, H-2’a), 2.72-2.80 (0.4 H, 
minor isomer, m, H-2’b), 3.94-4.00 (0.4H, minor isomer, m, H-3’), 4.31-4.37 (1.6H, m, major isomer H-
3’ and H-4’), 5.85 (0.6H, major isomer, d, J= 7.8 Hz, CH=CH), 5.89 (0.4H, minor isomer, d, J= 8.1 Hz, 
CH=CH), 6.15 (0.6H, major isomer, dd, J= 2.7 Hz, J= 7.5 Hz, H-1’), 6.25 (0.4H, minor isomer, app t, J= 
6.9 Hz, H-1’), 7.73 (0.4H, minor isomer, d, J= 8.4 Hz, CH=CH), 7.93 (0.6H, major isomer, d, J= 8.1 Hz, 
CH=CH).   
 
31P NMR (DMSO-d6): δ 23.63. 
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13C NMR (75 MHz, DMSO-d6): δ 24.65 (major isomer, C-6’), 26.40 (minor isomer, C-6’), 28.06 (major 
isomer, C-5’) 28.25 (minor isomer, C-5’), 72.72 (major isomer, C-3’), 72.86 (minor isomer, C-3’), 83.86, 
85.25, 89.00 and 89.14 (C-1’ and C-4’), 101.13 (major isomer, C-5), 102.33 (minor isomer, C-5), 
140.64 (minor isomer, C-6), 141.67 (major isomer, C-6), 150.62 (minor isomer, C-2), 150.74 (major 
isomer, C-2), 163.29 (minor isomer, C-4), 163.56 (major isomer, C-4).  
 
Exact mass (ESI-MS) for C10H14N2O7P [M-H]- found, 305.0539; calcd, 305.0544. 
 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-
bromouracil (4.26) 
O N
TBDMSO
NH
O
P
O
EtO
EtO
O
Br
 
 
To a solution of compound 4.22 (950 mg, 1.99 mmol) in DMF (15 mL) was added N-bromosuccinimide 
(NBS, 390 mg, 2.19 mmol) under N2. The reaction mixture was stirred at room temperature for 16 
hours. DMF was removed in vacuo and the residue was purified by column chromatography 
(CH2Cl2/MeOH 97:3) to afford 4.26 (538 mg, 49%) as a white foam. 
 
1H NMR (300 MHz, CDCl3): δ 0.082 (6H, app d, J= 1.8 Hz, TBDMS), 0.89 (9H, s, TBDMS), 1.34 (6H, t, 
J= 6.9 Hz, 2 x OCH2CH3), 1.82-2.02 (4H, m, H-5’a, H-5’b, H-6’a and H-6’b), 2.09-2.16 (1H, m, H-2’a), 
2.29-2.32 (1H, m, H-2’b), 3.81-3.84 (1H, m, H-4’), 4.07-4.19 (5H, m, 2 x OCH2CH3, H-3’), 6.13 (1H, t, 
J= 6.3 Hz, H-1’), 7.65 (1H, s, H-6), 9.83 (1H, s, 3-NH). 
 
31P NMR (CDCl3): δ 30.90. 
 
13C NMR (75 MHz, CDCl3): δ -4.83 and -4.56 (TBDMS), 16.46 and 16.54 (2 x OCH2CH3), 17.89 
(TBDMS), 21.38 (C-6’), 23.28 (C-5’), 25.68 (TBDMS), 40.85 (C-2’), 61.80 and 61.83 (2 x OCH2CH3), 
74.50 (C-3’), 85.57 C-1’), 86.53 (C-4’, d, J= 17.0 Hz), 97.10 (C-5), 139.01 (C-6), 149.47 (C-2), 159.03 
(C-4).  
 
Exact mass (ESI-MS) for C20H37BrN2O7PSi [M+H]+ found, 555.1323; calcd, 555.1286. 
 
General procedure for the synthesis of 5-modified nucleoside phosphonates via Suzuki-
Miyaura coupling  
 
A mixture of compound 4.26 (1 equiv.), aryl boronic acid (2 equiv.), Pd(PPh3)4 (0.1 equiv.) and Na2CO3 
(3.3 equiv.) in DMF and degassed H2O was heated (± 130 °C, oil bath) under argon for 6 h or until 
TLC indicated consumption of all starting material. The mixture was then concentrated and co-distilled 
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with toluene. The residue was purified by column chromatography (CH2Cl2/MeOH 94:6-98:2) affording 
the 5-modified analogues in moderate yield. 
 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-
phenyluracil (4.27) 
O N
TBDMSO
NH
O
P
O
EtO
EtO
O
 
 
Reaction of compound 4.26 (153 mg, 0.27 mmol) with phenylboronic acid (68 mg, 0.55 mmol), 
Pd(PPh3)4 (32 mg, 0.027 mmol) and Na2CO3 (96 mg, 0.91 mmol) in DMF (6.5 mL) and degassed H2O 
(0.8 mL) was performed as described in the general procedure to yield compound 4.27 as a colourless 
solid (120 mg, 79%). 
 
1H NMR (300 MHz, CDCl3): δ 0.084 (6H, s, TBDMS), 0.90 (9H, s, TBDMS), 1.25-1.32 (6H, m, 2 x 
OCH2CH3), 1.73-2.04 (4H, m, H-5’a, H-5’b, H-6’a and H-6’b), 2.11-2.20 (1H, m, H-2’a), 2.31-2.39 (1H, 
m, H-2’b), 3.83-3.86 (1H, m, H-4’), 4.00-4.11 (5H, m, 2 x OCH2CH3 and H-3’), 6.23 (1H, app t, J= 6.6 
Hz, H-1’), 7.33-7.71 (6H, m, Ph and H-6). 
 
31P NMR (CDCl3): δ 30.69. 
 
13C NMR (75 MHz, CDCl3): δ -4.73 and -4.46 (TBDMS), 16.48 and 16.56 (2 x OCH2CH3), 18.00 
(TBDMS), 21.44 (C-6’), 23.34 (C-5’), 25.80 (TBDMS), 40.67 (C-2’), 61.86 and 61.94 (2 x OCH2CH3), 
74.75 (C-3’), 85.30 (C-1’), 86.42 (C-4’, d, J= 17.0 Hz), 115.67 (C-5), 128.07-133.10 (Ph), 136.95 (C-6), 
150.02 (C-2), 162.39 (C-4). 
 
Exact mass (ESI-MS) for C26H42N2O7PSi [M+H]+ found, 553.2485; calcd, 553.2493. 
 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-
(naphthalen-1-yl)uracil (4.28) 
O N
TBDMSO
NH
O
P
O
EtO
EtO
O
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Reaction of compound 4.26 (122 mg, 0.22 mmol) with naphthalene-1-boronic acid (75 mg, 0.44 
mmol), Pd(PPh3)4 (25 mg, 0.022 mmol) and Na2CO3 (77 mg, 0.72 mmol) in DMF (5 mL) and degassed 
H2O (0.7 mL) was performed as described in the general procedure to afford compound 4.28 as a 
colourless solid (120 mg, 91%). 
 
1H NMR (300 MHz, CDCl3): δ 0.056 (6H, s, TBDMS), 0.87 (9H, s, TBDMS), 1.15-1.24 (6H, m, 2 x 
OCH2CH3), 1.77-2.03 (4H, m, H-5’a, H-5’b, H-6’a and H-6’b), 2.12-2.18 (1H, m, H-2’a), 2.26-2.31 (1H, 
m, H-2’b), 3.82 (1H, app s, H-4’), 3.95-4.13 (5H, m, 2 x OCH2CH3 and H-3’), 6.24 (1H, app t, J= 6.6 
Hz, H-1’), 7.42-7.82 (7H, m, naphthalene), 7.98 (1H, s, H-6), 8.43 (1H, s, 3-NH). 
 
31P NMR (CDCl3): δ 30.95. 
 
13C NMR (75 MHz, CDCl3): δ -4.87 and -4.62 (TBDMS), 16.28 and 16.36 (2 x OCH2CH3), 17.85 
(TBDMS), 21.31 (C-6’), 23.21 (C-5’), 25.65 (TBDMS), 40.50 (C-2’), 61.63 and 61.71 (2 x OCH2CH3), 
74.63 (C-3’), 85.26 (C-1’), 86.29 (C-4’, d, J= 17.0 Hz), 115.45 (C-5), 125.89-133.22 (naphthalene), 
136.91 (C-6), 149.88 (C-2), 162.26 (C-4).  
 
Exact mass (ESI-MS) for C30H44FN2O7PSi [M+H]+ found, 571.2430; calcd, 603.2650. 
 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-
(4-fluorophenyl)uracil (4.29) 
O N
TBDMSO
NH
O
P
O
EtO
EtO
O
F
 
 
Reaction of compound 4.26 (163 mg, 0.29 mmol) with 4-fluorophenylboronic acid (82 mg, 0.59 mmol), 
Pd(PPh3)4 (34 mg, 0.029 mmol) and Na2CO3 (102 mg, 0.97 mmol) in DMF (7 mL) and degassed H2O 
(0.9 mL) was performed as described in the general procedure to yield compound 4.29 as a colourless 
solid (141 mg, 84%). 
 
1H NMR (300 MHz, CDCl3): δ 0.010 (6H, s, TBDMS), 0.80-0.84 (9H, m, TBDMS), 1.21 (6H, app q, J= 
7.2 Hz, 2 x OCH2CH3), 1.68-1.94 (4H, m, H-5’a, H-5’b, H-6’a and H-6’b), 2.02-2.11 (1H, m, H-2’a), 
2.23-2.31 (1H, m, H-2’b), 3.74-3.78 (1H, m, H-4’), 3.93-4.02 (5H, m, 2 x OCH2CH3 and H-3’), 6.14 (1H, 
app t, J= 6.9 Hz, H-1’), 6.99-7.04 (2H, m, subs Ph), 7.34-7.42 (3H, m, subs Ph and H-6), 8.25 (1H, s, 
3-NH). 
 
31P NMR (CDCl3): δ 30.74. 
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13C NMR (75 MHz, CDCl3): δ -4.41 and -4.14 (TBDMS), 16.83 and 16.91 (2 x OCH2CH3), 18.33 
(TBDMS), 21.79 (C-6’), 23.69 (C-5’), 26.09 (TBDMS), 41.14 (C-2’), 62.07 and 62.19 (2 x OCH2CH3), 
75.07 (C-3’), 85.78 (C-1’), 86.73 (C-4’, d, J= 17.0 Hz), 115.19 (C-5), 128.61-132.59 (subs Ph), 136.93 
(C-6), 149.74 (C-2), 161.91 (C-4).  
 
Exact mass (ESI-MS) for C26H41FN2O7PSi [M+H]+ found, 571.2430; calcd, 571.2399. 
 
1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-
(furan-2-yl)uracil (4.30) 
O N
TBDMSO
NH
O
P
O
EtO
EtO
O
O
 
 
Reaction of compound 4.26 (47 mg, 0.085 mmol) with furan-2-boronic acid (20 mg, 0.18 mmol), 
Pd(PPh3)4 (10 mg, 0.0085 mmol) and Na2CO3 (30 mg, 0.28 mmol) in DMF (2 mL) and degassed H2O 
(0.3 mL) was performed as described in the general procedure to afford compound 4.30 as a 
colourless solid (36 mg, 77%). 
 
1H NMR (300 MHz, CDCl3): δ 0.0080 (6H, s, TBDMS), 0.80-0.84 (9H, m, TBDMS), 1.23 (6H, app dt, 
J= 2.1 Hz, J= 6.9 Hz, 2 x OCH2CH3), 1.73-1.99 (4H, m, H-5’a, H-5’b, H-6’a and H-6’b), 2.04-2.13 (1H, 
m, H-2’a), 2.23-2.31 (1H, m, H-2’b), 3.76-3.78 (1H, m, H-4’), 3.97-4.09 (5H, m, 2 x OCH2CH3 and H-
3’), 6.16 (1H, app t, J= 6.6 Hz, H-1’), 6.36 (1H, dd, J= 2.1 Hz, J= 3.6 Hz, furan), 6.97 (1H, d, J= 3.6 Hz, 
furan), 7.28 (1H, d, J= 1.2 Hz, furan), 7.71 (1H, s, H-6). 
 
31P NMR (CDCl3): δ 30.92. 
 
13C NMR (75 MHz, CDCl3): δ -4.71 and -4.44 (TBDMS), 16.53 and 16.61 (2 x OCH2CH3), 18.02 
(TBDMS), 21.49 (C-6’), 23.38 (C-5’), 25.81 (TBDMS), 40.97 (C-2’), 61.75 and 61.88 (2 x OCH2CH3), 
74.66 (C-3’), 85.43 (C-1’), 86.55 (C-4’, J= 16.8 Hz), 107.39, 109.50 and 111.97 (C-5 and furan), 
133.13 (C-6), 141.34 (furan), 145.86 (furan), 149.35 (C-2), 160.11 (C-6).  
 
Exact mass (ESI-MS) for C24H40N2O8PSi [M+H]+ found, 571.2275; calcd, 543.2286. 
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1-[3-O-tert-Butyldimethylsilyl-2,5,6-trideoxy-6-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-
(thiophen-2-yl)uracil (4.31) 
O N
TBDMSO
NH
O
P
O
EtO
EtO
O
S
 
 
Reaction of compound 4.26 (155 mg, 0.28 mmol) with thiophene-2-boronic acid (71 mg, 0.56 mmol), 
Pd(PPh3)4 (32 mg, 0.028 mmol) and Na2CO3 (98 mg, 0.92 mmol) in DMF (6.7 mL) and degassed H2O 
(0.8 mL) was performed as described in the general procedure to yield compound 4.31 as a colourless 
solid (117 mg, 75%). 
 
1H NMR (300 MHz, CDCl3): δ 0.090 (6H, s, TBDMS), 0.90 (9H, s, TBDMS), 1.26-1.37 (6H, m, 2 x 
OCH2CH3), 1.83-2.08 (4H, m, H-5’a, H-5’b, H-6’a and H-6’b), 2.14-2.23 (1H, m, H-2’a), 2.32-2.40 (1H, 
m, H-2’b), 3.85-3.90 (1H, m, H-4’), 4.06-4.18 (5H, m, 2 x OCH2CH3 and H-3’), 6.23 (1H, app t, J= 6.3 
Hz, H-1’), 7.01-7.04 (1H, m, thiophene), 7.25-7.29 (1H, m, thiophene), 7.39-7.44 (1H, m, thiophene), 
7.69 (1H, s, H-6), 9.97 (1H, s, 3-NH). 
 
31P NMR (CDCl3): δ 30.80. 
 
13C NMR (75 MHz, CDCl3): δ -4.77 and -4.50 (TBDMS), 16.48 and 16.56 (2 x OCH2CH3), 17.95 
(TBDMS), 21.46 (C-6’), 23.36 (C-5’), 25.74 (TBDMS), 40.91 (C-2’), 61.79 and 61.86 (2 x OCH2CH3), 
74.64 (C-3’), 85.62 (C-1’), 86.55 (C-4’, d, J= 16.8 Hz), 110.20 (C-5), 124.42, 125.37, 127.10 and 
133.63 (thiophene), 134.32 (C-6), 149.39 (C-2), 161.27 (C-4).  
  
Exact mass (ESI-MS) for C24H40N2O7PSSi [M+H]+ found, 559.2058; calcd, 559.2058. 
 
1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-phenyluracil (4.32) 
 
O N
HO
NH
O
P
O
EtO
EtO
O
 
 
Compound 4.27 (115 mg, 0.21 mmol) was dissolved in THF (1.3 mL). A solution of 1 M TBAF in THF 
(0.46 mmol, 0.46 mL) was added. After stirring for 1 h at room temperature, the reaction was 
completed. The solvent was evaporated and the dry residue was purified by column chromatography 
(CH2Cl2/MeOH 96:4) to give pure compound 4.32 (65 mg, colourless solid) in 71% yield. 
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1H NMR (300 MHz, DMSO-d6): δ 1.18 (6H, dt, J= 1.8 Hz, J= 6.9 Hz, 2 x OCH2CH3), 1.75-1.83 (4H, m, 
H-5’a, H-5’b, H-6’a and H-6’b), 2.06-2.14 (1H, m, H-2’a), 2.36-2.51 (1H, m, H-2’b), 3.71-3.72 (1H, m, 
H-4’), 3.89-3.99 (4H, m, 2 x OCH2CH3), 4.06-4.12 (1H, m, H-3’), 5.29 (1H, d, J= 4.5 Hz, 3’-OH), 6.17 
(1H, t, J= 6.9 Hz, H-1’), 7.29-7.40 (3H, m, Ph), 7.51-7.54 (2H, m, Ph), 7.63 (1H, s, H-6). 
 
31P NMR (DMSO-d6): δ 31.80. 
 
13C NMR (75 MHz, DMSO-d6): δ 16.13 and 16.20 (2 x OCH2CH3), 20.17 (C-6’), 22.03 (C-5’), 60.93 
and 61.01 (2 x OCH2CH3), 72.80 (C-3’), 84.46 (C-1’), 85.74 (C-4’, d, J= 17.0 Hz), 113.07 (C-5), 
114.76, 115.04, 129.29, 129.34, 130.23 and 130.34 (Ph), 137.87 (C-6), 149.89 (C-6), 162.05 (C-4). 
 
Exact mass (ESI-MS) for C20H28N2O7P [M+H]+ found: 439.1639, calcd: 439.1686. 
 
1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(naphthalen-1-yl)uracil 
(4.33) 
 
O N
HO
NH
O
P
O
EtO
EtO
O
 
 
Compound 4.28 (120 mg, 0.20 mmol) was deprotected using the same procedure as described for the 
synthesis of compound 4.32. Compound 4.33 was obtained as a colourless solid in a 65% yield (63 
mg). 
 
1H NMR (300 MHz, CDCl3): δ 1.17-1.25 (6H, m, 2 x OCH2CH3), 1.77-2.02 (4H, m, H-5’a, H-5’b, H-6’a 
and H-6’b), 2.12-2.21 (1H, m, H-2’a), 2.40-2.53 (1H, m, H-2’b), 3.91-4.07 (5H, m, 2 x OCH2CH3 and H-
4’), 4.16-4.20 (1H, m, H-3’), 5.28 (1H, s, 3’-OH), 6.26 (1H, t, J= 6.6 Hz, H-1’), 7.40-7.46 (2H, m, 
naphthalene), 7.53-7.58 (2H, m, naphthalene), 7.75-7.84 (3H, m, naphthalene), 7.96 (1H, s, H-6). 
 
31P NMR (CDCl3): δ 31.46. 
 
13C NMR (75 MHz, CDCl3): δ 16.37 and 16.49 (2 x OCH2CH3), 21.07 (C-6’), 22.96 (C-5’), 40.06 (C-2’), 
61.99 and 62.06 (2 x OCH2CH3), 73.85 (C-3’), 85.43 (C-1’), 86.25 (C-4’, d, J= 16.2 Hz), 115.60 (C-5), 
126.03, 126.31, 126.36, 127.25, 127.62, 128.09, 128.30, 130.00, 132.88 and 133.34 (naphthalene), 
137.17 (C-6), 150.29 (C-6), 162.61 (C-4).  
 
Exact mass (ESI-MS) for C24H30N2O7P [M+H]+ found: 489.1814, calcd: 489.1785. 
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1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(4-fluorophenyl)uracil (4.34) 
 
O N
HO
NH
O
P
O
EtO
EtO
O
F
 
 
Compound 4.29 (135 mg, 0.24 mmol) was deprotected using the same procedure as described for the 
synthesis of compound 4.32. Compound 4.34 was obtained as a colourless solid in a 32% yield (35 
mg). 
 
1H NMR (300 MHz, DMSO-d6): δ 1.18 (6H, dt, J= 2.4 Hz, J= 6.9 Hz, 2 x OCH2CH3), 1.70-1.82 (4H, m, 
H-5’a, H-5’b, H-6’a and H-6’b), 2.05-2.13 (1H, m, H-2’a), 2.37-2.44 (1H, m, H-2’b), 3.70-3.71 (1H, m, 
H-4’), 3.89-3.99 (4H, m, 2 x OCH2CH3), 4.06-4.09 (1H, m, H-3’), 5.28 (1H, d, J= 4.5 Hz, 3’-OH), 6.16 
(1H, t, J= 7.2 Hz, H-1’), 7.17-7.23 (2H, m, subs Ph), 7.55-7.60 (2H, m, subs Ph), 7.64 (1H, s, H-6), 
11.53 (1H, s, 3-NH). 
 
31P NMR (DMSO-d6): δ 31.80. 
 
13C NMR (75 MHz, DMSO-d6): δ 16.22 and 16.30 (2 x OCH2CH3), 20.29 (C-6’), 22.15 (C-5’), 60.91 
and 61.03 (2 x OCH2CH3), 72.80 (C-3’), 84.61 (C-1’), 85.86 (C-4’, d, J= 16.7 Hz), 113.07 (C-5), 
114.76, 115.04, 129.29, 129.34, 130.23 and 130.34 (subs Ph), 137.87 (C-6), 149.89 (C-6), 162.05 (C-
4).  
 
Exact mass (ESI-MS) for C20H27FN2O7P [M+H]+ found, 457.1547; calcd, 457.1534. 
 
1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(furan-2-yl)uracil (4.35) 
 
O N
HO
NH
O
P
O
EtO
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O
O
 
 
Compound 4.30 (113 mg, 0.21 mmol) was deprotected using the same procedure as described for the 
synthesis of compound 4.32. Compound 4.35 was obtained as a colourless solid in a 42% yield (38 
mg). 
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1H NMR (300 MHz, CDCl3): δ 1.32 (6H, dt, J= 1.5 Hz, J= 6.9 Hz, 2 x OCH2CH3), 1.87-2.13 (4H, m, H-
5’a, H-5’b, H-6’a and H-6’b), 2.20-2.29 (1H, m, H-2’a), 2.46-2.54 (1H, m, H-2’b), 3.96-3.99 (1H, m, H-
4’), 4.05-4.18 (4H, m, 2 x OCH2CH3), 4.23-4.29 (1H, m, H-3’), 6.28 (1H, t, J= 6.3 Hz, H-1’), 6.43 (1H, 
dd, J= 1.8 Hz, J= 3.3 Hz, furan), 7.02 (1H, d, J= 3.6 Hz, furan), 7.34 (1H, d, J= 1.2 Hz, furan), 7.80 
(1H, s, H-6). 
 
31P NMR (CDCl3): δ 31.57. 
 
13C NMR (75 MHz, CDCl3): δ 16.72 and 16.80 (2 x OCH2CH3), 21.26 (C-6’), 23.15 (C-5’), 40.49 (C-2’), 
62.27 and 62.36 (2 x OCH2CH3), 74.02 (C-3’), 85.65 (C-1’), 86.55 (C-4’, d, J= 14.3 Hz), 107.60, 
109.65, 112.19 (furan and C-5), 133.51 (C-6), 141.49 (furan), 146.12 (furan), 149.88 (C-6), 160.54 (C-
4).  
 
Exact mass (ESI-MS) for C18H26N2O8P [M+H]+ found: 429.1421, calcd: 429.1421. 
 
1-[2,5,6-Trideoxy-6-(diethoxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(thiophen-2-yl)uracil (4.36)  
 
O N
HO
NH
O
P
O
EtO
EtO
O
S
 
 
Compound 4.31 (117 mg, 0.21 mmol) was deprotected using the same procedure as described for the 
synthesis of compound 4.32. Compound 4.36 was obtained as a colourless solid in a 63% yield (59 
mg). 
 
1H NMR (300 MHz, CDCl3): δ 1.31 (6H, app dt, J= 2.1 Hz, J= 6.9 Hz, 2 x OCH2CH3), 1.86-2.08 (4H, m, 
H-5’a, H-5’b, H-6’a and H-6’b), 2.18-2.27 (1H, m, H-2’a), 2.46-2.54 (1H, m, H-2’b), 3.97-3.98 (1H, m, 
H-4’), 4.04-4.15 (4H, m, 2 x OCH2CH3), 4.19-4.26 (1H, m, H-3’), 5.30 (1H, s, 3’-OH), 6.25 (1H, app t, 
J= 6.6 Hz, H-1’), 6.97-7.00 (1H, m, thiophene), 7.24 (1H, d, J= 4.8 Hz, thiophene), 7.36 (1H, d, J= 3.0 
Hz, thiophene), 7.69 (1H, s, H-6). 
 
31P NMR (CDCl3): δ 31.48. 
 
13C NMR (75 MHz, CDCl3): δ 16.50 and 16.58 (2 x OCH2CH3), 21.10 (C-6’), 23.00 (C-5’), 40.27 (C-2’), 
62.07 and 62.17 (2 x OCH2CH3), 73.80 (C-3’), 85.72 (C-1’), 86.40 (C-4’, d, J= 15.9 Hz), 110.19 (C-5), 
124.35, 125.45, 127.08 and 133.64 (thiophene), 134.55 (C-6), 149.77 (C-2), 161.52 (C-4).  
 
Exact mass (ESI-MS) for C18H26N2O7PS [M+H]+ found, 445.1210; calcd, 445.1193. 
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General procedure for the deprotection of 5-modified nucleoside phosphonates  
 
The phosphonic ester (1 equiv.) was dissolved in CH2Cl2 under argon. TMSBr (2 equiv.) was added 
and the resulting solution was stirred overnight. The solvent was evaporated and the residue dissolved 
in a mixture of EtOAc/Et2O (1:1) and water. The organic phase was washed with water and the water 
layers were combined and lyophilized. Purification of the crude using RP-HPLC (Phenomenex Luna 
C-18, H2O/0.1% HCOOH in CH3CN, 90:10 → 0:100 in 23 min, flow 17.5 mL/min) afforded 2 series of 
compounds: the α- (retention time ≥ 12 min) and β-isomer (retention time ≈ 10-11 min) of each 
phosphonate. 
 
1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-phenyluracil (4.37) and 1-
[2,5,6-trideoxy-6-(dihydroxyphosphinyl)-α-D-ribo-hexofuranosyl]-5-phenyluracil (4.41)  
 
Reaction of compound 4.32 (27 mg, 0.061 mmol) with TMSBr (16 μL, 0.12 mmol) in CH2Cl2 (0.9 mL) 
as described in the general procedure affording the β- (4.37, 0.9 mg, 4%) and α-isomer (4.41, 3.2 mg, 
14%) as white powders.  
 
Compound 4.37: 
O N
HO
NH
O
P
O
HO
HO
O
 
 
1H NMR (300 MHz, DMSO-d6): δ 1.52-1.55 (2H, m, H-6’a and H-6’b), 1.79-1.91 (2H, m, H-5’a and H-
5’b), 2.07-2.11 (1H, m, H-2’a), 2.29-2.38 (1H, m, H-2’b), 3.73 (1H, app s, H-4’), 4.06 (1H, app s, H-3’), 
6.14 (1H, t, J= 6.6 Hz, H-1’), 7.27-7.40 (3H, m, Ph), 7.51-7.54 (2H, m, Ph), 7.63 (1H, s, H-6). 
 
31P NMR (DMSO-d6): δ 24.44. 
 
13C NMR (175 MHz, DMSO-d6): δ C-6’, C-5’ and C-2’ not visible, 72.78 (C-3’), 84.31 (C-1’), 86.69 (C-
4’, d, J= 19.3 Hz), 113.89 (C-5), 127.32, 128.11, 128.23 and 132.93 (Ph), 137.59 (C-6), 149.86 (C-6), 
162.08 (C-4).  
 
Exact mass (ESI-MS) for C16H18N2O7P [M-H]- found, 381.0836; calcd, 381.0857. 
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Compound 4.41: 
O
HO
P
O
HO
HO N NH
O
O
 
 
1H NMR (300 MHz, DMSO-d6): δ 1.49-1.57 (4H, m, H-5’a, H-5’b, H-6’a and H-6’b), 1.98 (1H, app d, J= 
14.1 Hz, H-2’a), 2.57-2.65 (1H, m, H-2’b), 4.11 (1H, app s, H-4’), 4.23 (H, app s, H-3’), 6.14 (1H, app 
d, J= 6.6 Hz, H-1’), 7.27-7.38 (3H, m, Ph), 7.51-7.54 (2H, m, Ph), 8.16 (1H, s, H-6). 
 
31P NMR (DMSO-d6): δ 23.62. 
 
13C NMR (75 MHz, DMSO-d6): δ C-6’, C-5’ and C-2’ not visible, 73.25 (C-3’), 86.00 (C-1’ and C-4’), 
113.32 (C-5), 128.50-134.13 (Ph), 139.88 (C-6), 150.71 (C-2), 162.88 (C-4).  
 
Exact mass (ESI-MS) for C16H18N2O7P [M-H]- found, 381.0851; calcd, 381.0857. 
 
1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(naphtalen-1-yl)uracil 
(4.38) and 1-[2,5,6-trideoxy-6-(dihydroxyphosphinyl)-α-D-ribo-hexofuranosyl]-5-(naphthalen-1-
yl)uracil (4.42)  
 
Reaction of compound 4.33 (63 mg, 0.13 mmol) with TMSBr (34 μL, 0.26 mmol) in CH2Cl2 (1.9 mL) as 
described in the general procedure affording the β- (4.38, 7.05 mg, 13%) and α-isomer (4.42, 8.77 mg, 
16%) as white powders. 
 
Compound 4.38: 
O N
HO
NH
O
P
O
HO
HO
O
 
 
1H NMR (300 MHz, DMSO-d6): δ 1.47 (2H, app br s, H-6’a and H-6’b), 1.80 (2H, app br s, H-5’a and 
H-5’b), 2.13 (1H, app br s, H-2’a), 2.27 (1H, app br s, H-2’b), 3.79 (1H, app s, H-4’), 4.09-4.14 (1H, m, 
H-3’), 6.14 (1H, app s, H-1’), 7.49-8.27 (8H, m, naphthalene and H-6). 
 
31P NMR (DMSO-d6): δ 20.97. 
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13C NMR (175 MHz, CDCl3): δ 22.59 (C-6’), 28.10 (C-5’), 39.40 (C-2’), 73.22 (C-3’), 84.41 (C-1’), 87.44 
(C-4’), C-5 not visible, 126.52, 127.63, 129.20, 126.84, 138.12 and 141.10 (naphthalene and C-6), (C-
2 and C-4 not visible). 
 
Exact mass (ESI-MS) for C20H20N2O7P [M-H]- found: 431.1041, calcd: 431.1014. 
 
Compound 4.42: 
O
HO
P
O
HO
HO N NH
O
O
 
 
1H NMR (300 MHz, DMSO-d6): δ 1.59 (4H, app br s, H-5’a, H-5’b, H-6’a and H-6’b), 1.99-2.06 (1H, m, 
H-2’a), 2.52-2.70 (1H, m, H-2’b), 4.13 (1H, app s, H-4’), 4.27 (1H, app s, H-3’), 6.18 (1H, app d, J= 5.7 
Hz, H-1’), 7.46-7.52 (2H, m, naphthalene), 7.66 (2H, d, J= 8.4 Hz, naphthalene), 7.88-7.91 (3H, m, 
naphthalene), 8.12 (1H, s, naphthalene), 8.31 (1H, s, H-6). 
 
31P NMR (DMSO-d6): δ 24.28. 
 
13C NMR (75 MHz, DMSO-d6): δ C-6’, C-5’ and C-2’ not visible, 72.61 (C-3’), 85.41 (C-1’ and C-4’), 
112.48 (C-5), 125.95-132.84 (naphthalene), 139.65 (C-6), 150.02 (C-2), 162.35 (C-4).  
 
Exact mass (ESI-MS) for C20H20N2O7P [M-H]- found: 431.1009, calcd: 431.1014. 
 
1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(4-fluorophenyl)uracil 
(4.39) and 1-[2,5,6-trideoxy-6-(dihydroxyphosphinyl)-α-D-ribo-hexofuranosyl]-5-(4-
fluorophenyl)uracil (4.43)  
 
Reaction of compound 4.34 (36 mg, 0.078 mmol) with TMSBr (21 μL, 0.16 mmol) in CH2Cl2 (1.0 mL) 
as described in the general affording the β- (4.39, 1.69 mg, 6%) and α-isomer (4.43, 3.19 mg, 12%) as 
white powders. 
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Compound 4.39: 
O N
HO
NH
O
P
O
HO
HO
O
F
 
 
1H NMR (300 MHz, DMSO-d6): δ 1.43 (2H, app br s, H-6’a and H-6’b), 1.76 (2H, app br s, H-5’a and 
H-5’b), 2.09 (1H, app br s, H-2’a), 2.28 (1H, app br s, H-2’b), H-4’ under H2O peak, 4.08 (1H, app s, H-
3’), 6.09 (1H, app s, H-1’), 7.21-7.62 (5H, m, subs Ph and H-6). 
31P NMR (DMSO-d6): δ 20.60. 
 
13C NMR (175 MHz, DMSO-d6): δ (C-6’, C-5’ and C-2’ not visible), 72.41 (C-3’), 84.25 (C-1’), 87.76 (C-
4’), 115.31 (C-5), 130.56 (subs Ph), (C-6, C-2 and C-4 not visible).  
 
Exact mass (ESI-MS) for C16H17FN2O7P [M-H]- found: 399.0762, calcd: 399.0763. 
 
Compound 4.43: 
O
HO
P
O
HO
HO N NH
O
O
F  
 
1H NMR (300 MHz, DMSO-d6): δ 1.44-1.58 (4H, m, H-5’a, H-5’b, H-6’a and H-6’b), 1.99 (1H, d, J= 
13.5 Hz, H-2’a), 2.52-2.65 (1H, m, H-2’b), 4.11 (1H, app s, H-4’), 4.20-4.25 (1H, m, H-3’), 6.12 (1H, 
app d, J= 6.9 Hz, H-1’), 7.19 (2H, app t, J= 8.7 Hz, subs Ph), 7.54-7.59 (2H, m, subs Ph), 8.15 (1H, s, 
H-6), 8.33 (1H, s, subs Ph). 
 
31P NMR (DMSO-d6): δ 22.19. 
 
13C NMR (75 MHz, DMSO-d6): δ (C-6’, C-5’ and C-2’ not visible), 72.22 (C-3’), 85.16 (C-1’), 111.49 (C-
5), 114.67, 114.96, 129,57 and 129.67 (subs Ph), 139.00 (C-6), 149.84 (C-2), 162.04 (C-4).  
 
Exact mass (ESI-MS) for C16H17FN2O7P [M-H]- found: 399.0743, calcd: 399.0763. 
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1-[2,5,6-Trideoxy-6-(dihydroxyphosphinyl)-β-D-ribo-hexofuranosyl]-5-(thiophen-2-yl)uracil (4.40) 
and 1-[2,5,6-trideoxy-6-(dihydroxyphosphinyl)-α-D-ribo-hexofuranosyl]-5-(thiophen-2-yl)uracil 
(4.44) 
 
Reaction of compound 4.36 (59 mg, 0.13 mmol) with TMSBr (35 μL, 0.27 mmol) in CH2Cl2 (2.0 mL) as 
described in the general procedure affording the β- (4.40, 5.2 mg, 10%) and α-isomer (4.44, 9.6 mg, 
19%) as white powders.  
 
Compound 4.40: 
O N
HO
NH
O
P
O
HO
HO
O
S
 
 
1H NMR (300 MHz, DMSO-d6): δ 1.50 (2H, app br s, H-6’a and H-6’b), 1.80 (2H, app br s, H-5’a and 
H-5’b), 2.04-2.12 (1H, m, H-2’a), 2.27-2.31 (1H, m, H-2’b), 3.80 (1H, app br s, H-4’), 4.09 (1H, app br 
s, H-3’), 6.10 (1H, d, J= 6.6 Hz, H-1’), 7.06 (1H, t, J= 4.8 Hz, thiophene), 7.45 (2H, app dd, J= 4.8 Hz, 
J= 14.4 Hz, thiophene), 7.89 (1H, s, H-6). 
 
31P NMR (DMSO-d6): δ 23.13. 
 
13C NMR (75 MHz, CDCl3): δ (C-6’, C-5’ and C-2’ not visible), 73.42 (C-3’), 85.35 (C-1’), 109.21 (C-5), 
123.93-134.26 (thiophene), 135.74 (C-6), 149.97 (C-2), 161.94 (C-4).   
 
Exact mass (ESI-MS) for C14H16N2O7PS [M-H]- found:387.0377, calcd: 387.0421. 
 
Compound 4.44: 
O
HO
P
O
HO
HO N NH
O
O
S
 
 
1H NMR (300 MHz, DMSO-d6): δ 1.40-1.72 (4H, m, H-5’a, H-5’b, H-6’a and H-6’b), 2.02 (1H, app d, J= 
14.4 Hz, H-2’a), 2.59-2.68 (1H, m, H-2’b), 4.13 (1H, app d, J= 4.8 Hz, H-3’), 4.27 (4H, app s, H-4’), 
6.16 (1H, app d, J= 5.7 Hz, H-1’), 7.04-7.07 (1H, dd, J= 3.6 Hz, J= 4.8 Hz, thiophene), 7.37-7.38 (1H, 
m, thiophene), 7.44-7.45 (1H, m, thiophene), 8.46 (1H, s, H-6). 
 
31P NMR (DMSO-d6): δ 25.63. 
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13C NMR (75 MHz, DMSO-d6): δ 23.39 (C-6’), 25.19 (C-5’), (C-2’ under DMSO peak), 72.59 (C-3’), 
85.51 (C-1’), 88.91 (C-4’), 107.71 (C-5), 122.58-134.28 (thiophene), 136.98 (C-6), 149.53 (C-2), 
161.87 (C-4).  
 
Exact mass (ESI-MS) for C14H16N2O7PS [M-H]- found: 387.0416, calcd: 387.0421. 
2.6.2 Experimental Assays 
Antiviral and Cytotoxicity Assays for Compounds 4.37-4.44 
 
The antiviral activity of the new compounds was determined using a cytopathogenicity assay against 
herpes simplex virus type 1 (HSV-1) (KOS strain), herpes simplex virus type 2 (HSV-2) (G strain), 
vaccinia virus, vesicular stomatitis virus, HSV-1 TK– KOS ACVr in HEL cell cultures. Stock solutions of 
the test compounds were prepared in DMSO at a concentration of 10 mg/mL. Cells, grown to 
confluency in 96-well plates, were infected with 100 CCID50 of virus, one CCID50 being the 50% cell 
culture infective dose in the presence of varying concentrations of the test compounds. Cultures were 
further incubated until complete cytopathogenicity was observed in the infected and untreated virus 
control. The cytotoxicity of the compounds was evaluated in parallel with their antiviral activity in 
uninfected cells and is expressed as the minimum cytotoxic concentration (MCC) that causes a 
microscopically detectable alteration of normal cell morphology. The symbol ‘‘>’’ is used to indicate the 
highest concentration at which the compounds were tested and found not to be antivirally active. 
 
For the anti-HCMV and anti-VZV assays, HEL fibroblasts were infected with 100 PFU per well. 
Compounds were added after a 1 h-incubation period, and the cells were further incubated at 37 °C. 
After 5 (VZV) and 7 days (HCMV) of incubation, plaques (VZV) or virus-induced cytopathogenicity 
(HCMV) was monitored microscopically after ethanol fixation and staining with Giemsa solution. The 
cytotoxicity of the compounds was evaluated in parallel with their antiviral activity in uninfected cells 
and is expressed as the minimum cytotoxic concentration that causes a microscopically detectable 
alteration of cell morphology (MCC) and the concentration required to reduce cell growth by 50% 
(CC50). 
 
Determination of the anti-HIV activity of the compounds was based on virus-induced cytopathogenicity 
of HIV-infected CEM cells, measured at day 4 to 5 post virus infection by the microscopically 
estimating virus-induced syncytia. Results are expressed as the 50% effective concentration (EC50) as 
reported in Table IV.3. The cytostatic activity of the compounds was evaluated in parallel with their 
antiviral activity in uninfected cell cultures and is expressed as the 50%-inhibitory concentration for the 
proliferation of the T-lymphocyte CEM cells (CC50). 
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GENERAL CONCLUSIONS 
Modification of naturally occurring nucleosides is an important strategy in the search for new agents 
with therapeutic potential. Structural modifications of either the base or sugar moiety of nucleosides 
may afford promising tool compounds interfering with many therapeutically interesting targets. Based 
on this principle, 3’-deoxy-3’-arylthiourea derivatives of thymidine were earlier discovered as highly 
active to and selective inhibitors of human mitochondrial thymidine kinase 2. We aimed at synthesizing 
3’-modified thymidine analogues in which the thiourea, known as a perpetrator of toxicity, was 
replaced with an alternative linker. Selected compounds, featuring a 1,2,3-triazole or an amino-
tetrazole moiety, proved very potent inhibitors of TK-2 with IC50 values in the nanomolar range (Figure 
IV). A main drawback of these compounds is their difficult uptake into the mitochondria. Therefore, 
further research should be focused on a better mitochondrial uptake rather than an increased 
inhibitory activity. Concerning this issue, it would be of interest to investigate the use of mitochondrial 
targeting peptides or the introduction of lipophilic positively charged conjugates which improved the 
mitochondrial uptake of other compounds in the past.230,231 
 
1.53: R = 4-chlorophenyl; IC50 = 46 nM
1.54: R = 3,4-dichlorophenyl; IC50 = 42 nM
O N
HO
N
NH
O
N
N
R
O
O N
HO
HN
NH
O
O
Br
N
N N
NCl
F3C
1.90: R = CH3; IC50 = 35 nM
1.100: R = bromovinyl; IC50 = 14 nM  
Figure IV 
 
Based on the reported close structural similarities between TK-2 and TMPKmt and the reasonable 
correlation of the IC50 values of known inhibitors of both targets, some analogues originally designed 
as TK-2 inhibitors, were also evaluated for their inhibitory activity against thymidylate kinase of M. 
tuberculosis. Several 3’-modified thymidine analogues showed inhibitory activity in the low micromolar 
range and represent valuable tools to gain further insight into the S.A.R. of TMPKmt inhibitors, further 
demonstrating that cross screening may be very useful and lead to the discovery of promising 
compounds against alternative targets with minimal efforts. With a Ki value of 0.17 μM, 5’-arylthiourea 
4-thio-α-thymidine analogue 2.23 is one of the most potent TMPKmt inhibitors reported today (Figure 
V). This compound is capable of inhibiting mycobacterial growth at a concentration of 25 μg/mL, 
further promoting TMPKmt as an attractive target for further inhibitor design. 
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In the third part of this thesis, new ligands for the P2Y2 receptor were synthesized that combine an 
aromatic substituent at position 5 of the uracil base and a methylene phosphonate at C-5’ of the 
ribofuranose ring. These compounds were synthesized via a 7-step procedure including a Wittig 
reaction and a Suzuki-Miyaura coupling. Within this series, all compounds activated the P2Y2 receptor 
with a range of apparent potencies, and the maximal effect observed with each of these molecules 
was around 30-40% of that observed with UTP. Preferred modifications at position 5 of the uracil 
moiety of compound 3.7 are depicted in Figure VI. Remarkably, these analogues failed to inhibit 
activity of UTP down to the level of activity seen with the 5-modified analogues alone as would be 
expected for classical partial agonists. A possible explanation for this phenomenon is that these 
phosphonates are producing their effects by interacting with a receptor site distinct from the orthosteric 
site. Phosphonate 3.49 may become a useful tool compound for further pharmacological 
characterization of the P2Y2 receptor. 
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3.44: R = phenyl
3.45: R = naphthalen-1-yl
3.46: R = 4-fluorophenyl
3.48: R = p-tolyl
3.49: R = furan-2-ylO
R
 
Figure VI 
 
Exploration of a similar chemical strategy on different starting materials may allow to discover 
interesting probe compounds that are rather similar from a chemical point of view, but may show 
promising totally different biological activities. Therefore, several 5-modified 5’-methylene 
phosphonate 2’-deoxyuridine analogues were synthesized as possible antiviral agents. Hence, the 
only difference with those derivatives (PART IV) and those modulating the P2Y2 receptor is that the 
latter feature a ribofuranose moiety (as present in the endogenous UTP agonist), while for the possible 
antiviral agents 2’-deoxyuridine was selected as a preferred scaffold for drugs acting against DNA 
viruses. A similar reaction sequence as for the P2Y2 receptor ligands was used but resulted in a 
mixture of α- and β-analogues due to an unexpected anomerisation during the phosphonate 
deprotection step. This proves that, although the starting material is quite similar, a same reaction can 
give rise to different and something unexpected products. After separation of the α- and β-analogues, 
all compounds were tested against a broad panel of different viruses. Unfortunately, none of the 2’-
deoxyuridine analogues exhibited significant antiviral activity. 
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